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The effects of low-molecular-weight (<1000 g/mol) chemi-
cals on biosystems ranging from membranes to organisms
are of interest in medicinal chemistry, chemical biology,
pharmacokinetics, pesticide science, environmental toxicol-
ogy, and several other areas of science and technology. Most
effects are difﬁcult to predict, because of their heavy
dependence on the chemical structures. The effects in
homologous series in biosystems containing at least one
membrane, however, are often (6174 cases documented)1,2
a smooth function of the physicochemical properties of
chemicals, most frequently represented by the reference
partition coefﬁcients (4223 cases),1,2 but also by electronic
parameters and steric characteristics. The structure-nonspe-
ciﬁc effects described by nonlinear dependencies on the
reference partition coefﬁcients (553 cases)1,2 are mostly
related to the passive distribution of chemicals in the aqueous
and less-polar phases of biosystems rather than to the
structure-speciﬁc interactions with the receptors, enzymes,
and transporters. The disposition-related homologous series
data provide initial outlines of the relationships between
structure and disposition, equivalent to the cross sections
along one variable through complex dependencies. Can the
relationships be extended to cover broader classes of
chemicals or eventually the entire chemical universe?
The research area that is striving to understand the
principles of distribution of chemicals at the subcellular level
of biosystems, in terms of the structures and properties of
chemicals, can be appropriately called structure-based sub-
cellular pharmacokinetics (SBSP). Theoretical fundamentals,
status, applications to experimental data, and probable future
development trends of SBSP are reviewed here. Numerous
reviews are available on different aspects of distribution and
how it is related to the properties of the chemicals,3–25 and
the subject is covered, to some extent, in several monographs
on quantitative structure-activity relationships (QSARs),26–32
drug design,33–41 pesticide design,42,43 and medicinal chemis-
try.44–50 This treatise introduces several new concepts and
presents a systematic, critical, integrative, and chemically
oriented view. To foster readability, a uniﬁed nomenclature
is used throughout the text, and the details of the model
development are deferred to section 10. These details can
be skipped without a major impact on the understanding of
the remaining content.
For a quick, semi-quantitative overview of the disposition
of chemicals in biosystems and its relation to structure of
chemicals, the reader is referred to the following psrts of
the paper. In section 1.2, relevant physiology is concisely
summarized and prevailing transport routes in individual
organs are identiﬁed. Section 2.1.2 relates the trans-bilayer
transport rates to the interactions of chemicals in the bilayer
regions, which can be characterized using surrogate solvent
systems, as described in section 2.1.3. These results are used
in section 2.1.4.6 to obtain coarse estimates of equilibration
times for crossing a single bilayer on a gross time scale, in
regard to its dependence on the structure of the chemicals.
1.1. Subcellular Pharmacokinetics
The main goal of structure-based subcellular pharmaco-
kinetics (SBSP) is a model-based description of the kinetics
of the distribution of chemicals, in terms of the properties
of both chemicals and biosystems. For this purpose, the
conceptual kinetic models are constructed, comprising physi-
cally distinct subcellular compartments such as membranes
or their regions, and the extracellular and intracellular
aqueous phases. The considered processes include transport
and accumulation in a set of the aqueous phases and
membranes, as well as protein binding, metabolism, hy-
drolysis, and other reactions of chemicals with body con-
stituents. The resulting differential equations are solved either
numerically (see section 5) or explicitly (see sections 6 and
7), depending on the complexity of the model. To simplify
the solutions, the complexity of mathematical description of
the subcellular models is often reduced in the process of
solving the pertinent differential equations, using the ex-
perimentally veriﬁed time hierarchy of the processes that
determine the disposition of chemicals. Individual rate and
equilibrium parameters are related to the computed charac-
teristics or experimentally determined physicochemical prop-
erties by the extra-thermodynamic linear free-energy rela-
tionships (LFERs).51,52 The properties of chemicals characterize
their behavior in water (hydration, ionization, spontaneous
hydrolysis rate) or in macroscopic surrogate systems imitat-
ing parts or processes in the biosystem, which are either
difﬁcult to analyze directly, or for which generalizations are
sought (reference partitioning systems (section 2.1.3), protein
binding (section 2.4), in vitro enzymatic reactions (section
2.5.1), and surrogate chemical reactions (section 2.5.2)).
Like most other models of biological processes, the SBSP
models belong to the category of a posteriori semi-empirical
models,53,54 because the modeled system is not known in
sufﬁcient detail to allow for the formulation of a priori
theoretical models. The unknown properties, which do not
change under given experimental conditions and are difﬁcult
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which are then optimized by regression analysis to provide
the best agreement between the model and experiment. To
formulate tractable models, decisive features governing the
behavior of the system must be identiﬁed and captured in
the description. For a meaningful optimization of the
regression coefﬁcients in the SBSP models, a proper balance
between the number of adjustable coefﬁcients and the
information content of available experimental data is re-
quired. In the following, every attempt will be made to follow
these principles in the descriptions of chemicals’ disposition.
Individual steps in the SBSP model construction are analyzed
in section 10.
The functional form, in which the time is incorporated in
the SBSP models, has been repeatedly proven by classical
pharmacokinetics. Therefore, a proper application of the
SBSP concepts to the chemicals’ disposition in organisms
should result in expressions that provide similar time
dependencies as the equations of classical pharmacokinetics
(sections 3.8 and 8.2).
As the ultimate outcome of the SBSP modeling, the
kinetics of disposition is expressed as a nonlinear disposition
function of properties, with adjustable coefﬁcients containing
the biological and chemical attributes, which do not vary
under given experimental conditions. The properties are
represented by the reference partition coefﬁcients, acidity,
reactivity, and other parameters, which may also include
three-dimensional (3D) structures of chemicals and structure-
related characteristics. The disposition function is calibrated
using experimental data of, typically, several dozens of
compounds, and then used for the prediction of distribution
of untested chemicals under identical experimental condi-
tions. The SBSP models have a better predictive ability than
empirical models, especially outside the ranges of tested
properties55 (section 8.1). Finally yet importantly, the con-
ceptual nature of the SBSP models facilitates their ﬂexible
extensions accommodating some changes in experimental
protocols (e.g., section 7.3.3).
SBSP has its roots in the distribution-based quantitative
structure-activity relationships (QSAR or QSTAR, if the
exposure time, T, is included), as deﬁned by the pioneering
works of Hansch and Fujita,56 Stehle and Higuchi,57 Pen-
niston,58 McFarland,59 Yalkowsky and Flynn,60,61 Leo,62
Martin,63 Kubinyi,64 Dearden,65 van de Waterbeemd,66 Coo-
per,67 Seydel,68 Schaper,69 Franke,70 Berner,71 Amidon,72
Anderson and Xiang,73 Benet,74 and others. SBSP is also
related to classical pharmacokinetics,75 with which it shares
the representation of biosystems as a set of compartments.
However, the compartment size has been reduced to sub-
cellular dimensions, with the SBSP compartments represent-
ing the membranes or their regions, and extracellular and
intracellular aqueous phases. The nanoscale dimensions
ensure fast diffusion of chemicals inside the less-structured
subcellular compartments (section 10.1.1). Fast diffusion
makes the SBSP models suitable for modeling the effects
of chemicals by facilitating a coherent description of their
concentrations in the immediate surroundings of the recep-
tors, as known in chemical kinetics. The rate/equilibrium
constants, characterizing elementary steps in the subcellular
distribution, are related to physicochemical properties of
chemicals via the extra-thermodynamic LFERs, as known
in the QSAR research and physical organic chemistry.51,52
SBSP relies on other disciplines for methodological
support: principles of dynamic modeling53 are used to
simplify the models; computational chemistry provides
simulation techniques and molecular characteristics; chemical
kinetics supplies some modeling schemes and approxima-
tions; physical organic chemistry lends LFER; biophysical
methods are used to study transport; and biochemical
approaches deliver the binding data for the interactions of
chemicals with body constituents. The interplay between
SBSP and other disciplines is outlined in Figure 1. A special
effort has been made to compare and integrate, where
feasible, the approaches to the analysis of the same phe-
nomenon in different areas.
Experimental techniques providing data for the calibration
of the SBSP models can be classiﬁed as indirect and direct,
depending on whether the phase, where the concentration
of chemicals is determined, has been separated in the course
of the experiment from the rest of the biosystem or not,
respectively. The indirect techniques include measurement
of the chemical’s uptake into membranes,76 vesicles,77
subcellular organelles,78 cells,79 tissues,80 and organs.81 The
direct approaches, suitable for simpler biosystems, are
represented mainly by spectroscopic techniques: ultraviolet
and visible (UV Vis) difference spectroscopy,82–85 circular
dichroism,84–86 ﬂuorescence lifetime measurements,87 ﬂuo-
rescence quenching techniques,88–95 ﬂuorescence anisotropy,96
Fourier-transform infrared (FT-IR) spectroscopy84 combined
with attenuated total reﬂection (ATR)97 and high pressure,98
electron paramagnetic resonance (EPR) with phospholipids
containing spin labels in different positions,99–104 and various
nuclear magnetic resonance (NMR) techniques,84,87,90,99,105–129
including the measurement of nuclear Overhauser enhance-
ment spectroscopy (NOESY)130,131 cross-relaxation rates.127
Other direct techniques include neutron diffraction,132–138
small-angle X-ray diffraction (XRD),139 autoradiography,140
and ﬂuorescence microscopy.141,142
The time courses of the concentrations of chemicals in
individual cells and their organelles are difﬁcult to measure
precisely, and the intracellular data for the calibration of the
SBSP models are quite scarce. For this purpose, the uptake
and release kinetics of chemicals, monitored in the extra-
cellular media, are often used. This is a rigorous approach,
because the extracellular and intracellular concentrations are
variables of the same model and any of them can be, in
principle, used for the model calibration. Although this
statement is not valid for all types of compartment models,
Figure 1. Structure-based subcellular pharmacokinetics and related
sciences. Two-sided arrows indicate mutual inﬂuence; one-sided
arrows indicate supportive roles.
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a biological effect, which has been assumed or shown to be
(i) an immediate consequence of the chemical’s presence in
a biological phase,143 and (ii) proportional to the chemical’s
concentration,144 as a measure of the time course of the
chemical’s concentration in the relevant biological phase.
According to the dependence on the detailed molecular
structures of chemicals, the processes in which chemicals
participate in biosystems can be classiﬁed in two groups: (i)
disposition of chemicals in biosystems, except protein-
mediated transport and enzymatic biotransformation; and (ii)
interactions of chemicals with speciﬁc macromolecules,
which are responsible for biological effects, mediated
transport, and biotransformations of the compounds. The
processes in the ﬁrst group can be fully characterized by
properties of chemicals in aqueous solutions (ionization,
hydrolysis) and surrogate systems (e.g., partitioning, reactiv-
ity, redox potential). The processes in the second group
depend predominantly on the molecular structure of com-
pounds, given as the 3D constitution of atoms, and a spatial
distribution of the structure-related properties. These pro-
cesses can be examined in vitro, using the relevant macro-
molecule(s). The ﬁrst-group processes governing disposition
of chemicals, except enzymatic biotransformation and protein-
mediated transport, are considered property-related or con-
formation-aVeraged processes, and the second-group inter-
actions with the fate- and effect-determining macromolecules
are deemed structure-speciﬁc or conformation-dependent
processes. The property-related processes are easier to model
and the models can be generalized for all biosystems. The
conformation-dependent processes convey structural speciﬁc-
ity to the disposition of chemicals and must be modeled
individually for each biosystem. The overall description of
disposition for diverse chemicals requires that the results for
conformation-dependent processes are embedded in the
models for property-dependent processes.
With the improvement of experimental techniques, mul-
tiple binding modes are detected with increased frequencies
in some binding processes.145 The processes still retain a
signiﬁcant level of structural speciﬁcity and require speciﬁc
treatment in QSAR modeling.146 The methods for descrip-
tions of both process types have been developed separately.
SBSP conceptually combines modeling of both the property-
related processes and the structure-speciﬁc processes, as
illustrated in eq 7 in section 4. Therefore, SBSP represents
a suitable framework for integrated description of the fates
of chemicals in biosystems. One of the outcomes is the cell-
QSAR approach, which extends, by incorporating the
disposition function, conceptual 3D-QSAR techniques for
the application to cell-level assay data.
1.2. Disposition in Organisms
To elicit an effect in a biosystem, a chemical must reach
the site of action, frequently located far away from the points
of entry, which, for higher organisms, are typically the
gastrointestinal and pulmonary tracts, skin, mucosa, and
cornea. We will ﬁrst focus on the physiologic aspects, and
later, in section 2, cover the mechanisms of the transport
processes.
In higher organisms, the ﬁrst step is absorption, which
brings the molecules from the point of entry or the site of
administration into the bloodstream or the lymphatic system.
Although the lymph circulation is much slower than that of
the blood,147 very lipophilic chemicals may use the former
route for distribution, piggy-backing on the transport systems
of lipophilic nutrients.148–150 These compounds may also
exhibit slow absorption into the blood and lymph capillaries
in the villi, and enter the lymph via endocytosis in the Peyer’s
patches in ileum, especially in lipid-based formulations.151–160
Absorption mostly proceeds by the transcellular route, with
the molecules crossing epithelia and other tissues by passive
and active transport through the bilayers and cell interiors.
An exception is the absorption through the skin, where the
only cells in the external stratum corneum layer are kerati-
nized corneoytes.161 Corneocytes are embedded in a lamellar
phase of lipids,162 with the composition differing from that
of other membranes. Absorption through stratum corneum
is assumed to proceed mainly by passive lateral diffusion163
through the lipid phase.164 Could a similar passage through
a cell layer by lateral diffusion in the bilayers,165 without
entering cell interiors, be accomplished by amphiphilic
molecules in other tissues? This does not seem to be a
widespread mechanism. Tight junctions would need to be
bypassed by the ﬂip-ﬂop to the cytoplasmic side of the
bilayer, followed by the return to the outside leaﬂet before
the release into medium on the opposite site of the cell layer.
Moreover, for many amphiphilic compounds, the ﬂip-ﬂop
is a slow process (section 2.1.4.6).
Once in the blood or lymph, chemicals quickly reach
distant body parts by convection and diffusion, although
circulation of the lymph is slower. The details of vasculature
have been long known in great detail, starting with the
description of capillaries by Malpighi in 1661, the capillary
walls by Schwann in 1839, and the cellular nature of the
capillary walls by von Recklinghausen in 1862, as well as
the introduction of the term “endothelium” by His in 1865.166
The distribution of chemicals from the biological ﬂuids into
tissues involves (i) paracellular transport into interstitial ﬂuid
directly mixing with the content of blood and lymph
capillaries and (ii) transcellular transport bringing the
molecules of chemicals into the cells. In the hierarchy of
the vasculature, we shall focus on the capillaries, because
(i) their walls are composed of a single layer of endothelial
cells and have openings in some organs, in contrast to larger
blood vessels, which have continuous and more-complex
structures, and are more difﬁcult to permeate; and (ii) they
represent the majority of ∼300 m2 of the vascular endothe-
lium surface and of ∼19 000 km of overall length of blood
vessels in a standard 70-kg man.167
The walls of blood capillaries in individual organs differ
in porosity (Table 1). Continuous capillary walls with
endothelial cells connected by tight junctions and supported
by a complete basement membrane are encountered in places
requiring a barrier protection, as in brain (but not choroid
plexus), lungs, intestine, placenta, and testis. Continuous
endothelia are still capable of paracellular transport of small
molecules, with diameters of <3 nm, such as urea and ions.168
The endothelial junctions are regulated by various signaling
mechanisms and can operatively respond to physiological
conditions.168 The pores in capillary walls are associated with
speciﬁc functions. Renal glomerulus, serving for plasma
ﬁltration in the kidney, exhibits 30-60 nm openings between
the endothelial cells, which are supported by a complete
basement membrane. The most porous capillaries allow the
transcellular passage of macromolecules and even some cells,
thanks to the broken basement membrane and the openings
with the diameters reaching 100-300 nm in the bone
marrow, spleen, and sinusoids of the liver,169–171 and up to
1796 Chemical Reviews, 2009, Vol. 109, No. 5 Balaz1.2 µm in tumors.172 For a point of reference, the average
capillary diameter is only slightly larger than the average
diameter of erythrocytes (7.5 µm),173 and the minimum
capillary diameter is ∼4 µm.167 Lymph capillaries are also
porous.167 The exchange of water between the blood and
interstitium through the leaky blood capillaries attains 70%
of the volume per minute174 and is somewhat slower for the
lymph capillaries, because of the difference in hydrostatic
pressures. Because all pores are substantially larger than
small organic molecules, the transport through the leaky
capillary walls into the interstitial space proceeds mainly
through the paracellular route on the time scale of minutes.
This type of transport has the speciﬁcity determined only
by the interactions of chemicals with cells that affect the
free concentrations and, thus, the overall transport rates. In
contrast, the transcellular route that the chemicals must use
to cross the nonporous capillaries exhibits widely differing
transport rates and mechanisms, which depend on the
properties of the chemicals (section 2.1.4.6).
Chemicals can enter the tissues cells directly from the
capillary walls, from the interstitial ﬂuid or from other tissue
cells. Individual organs differ in density of vasculature and,
consequently, in the number of cells, which do not maintain
a direct contact with the capillaries or primary interstitial
ﬂuid directly mixing with the blood.175,176 According to the
decreasing capillary densities, the tissues can be classiﬁed
into four categories: (i) lungs; (ii) kidney; (iii) brain, liver,
intestines, and heart; and (iv) muscles, connective tissues,
fat, and bones (Table 1). The average thickness of the cell
layer served by a capillary increases in this order. The basal
blood ﬂows for individual organs are also summarized in
Table 1. The basal blood ﬂow can be increased 5-10 times
in most organs during physical exercise and other conditions.
The exceptions are brain and kidneys, where the blood ﬂow
is buffered, and the basal ﬂow cannot increase more than
twice.167 These data determine relative equilibration times
for individual tissues, which are primarily given by the
number of crossed bilayers, including, in each cell, cellular,
and organelle membranes, as well as endoplasmic reticulum.
For a single bilayer, the equilibration times vary between
less than a second and several days, depending on the
structure of the transported chemical (section 2.1.4.6). The
growing number of crossed bilayers increasingly magniﬁes
these differences.
Chemicals can be eliminated by processes that do or do
not change their molecular structure, i.e., by metabolism or
excretion, respectively. Metabolism and excretion processes
collectively represent elimination.
The prevailing portion of metabolism in higher organisms
happens in the liver, where the majority of metabolizing
enzymes, predominantly cytochromes P450 (CYPs, section
2.5.1.1), are located. However, CYPs and other metabolizing
enzymes are also expressed in the intestine and some tissues.
Many chemicals can also participate in spontaneous reactions
with body constituents (section 2.5.2).
The excretion of chemicals and their metabolites proceeds
mainly in the kidneys, although excretion into feces, bile,
saliva, and sweat, as well as transpiration into air, may
contribute. From more than a liter of the blood passing
through the kidneys every minute, ∼100 mL of plasma are
ﬁltered at the glomerulus of nephrons, through the 30-60
nm pores, which are normally too narrow to allow the
passage of proteins and protein-bound chemicals. Active,
protein-mediated secretion and reabsorption of chemicals
proceed in the proximal tubule (sections 2.3.1.2 and 2.3.2.1),
and passive reabsorption happens along the entire tubule.
Water is also reabsorbed, reducing the volume of the ﬁltrate
by a factor of ∼100.
The time courses of concentrations of chemicals in
individual parts of higher organisms are determined by
absorption, distribution, metabolism, and excretion (ADME).
We will refer to these processes collectively as disposition,
although, in classical pharmacokinetics, the term disposition
denotes only the last three processes.75 In vitro cellular
systems (e.g., microbial populations) do not possess special-
ized structures participating in absorption and excretion, and
the processes that the chemicals undergo can be classiﬁed
as distribution (or transport) and metabolism.
During absorption, distribution, and elimination, the
majority of chemicals seem to enter and leave the majority
of the cells through phospholipid bilayers of the membranes
by passive diffusion, without the help of protein carriers,
unless the chemicals are analogs of physiologic molecules
with active or passive carrier-mediated transport. The base-
line diffusional trans-bilayer transport rates of many chemi-
cals may be increased by inﬂux transporters in the intestine,
liver, and kidney177 (section 2.3.1) or decreased by the efﬂux
pumps and transporters (section 2.3.2), which are expressed
in organs with excretory functions such as the kidney and
liver; in sheets or tissues with barrier functions such as the
intestine and capillaries of brain, testis, and placenta; and
also in tumors.178 The list of chemicals undergoing facilitated
or active transport is steadily growing, because this area is
a subject of extensive research, because of the obvious
importance in drug delivery.179 It is assumed that practically
each drug is a substrate of a transporter somewhere in the
Table 1. Perfusion Characteristics of Some Organs in a Standard 70-kg Human167,175,176
Blood Flow Capillary Density
organ relative volume (%) fraction of cardiac output (%) (mL g-1 min-1) capillary type a served cellsb per mm3
lungs 1.6 100 5 C 1 5000
kidneys 0.5 22 4 C, F c 2 2500
intestines 1.7 21 0.9 C 5 500
liver 2.3 27 0.8 S 5 500
heart 0.4 4 0.7 C 5 500
brain 2.0 14 0.5 C, F d 5 500
spleen 0.3 1.5 0.4 S 5 500
skin 11 6 0.04 C 15 50
fat 20 4 0.03 C 15 50
muscles 43 15 0.02 C 15 50
bones 16 5 0.02 S 15 50
a C ) continuous, complete endothelial layer and basement membrane; F ) fenestrated, complete basement membrane, endothelial layer has
openings 30-60 nm in diameter; S ) sinusoids, broken basement membrane, endothelial layer has openings 100-300 nm in diameter. b The average
number of cell layers served. c C in proximal and distal tubule and the loop of Henle, F in glomerulus. d F only in choroid plexus.
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relevant.180 If the trans-bilayer transport is fast, its further
enhancement has no signiﬁcant impact on the overall process.
Understanding of both passive and mediated transport
mechanisms is necessary for prediction of distribution of
chemicals. The generalizing conclusions about the key roles
of transporters for the entry of all drugs into all cell types181
are not based on sound arguments. The transport mechanisms
utilizing protein carriers can be described in terms of structure
in a similar way as other structure-speciﬁc processes, using
receptor-based or ligand-based approaches (section 2.3).
After crossing the cell membrane, intracellular distribution
of chemicals proceeds chieﬂy by passive diffusion through
the bilayers of organelles and of endoplasmic reticulum,
although several transporter proteins are expressed in intra-
cellular membranes and may affect the transport rates. Some
hydrophobic chemicals, planar aromatic hydrocarbons, and
similar compounds182 enter the nucleus in a complex with
the aryl hydrocarbon receptor,183,184 but the passive diffusion
across the nuclear envelope cannot be excluded.
In summary, passive trans-bilayer diffusion is a ubiquitous
and most important process affecting the distribution of
chemicals in biosystems. Because of frequent references to
this process, we will use the term “transport” to denote the
ﬂux and the term “accumulation” to characterize the pseudo-
equilibrium retention of chemicals in bilayers. The SBSP
models are essentially common mass-action based models
for the interactions of chemicals with body constituents,
which are placed within the framework of intracellular and
extracellular compartments separated by membranes. The
term “baseline disposition” can be used to denote the
disposition that is not affected by protein-mediated processes,
such as active or passive mediated transport or enzyme-
catalyzed metabolism. The baseline disposition is always
occurring in any biosystem and is implicitly assumed if no
speciﬁc knowledge about the concentration and kinetics of
transporters or metabolizing enzymes is available. The
carrier-mediated inﬂux or efﬂux become important if they
signiﬁcantly change the baseline disposition. Understanding
the transport and its interplay with other property-related
processes (ionization, hydrolysis) is a crucial requirement
for the development of the relationships between the baseline
disposition kinetics and structure or properties of chemicals.
The interactions of chemicals with biosystems will be
analyzed at the elementary level of individual processes in
section 2, and for the biosystems of increasing complexity
in section 3.
2. Individual Steps vs. Properties
To describe chemical disposition via explicit or numerical
solutions of appropriate differential equations, the rate and
equilibrium parameters for individual processes must be
expressed as functions of physicochemical properties of
chemicals and biosystems. In sections 2.1-2.5, we will focus
on the structural dependencies of the interactions with lipids,
protein carriers, inert proteins, and enzymes, which are
involved in disposition of chemicals.
2.1. Interactions with Lipids
Lipids of mammalian cells can be classiﬁed as bilayer-
forming lipids and other lipids. The ﬁrst category is
represented by phospholipids, cholesterol, sphingomyelins,
and other species,185 whereas the second category consists
mainly of triglycerides and their derivatives. Triglycerides
are contained in lipoproteins and lipid droplets, which are
present in practically all cells, and accumulate to a large
extent in adipocytes (section 2.1.4.2).186
From the viewpoint of chemicals’ disposition in biosys-
tems, transport through phospholipid bilayers and accumula-
tion in phospholipid bilayers are among the most important
processes. Chemicals usually interact with lipid aggregates,
not with individual lipid molecules. Therefore, the interac-
tions are mostly of structure-nonspeciﬁc nature, resemble
interactions with phases or solvents, and can be analyzed
using the data obtained in macroscopic surrogate systems
(section 2.1.3). These facts permit generalization of the rules
for the interactions of chemicals with phospholipids to the
level of predictions of the kinetics and equilibria from the
structure of chemicals.
2.1.1. Bilayer Structure and Properties
History of the research on bilayer structure and properties
is tightly interwoven with structural studies of biological
membranes. The timeline showing the major events in the
history of the bilayer structural studies is given in Figure 2,
with the details and references summarized in the next
section. The key ﬁndings about the protein interactions with
the bilayer, if not related to the bilayer structure, are only
mentioned in the text. The bilayer structure is analyzed in
more detail in section 2.1.1.5.
2.1.1.1. History of Membrane Structure. The concept
of the cell membrane originated in the second half of the
19th century from the work of botanists, who recognized
that the protoplasm of plant cells was separated from the
cell walls by an osmotic barrier.187–189 The determination of
surface tension was established as the measurement of the
force needed to pull a metal plate out of the interface.190
The predecessor of the Langmuir trough was invented and
used to measure the dynamic surface tension.191 Numerous
observations of lipid-soluble compounds partitioning into the
membrane led to the hypothesis about the lipid character of
the membrane.192 The measurements of the area to which
oils were able to spread at the air/water interface resulted in
the proposal for the monolayer structure of fatty acids having
the headgroups immersed in water and chains protruding into
air.193 The notion of a double lipid layer came from the
observations showing that the lipid content of erythrocytes
from several animals was just sufﬁcient to cover the cell
surface by two monolayers.194 The resulting structural model
Figure 2. Historical milestones in the elucidation of bilayer
structure.
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protein layers holding the lipids in place195 was later
modiﬁed, on the basis of electron-microscopic observations,
to a self-standing bilayer with adsorbed polypeptide and
possibly polysaccharide layers,196 and ﬁnally to the ﬂuid
mosaic model with the bilayer representing a support for
peripheral and integral proteins.197 The geometry of phos-
pholipid molecules was considered a factor in formation of
the maximal bilayer curvature.198 The X-ray199 and calori-
metric200 observations indicated the presence of the gel and
liquid-ordered lipid phases in the membranes. The X-ray
structural studies clariﬁed the orientation of hydrocarbon
chains.201 The hydrophobic effect, attributed to entropy-
driven changes in water structure,202 which was initially
studied in connection with colloid behavior,203–205 water-
prooﬁng of textiles,206 and protein folding,207,208 was recog-
nized as the driving force in the formation of the bilayer.209
The structure of the phospholipid bilayer in the gel phase
was studied by neutron diffraction.210–212 The headgroup
dipoles change orientations in response to the overall charge
of the bilayer.213 Integral proteins were shown to interact
with the bilayer core via hydrophobic residues.214 In a bilayer
composed of a lipid mixture, the lipids with the lengths of
the fatty acid chains matching the dimensions of the
hydrophobic exteriors of integral proteins concentrate around
the proteins, to minimize hydrophobic mismatch.215 Com-
bined X-ray and neutron diffraction analyses provided a
detailed picture of distribution of individual phospholipid
fragments along the normal of a liquid-ordered phosphati-
dylcholine (PC) bilayer.216–220 High-resolution X-ray diffrac-
tion was used to determine the key structural parameters of
the fully hydrated PC bilayer.221 Coexistence of the gel and
liquid-ordered phases was directly observed by atomic force
microscopy.222 These observations contributed to the current
view of biological membranes as dynamic structures, where
peripheral and integral proteins interact with the bilayer
containing different phospholipids and other lipid species in
liquid-ordered and gel states.
2.1.1.2. Membrane Composition. Phospholipid bilayers
form the basis of endomembranes, including cell membrane,
endoplasmic reticulum, Golgi bodies, vesicles, and nuclear
envelope, which participate in several vital processes in
eukaryotic cells, such as attachment, intracellular compart-
mentalization, energy transduction, signaling, protein sorting,
and other secretory and endocytic processes. The protein and
lipid contents are roughly equal on the weight basis, with
signiﬁcant deviations for specialized membranes. For in-
stance, myelin, the multilayered insulating sheath of neural
axons contains 80% lipid, and mitochondrial membranes, the
locale of respiration, oxidative phosphorylation, and intense
metabolism, contain 80% protein. In the simplest case of
inert proteins, the signiﬁcant protein content decreases the
area available for passive trans-bilayer transport and modiﬁes
the structural arrangement of surrounding bilayer phospho-
lipids. The irregularities may increase the transport rates, as
described for the perturbed bilayer structures at the transition
temperature (sections 2.1.1.4 and 2.1.4.3).
Mammalian bilayers are composed of phospholipids,
sphingomyelin, glycolipids, cholesterol and other sterols, and
many other non-bilayer-forming lipid species.185 Phospho-
lipids, mainly PC, less phosphatidylserine, phosphatidyle-
thanolamine,andphosphatidylinositides,accountfor40%-80%
of the bilayer weight. Cholesterol, the preponderant mam-
malian sterol, is equimolar with phospholipids in hepatocytes,
erythrocytes, and myelin; it represents 20% w/w of stratum
corneum223 and is less abundant in other cells and tissues.
The lipid composition of individual membranes varies
widely, even between the membranes of the same cell,224
and affects the permeation rates. The tubular cells of barrier
epithelia in the kidney nephrons, manifesting low membrane
permeability, contain the outer bilayer leaﬂets composed of
a speciﬁc mixture of PC, sphingomyelin, glycosphingolipids,
and cholesterol. The omission of any component dramatically
increases permeability.225 Caveolae, invaginated membrane
structures with high levels of cholesterol, sphingomyelin, and
caveolin (section 2.2.1), exhibit high permeabilities, thanks
to a high degree of unsaturation of fatty acid chains.226
2.1.1.3. Phospholipid Distribution in Membranes. Phos-
pholipids in membrane bilayers do not form homogeneous
mixtures. Lipid distribution may differ, under physiological
conditions, for different cells or different membranes of the
same cell, for the two monolayers forming a bilayer, and
for a monolayer. For different cell membranes, sphingolipids
and sterols form gradients along the secretory pathways, with
the highest abundance in the plasma membranes and the
lowest level in endoplasmic reticulum.
In a bilayer, lipids display asymmetric trans-bilayer
arrangements maintained by energy-dependent transporters:
sphingomyelin, glycolipids, and PC concentrate in the outer
leaﬂet of the normal cell membrane, whereas phosphati-
dylserineandotherphospholipidsprefertheinnermonolayer.227,228
These differences are particularly pronounced in renal and
intestinal epithelial cells, which exhibit low permeabilities
to carbon dioxide and ammonia.229 Perturbation of this
asymmetry, especially the appearance of phosphatidylserine
at the cellular surface, is a hallmark of apoptosis, which
enables an orderly removal of the affected cell by phago-
cytes.230
In any of the two monolayers of the bilayer, some mixtures
of lipids are immiscible to various degrees and may form
lateral domains, occasionally termed lipid rafts, especially
in the surroundings of proteins.215,231–237 Formation of a
domain in a monolayer affects the phospholipid distribu-
tion in the opposite monolayer.238–242 The domains participate
in many of the membrane-related vital processes mentioned
in the introductory paragraph of section 2.1.1.2,243–252 as well
as in the transport253,254 and accumulation255–258 of chemicals.
The perturbed bilayer structures at the raft perimeters may
affect the transport rates, because increased permeabilities
were observed for coexisting phases at transition temperatures
(see the next section).
2.1.1.4. Phase Behavior of Bilayers. Phospholipid mol-
ecules in aggregates exhibit collective behavior. The main
determinant of this behavior, for the given composition and
normal pressure, is temperature. At lower temperatures, the
bilayer is in the gel phase, with the fatty acid chains tightly
packed and ordered, and mostly assuming extended trans
conformations.259 When the temperature increases above the
main transition temperature, the bilayer enters the liquid-
ordered phase, with less-regular conformations of fatty acid
chains. Among additional chain-ordered phases, the ripple
phase of PC and phosphatidylglycerols, exhibiting periodic
ripples several hundred angstroms apart,260 is most frequently
studied. The proﬁle of individual ripples may be symmetrical
or asymmetrical, with the two shoulders differing in the
thickness: one side has the same thickness as the gel phase
and the rest is thinner, possibly because of a different tilt or
the melted state of the chains.261 The formation of ripples,
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monolayers, which were periodically arranged for geo-
metrical and topological reasons, was modeled by Monte
Carlo (MC) simulations260 and other computational methods
(section 2.1.5.1). In PC, the ripple phase occurs just below
the gel-to-liquid transition chain-melting temperature that
marks the coexistence of the gel and ﬂuid phases.261
In biological membranes, the main chain-melting transition
occurs within the range of 20-60 °C. The heat capacity, as
well as the volume and area compressibility, reach their peak
values during this transition.262 The heat-capacity changes
seem to be proportional to the volume changes,263 as well
as to the relaxation times, which range from seconds to
approximately a minute.264 Usually, the transition temperature
is affected less by the headgroup composition than by that
of the tails: it increases with the length and saturation of the
fatty acid chains. The transition temperature exhibits a
decreasing sigmoidal dependence on hydration: the upper
limit is observed for dehydrated bilayers, whereas the lower
limit is achieved at the saturation of water-binding capacity
of the lipids. The gel-liquid transition occurs in a narrow
temperature interval in pure phospholipid bilayers, especially
for multi-bilayer liposomes.264 Additives usually broaden the
transition temperature interval. In the gel phase, cholesterol
decreases the fatty acid chain ordering and reduces the main
transition temperature.265
The gel-liquid phase change results in an abrupt increase
in bilayer volume (∼4%),266 area (∼25%),267 enthalpy
(20-40 kJ/mol),268 and the headgroup hydration269 (ap-
proximately three-fold in PC).270 The thickness of the bilayer
decreases upon the chain-melting transition,271 as reﬂected
in the disproportionate changes of the volume and area.
Above the transition temperature, further temperature eleva-
tion results in an increased abundance of folded conforma-
tions, leading to a continuous reduction of phospholipid
surface density and bilayer thickness272 and a concomitant
increase in headgroup hydration.270 Within a range of ∼20°,
these changes are dependent on temperature in an ap-
proximately linear way.271 The relationship between the
phospholipid surface area and the average number of water
molecules intercalated in the headgroup region is almost
linear.273 Cholesterol increases the fatty acid chain order in
the liquid-ordered phase, as opposed to its effect in the gel
phase.265 The increased order, thanks to cholesterol or
diminished unsaturation, is associated with a decrease in the
water concentration in the core.274 Hydration of the head-
groups is not closely correlated with the chain order.274
2.1.1.5. Bilayer Structure at Atom Level. The dynamic
bilayer structure is characterized by average attributes. The
most important structural characteristic is the surface area
per lipid molecule that is related to the bilayer thickness via
the speciﬁc volume. To describe the thickness, one can use
(i) the steric thickness, characterizing interbilayer distances
in multilayer preparations; (ii) the electron density thickness,
obtained from electron density proﬁles as the head-head
separation; (iii) the hydrophobic thickness, which is most
important for hydrophobic matching of protein structures to
bilayers; and (iv) the Luzzati’s thickness, obtained by the
gravimetric X-ray method,275 as amended by inclusion of
the compression to eliminate hydration defects.276
XRD determines the electron density proﬁles along the
bilayer normal.199,201,275 Neutron diffraction provides the mean
positions of the deuterium atoms in bilayers containing
selectively deuterated lipids.219,277,278 The experimental data
have been available earlier for the more-ordered gel phase210–212
than for the liquid phase. A combination of the XRD and
neutron diffraction data provided a detailed picture of
distribution of individual phospholipid atoms along the
normal of a liquid-ordered PC bilayer with comparatively
low hydration.216–220 High-resolution XRD and a computa-
tional reduction of the ﬂuctuations enabled determination of
the key structural parameters of the fully hydrated PC bilayer,
including the area and volume per lipid.221
The status of the fatty acid chains can be monitored in
the bilayers containing selectively deuterated lipids. 2H NMR
results allow for the calculation of the order parameters,
isomerization times, and trans/gauche populations of the fatty
acid chains.279,280 The latter attribute can also be studied by
Raman spectroscopy281 and IR spectroscopy: the CD2 bands
differ for trans and gauche orientations of the adjacent C-C
bonds.259,282
2H-NMR spectroscopy was used to study hydration of the
headgroups,283 and, in combination with 31P-NMR, to
characterize conformations and orientations of the head-
groups.284 Monitoring of the phosphate and carbonyl bands
by FT-IR allowed quantiﬁcation of hydration and interactions
with cations.285 For oriented bilayers, 2H-NMR was used to
determine the overall tilt of the phospholipid molecules.286
The bilayers formed by the most abundant mammalian
phospholipids, PCs, are studied most frequently. Individual
parts of the PC molecules exhibit the following approximate
time-averaged orientations, with respect to the bilayer plane.
The dipoles formed by the zwitterionic phosphocholine
groups align at angles starting at ∼0° and increasing287 up
to ∼50°, when the surface charge becomes more positive.213
A similar movement of the dipoles, from the in-plane
orientation to an orientation more parallel to the bilayer plane
normal, was observed in the PC monolayer at the air/water
interface upon compression from the liquid-ordered phase
to the gel phase.269 The glycerol backbones are almost
perpendicular or slightly slanted, to improve the access of
sn-1 carbonyl to water molecules,288 although the sn-2
carbonyl remains better hydrated.289 The fatty acid chains
are tilted to compensate for the larger surface area of the
headgroup, compared to the relevant cross section of the
extended acyl chains. The charged phosphocholine groups
form a regular network of electrostatic interactions.290 The
thickness of the bilayer increases291 and the area per
phospholipid decreases with prolongation of the acyl
chains.272,273
Despite intense thermal motion,220,221 the subregions of (i)
low headgroup density, (ii) high headgroup density, (iii) high
tail density, and (iv) low tail density were discerned in the
structure of a hydrated PC bilayer patch that was simulated
by molecular dynamics (MD).292 The borders of the subre-
gions cannot be precisely expressed in terms of the phos-
pholipid structural elements because of their thermal ﬂuc-
tuations. The ranges of thermal motions and the subregion
borders of a ﬂuid PC bilayer are outlined in Figure 3.
Subregion 1 (perturbed water) is represented by a water
layer, whose structure is affected by interactions with
trimethylammonium and phosphate groups, which tempo-
rarily protrude into this subregion. Subregion 1 starts where
the orientational ordering of water by the headgroups can
be observed and ends where the densities of water and lipid
become comparable. In this direction, the overall mass
density is gradually increasing along the normal to the bilayer
plane. Signiﬁcant lipid movement in the direction of the
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averages in time to a smooth density proﬁle. Just above the
gel-liquid transition temperature, the primary hydration shell
consists of 12-16 water molecules per the PC headgroup.293,294
The thickness of this subregion is ∼1n mi nP Ca n di s
affected by the surface charge density.213 Sometimes, this
subregion is considered to be part of the bulk water phase.295
Subregion 2 (interphase) extends over 0.8 nm and includes,
most of the time, the hydrated headgroup atoms up to the
ester groups and the ﬁrst two or three tail methylenes. The
distance between the phosphate groups and the headgroups/
core interface is 0.41-0.54 nm.273 This subregion has the
highest density and the lowest free volume fraction. Just
above the gel-ﬂuid transition temperature, practically all
water molecules are engaged in hydration shells of the
headgroup atoms. The extent of hydration and the phospho-
lipid surface area increase with temperature as described
previously.270–273
Subregion 3 (soft polymer) starts close to the carbonyl
groups, where the water density drops to 1% of bulk water
density. It contains the ﬁrst 6-8 methylene segments of the
fatty acid chains, with the thickness equal to ∼0.7 nm. The
chains are tightly packed, with restricted atom movement,
so that the subregion behaves like a viscous liquid. The chain
order parameters do not vary much for individual methylene
segments. The exception is the second sn-2 methylene, which
seems to be less ordered than the other methylenes due to
two prevalent conformations.265 The mass density in subre-
gion 3 is lower than that in subregion 2.
The decrease in density continues in subregion 4 (al-
kane),296 which starts where the mass density becomes equal
to the density of hexadecane. Subregion 4 represents the
center of the hydrocarbon core and is formed by the
remaining portions of the fatty acid chains. This subregion
resembles a liquid alkane with low viscosity.292 Thanks to
the diffusive hopping transport,292,297,298 some water is present
in the bilayer core formed by subregions 3 and 4;299,300
however, the actual concentrations may be too low to
measure by some techniques.218,301
Phosphatidylethanolamines (PEs), the most abundant
bacterial phospholipids, differ from PC mainly in the
hydration of the headgroups. The amine hydrogens partici-
pate in hydrogen bonds with water molecules and phosphates
of other PE molecules. These interactions, along with the
smaller headgroup size, result in a signiﬁcant decrease in
the surface area per lipid molecule.302
The surface charge of the bilayer is dependent on the ion
composition of the aqueous phase, and on adsorption of
charged chemicals, in addition to the headgroup composition.
A difference in the monovalent salt concentrations on the
two sides of the bilayer can induce signiﬁcant asymmetry
in structure, dynamics, and electrostatic properties of the
bilayer.303 Surface charge density affects the conformation
of the zwitterionic phosphate-nitrogen dipoles213 and the
partitioning of charged solutes.304–306 The surface charge at
the shear plane of the bilayer, ∼2 Å from the surface,307 is
characterized by the zeta potential,308 which is related to
electrophoretic mobility. This attribute was used to determine
the liposome/water partition coefﬁcients of charged and
neutral solutes by capillary electrophoresis with liposomes
(section 2.1.2.1) acting as a pseudo-stationary phase.309 The
electrostatics of the surface are also affected by the dipole
potential310,311 which originates from the alignment of electric
ﬁelds of the charged groups, carbonyls of the ester groups,213
and the ﬁrst layer of hydrating water molecules.312 The
inﬂuence of the dipole potential on electrostatic properties
of the headgroup region is smaller than that of surface charge
but not negligible.
2.1.2. Phospholipid Systems
Interactions of chemicals with phospholipids represent
critical factors for the kinetics of both disposition and effects
of chemicals. Accumulation in biological membranes is
important primarily for understanding pseudo-equilibrium
pharmacokinetic parameters such as the volume of distribu-
tion and the tissue/blood partition coefﬁcients, as well as
for elucidation of the biological effects of chemicals. The
trans-bilayer transport is a key process in absorption and
distribution. Direct measurements on biological membranes
are obstructed by interactions of chemicals with proteins and
other membrane components, complex membrane architec-
ture, and variability of membrane composition. To avoid
these complications, self-aggregating phospholipid systems
are frequently used instead of biological membranes to study
the interactions of chemicals with phospholipids.
The bilayer/water partition coefﬁcients are expected to be
good descriptors of equilibrium partitioning in tissues and
organisms, because the bilayers are the parts of biological
membranes where many compounds accumulate. Published
studies indicate successful descriptions for a limited series
of compounds.313–315 A broader application to more-diverse
compounds may be limited by the variable phospholipids
composition of biological membranes.
An important goal of the SBSP modeling is the prediction
of the bilayer interactions from structure of chemicals. The
bilayer partitioning is a composite process that generally
includes interactions with the headgroups, interface, and core.
Consequently, the overall bilayer/water partition coefﬁcients
are more difﬁcult to scale in the extrathermodynamic
relationships (e.g. eq 1 in section 2.1.3.1) than the elementary
core/water, interface/water, and headgroups/water partition
coefﬁcients. Deconvolution of the liposome partitioning into
core/water and interface/water contributions was attempted
for limited datasets.316,317
An inherent drawback common to all bilayer systems is
the potentially long incubation time needed to achieve the
equilibrium for amphiphilic compounds: the ﬂip-ﬂop between
the two interfaces of the bilayer can signiﬁcantly slow the
partitioning process,20 as well as lead to experimental errors,
because of the termination of the experiment before reaching
Figure 3. Thermal motion and subregions of the liquid-ordered
dioleoylphosphatidylcholine bilayer. The arrows indicate the range
of 95% probability of occurrence of (from left) terminal methyls
(red), double bonds (blue), carbonyls (red), glycerol (green),
phosphate (light blue), choline (black), and hydration water (blue).220
The subregions are approximated according to the MD simulation
results.292
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extreme lipophilicities (section 2.1.4.6);20 however, the errors
caused by a premature experiment termination are less
frequent and less signiﬁcant. For very hydrophilic chemicals,
there is no fast step providing the illusion of reaching the
equilibrium. Very lipophilic chemicals may have biphasic
kinetics but the slow second phase is the partitioning into
the small volume of internal water, which is less extensive
and causes comparatively small errors. For the monolayer
systems, the risk of a slow kinetics is limited to hydrophilic
chemicals, which may exhibit a slow entry into the core.
Depending on the preparation, the support used, the lipid
composition, the lipid concentration, and the temperature,
the phospholipid aggregates can have nanoscale dimensions
and spherical, discoid, or oblate ellipsoid shapes (see Figure
4), or macroscopic spherical or planar geometries. The
aggregates include free and gel-trapped liposomes and other
bilayer-based corpuscles, supported bilayers, and monolayers
at solid, liquid, and gas interfaces with water.
2.1.2.1. Liposomes and Other Bilayer Microsystems.
Liposomes are spherical corpuscles consisting of the aqueous
central phase surrounded by one (Figure 4A) or more
phospholipid bilayers, which are separated by thin layers of
water. They were ﬁrst described by Bangham et al. in
1965,318 although the suspensions of phospholipids, stained
by histological dyes, have been microscopically observed
much earlier.192 Free (Figure 4A), immobilized, and sup-
ported liposomes (Figure 4B) have a long history of being
used as surrogate systems for membranes. In these studies,
unilamellar vesicles are preferred to multilamellar liposomes
because of better-deﬁned and simpler structures. Based on
the size, liposomes are classiﬁed into three categories: the
minimum-size unilamellar vesicles (diameters of 15-30 nm),
large unilamellar vesicles (up to several hundred nanometers),
and giant unilamellar vesicles (on the order of micrometers).
The enthalpy and entropy contributions to binding may differ
in small and large unilamellar vesicles,319 although the area
per lipid, chain ordering, and dynamics seem to be similar.320
The enthalpy--entropy compensation may lower the differ-
ences in the overall free energies.319
Giant unilamellar vesicles are generated from speciﬁc lipid
mixtures by various techniques including detergent dialysis
from aqueous mixtures of organic solvents321,322 and chao-
tropic solutions,323 freezing-thawing,324 gentle hydration,325,326
rapid solvent evaporation,327 and electroformation on elec-
trodes.328 The vesicles are sufﬁciently large to be observed
by optical microscopes and manipulated by micropipettes.329
They are well-suited for the ﬂuorescence monitoring of lateral
inhomogeneities also called lipid rafts or domains,224,330,331
examination of mechanical332 and electrical333 properties, and
patch-clamp recording of incorporated ion channels.334
Limitations such as a complicated kinetics with the
difﬁcult-to-predict duration of transport for some com-
pounds,20 a tedious separation,335,336 a laborious spectroscopic
data analysis that is due to the light scattering if the separation
step is omitted,337–339 and low stability of some preparations340
restrict the use of liposomes in routine experiments with
increased throughput. The direct approaches, avoiding the
separation of liposomes, are limited to ﬂuorescent and UV-
Vis-absorbing compounds82 or ionized compounds.341,342
Immobilization of liposomes by embedding in agarose gel
beads,343 adsorption on alkylated surfaces,344 or by biotin-
avidin interactions alleviate the problem of liposome separa-
tion but introduce the risk of the matrix effects.345 Similar
issues may arise with the liposomes that were noncovalently
attached to a sensor chip and had the kinetics and equilibria
of interactions with drugs analyzed using the surface plasmon
resonance technology that measures the changes in liposome
mass caused by drug binding.346–349 The examination of
matrix effects signiﬁcantly increase the workload, especially
if it is rigorously performed for each studied compound.
Planar bilayers of nanoscale dimensions and circular shape,
reminiscent of some plasma lipoproteins (section 2.1.4.2),
can be stabilized if their edges are covered by either
membrane scaffold proteins350,351 (nanodisks; see Figure 4D)
or by phospholipids with shorter fatty acids and deterge-
nts352–354 (bicelles; see Figure 4F). They are mostly used in
imaging,355 NMR studies,356 and stabilization357 of membrane
proteins and less in the studies of chemicals’ accumulation,
because the stabilizing proteins, lipids, or detergents could
interfere with the solute binding. The lipid-protein interac-
tions in nanodisks were analyzed using MD simulations358
and mesoscale modeling.359 The self-assembly of lipoprotein
nanodisks and their disassembly caused by cholate addition
were studied by mesoscale modeling and small-angle X-ray
scattering.360,361
To improve stability and separation properties of lipo-
somes, microspherical supported phospholipid bilayer sys-
tems (Figure 4B) have been developed. The most commonly
used solid supports are silica362,363 (Transil beads364), mica,365
glass366,367 (supported spherical vesicles368), and polydim-
ethylacrylamide hydrogel (Lipobeads).369 The attachment of
phospholipids is generally based on either chemisorption on
the contact monolayer366,370,371 or adhesion of the bilayer due
to preferred planar shape of the bilayer formed by certain
type of phospholipids.365
Polymerized liposomes containing rafts of nonpolymerized
phospholipids exhibit concentration-dependent blue-red
color shift upon interaction with chemicals.372 The effective
concentration ranges seem to be speciﬁc for three elementary
mechanisms: interaction with the surface, bilayer penetration,
and no interaction. Polymerized liposomes undergo color
transitions in response to external stimuli such as changes
of pH or temperature, or binding of chemicals even if no
Figure 4. Cross sections of spherical or discoid phospholipid
aggregates: (A) liposomes, (B) supported bilayers on microspheres,
(C) monolayers on alkylated microspheres, (D) nanodisks, (E)
immobilized artiﬁcial membranes, and (F) bicelles. The schematic
structures are not drawn to proportion. More details are given in
the text.
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phospholipids in the response to binding is conﬁrmed, the
system could be used for a fast screening of chemicals for
interactions with phospholipids.
2.1.2.2. Planar Bilayer Systems. The use of planar
membranes for elucidation of some aspects of membrane
transport dates back to the 1920s. The ﬁrst membranes’ only
attribute shared with the biological membrane was the
presence of pores. The gelatine membranes that had been
hardened in formaldehyde374 and contained copper ferrocya-
nide,375,376 as well as collodion membranes377 exhibited
selective permeability, based on the size of the permeants.
The membranes with the structure of phospholipid bilayers
were produced four decades later. A macroscopic planar
bilayer can be generated at an aperture in a thin Teﬂon barrier
separating the donor and acceptor aqueous compartments.378-380
A drop of the solution of phospholipids in an organic solvent
is transferred on the aperture that is ∼1 mm in diameter and
is immersed in an aqueous phase. The bilayer forms
spontaneously, creating a black spot in the microscope view
of the rainbow-colored droplet. Based on this phenomenon,
the system is called the black lipid membrane (BLM).
Asymmetrical bilayers were created using two different air/
water monolayers separated by a barrier with an aperture,
upon lowering the barrier across the interface.381 A similar
principle was used for the formation of the bilayer in a
microﬂuidic chip.382 Polycarbonate ﬁlters with the apertures
in the micrometer range were used as a support for the
formation of the PC/cholesterol bilayers and provided
enhanced mechanical stability.383–385 Accessibility of the
apparatus to analytical, electrical,386 optical, and mechanical
measurements makes BLM an excellent tool for detailed
studies of transport,387–390 bilayer electroporation,391 recon-
stitution of membrane proteins392 or channels,393–395 and other
bilayer-related phenomena.
The bilayer stacks of skin lipidsscholesterol, ceramides,
and free fatty acidsscan be reconstituted in vitro.396 The
multilamellar sheets mimic the real situation better than
liposomes397,398 and can be used for permeability measure-
ments.399
Macroscopic solvent-free planar bilayers were formed from
the corresponding monolayers or by bilayer adsorption
between two porous cellulose sheets,400 on patch-clamp
pipette opening,401 quartz,402 glass, mica,362 silicon,403 agar
gel,404 organosulfate- and organophosphate-modiﬁed gold
surfaces,405 metal (stainless steel,406 silver,407 platinum408) and
metal-coated (gold,370 platinum408) or polymer-coated409 glass
plates, and porous supports.410–412
The throughput of the experiments with planar bilayers
was signiﬁcantly increased by the introduction of the Parallel
Artiﬁcial Membrane Permeation Assay (PAMPA).413–415 A
multiwell microtiter plate is sandwiched with the multiwell
ﬁlter plate of the same format. The porous hydrophobic ﬁlter
is impregnated with a mixture of PC (2%-10%) in alkane
solvents. The opposite well pairs, separated by the ﬁlter,
represent the aqueous donor and acceptor compartments.
Individual wells can be stirred to regulate the thickness of
the stagnant water layer so that it imitates that in the intestine,
and to accelerate the procedure for lipophilic compounds.416
Other support materials were examined,417,418 and the com-
position of the impregnating mixture was optimized to
reproduce permeation through the Caco-2 cell monolayer,419
intestine,420,421 blood-brain barrier,422 and skin.423 The cor-
rections for the effects of the ﬁlter porosity424 and the
unstirred water layers were introduced to provide more-
realistic permeabilities.425 Later, the PAMPA approach was
modiﬁed to measure the permeabilities and the partition
coefﬁcients of chemicals in hexadecane424 and 1-octanol.426
The PAMPA permeabilities of a limited set of compounds
depend in a bilinear way on the reference partition coef-
ﬁcients, and linearly on the indicator variables for some
ionizable groups.427 The permeability parameters were mod-
eled in terms of hydrogen-bond donor and acceptor abilities,
refraction, and polarizability using the solvatochromic LFER
approach.428
In view of the extensive industrial use, it is interesting
that the structure of the impregnated PAMPA ﬁlters has not
been investigated in detail, although the formation of multiple
bilayers in the ﬁlter pores was anticipated.429,430 Some
assurance about the bilayer formation comes from the
following facts. The phospholipid-alkane mixtures used for
the impregnation of the ﬁlters have similar composition as
those used to prepare BLM.378-380 The phospholipids in the
ﬁlters are capable of fusion with phospholipid vesicles.431–433
A multiple-bilayer structure was inferred from electrical
resistance measurements on a hydrophobic ﬁlter impregnated
with a synthetic lipid analog.434–436 The formation of a single
PC/cholesterol bilayer in the pores of a polycarbonate ﬁlter
was inferred from the current-voltage relationships and the
response to the polyene antibiotics amphotericin-B383 that
forms a trans-bilayer channel in association with sterols. A
better deﬁned bilayer structure in the ﬁlter pores could
deﬁnitely improve the reproducibility and interlaboratory
variation of the PAMPA measurements, as well as interpre-
tation of the results. A nonsolvent version of the impregna-
tion, with liposomes ﬁlling the pores and forming a layer
on the ﬁlter, was recently reported.437–439
2.1.2.3. Monolayers at the Air/Water Interface. Lipid
monolayers have been widely used to study the behavior of
lipid bilayers, with the underlying assumption that two
weakly coupled monolayers, having appropriate surface
pressure,440,441 imitate the bilayer’s adsorption and partition-
ing behavior. From the viewpoint of the interactions with
chemicals, monolayer systems differ from the bilayer, inter
alia, by the absence of the opposite headgroup region that
leads to a faster achievement of the equilibrium due to the
removal of the potentially slowest step, the ﬂip-ﬂop of
amphiphilic molecules between individual bilayer leaﬂets
(section 2.1.4.6). Phospholipid monolayers have been de-
posited on the interfaces between water and other phases,
which can exist in the gas, liquid, or solid state. Each system
has unique advantages and disadvantages. However, the
monolayers with liquid support or solid support formed by
hydrocarbon chains have the cores, which have the appropri-
ate structure and sufﬁcient size to solvate the permeants in
a similar way as the bilayer core.
The Langmuir trough with a movable barrier that can
regulate the surface pressure in the monolayers191,193,442 at
the air/water or argon/water441 interfaces is a classical tool
of surface chemistry. Its invention191 and use greatly
contributed to the elucidation of monolayer and bilayer
structures. Adsorbed phospholipids have the headgroups
solvated in the aqueous phase. Their fatty acid chains are
facing the air,193 where they may exhibit a higher ordering
of the end methylenes than that in bilayers.443 The typical
trough experiments monitor surface pressure, i.e., the ten-
desurface pressurency to keep the current volume, surface
area, and shape, in the relation to the overall surface area.
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area leads to a straightforward determination of the phos-
pholipid surface area and its change upon binding of the
chemicals.444 The entire dose-response curve can be measured
for one monolayer using the continuous exchange of the
chemical solution in the subphase for the stock chemical
solution under the conditions of rapid mixing.441 The surface
pressure versus area measurement, combined with other
techniques, provides a basis for the inference about the
approximate positions of interacting chemicals in the
monolayer.445,446 Surfactants, amphiphilic compounds with
clearly separated polar and nonpolar parts, reduce the surface
pressure at the air/water and lipid/water interfaces.
The lateral dimensions of the monolayer allow the use of
a broad palette of techniques, ranging from electrochemical
methods such as the surface potential measurements,445 to
analytical methods that examine the composition of the
aqueous phase, and surface imaging. The last category
includes ﬂuorescence microscopy examining surface domains
in phospholipid monolayers doped with ﬂuorescent phos-
pholipid analogs447–449 or lateral diffusion of phospholipids
after photobleaching,450 as well as specular neutron reﬂec-
tion,451 ellipsometry, FT-IR reﬂectance,452 X-ray reﬂec-
tance,453 and grazing incidence XRD454 determining some
geometry aspects of the molecules of phospholipids or
interacting chemicals.455 Binding of radioactive compounds
to phospholipid monolayers can be easily tracked using a
detector positioned closely above the interface. The method
was widely applied to monitoring the adsorption of Ca2+
ions456 and proteins.457,458
There are two concerns with the phospholipid monolayer
at the air/water interface as a mimic for phospholipid bilayers
and membranes. First, only the aqueous subphase can be
sampled for the change in the concentrations of the studied
chemical so the experiments do not clearly locate the
chemical in the headgroup or core regions of the monolayer.
Second, the hydrocarbon core is too thin to effectively solvate
larger hydrophobic molecules. The hydrocarbon layer can
be made thicker by adding hydrocarbons that ﬂoat on top of
the fatty acid chains. This phenomenon, however, was only
observed for hexane. Longer hydrocarbons (12-16 carbons),
which would be preferred because of lower volatility,
intercalate between the fatty acid chains and reduce their
tilt angle so that the chains become practically perpendicular
to the interface.453,454
2.1.2.4. Monolayers at the Solvent/Water Interface. The
hydrocarbon-doped monolayers described in the previous
paragraph represent a transition between air/water and alkane/
water interfaces. While a microscopic alkane layer at the
air/water interface in the former setup is a prerequisite for
surface imaging, thicker layers in the latter arrangement
enable one to use conventional analytical and electrochemical
techniques to monitor concentration changes in the nonpolar
phase.459 The performed experiments focused on the behavior
of phospholipids at the interfaces between water solutions
and 2,2,4-trimethylpentane,460 heptane,461 and other al-
kanes.462 If the alkanes are of comparable lengths with the
fatty acyl chains, they intercalate into the monolayer, which
then assumes a different state than that of the bilayer.462
The ﬁrst systems of this nature were created at the
beginning of the last century. The globules, formed by mixing
the solutions of PC in various water-immiscible solvents with
water,192,463 were ∼0.1 mm in diameter and could be
observed microscopically, after staining with histological
dyes. The structure of the monolayer was not known at that
time. If sufﬁciently stable and uniform, the globules could
become a valuable tool for studying the interactions of
chemicals with the phospholipids, thanks to the absence of
the second interface, which eliminates the potentially slow
ﬂip-ﬂop step (section 2.1.4.6).
2.1.2.5. Monolayers on Solid Supports. The phospholipid
monolayers on solid supports, which can be easily adapted
for routine experiments with an increased throughput, are
more relevant to pre-clinical drug candidate screening and
other high-throughput applications than other monolayer
setups. The monolayers can be bound to the support by
covalent or noncovalent forces.
Phospholipids or their derivatives, which are covalently
immobilized to the surfaces of porous silica microspheres,
served as a column material in high-pressure liquid chro-
matography. They are called immobilized artiﬁcial mem-
branes (IAMs) and the structure is sketched in Figure 4E
(the monolayer can also form inside the pores).464 The
retention factors were used as descriptors for the prediction
of trans-bilayer transport of chemicals.465–469 The liposome
and IAM binding were correlated for some compounds470
and not correlated for other compounds.471,472 A systemati-
cally higher partitioning to IAMs than to liposomes was
measured for several other series of compounds.343,473 The
IAMs were not recommended for the characterization of
ionized chemicals, because the matrix charges seemed to be
insufﬁciently shielded.474 In the molecular dynamics simula-
tions,475 no structural differences were observed between the
PC headgroup in IAMs and the liquid-ordered bilayer.
However, the 31P-NMR studies476 indicated that the surface
density of IAM headgroups is signiﬁcantly lower than that
in liquid-ordered membranes. The decrease is ∼30% for
ether-linked PC and ∼40% for ester-linked PC.477 The
hydrocarbon core of IAMs is characterized, in comparison
with the bilayer core, by smaller thickness,470 higher packing
density,475 and, consequently, lower rotational freedom of
the fatty acid chains. Moreover, the ends of the phospholipid
fatty acid chains in IAMs are covalently bound to porous
silica beads, which may exhibit extreme surface curvatures,
especially in the pores.478 At these spots, disturbances in the
continuous bilayer may exist, which are not seen in the
averaging NMR experiments. Diffusion of chemicals in the
pores may complicate the measurement of the transport rates,
if attempted.
Monolayers adsorbed on alkylated surfaces are expected
to resemble the bilayer more closely than IAMs. Adsorbed
monolayers can be prepared by several techniques. A
multistep immersion process has been used to create layers
of dimyristoylphosphatidylcholine (DMPC) on the surface
of silica plates with covalently attached octadecyl chains.479
The uneven coverage of the hydrophobic surface and the
formation of multilamellar islands make this technique
unsuitable for the exact bilayer partitioning studies where a
well-deﬁned system is needed. The Langmuir-Blodgett
technique480 produced a phospholipid monolayer on the
surface of gold-coated plates with covalently attached
octadecyl chains.481 The obtained monolayer was uniform
and stable in both dry and rehydrated forms. Alkylated glass
plates were used to obtain a phospholipid monolayer by
vesicle fusion.482 The solid lipid nanoparticles with the
triglyceride core covered with adsorbed phospholipids and
other surfactants have been obtained by industry-scale
processes, such as emulsiﬁcation of melted triglycerides and
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the solid core that makes the suspension a useful drug
delivery vehicle, is a drawback for mechanistic studies of
interactions of chemicals with phospholipids, along with the
presence of surfactants, irregular coating, and nonspherical
shapes.488
We have developed a monolayer system that overcomes
most of the aforementioned problems. The system consists
of uniform nonporous octadecylated silica (ODS) particles
(1.5 µm in diameter) that are coated with phospholipids
(Figure 4C).492 The coating is based on a spontaneous self-
assembly of phospholipid molecules that is expected to lead
to formation of a monolayer with the packing density
comparable to that in liposomes. Formation of a continuous
monolayer in a similar setting has also been demonstrated
for planar surfaces.481
The presence of a single interface eliminates the possibility
of the time-consuming ﬂip-ﬂop process and leads to a
signiﬁcantly faster binding and simpler kinetics, compared
to that observed in free or immobilized liposomes. The
smooth surface of the nonporous particles is a prerequisite
for formation of a defect-free monolayer. The hydrocarbon
core, formed by phospholipid acyls and the octadecyl chains
attached to the microspheres, is expected to be more similar
to the bilayer core in thickness and solvation properties than
the core in IAMs. The used ODS particles provide a
signiﬁcantly larger speciﬁc surface area than that of planar
systems. Easy separation of the DMPC-coated ODS-particles
from the medium is a prerequisite for a plate-friendly assay
that is suitable for routine testing with higher throughput than
using liposomes or IAMs. If an estimate of the overall bilayer
partitioning is of interest, the monolayer partition coefﬁcients
are ﬁrst deconvoluted into the core and headgroup contribu-
tions, and the headgroup contribution is counted twice.492
2.1.3. Surrogate Solvent Systems
Individual regions of phospholipid bilayers are difﬁcult
to access experimentally, especially in biological membranes.
Various organic solvents, imitating the bilayers differing in
lipid composition, packing, and hydration levels, have been
examined as membrane or bilayer surrogates, with the
objective of obtaining thermodynamic or kinetic information
on the partitioning process.52,56,73,272,389,493–508 Curiously, air
was also used as the surrogate phase imitating the nonpolar
hydrocarbon core of the bilayer. The measurements of the
surface pressure of chemicals at the air/water interface have
been miniaturized and adapted for a high throughput.509 A
parameter approximating the bilayer/water partition coef-
ﬁcient was derived using the experimental data for the air/
water partition coefﬁcient and the surface area.
Partitioning equilibria of solutes in bilayer regions result
from the interplay of several factors, which include the
interactions of solutes with phospholipids and water mol-
ecules, the energy for creation of the cavities for solute
molecules,510–512 electrostatic interactions with the membrane
and dipole potentials,513 and entropic consequences of
partitioning in individual regions.514–516 Estimates for the ﬁrst
factor have traditionally been obtained using organic solvents
as surrogates of the bilayer or one of its regions.
2.1.3.1. Collander Equation. The partition coefﬁcients
(Px) of a set of compounds in a solvent system that is capable
of similar interactions with the studied compounds as the
reference system, are related to the reference partition
coefﬁcient P via the Collander equation52,517 as
Px)AxP
 x (1)
where Ax (A represents accumulation) and  x are empirical
adjustable coefﬁcients, which are speciﬁc for system x. The
coefﬁcients Ax and  x are obtained by the ﬁt to experimental
data. The approach has been widely used in the design of
bioactive compounds,518 computational chemistry,519 protein
folding,520 and other areas.31 At the biological levels, from
cells to organisms, the empirical coefﬁcients also account
for the variability in the composition of bilayers.
2.1.3.2. 1-Octanol as the Reference Solvent. After early
experiments with loosely deﬁned oils192,493–497,521 and other
solvents,52,498,517,522,523 the studies of Hansch and Fujita,56 as
well as those of Leo et al.,524 have established 1-octanol as
a widely used bilayer-mimicking solvent. The authors, and
many followers in the areas of QSAR and the design of
bioactive compounds, intuitively considered hydrated 1-oc-
tanol to be a hydrocarbon core surrogate, despite its
comparatively high equilibrium water content at room
temperature (2.18 mol/L).525 There is some water in the
bilayer core, because of trans-bilayer water transport.292,297,298
The equilibrium water concentrations in the core increase
as the fatty acyl chains become more disordered,274 but they
are generally low218,301 (section 2.1.1.4).
Contrary to the core-surrogate hypothesis, studies in
peptide binding to liposomes526 (section 2.1.2.1) and in
transport through BLM507 (section 2.1.2.2) assumed that
1-octanol mimics the interfacial region of the bilayer.
Interestingly, both views can be correct for different com-
pound sets: XRD analyses,527 spectroscopic experiments,528
and MD simulations529,530 of the structure of liquid, water-
saturated 1-octanol revealed ﬂuctuating inverted micellar
aggregates encompassing polar and nonpolar regions, which
could imitate hydrated headgroup regions and cores, respec-
tively. Inverted micelles consist of the centers comprising
hydrated hydroxyl groups,531 which are surrounded by
outward-extending alkyl chains.527,529 The centers are thin
and prolonged in neat 1-octanol and become longer and more
spherical in hydrated 1-octanol.530
As the criteria for selection of a proper bilayer surrogate,
early studies used the uptake of chemicals into cells and
transport through biological sheets, which were affected by
protein binding and other factors. These problems are avoided
when using phospholipid liposomes, which are more suitable
for evaluation of the surrogate phases.
Liposome partitioning is affected by several factors,185
including surface charge density, especially for ionized
solutes,304–306 and phospholipid surface density, which, in
turn, is dependent on temperature,272,504 fatty acid composi-
tion,532 and cholesterol content272,504 (section 2.1.1). Ideally,
all data used for comparisons should be measured under
identical conditions that imitate the studied biosystem, so
that the variation can be taken into account by the empirical
regression coefﬁcients in eq 1. Simple chemicals affect
various bilayer properties at higher concentrations: surface
charge,304,533 thickness,534 ﬂuidity in individual regions,397,398
and transition temperatures, to name just a few. Chemicals
in biosystems act at low concentrations, except for the ﬁrst
bilayers coming into contact with the dose (section 2.1.4).
Tomimictherealityforthemajorityofchemical-phospholipid
interactions, the liposome partitioning data should be mea-
sured at low concentrations of chemicals or, if feasible,
extrapolated to zero concentrations.
The correlations of the partition coefﬁcients of chemicals
in liposomes and in the 1-octanol/water system become
Modeling of Subcellular Disposition of Chemicals Chemical Reviews, 2009, Vol. 109, No. 5 1805nonlinear for large molecules, presumably because of the
energy needed to create a cavity535 in the structured bilayer
subregions 2 and 3 (section 2.1.1.5). The correlations
displayed separate trends for neutral, negatively charged, and
positively charged molecules, with the last category exhibit-
ing the largest scatter.536 The relationships broke down even
for a homologous series exhibiting different preferred bilayer
locales for individual members.537 If more-diverse chemicals
were considered, the relationship seemed to hold, with a
broader scatter and within certain size and lipophilicity
limits,535,538 for neutral molecules539 but not for charged
molecules.342,540 The differences are more signiﬁcant for
acids, as opposed to bases, because the former show more-
pronounced pH dependences of the bilayer/water partition
coefﬁcients (PB/W) than the latter. This phenomenon is caused
by the interactions with the headgroups of neutral and acidic
phospholipids, which lead to a rearrangement in the
headgroups.541,542 The former proﬁles are still rather shallow
in comparison with those for the 1-octanol/water partition
coefﬁcients (PO/W). The differences of the PB/W values for
different pH of the aqueous phases are dependent on the
ionization character of the chemical: they are comparatively
small for bases and can reach a magnitude100-fold larger
for acids.543 The PO/W values of both acids and bases can
differ by 3-4 orders of magnitudes in the systems with
differing pH values of the aqueous phase. A careful
comparison of the data measured above the gel-to-liquid
transition temperature with the experimental or calculated
PO/W values544 showed that, even for neutral chemicals,
different lines can be discerned for polar compounds with
or without hydrogen-bond donor ability538 and nonpolar
compounds,532 as shown in Figure 5. On the bilogarithmic
scale, the lines have the slopes of 0.63 for nonpolar
compounds, 0.82 for polar compounds without hydrogen-
bond donor groups, and 1.27 for the group consisting of
hydrogen-bond donors and acceptors (phenols and alcohols).
However, the entire dataset exhibits a reasonable linear
relationship with the squared correlation coefﬁcient r2 )
0.950, as noticed previously.539
In summary, the PO/W describes partitioning in the phos-
pholipid bilayer very well for a homologous set of com-
pounds,537 and acceptably for diverse neutral molecules
(Figure 5), within certain size limits. In both cases, the
relative afﬁnities of the chemicals for the headgroups and
core must not signiﬁcantly vary among the studied chemicals.
PO/W is a perfect reference coefﬁcient in the cases when
overall partitioning is targeted, e.g., for the description of
pseudo-equilibrium disposition (section 7). Other surrogate
solvent systems are needed if the distribution between bilayer
regions is of interest: the hydroxyl group of 1-octanol can
hardly emulate the interaction capabilities of phosphate,
ammonium, and carbonyl functionalities of the phospholipid
headgroups. In addition to the main advantage that 1-octanol
resembles some membranes as assessed through the applica-
tion of eq 1, other desirable properties of this solvent include
chemical stability, easy availability and puriﬁcation, UV-
Vis transparency (which is important for the spectrophoto-
metric determination of many chemicals), and a low vola-
tility.518
2.1.3.3. Other Solvent Systems. The studies with BLM
(section 2.1.2.2) showed that the selectivity of the bilayer to
the partitioning of the hydrogen-bonding groups lies some-
where between those of 1-octanol and pure hydrocarbons,389
but it is signiﬁcantly closer to the latter.545,546 Additional
support for the use of hydrocarbons as core surrogates500,501
comes from the experimental observation of similar molec-
ular packing of the fatty acid methylene and methyl groups
in subregion 4 of the bilayer and in bulk liquid alkanes219
(section 2.1.1.5). The hydrocarbon cores seem to have similar
solvation properties in all bilayers, although ﬁne differences
were noted.507,508 Most likely, a single reference phase, e.g.
n-hexadecane, can be used, with the differences being taken
into account by applying the Collander equation (eq 1).
Whereas alkanes approximate solvation properties of the
hydrocarbon core, is there a phase that emulates most
interaction capabilities of the headgroups? Four solvents were
used to model the amphiprotic, hydrogen-bond acceptor and
donor, and hydrophobic properties of membranes: 1-octanol,
propylene glycol dipelargonate (PGDP), chloroform, and
alkanes, respectively.503 The structure of PGDP contains
some fragments found in phospholipids; however, no sub-
structure imitates the charged functional groups, and an
equivalent of the hydroxy group of PGDP is not found in
PC. Other tested solvents include isopropylmyristate547 and
N-butyl-acetate.548 The ethylene glycol-heptane system549–551
represents a rare attempt to imitate separately the headgroup
and core regions of the bilayer. None of the solvents used
so far emulates the charged functional groups of phospholipids.
A straightforward approach to inclusion of all functional
groups of a phospholipid into the surrogate system is
represented by the direct use of acylated headgroups. We
have found552 that the PC headgroup with truncated fatty
acid chains, diacetylphosphatidylcholine (DAcPC), when
dissolved in water in a molar ratio of 1:14, resembling the
conditions in the hydration shell of the PC headgroups in
the bilayer slightly above the transition temperature,265,553
forms a homogeneous and only slightly viscous solution.
Albeit isotropic, the hydrated DAcPC imitates the type of
solvation that solutes experience in the PC headgroup region,
including the lack of free water molecules. The methyl
groups in acetyls mimic the ﬁrst two or three methylenes of
the sn-2 fatty acid chain, which thermally ﬂuctuate at the
level of sn-1 carbonyls in a PC bilayer and can be considered
a part of the headgroup region.
The DAcPC molecules do not measurably partition from
the concentrated aqueous solution (1.96 mol/L) into n-
hexadecane (C16) in the two-phase system. For a set of 16
Figure 5. Dimyristoylphosphatidylcholine bilayer/water532,538 ver-
sus 1-octanol/water partition coefﬁcients544 P for (b) nonpolar
compounds, (2) phenols, (4) alcohols, (1) anilines, and (f) polar
compounds with no hydrogen-bond donor group. Lines represent
linear ﬁts to the data for (s) nonpolar compounds, (- - -) phenols
and alcohols, and (··· ) polar compounds without hydrogen-bond
donor ability. More details are given in the text.
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measured and used to estimate the prevalent location of the
compounds in the bilayer. The difference logPC16/W - logPO/W
(formally equal to logPC16/O) is frequently considered to be
an indicator of the hydrogen-bonding ability,549,550,554,555 a
correlate for permeability,556 and a parameter characterizing
the preferential location of solutes in the bilayer. The fraction
of compounds present in the core, as estimated from the C16/
DAcPC partition coefﬁcients, is plotted against log PC16/O in
Figure 6. To connect the compounds with known locale in
the headgroups or in the core, the data were ﬁtted557 with
the Boltzmann sigmoidal function:552
Fcore)100-
100
1+exp[(log PC16⁄W-log PO⁄W+0.776)⁄0.215]
(2)
Standard deviations of the two optimized coefﬁcients are
<20% of the coefﬁcient values, and the squared correlation
coefﬁcient is r2 ) 0.992. The locales estimated using the
C16/DAcPC partitioning (Figure 6) are in perfect agreement
with the known locales for all compounds where this
information is available. However, eq 2 can be used to obtain
approximate estimates in the absence of C16/DAcPC data.
The solvation energies of a solute in C16 and in hydrated
DAcPC phase can be rationalized in terms of two contribu-
tions: the energies needed to form cavities in both phases,
and the interactions of the solute molecules with the solvent
molecules lining the cavities.548 The cavity formation energy
is maximal in bulk water and decreases in the headgroup
region, to a minimum in the core.513,558 The cavities in the
isotropic DAcPC solution can probably be formed easier than
those in the headgroups, because the headgroup anchoring
effect of the high-density tail subregion 3 (section 2.1.1.5)
is missing in DAcPC. Based on these facts, we expect that
the main contributions to the solvation energies in DAcPC
and C16 will come from the solute-solvent interactions. Thus
partitioning in the C16/DAcPC system is expected to provide
only information about one of the factors contributing to the
location in the bilayer, namely, the energy of interactions
with the phospholipids. The cavity formation energy, the
energy of electrostatic interactions of the permeants with the
membrane and dipole potentials, and entropic factors are not
included. The C16/DAcPC data can help factorize the
contributions to solvation energies in individual bilayer
regions.
Lipophilic chemicals also partition into plasma lipoproteins
and the adipose tissue (section 2.1.4.2). Triacylglycerols
(TAGs), representing ∼90% of the adipocyte’s mass176 and
forming the lipoprotein cores, lack structural similarity to
common surrogate molecules: alkanes miss the hydrogen-
bond acceptor abilities of the TAG ester carbonyls, 1-octanol
has a surplus hydrogen-bond donor function, and DAcPC
features additional charged groups. Olive oil has been
advocated as the best surrogate;559 however, a chemically
deﬁned phase would provide more-reproducible results.
Long-chain TAGs with saturated chains are solid at room
temperature. The melting temperatures decrease with short-
ening the chains, e.g., trioctanoylglycerol melts at 6 °C. This
clear liquid boils at 233 °C and can be distilled easily.
Trioctanoylglycerol seems to be suitable for partitioning
studies at room temperature, although no experiments have
been performed yet. Triolein (trioleoylglycerol)192,560–563
represents another option.
Surrogate phases were also used to mimic the binding sites
of proteins, using solvents that represent the fragments of
amino acid side chains: benzene, toluene, pyrrole, 1-propane-
thiol, and methyl ethyl sulﬁde.564 The applicability of the
approach to protein interactions is limited, because the protein
binding sites are much more heterogeneous than the bilayer
regions. The protein phases, which could represent homo-
geneous environments, are not large enough to completely
solvate the interacting drug molecules, as observed in the
macroscopic surrogate phases.
2.1.3.4. Partitioning and Interfacial Transfer. Experi-
mental techniques for monitoring transport of chemicals
through the planar387,389,390,506,565–567 or spherical bi-
layers73,397,507,546,568–585 focus on overall permeability. The
elementary steps have not been studied, with the sole
exceptionoftheﬂip-ﬂopratesforamphiphiliccompounds.586,587
Computational simulations of chemical distribution in hy-
drated bilayer patches588 (section 2.1.5.3) do not analyze this
phenomenon either, because no experimental data are avail-
able for comparison. Despite this lack of interest, the rate of
interfacial transfer is an important characteristic for all
chemicals, which accumulate in the bilayer regions. Some
information about the process can be obtained from the data
on interfacial transfer between water-immiscible organic
solvents and water (see below).
Structure and dynamics of liquid-liquid interfaces is a
matter of intense experimental research relying mainly on
voltammetry,589 vibrational sum frequency spectroscopy,590–596
and X-ray reﬂectance,597–603 as well as on computational
simulations.558,604–607 The interface structures are rather
different, even for similar organic solvents. For lower
alkanes597 and carbon tetrachloride systems, where the
nonpolar phase has no hydrated groups interacting with
water, the interface is only a few angstroms wide and exhibits
molecular sharpness, with a slight mutual permeation of both
solvents due to thermally excited capillary waves. Interfaces
of higher alkane systems are wider than predicted from the
capillary-wave theory, and the deviations increase with the
chain length.608,609 Dichloromethane also exhibits a wide,
more diffuse interface in contact with water.610 The interface
is broader for the solvents with well-hydrated functional
groups, including alcohols602,611,612 and ketones,600 as well
as for other solvents containing amphiphilic compounds, such
Figure 6. Fractions of the chemicals in the core region, as predicted
from the C16/DAcPC partitioning, versus the difference between
C16/W and C16/O partition coefﬁcients. The compounds with
experimentally determined locale are shown as full points. The
sigmoidal curve connects the compounds with known locales in
the headgroups or the core and corresponds to eq 2.552
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interface. Physical resemblance of the interfaces between
bilayer/water and organic solvent/water systems is closer for
the solvents with functionalized molecules than for alkanes.558
Computational simulation of partitioning at the interfaces
suggested interesting behavior of several polar solutes, such
as alcohols, anesthetics,615 monoﬂuoromethane, diﬂuo-
romethane, and triﬂuoromethane (but not methane and
tetraﬂuoromethane),513 as well as triﬂuoroethane (but not
hexaﬂuoroethane)616 at the hexane/water and glycerol-1-
monooleate/water interfaces. The solutes exhibited ac-
cumulation at the interface, although molecular structures
of at least some of them did not show a clear separation of
polar and nonpolar fragments as known for surfactants. This
fact indicates that interactions of functional groups and
substructures with interfaces may be difﬁcult to extrapolate
from hydration energies.
Despite the dissimilarities of interfaces, solvent/water
systems have been used to monitor the solute transfer, in
the hope that relative trends can be discerned, which would
also hold for the bilayer/water interface. The experimental
arrangement for the measurement of the transfer rate
parameters from an organic phase to water and backwards
is simple.498 Both immiscible phases sit one above the other
in a temperature-controlled jar and are stirred at an optimal
rate that secures sufﬁciently rapid equilibration in the bulks.
Under the stirring conditions, the interface is usually not
planar and adopts a slightly conical shape, but the interfacial
area can be approximately calculated. The studied chemical
is added to the phase in which it has a higher solubility, and
the kinetics of its partitioning is monitored, preferably in
both phases. From the time courses of the concentrations,
the rate parameters of transfer, li and lo (for the direction
from water to the organic phase and backwards, respectively),
are determined. This so called slow-stirring method precisely
determines the partition coefﬁcient P ) li/lo, because the
achievement of the equilibrium is veriﬁed in the course of
the experiment, and the risk of the mutual droplet cross-
contamination of the phases is completely eliminated,617 as
opposed to the more frequently used shake-ﬂask approach.
The slow-stirring method was also used to measure the P
values of unstable compounds with the rate of decomposition
comparable to the rate of transfer.618 Arrangements of
multiple phases have been used in the water-1-octanol-water
system619,620 and in the system consisting of a series of 11
alternating aqueous and 1-octanol phases.621 A moving-drop
technique was developed and used to measure the transfer
rates of short-chain alcohols and tritiated water across the
1-octanol/water interface.622 Electrochemical techniques are
useful for the monitoring of the interfacial transfer in solvent/
water systems.589,623–630
For the QSARs of the compounds, which do not interact
with the headgroups, the relationships between P and the
rate parameters li and lo are of special interest. Experimental
observations620 were quantiﬁed as631
li)
AtP
BtP+1
and lo)
At
BtP+1
(3)
where At and Bt (the subscript “t” denotes the transfer) are
empirical coefﬁcients, which are dependent on the organic
phase, the geometry of the apparatus, and the stirring rate,
but are independent of the molecular structure of the tested
chemicals. The rate parameter li for the transfer from water
to the organic phase initially increases with the partition
coefﬁcient (P ) li/lo) and levels off for high P values. The
rate parameter for the reverse direction (lo) is constant for
lower P values and drops for high P values. The observation,
summarized in eqs 3, was later extended to chemicals that
do not belong to a homologous series, may ionize or form
ion pairs.66 The plateaus in the dependencies were assumed
to originate as a consequence of the diffusional control of
partitioning in the diffusion layers.
In a steady-state treatment of the interfacial transport
process,66 the empirical coefﬁcients in eqs 3 were expressed
using the diffusion coefﬁcient D and the effective thickness
h of the corresponding diffusion layer as At ) Dorg/horg and
Bt ) Dorghaq/(Daqhorg). The apparent independence on the
molecular structure of the coefﬁcient At is rather puzzling
as the diffusion coefﬁcients in the apolar solvents are known
to vary with the molar volume.632 A small dependence of
the permeability coefﬁcient on the molar volume was
observed633 in experiments with rotating diffusion chamber,634
which, however, monitor transport through planar systems
(section 2.1.2.2) that is more complex than the simple
interfacial transfer. Another view of the empirical coefﬁcients
At and Bt was provided by considering convective diffusion
caused by the laminar ﬂow in the vicinity of the interface.635
Practical impact of these observations on the distribution of
chemicals in biosystems remains to be assessed.
A further matter of dispute is the interfacial resistance to
transfer of chemicals through the phase interface, which is
sometimes found to be an effective barrier to the chemical
transfer634,636 and, in other cases, turns out to be negligible.637,638
This phenomenon probably is dependent on the ability of
transported chemicals to bind to individual bilayer regions
(see sections 2.1.4.1 and 10.1.2), as shown in MD simulations
of trans-bilayer transport.588
2.1.4. Accumulation and Transport
Historically, transport and accumulation were ﬁrst mea-
sured using cells (section 3.3) and biological sheets (section
3.5). Most organic molecules with molecular weights up to
1000 g/mol are expected to pass the bilayer through the
bilayers. The measurements on spontaneously aggregating
phospholipid systems, void of the effects of other membrane
components, started after liposomes (section 2.1.2.1) and
BLM (section 2.1.2.2) were discovered.
Typically, the measurements in phospholipid systems use
high chemical-to-lipid ratios, corresponding to molar frac-
tions of 0.1 and more. Such high concentrations of chemicals
are relevant only for the bilayers, which come into a direct
contact with certain types of local doses of chemicals. Upon
absorption from the gastrointestinal and pulmonary tracts or
through the skin, and subsequent distribution, however, the
chemicals become signiﬁcantly diluted. A typical ballpark
value for the drug dosing is 1 mg/kg, because only ∼10%
of the drug candidates show some potency in the 0.1 mg/kg
range.639 For the lipid weight fractions in lean human
tissues,176 ranging from 0.01 to 0.1, there are 104-105 times
more lipids than drug molecules under pseudo-equilibrium
conditions (section 7). Even if all molecules would ac-
cumulate in the lipid phases, the chemical-to-lipid ratios are
much lower than in the experiments with phospholipid
aggregates. The measured data usually must be extrapolated
to zero concentrations, to become relevant for the majority
of observed chemical-bilayer interactions in human body.
From this viewpoint, the experimental methods that “see”
1808 Chemical Reviews, 2009, Vol. 109, No. 5 Balazthe molecules of chemicals reﬂect the real conditions better
than the methods that examine lipids.
While the used biological systems such as cells and
biological sheets contain several bilayers, the data were
frequently processed by the models consisting of a single
bilayer. In several studies of transport mechanisms, the results
from different test systems were used interchangeably,
although the number of crossed membranes varied signiﬁ-
cantly. The outcomes of these studies will be sorted out and
presented separately for different test systems: bilayers in
sections 2.1.4.4-2.1.4.6, and membrane vesicles, subcellular
organelles, cells, cell monolayers, biological sheets, tissues,
organs, and organisms in sections 3.1-3.8, respectively.
2.1.4.1. Binding in Bilayer Regions. The headgroup and
core regions of the phospholipid bilayer differ in the types
of interactions with the transported molecules of chemicals,
and in the ability to shield electrostatic charges. Both regions
are sufﬁciently voluminous to fully solvate the molecules
of chemicals.220 The headgroup region can be subdivided
into perturbed water and interphase (subregions 1 and 2),
and the core region consists of soft polymer and alkane
(subregions 3 and 4), as described in section 2.1.1.5.
Chemicals can accumulate in the headgroup subregions 1
a n d2( cephalophiles), subregions 2-3( amphiphiles), and
core subregions 3-4( lipophiles). Taking into account that
the solvation properties of the headgroup region differ from
those of bulk water, the existence of the headgroups/water
interface is justiﬁed. Published examples of individual
interaction modes are summarized in Charts 1-3, with
Tables 2-4 providing more details. The headgroup region
is well-hydrated but the water molecules are tightly bound
to the phospholipids headgroups. Consequently, the solvation
properties of the headgroup region differ from those of bulk
water. Therefore, we prefer to use the term “cephalophilicity”
to denote the tendency to accumulate in the headgroup
region, instead of “hydrophilicity”, as occasionally seen.640–643
Structural determinants of binding in individual bilayer
regions are quite subtle, and the overall outcome is dependent
Chart 1. Cephalophiles Accumulating in the Headgroup
Region of the Phosphatidylcholine Bilayera
a The headgroup/core interface is assumed to pass through the deeper
ester group of phosphatidylcholine.
Chart 2. Amphiphiles Accumulating at the Interface
between the Headgroups and Core of the
Phosphatidylcholine Bilayera
a The headgroup/core interface is assumed to pass through the deeper
ester group of phosphatidylcholine. The position of the headgroup/core
interface is shown, where available. For 35, the upper interface is valid for
R1 ) C4H9,R 2 ) CH3, and the lower interface holds for R1 ) C2H5,R 2 )
C8H17 (the molecule is tilted to allow a part of the n-octyl chain to interact
with the core).
Modeling of Subcellular Disposition of Chemicals Chemical Reviews, 2009, Vol. 109, No. 5 1809on a ﬁne balance of individual structural elements of the
molecule, including their spatial arrangement. Benzene
derivatives, for instance, accumulate in the core (42 in Table
4 and Chart 3),644–646 unless a hydrogen-bonding substituent
is available to anchor them in the headgroup region as seen
for benzyl alcohol (2 in Table 2 and Chart 1).647 The
partitioning in the hydrocarbon core prevails, however, if
the hydrogen-bonding ability of the substituent is obstructed
by other groups as in 2,6-di-C(CH3)3-phenols (42 in Table
4 and Chart 3).648
Several experimental techniques, summarized in Tables
2-4, have been used to characterizesoften only qualitatively
or semi-quantitativelyspreferred locations of compounds in
the phospholipid bilayer. This information is important for
quantitative assessment of the transport rates, because
analyses of published trans-bilayer transport data (section
2.1.4.6) indicate that the transport rates are dependent on
the tendencies of chemicals to interact with the hydrocarbon
core and the headgroup region. The two tendencies of
chemicals are lipophilicity and cephalophilicity, respectively.
Amphiphilicity denotes a mixed scenario, when a molecule
interacts with both headgroup and hydrocarbon regions.
Smaller amphiphilic molecules bind in subregions 2 and 3;
larger molecules reach into subregions 1 and 4. Our
preliminary data indicate that some chemicals could also
accumulate at the interface between the bulk water and the
headgroups, pointing to the possibility that there may be two
types of amphiphilicity.
Lipophilicity is usually parametrized by a reference
partition coefﬁcient (section 2.1.3), which is deﬁned as the
Chart 3. Lipophiles Accumulating in the Hydrocarbon
Core of the Phosphatidylcholine Bilayer
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Modeling of Subcellular Disposition of Chemicals Chemical Reviews, 2009, Vol. 109, No. 5 1811ratio of activities (or concentrations, if they are sufﬁciently
low) of the solute in a surrogate phase and the aqueous phase
under equilibrium conditions. Because lipophilicity is given
by the relative levels of accumulation in the hydrocarbon
core of the bilayer and in bulk water, the core/water partition
coefﬁcient is the most suitable parameter for characterization
of lipophilicity in the context of bilayer transport and
accumulation.
Lipophilicity generally is deﬁned vaguely, because there
are different nonpolar phases in the body: bilayer cores, lipid
droplets, and hydrophobic lipoprotein interiors. To avoid
having different lipophilicities reﬂecting composition vari-
ability of biological nonpolar phases, we prefer to deﬁne
lipophilicity as the core/water partition coefﬁcient for a
saturated PC, which should be properly parametrized by the
hexadecane (C16)/water partition coefﬁcient (section 2.1.3),
according to eq 1 in section 2.1.3.1. Fatty acid chains are
hydrocarbons, which only differ in the length, number, and
positions of double bonds, and sometimes in branching. This
variability should not lead to pronounced differences in the
interactions of the chains with chemicals. Therefore, the
Collander equation (eq 1) can be used to correlate the core/
water partition coefﬁcients for the cores of varying composi-
tion with the C16/water partition coefﬁcient. Other reference
partition coefﬁcients may be more suitable for lipid droplets
and lipoprotein cores (section 2.1.3.3). All partition coef-
ﬁcients are additive-constitutive properties, which can be,
in principle, partitioned among individual fragments of the
molecule.501,518,649–652 This procedure allows for a fast
structure-based prediction of all partition coefﬁcients.
Cephalophilicity denotes the tendency of a chemical to
bind in the headgroup region, forming the interactions in
subregion 1 and, predominantly, in subregion 2. Experimen-
tally, cephalophilicity can be quantiﬁed as the headgroups/
core or headgroups/water partition coefﬁcients, which are
quite tedious to measure directly in the bilayers. In the
absence of fast and convenient microtechniques, which would
be capable of a routine monitoring of the concentrations in
the bilayer regions, solvation energies in the systems
imitating the bilayer environments have been used to provide
initial estimates. As mentioned in section 2.1.3.3, we have
found that diacetylphosphatidylcholine (DAcPC) forms a
homogeneous solution with acceptable viscosity, when mixed
with water in a similar ratio as in the fully hydrated bilayer
headgroup region. From this solution, the DAcPC molecules
practically do not partition into nonpolar solvents. The two-
phase system n-hexadecane/DAcPC aqueous solution was
used to precisely determine the differences in solvation
energies of organic chemicals, which can be used to estimate
the preferred bilayer location (section 2.1.3.3)552 and the
transport rates (section 2.1.4.6).
Amphiphilicity corresponds to the ability of a molecule
to have, in at least one conformation, lipophilic and ceph-
alophilic parts placed in two subspaces separated by a plane,
so that they are able to interact with the headgroup region
and the hydrocarbon core across the headgroups/core inter-
face. Amphiphilicity has been roughly expressed as asym-
metry of the spatial distribution of lipophilicity in the
molecule. For a given conformation, amphiphilicity was
characterized by the lipophilic moment653 and similar
parameters,316,654–656 or by an empirical function describing
position-dependent solvation energies.640 All these ap-
proaches utilize the hydration characteristics of chemicals
in bulk water instead of true cephalophilic characteristics.
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1812 Chemical Reviews, 2009, Vol. 109, No. 5 BalazThese characteristics may not be adequate because the water
molecules, although abundant in the headgroup region, are
mostly conﬁned forming strong hydrogen bonds in the
hydration shells and behave differently than those in bulk
water. Cephalophilic fragment contributions must be devel-
oped, in a similar way as known for lipophilic contribu-
tions.518
2.1.4.2. Interactions with Plasma Lipoproteins and
Lipid Droplets. A common feature of plasma lipoproteins
and intracellular lipid droplets is the presence of a core that
is composed mainly of triacylglycerols (TAGs). TAGs have
different solvation properties than phospholipids. Speciﬁc
surrogate phases are needed for a precise estimation of the
partitioning of chemicals into TAGs.
Plasma lipoproteins are spherical or discoidal particles,
which are composed of apolipoproteins, a phospholipid-
cholesterol monolayer coat, and the core that mainly contains
TAGs and esteriﬁed cholesterol. They are classiﬁed into four
groups, based on the particle density, decreasing from 1.21
g/mL to <0.95 g/mL, as follows: high-density lipoproteins,
low-density lipoproteins, very-low-density lipoproteins, and
chylomicrons. In this order, the diameter of the particles rises
from 35 Å to 6 µm, the TAG content increases from 2 % to
88 % d.w., and the protein, cholesterol, and phospholipid
contents decrease.657 The self-assembly of lipoprotein nano-
disks and their disassembly caused by cholate addition were
analyzed by mesoscale modeling and small-angle X-ray
scattering.360,361 The physiological function of plasma lipo-
proteins is the transport of, respectively, cholesterol from
tissues to the liver, cholesterol to tissues, endogenous TAGs,
and exogenous TAGs and cholesterol. Interactions with
lipoproteins can signiﬁcantly contribute to intestinal absorp-
tion of lipophilic chemicals via lymph.148–150 The potential
to be absorbed by this pathway was assessed using the
binding to chylomicrons658 and predicted using the partial
least squares (PLS) regression analysis of numerous VolSurf
descriptors.659
Lipid droplets are ubiquitous cellular structures, composed
mainly of TAGs. They are highly concentrated in adipocytes,
which contain ∼90% (w/w) TAGs. Partitioning into adipose
tissues heavily affects the distribution of lipophilic compounds.
Synthetic TAGs with saturated fatty acids melt in the range
of 60-80 °C, and the melting temperatures rise with chain
prolongation. Solid TAGs mixed with emulsiﬁers form
platelets with discrete molecular layers.660,661 Liquid TAGs
under physiological conditions are not completely isotro-
pic,662 and loose remnants of the layered organization from
the solid state can be recognized.663 The aggregates of the
ester groups are more diffuse than the headgroup regions
observed for phospholipid bilayers (section 2.1.1), bind much
less water than the phospholipid headgroups, and do not form
distinct phases. Consequently, the solvation behavior of
TAGs can probably be emulated by one solvent, although
the solubilization process can be complex in some cases.664
Vegetable oil has been proposed as a TAG surrogate,665 but
the dependence of the composition on the source may be a
problem. The partition coefﬁcients of chemicals have been
measuredinthetriolein(trioleoylglycerol)-watersystem,192,562,563
and used for structure-based predictions561 and in correlations
with bioconcentration in ﬁsh.666
2.1.4.3. Transport versus Bilayer Fluidity. The bilayers
exhibit generally higher permeabilities in the liquid-ordered
phase than in the gel phase.667 Several barrier epithelia such
as gastric mucosa, and those in the renal collecting duct and
urinary bladder, maintain high solute gradients between body
compartments and the blood. Low ﬂuidity of their apical
membranes has been postulated as the mechanism underlying
the low permeabilities.225,668–670 Regulation by the lipid
composition of the bilayer ﬂuidity at the body temperature
has been considered a major mechanism for controlling
bilayer permeability.225,226,670,671 Expulsion from the bilayer
into bulk water of di-tert-butyl nitroxide,672 perylene,673
propranolol (34 in Table 3 and Chart 2), timolol,674 benzene,
hexane,272 and Bay K 8644, which is a 1,4-dihydropyridine
derivative (27 in Table 3 and Chart 2),675 was observed after
cooling liquid-ordered bilayers to the gel state. Increasing
the surface density of the liquid-ordered phospholipids by
addition of cholesterol, cooling in the temperature range
above the transition temperature, or extending the fatty acid
chains resulted in decreased partitioning of benzene,272
hexane,504 non-ionized acetic acid,505 and polychlorinated
biphenyls.532 Increased surface density also reduced perme-
ability of acetic acid through the bilayer composed of DMPC
and cholesterol.505
The temperature dependence of the bilayer transport is not
monotonously sigmoidal. At the gel-to-liquid transition
temperature, the inhomogeneous bilayer structure results in
the peak values of the transport rates, as observed for
water,676 Na+ cations,673,677,678 glucose, methylphosphoetha-
nolamine,580 and trimeprazine,572 as well as in a faster
insertion of an amphiphilic hydroxycoumarin alkylammo-
nium ﬂuorophore.256 These phenomena have been observed
in the bilayers composed of pure phospholipids, where the
transition occurs in a narrow temperature interval, as opposed
to the bilayers consisting of mixed phospholipids and
membranes. In membranes, the interactions of phospholipids
with integral proteins may cause distortions in the bilayer
structure. These irregularities could have a similar enhancing
effect on the transport rates as observed during gel-to-liquid
transitions.
2.1.4.4. Steady-State Transport. Most experimental data
on the steady-state trans-bilayer transport were obtained using
the BLM technique, utilizing a small-area bilayer separating
two aqueous compartments (section 2.1.2.2). Many models
used to describe the BLM data were previously derived for
the cellular and sheet systems (sections 3.3 and 3.5,
respectively), represented by the oversimpliﬁed one-mem-
brane or one-compartment systems.
Before looking at detailed descriptions, let us make a few
general remarks on the steady-state disposition of chemicals
in biosystems. A ﬂow-through transport system reaches the
steady state, when a constant ﬂux passes through each cross
section of the system, and the concentrations of the trans-
ported chemical in all parts of the system become time-
invariant. For this situation to happen, the concentration in
theentrycompartmentsand,consequently,theentryratesmust
be constant for a sufﬁciently long time. Although membrane
transport studies are mostly performed in closed systems,
the data are often processed using the assumption of the
steady-state conditions in the membrane, because the con-
centrations of the permeant in the bilayer regions are assumed
to be much smaller than those in the donor aqueous
compartment. Consequently, the respective gradients are
close to zero and considered to be approximately constant.
The constant ﬂux through the bilayer is described by the
permeability coefﬁcient, which is quantiﬁed as the slope of
the approximately linear increasing part of the concentra-
tion-time curve in the acceptor compartment. The shape of
Modeling of Subcellular Disposition of Chemicals Chemical Reviews, 2009, Vol. 109, No. 5 1813this curve documents the adherence of the situation to the
steady-state conditions. The presence or absence of an initial
lag phase indicates that the permeant at least temporarily
does or does not accumulate in one or more bilayer regions.
The leveling off at the end of the transport experiment reﬂects
the achievement of the equilibrium, when the chemical
potentials in both aqueous compartments become equal. For
the non-ionized solute not interacting with the bilayer, the
equilibrium concentrations are easy to calculate using the
initial concentration in the donor compartment and the
volumes of the two compartments. For the opposite case,
membrane accumulation can be determined from the differ-
ence between the experimental equilibrium concentration and
the hypothetical concentration for the situation without
membrane accumulation. In summary, for chemicals inter-
acting with the bilayer, the permeability coefﬁcient alone
does not sufﬁce to describe and predict the overall distribu-
tion of chemicals, and additional parameters are needed to
account for the possible lag phase and the ﬁnal phase of the
distribution kinetics. Despite this shortcoming, the perme-
ability coefﬁcient is frequently used as a characteristic of
the interactions of chemicals with bilayers in pharmaceutics
and in membrane biology.
Asshownseveraldecadesagoforthecellulartransport,521,679,680
the permeability coefﬁcient for the steady-state ﬂux through
the bilayer was linearly related, on the bilogarithmic scale,
to the surrogate partition coefﬁcient (section 2.1.3) of the
transported chemicals forming a homologous series.297,668,681–685
In terms of elementary steps, this dependence was explained
by the solubility-diffusion mechanism, which assumes a fast
dissolution of the permeant into the entry region of the
bilayer, slow diffusion through the interior, and another fast
dissolution step at the distal bilayer/water interface. Within
the framework of this mechanism, the permeability coef-
ﬁcient is proportional to the product of the partition coef-
ﬁcient and the diffusion coefﬁcient, with both quantities
mostly measured in surrogate systems. The linear log-log
relationships between trans-bilayer permeability and the
partition coefﬁcients for more-diverse chemicals were aug-
mented by molecular weight as another linear term, because
the diffusion coefﬁcient is inversely related to molecular
weight. This relation was obtained based on a structural
model of the bilayer as a homogeneous, hydrophobic slab.
The model has been made more realistic by the addition of
two resistances at the interfaces,499 and signiﬁcantly improved
by inclusion of scaling factors accounting for the effect of
chain ordering506 and the permeant size and shape.73
2.1.4.5. Speciﬁc Mechanism for Small Molecules. Wa-
ter,298 urea, formic acid,387 formamide,297 oxygen,686 and nitric
oxide687 are frequently assumed to permeate the bilayer using
a mechanism that is speciﬁc for small molecules.292,688 Details
of this mechanism may include mobile chain kinks taking
the permeants along,689 hopping of the permeant molecules
between the kinks690 or between free volumes created by
thermal ﬂuctuations in the headgroup region and in the
core,677,691 and collective density ﬂuctuations (phonons).692
Longer, transient, and water-ﬁlled pores693 were implicated
in trans-bilayer permeation of monovalent cations including
protons and potassium.684 Molecular simulations indicated
that the mechanisms involves active participation of the ions
such as protons, Na+ cations, and hydroxyls.694 The main
support for the involvement of transient pores comes from
the fact that the measured transport rates are higher than
predicted from the corresponding permeation models. Im-
perfections in these models, demonstrated in sections
2.1.4.4-2.1.4.6, indicate that this criterion may not suf-
ﬁciently support the claim that the special mechanisms are
the main transport route, at least for some small molecules
and in some membranes.
A rare experimental opportunity to examine the trans-
bilayer transport mechanism is based on the fact that the
pores produced by thermal ﬂuctuations occur less frequently
for longer phospholipid molecules,695 resulting in an expo-
nentially decreasing dependence of the permeability coef-
ﬁcient on the bilayer thickness.696 Experiments with the
bilayers made of PC with unsaturated fatty acids of varying
lengths showed that water, urea, glycerol,684 and halide
anions685 do not use the short-lived pores as the dominant
transport mechanism. Protons and Na+ cations do utilize this
mechanism as the main route, but only for thinner membranes.
Apparently, more experiments are needed to reconcile the
contradictory views. The thermal ﬂuctuations occur with
differing frequencies in individual bilayer regions. Therefore,
it is possible that some molecules will cross the bilayer using
a combined mechanism consisting of classical diffusion in
the more-dense subregions 2 and 3 and a pore-hopping
mechanism in subregion 4. The question of the transport
mechanism is fundamental for the phenomenological de-
scription of transport kinetics. For a pore-hopping mecha-
nism, the maximum concentration of a chemical in a bilayer
region would be limited by the pore density, whereas no such
limits are expected for diffusing chemicals.
2.1.4.6. Kinetics of Transport. The overall kinetics of
transport and accumulation is described completely and
exhaustively by mechanistic models with several rate con-
stants, characterizing the transfers between individual bilayer
regions. The use of transient kinetics prevails in the areas
of drug design and membrane biophysics. The observed
trans-bilayer transport rates of diverse chemicals range from
seconds to days, which are needed to achieve the partitioning
equilibrium across a single liquid-ordered bilayer. The
transient kinetics of transport provides a more-complete
picture of the overall process, including accumulation in
individual regions of the bilayer that is important for the
description of the interactions of chemicals with the transport
proteins, metabolizing enzymes, and the receptors. The ﬁrst
kinetic model of transport in a multicellular system assumed
slow transfers through both bilayer interfaces, which can
include subregions 1-3 (section 2.1.1), and fast diffusion
in the core, where the chemical could accumulate.58 This
mechanism is in accordance with the bilayer density proﬁle
(section 2.1.1.5), and accurately describes the trans-bilayer
transport of some chemicals, as summarized below. The
resulting peak-shaped dependencies of the transport rates on
the partition coefﬁcients were frequently observed at the
cellular level.1 The model was extended by considering
the different solvation abilities of the headgroup regions and
the core in some cases.667,697 The prediction of trans-bilayer
transport rates remains elusive, despite tremendous efforts
to develop descriptors of compounds that would correlate
with this property.469 Here, we present an analysis of the
transport data and properties of the permeants that could help
in resolving the prediction problem.
Tendency to associate with the headgroups, interface, and
core, as reﬂected in cephalophilicity, amphiphilicity, and
lipophilicity of chemicals (section 2.1.4.1), leads to the
compartmentalization of the bilayer for transport models. The
observed situations are summarized in Figure 7. Cephalo-
1814 Chemical Reviews, 2009, Vol. 109, No. 5 Balazphilicity is not included in this scheme because, at this point,
we do not completely understand structural determinants of
this property and cannot tell whether a permeant accumulates
in the headgroups, as compared to the bulk water or not.
Lipophilicity is precisely characterized by the reference
partition coefﬁcient and, therefore, three levels of lipophilicity
are distinguished in Figure 7. Amphiphilicity is considered
in a semi-quantitative way, with high magnitudes expected
for compounds with separated polar and nonpolar parts, and
low magnitudes otherwise. The interface regions, where the
amphiphiles partition, are drawn in Figure 7 as the volumes
comprising parts of subregions 2 and 3, i.e., the high-density
headgroup and core regions (section 2.1.1.5), which are
sometimes called the diffusion layers.698
The compartmentalization rules are simple. The aqueous
phases are always regarded as compartments. The bilayer
can be represented by maximally ﬁve compartments: two
headgroup regions, two interfaces, and the core. The actual
number of compartments is given by the permeant properties.
The compartments, in which the permeant exhibits measur-
able accumulation, are included in the scheme. Although the
headgroups are shown in Figure 7, we do not yet know which
types of chemicals prefer to partition there. Therefore, in
the following paragraphs, we will only deal with the
amphiphilicity and lipophilicity of chemicals.
Let us ﬁrst consider non-amphiphilic chemicals. If hydro-
philic, they do not interact signiﬁcantly with any part of the
bilayer, which then becomes just an inert barrier between
the two aqueous compartments (row 1). If lipophilic, they
accumulate in the hydrocarbon core of the membrane, which
then represents a compartment (rows 2 and 3). Amphiphilic
chemicals tend to interact with the headgroup/core interface,
forming one additional compartment on each side of the
bilayer. For hydrophilic amphiphiles, the interfaces are the
only two compartments of the bilayer. The third bilayer
compartment, corresponding to the hydrocarbon core, is
added for chemicals that are both amphiphilic and lipophilic.
The experimentally observed rates of trans-bilayer trans-
port of chemicals vary in a wide range. The results of
published transport studies are summarized in a common
framework in Figure 7. Diffusion in bulk water, as well as
in the low-density headgroup and core subregions 1 and 4,
is much faster than the steps, which involve crossing of the
more-structuralized interface subregions 2 and 3 (sections
2.1.1 and 10.1.1).699 The four schemes represent known
mechanisms that have been used to describe the trans-bilayer
transport.
The ﬁrst row, which is valid for non-amphiphilic hydro-
philic chemicals, represents the inert barrier concept.700 A
single parameter, the permeability coefﬁcient PC is sufﬁcient
for a complete description of the process. A typical duration
of the transport process is minutes to hours,569,701–703 because
molecules of the bilayer-inert chemicals enter the bilayer with
difﬁculty. Because the membrane accumulation is negligible
and the intracellular aqueous phases are usually much smaller
than their extracellular counterparts, the transport of these
chemicals is ideally measured as their release from preloaded
vesicles. The scheme in the ﬁrst row is also suitable for
description of kink-based and pore-based mechanisms for
the permeants with a low bilayer accumulation.
The second and third rows describe the situation of the
non-amphiphilic chemicals with a higher lipophilicity, which
can accumulate in the bilayer core56 but do not interact with
the interfaces. Two rate parameters, li and losfor entering
and leaving the core, respectivelysare needed for a complete
description in this case. Both rate parameters and, conse-
quently, the overall transport rate are dependent on lipophi-
licity631 (see eq 3 in section 2.1.3.4). The fastest transport,
with the equilibrium reached in the time interval ranging from
milliseconds to several seconds,82,577,704 is observed for
chemicals with intermediate lipophilicity. Very hydrophilic
chemicals (row 1) and very lipophilic chemicals (row 3) cross
the bilayer at much slower rates.56,143,705 This mechanism has
been most extensively used in simulations of transport in
biosystems.16,58,706 The agreement between phenomenological
simulations and the experiment (sections 5 and 6) supports
the adequacy of the used description, at least for this
mechanism.
The fourth row applies to chemicals, which are both
hydrophilic and amphiphilic. The adsorption and desorption
rates, characterized by the parameters la and ld, respectively,
are usually high (on the order of milliseconds707 or sec-
onds708). The ﬂip-ﬂop between the two interfaces of the
bilayer, characterized by the rate parameter lf, can take
minutes,578,584 hours,709 or days,710–712 depending on the
strength of the interaction between the chemical and the
headgroup region. This point is illustrated by the fact that
the ﬂip-ﬂop rates are much higher for the non-ionized species
of amphiphilic molecules compared with the ionized spe-
cies.713
The ﬁfth and sixth rows in Figure 7 describe the interac-
tions with the interfaces, combined with the accumulation
in the core, which are typical for amphiphilic and lipophilic
chemicals. Two rate parameters (ldc and lac) for the desorp-
tion/adsorption between the interface and the core were
added. The desorption from the interface into water was
accomplished within a fraction of a second.714 This mech-
anism has been described for ionizable chemicals, with the
Figure 7. Compartmentalization of the bilayer for the description
of passive transport of chemicals as dependent on lipophilicity and
amphiphilicity of chemicals. The headgroups and the core are
represented by the low-density bilayer subregions 1 and 4,
respectively. The core/headgroups interface is depicted as a volume,
where amphiphilic chemicals accumulate and includes (portions of)
the high-density subregions 2 and 3. The headgroups/water interface
is not shown, because of insufﬁcient information about the
accumulation of chemicals there. The schematic phospholipid
structures in the bottom right corner indicate these correspondences.
The overall transfer time is the time needed for a complete
equilibration of a chemical across a liquid-ordered bilayer, based
on the experimental data referenced in the text. The transfer rate
parameters are listed in the order of individual steps, from the donor
aqueous phase (left) to the acceptor aqueous phase (right). For the
backward processes, the order of individual steps is in the right-
to-left direction.
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neutralization.107–110,429
The conclusions summarized in Figure 7 can be extended
by including cephalophilicity. The four laminae, two phases
(the headgroups and the core) and two interfaces (between
the bulk water and the headgroups and between the head-
groups and core) play important roles in the overall bilayer
permeability. Our hypothesis is that an intermediate strength
of interactions of a chemical with all four laminae is
necessary for its fast trans-bilayer transport. Any deviation
of the interaction strengths from the intermediate values, even
for a single lamina, leads to a slowdown in the overall
transport. The hypothesis is based on simple and straight-
forward logic: weak interactions with a lamina prevent a
compound from entering it, and strong interactions keep the
compound inside the lamina. This behavior has been previ-
ously postulated for the bilayer core by Hansch and Fujita,56
and used as a theoretical basis for an interpretation of the
concave activity-lipophilicity proﬁles.
For the frequent case of non-amphiphilic chemicals, a cell
or a higher biosystem can be represented by a catenary set
of alternating aqueous and membrane compartments, as it
has been proposed for pure transport of non-amphiphilic
compounds.58 All presented models reviewed below in
sections 5 and 6 apply to chemicals, which do not differ in
cephalophilicity and amphiphilicity. The assumption of the
instantaneous diffusion in bulk water and the core allows
the use of the conventional mass balance description of the
kinetics and equilibria of all processes affecting the fates of
chemicals within the compartments (part 10.1.1).
2.1.5. Computational Approaches
Simulation of different types of the bilayer behavior is
complicated by widely differing length and time scales of
the studied system: microscopic thickness contrasts with
almost macroscopic surface area, and the rates of the bilayer
processes including the transport (section 2.1.4.6) vary in a
broad range. Another complicating factor is the rich phase
behavior of phospholipid aggregates, which may adopt the
form of micellar, lamellar, hexagonal, and cubic phases.
The time scales of individual motions in the bilayer715
increase in the following order: ﬂuctuations of bonds, angles,
and dihedrals within the same conformation (femtoseconds
for covalent bonds to non-hydrogen-bonded hydrogens,
picoseconds for other covalent bonds); trans-gauche isomer-
izations of dihedrals (tens of picoseconds in the core to
nanoseconds in the headgroups); lipid rotation along the long
axis and “wobbling” (nanoseconds);716 lipid position changes
in the monolayer due to lateral diffusion (nanoseconds to
microseconds);265 collective undulatory motions of lipids (on
the order of 0.1-10 ms, and sped up, with a smaller
amplitude,byproteinbinding),717relaxationduringtransitions,264,718
trans-bilayer transport of drugs and other small molecules
lacking strong interactions with bilayer regions as sum-
marized in section 2.1.4.6 (seconds to minutes); and, ﬁnally,
the spontaneous ﬂip-ﬂop of some lipids and lipid derivatives
between monolayers of the same bilayer,711,719–721 and
transport of chemicals with extreme lipophilicity and am-
phiphilicity, as described in section 2.1.4.6 (minutes to days).
The major events and their time scales are summarized in
Figure 8.
Atomistic MD simulations belong to the most informative
computational approaches for studying bilayers. The maxi-
mum duration of published force-ﬁeld-based MD studies of
hydrated patches of phospholipids, currently a hundred722 or
more nanoseconds,723 is by a wide margin too short to cover
many bilayer-related phenomena with signiﬁcant time-scale
(Figure 8) and length-scale differences. In addition, the
slower phenomena usually require the use of a larger
phospholipid ensemble than those currently utilized.724 Modi-
ﬁed approaches are needed for the situations where atomistic
simulations cannot provide answers.
A broad palette of available computational approaches can
be classiﬁed based on (i) the used lipid molecule represen-
tationsssimpliﬁed particles or all-atom molecules; (ii)
solvationsapproximated by a continuum or explicit solvent
molecules; (iii) interactions between moleculessvarying
levels of approximation; (iv) spatial arrangement of the
molecular representationssone-dimensional to study, e.g.,
some aspects of the ripple phase, two-dimensional to study
surface phenomena, or three-dimensional to study complete
structures; (v) movement of moleculessfree, conﬁned to a
lattice, or none, i.e. the use of average equilibrium positions;
and (vi) the used simulation method - in the order of
increasing complexity: energy minimization, Self-Consistent
Mean-Field Theory (SCMFT), MC simulations to study
mainly equilibria, and Brownian dynamics (BD) and MD to
study both kinetics and equilibria. Selection of the approach
is dependent on the structures and/or processes to be
modeled. The approaches are frequently combined and the
multiscale methods are of special promise.725–735
2.1.5.1. Bilayer Formation and Rearrangements. Col-
lective phenomena requiring the use of large systems and
long time scales are usually simulated using approximate
molecular representations of lipids and other participating
molecules. The mesoscale approaches can be classiﬁed as
faster lattice-based models677,736–741 and more-detailed off-
lattice models.742 The lateral rearrangements are frequently
studied in two dimensions: on-lattice MC models were used
to simulate the ripple phase formation743–745 and de-mixing
of lipids differing in chain ﬂexibility caused by cholesterol746,747
(also analyzed by SCMFT748) or membrane proteins.234,236,746,749
The off-lattice models were utilized to analyze complex
phenomena proceeding at long time scales such as lipoprotein
nanodisk359–361,750 and micelle742,751 formation, bilayer
formation,752–754 dissolution and rearrangements755 (also
analyzed by SCMFT756), mechanical properties,757–759 pore
formation,752 vesicle shape ﬂuctuations760–763 (also analyzed
by SCMFT764), vesicle tubulation upon interaction with a
Figure 8. Time scales of the movements of phospholipids and
permeants in a ﬂuid phospholipid bilayer. More details are given
in the text.
1816 Chemical Reviews, 2009, Vol. 109, No. 5 Balazprotein,765 vesicle fusion,766,767 lipid interactions with trans-
membrane proteins,733 lipid-cholesterol interactions,241,768–770
lipid lateral diffusion,241,768,769,771 and lipid demixing.241,768,769,772
These approaches, also known as coarse-grained simulations,
use the representations of small groups of atoms by beads
or particles with speciﬁed interaction potentials. The particle
consistency can be either hard742 or penetrable and interacting
via soft potentials such as in dissipative particle dynamics
(DPD).755,766 Coarse-grained models with particles corre-
sponding to individual phospholipid substructures, which
interact through potentials resembling atomistic force
ﬁelds,359–361,750,752–754,773–779 provide more quantitative results.
Mesoscale modeling methods have become more available
after the release of specialized software suites, such as
Mesodyn780 and DPD.781
2.1.5.2. Bilayer Structure and Dynamics. Early ap-
proaches to characterization of bilayer structure focused on
the acyl chains using an SCMFT approach782–785 and BD
simulations of a single lipid molecule786,787 with a continuous
version of the mean-ﬁeld potential.782 The force-ﬁeld energy
minimization of the monolayer and bilayer models788,789 was
used to analyze the intrinsic dipole potential,790–792 acyl chain
packing,793–797 and the mode of insertion of drugs641–643 and
proteins.798
More-extensive sampling of the simulated systems can be
obtained using either the probabilistic MC methods or the
deterministic MD methods. The explicit time dependencies
resulting from the integration of equations of motion for all
atoms in a system made MD the preferred technique in most
applications. In MC approaches, time-dependent properties
can be, at best, obtained indirectly. For some situations,
especially for the analysis of the equilibrium characteristics
of processes, which are slow at the time scale covered by
the MD simulations, MC can be the method of choice.799
The ﬁrst MC studies of the bilayer structure in three
dimensions focused on the chains that were anchored at the
interface, with the surface density corresponding to that of
the respective phospholipid bilayer. The dihedrals were
initially restricted to three states746 or to a three-dimensional
diamond lattice,800 to allow the simulations to ﬁnish in a
reasonable time. The order of chains was studied, both for
neat chains and under the inﬂuence of cholesterol,801 a simple
cylindrical protein model,749 and gramicidin.802 United-atom
phospholipid models, conﬁned to the diamond lattice and
used in fast MC simulations of bilayer structure,803 repro-
duced all states of the bilayer along the temperature scale,
from the crystal phase through liquid-crystal and quasi-
hexagonal phases to an isotropic liquid. United-atom repre-
sentation of phospholipid molecules was used in the MD
simulations combined with: (i) an MC procedure to analyze
the distribution and shapes of the free volumes804 and (ii)
the mean-ﬁeld potential BD approach to study the chain
properties.805
An early full-atom MC simulation of the bilayer patch of
36 phospholipid molecules806 analyzed the chain-order
parameters and hydration differences between the gel and
liquid-ordered phases. The used Metropolis procedure did
not approach the recommended thousand moves per a degree
of freedom.807 To enhance the sampling, several techniques
were proposed to replace the random moves in the studied
system, including conﬁgurational bias808 and extension-based
rotation sampling.799 The techniques enabled full-atom stud-
ies that analyzed orientation of water molecules,809 provided
structural information on pure bilayers and on the effects of
cholesterol,810–812 and simulated voids in the bilayers of pure
saturated813 and unsaturated phospholipids,814 as well as
phospholipid-cholesterol mixtures.815 The analysis of voids
is relevant for the hypothetical transport mechanism of small
molecules, as described in section 2.1.4.5.
Availability of the general-purpose molecular simulation
suites such as CHARMM,816 AMBER,817 GROMOS,818
OPLS,819 and later NAMD722,820,821 promoted the use of MD
methods. Two monolayers separated by a pool of water
molecules were used to analyze the repulsive hydration
force,822–824 as well as the structure of hydrating water,823–826
the headgroup region,823,824,826,827 and the core region.826–828
Structure and dynamics of hydrating water were also
analyzed in monolayer systems.829,830
For the bilayer, the initial coarse-grained models utilizing
particles,804,831 hexadecane chains conﬁned on one end,832
and other surfactants, with either continuum solvent
approximation833–835 or with explicit solvent,513,616,836–838 were
soon replaced by atomistic models of fully hydrated phos-
pholipid molecules.839–843 Several technical issues, including
the reﬁnement of force ﬁelds,838,844–853 the choice of simulated
ensembles maintaining the invariability of selected traits
(pressure, box dimensions, surface area per lipid),846,854–858
the choice of periodic boundary conditions,859 and effective
calculation of electrostatic840,860–862 and van der Waals
interactions842 had to be resolved before the force-ﬁeld MD
simulations could be deployed for the analyses of structural
and dynamical issues in bilayers. Regarding the use of
surface tension,553,863,864 it seemed that this need was
diminished for the simulations of larger systems.865 The
equilibration times were signiﬁcantly shortened by augment-
ing MD simulations with carefully chosen MC steps.866–868
The MD simulations of bilayer patches were mostly
applied to liquid-ordered phases but the behavior of the gel
phase was also analyzed.869 Among individual phospholipids,
PC as the most abundant mammalian phospholipid was the
most frequently studied molecule. Behaviors of other zwit-
terionic phospholipids, phosphatidylethanolamine302,826 and
sphingomyelin,870 and anionic phosphatidylserine871–875 and
phosphatidylglycerol,443 were also analyzed. As admixtures,
cholesterol810,876–884,884–886 and sphingomyelin887–889 were
studied most frequently; the former because of its abundance
and physiological signiﬁcance, and the latter because of
the role as a component of the canonical mixture forming
the lipid rafts.890 The most popular tails were myristoyl and
palmitoyl chains but MD simulations for lauroyl chains,825,826
stearoyl chains,891 branched chains892 as components of
archaeal and thermostable bacterial membranes, unsaturated
oleoyl chains,294,849,875,893,894 (also analyzed by the molecular-
level SCMFT895), di-unsaturated linoleoyl chains,896 and poly-
unsaturated docosahexaenoyl chains891,897,898 were performed.
The simulated bilayer patch usually contained 64
lipids842,854,891,899–901 or 72 lipids;716,856,857,897,902 however, in
some cases, larger systems294,553,903–905 up to 1600 lipid
molecules,870 were analyzed. The size of the patch is
important for lateral lipid diffusion and does not affect
internal dynamics of the lipid molecules.906 The duration of
simulation extended up to several hundred nanoseconds.723
The studied aspects included ﬂuidity of the fatty acyl
chains,839,842,907–911 structure of the four bilayer subregions
differing in density (section 2.1.1.5),292,912 structure of the
headgroup region,913 hydration,294,302,902,914–916 free volume
distribution,912 lateral diffusion of phospholipids,917 and the
bilayerstructurechangesundertheinﬂuenceofions,872–875,918–921
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unsaturation.849,886,896,897,922–924 Extended MD simulations were
used to analyze slower phenomena, such as undulatory and
thickness ﬂuctuations;904 the evolution of hydrophobic de-
fects;925 the development of lipid domains,888,889,926 the
hexagonal phase,927 and the ripple phase;928 the pore opening
by mechanical929–931 and electrostatic forces;929,930 the forma-
tion of the bilayer905 and a vesicle932 from diluted phospho-
lipid solutions; and bilayer fusion.933,934
The MD simulations involve details that are frequently
beyond the reach of current analytical and imaging tech-
niques, so that the match of simulations with experiments
can only be tested in a limited number of cases. Special
protocols have been developed to compare the MD results
with some NMR data,716,723,856,935,936 IR data,911 and with the
results of diffraction experiments.937
As common in the modeling research, plausibility of the
simulations is judged by their ability to imitate known
phenomena. The situation that is selected for testing the
suitability of an approach should imitate, as closely as
possible, the studied structure, event, or effect. Although
atomistic simulations are able to reproduce several bilayer-
related phenomena, they are under continuous development.
For instance, the two most frequently used MD simulation
packages, GROMOS and CHARMM, in then-current phos-
pholipid parameterization, were not able to completely
reproduce experimental bilayer structure from diffraction
experiments.937 The largest deviations were seen in the
distribution of terminal methyl groups of acyl chains.937
These analyses led to the development of constraints ensuring
the agreement of the observed and simulated bilayer struc-
ture,938 as well as to further developments in the phospholipid
force ﬁelds.853
The limitations of the used approach with respect to the
simulated event should always be kept in mind to avoid over-
interpretation of obtained results. In particular, the simula-
tions are based on numerous parameters, including, for the
most detailed MD approaches, partial charges,844 the force-
ﬁeld parameters for van der Waals interactions, and the
equilibrium values and force constants for bonds, angles, and
dihedrals. Many of these parameters are obtained from either
experimental or quantum mechanical results for simpler
compounds. The simpliﬁed forms of the common potential
functions currently do not include polarizability of atoms
and induced electrostatic effects, although a vigorous de-
velopment is noticeable in this area.939–948 The most common
force ﬁelds can only be used for systems exhibiting weak
interactions and no covalent bond changes. Even for such
systems, there is no guarantee that the simulations will
provide quantitatively correct results. For instance, free
binding energies of ligand-protein interactions are best-
described by the methods that recalibrate the simulation
results by optimization of additional coefﬁcients.949,950 This
approach could work also for the interactions of chemicals
with bilayers but the experimental data required for such
recalibration are scarce.
2.1.5.3. Equilibrium Partitioning of Chemicals. The
interactions of chemicals with bilayers are affected by ﬁne
structural details. Mesoscale models do not work well in this
context,753 and atomistic simulations are the methods of
choice. The overall partitioning is often the only experimen-
tally measured quantity, and the intra-bilayer distribution of
the studied compounds remains largely unknown. The
compounds with known bilayer locations are listed in section
2.1.4.1, in Tables 2-4 and Charts 1-3.
The importance of partitioning is occasionally underesti-
mated because the concentrations of compounds in the
bilayer are believed to be too low to play signiﬁcant roles.
As summarized in section 2.1.4, some chemicals accumulate
in the bilayer regions in much-higher concentrations than in
the aqueous phases. Although the volume of all bilayers in
the cell is 2-3 orders of magnitude smaller than the cell
volume, the amount in the bilayer is higher than that in water
for all chemicals with the bilayer/water partition coefﬁcient
being >1000. The transfers between the bilayer subregions
(section 2.1.1.5) and between the headgroup region and
surrounding water proceed at widely different time scales.
The fast processes can be described as pseudo-equilibria in
the kinetic models of slow processes. Under such circum-
stances, the equilibrium partitioning in the bilayer regions
is of interest, even for kinetic transport studies.
Early approaches to partitioning of chemicals used a
continuum representation of the bilayer, most frequently in
the form of a hydrophobic slab wetted by two water phases.
Conformational analysis, utilizing different dielectric con-
stants for the aqueous and nonpolar phases, and atomic
transfer energies between the two phases were used to
estimate the overall energetics. Selected conformations were
optimized by energy minimization.951–953 The initial insertion
of chemicals and peptides was guided by the hydrophobic
and hydrophilic centers of the molecules that were deter-
mined using the atomic energies of transfer between water
and a nonpolar solvent.641 The binding mode was reﬁned by
a force-ﬁeld geometry optimization of a complex with several
phospholipids.642 The approach was extended to membrane
proteins,954 utilizing a combination with hydrophobicity
proﬁles,955 molecular lipophilicity potential,956–958 and an MC
procedure with a continuous lipophilicity function.959–962
A continuum approach with a smooth function describing
the bilayer properties was devised for geometry optimization
and MD simulation of bilayer interactions with solutes640 and
for insertion of proteins into bilayer.963 The location of
comparatively complex chemicals in the bilayer was studied
by the molecular-level SCMFT models.964,965 United-atom
phospholipid models, with the movements restricted to a
diamond lattice, were deployed in MC simulations of peptide
insertion into bilayers.966,967 The partitioning of six noble
gases was analyzed using MD simulations and the particle
insertion method968 for the united-atom representations of
phospholipids, with the simpliﬁed headgroups tethered to a
mobile plane by a harmonic potential.969 Solute-lipid
interaction energies increased more rapidly with the molec-
ular size than the reversible work for cavity creation, leading
to a more-favorable partitioning of larger noble gas molecules
in the bilayer core.
The atomistic models with frozen bond length and angles
were used to obtain free-energy proﬁles for small molecules
such as H2O, O2, CO, CO2, NO, NH3, chloroform, and
formamide, using the particle insertion968 MC simulations
in the bilayers of pure DMPC970 and phospholipid-cholesterol
mixtures.971 This approach utilizes pre-existent voids in the
bilayer for the placement of the solute molecules. In this
way, it counteracts the nonphysical assumption of the
particle-insertion method that the lipid environment remains
unperturbed by the inserted solute molecules. The use of
voids is relevant because small molecules may utilize them
for trans-bilayer transport, which is faster than predicted from
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be guided by detailed analyses of the size distribution of the
voids in individual bilayer regions.813,815 The method could
possibly be extended to larger molecules using the idea of a
gradual growth of the solute molecules.972,973
Estimates of partitioning from the MD-simulated trajec-
tories have been attempted by monitoring the time that the
solute molecules spent in different regions616,969 or probability
distribution of molecules.973 Taking into account that the
experimental values of the partition coefﬁcients of chemicals
span a dozen orders of magnitude, these direct approaches
seem to be limited to the chemicals with comparable afﬁnities
for water and the bilayer.
Partitioning between water and a given region of the
bilayer is quantitatively characterized by the difference in
chemical potentials in these two phases representing the
reversible work to bring the solute from bulk water to a given
position in the bilayer. To sample the interactions in different
bilayer regions in reasonable time, the permeants can be
dragged through the bilayer. This approach was used in the
steered MD simulations of oxygen diffusion in a monolayer
of hexadecane and cholesterol molecules, with one end
constrained by a harmonic potential to imitate the headgroup
attachment.832 The techniques for reconstruction of the free-
energy proﬁles from these experiments are being develop-
ed.974–976 The placement of the permeants’ molecules at
various positions in the bilayer at the start of the simulation
and subsequent monitoring of the trajectories, or conﬁnement
of the permeants to certain depths have also been used.616
For the majority of studied chemicals, MD simulations
provided mostly qualitative results because of the complica-
tions arising from the size and interactions of permeants with
the bilayer. A possible solution to the size problem is a
gradual grow of the permeants’ molecules in the bilayer.972,973
The ﬁrst atomistic MD simulations of non-physiological
molecules514,977,978 in the fully hydrated DMPC bilayer patch
used the mean displacement method to calculate the diffusion
coefﬁcients. The role of the void size in transport of small
molecules was illustrated for benzene on one hand, and
adamantane and a nifedipine derivative (skeleton 27 in Chart
2) on the other hand.979 Benzene exhibits faster diffusion in
subregion 4 of the bilayer, where the voids are concentrated.
Curiously, the two larger molecules did not differ in the
diffusion rates in individual bilayer subregions. Benzene was
mainly found in subregion 4 at 310 K, and in subregion 3 at
340 K (the subregions are speciﬁed in section 2.1.1.5). A
preference of rigid aromatic molecules for subregion 3 was
also observed in other simulations (see below). This phe-
nomenon was explained by a lower entropy loss for
intercalation in the ordered subregion 3, compared to the
loss of chain mobility that would be elicited by partitioning
in subregion 4.
A ﬂuorescent probe, 1,6-diphenyl-1,3,5-hexatriene (DPH,
33 with R ) H in Table 3 and Chart 2) in a dipalmitoylphos-
phatidylcholine (DPPC) bilayer patch was studied in 250-
ps980 and 50-ns simulations.515 The latter study showed that
DPH assumes the position with the mass center in subregion
3, and the long axis approximately parallel with the acyl
chains. This orientation affects chain packing and lateral
diffusion of DPPC molecules.981 Fluorescence anisotropy96
indicated a wide bimodal orientational distribution along the
molecular axis that was pronounced for angles that are
parallel and perpendicular to the bilayer normal. A fraction
of DPH associated with headgroups has also been detected.982
As shown by 2H NMR experiments, the order parameter of
deuterated DPH decreases with temperature and increases
with the cholesterol content.111
MD simulations placed pyrene into subregions 3 and 4
(section 2.1.1.5) of the 1-palmitoyl-2-oleoylphosphatidyl-
choline (POPC) bilayer.983 Pyrene molecules adopted, pre-
sumably for entropic reasons, the orientation parallel with
the chains, similar to that of DPH, as shown by solid-state
2H NMR of oriented bilayers and extended MD simula-
tions.516
Numerous MD simulations focused on ﬁnding the pre-
ferred locale and the effects of chemicals on the bilayer.
Dihydropyridine calcium channel antagonists nifedipine and
lacidipine (skeleton 27 in Table 3 and Chart 2) were shown
to interact with subregions 2 and 3 (section 2.1.1.5) of a
DMPC bilayer patch.984 The changes in the dioleoylphos-
phatidylcholine (DOPC) bilayer caused by trichloroethane985
were monitored. The MD simulations of benzyl alcohol (2
in Table 2 and Chart 1) in a DMPC bilayer patch986 placed
this molecule in subregion 3, in contrast to experimental data
indicating the headgroup subregion 2 as the main locale.647
In the POPC bilayer, indole and N-methylindole (10 in
Table 2 and Chart 1) were located in subregion 2, using the
interaction energies, or in subregion 3, based on the free
energies.718 Experimental data indicate that subregion 2 is
the preferred locale.123,124 This study was undertaken to help
explain frequent observations of the placement of tryptophan
in trans-membrane helices in the headgroup region,987
although the partitioning studies using surrogate solvents
indicate Trp’s lipophilicity, which would indicate partitioning
in subregions 3 and 4. The authors assumed that rigidity of
Trp prevents its partitioning into the core for entropic reasons,
and the quadrupole potential facilitates electrostatic interac-
tions in the headgroup region.
Anesthetics exhibit interesting interactions with the bilayer.
Halothane (3 in Table 2 and Chart 1) was found mainly in
subregion 3 of the DPPC bilayer,973,988 in accordance with
the 2H and NOE NMR studies,119 and contrary to the FT-IR
ATR spectroscopy results97 and the 19F NMR experiments
in combination with the use of paramagnetic shifting
agents.106 Hexaﬂuoroethane accumulated in subregions 3 and
4, with a slight preference for the latter.989 An anesthetic
bicyclo[4.1.0]heptan-3-one derivative, KP-23, was found to
associate mainly with the interface of the POPC bilayer. The
protonated form preferred the headgroup region and the neu-
tral form intercalated deeper and protruded into the hydro-
carbon region.990
Two pools of  -carotene were identiﬁed in the POPC
bilayer patch, both having the cyclohexene rings localized
in the headgroup regions, and differing in the chain confor-
mations, with bent and stretched geometries.991 Salicylate
in the DPPC bilayer assumed the position typical for
amphiphilic compounds, led to a decreased area per lipid
and a higher chain order, and affected the electrical properties
of the bilayer.992 Pentachlorophenol mostly diffused into the
positions in subregions 2 and 3, with the hydroxy group
interacting with the water and lipid oxygens, regardless the
starting position in bulk water or in the core of the
1-palmitoyl-2-oleoylphosphatidylethanolamine and POPC
bilayers.993
Large anions were found to intercalate deeper than small
anions into the POPC bilayer patch, below the level of
phosphate groups,921 presumably as a consequence of the
easier shedding of the less-structured hydration shell, and
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accordance with the experiments showing that chaotropic,
water-structure-perturbing anions affect the conformations
of the PC headgroups994 and reduce the dipole potential.995
Both phenomena behave as the Hofmeister effects,996 i.e.,
exhibit the magnitudes proportional to the surface charge
density of anions.
A detailed MD study of partitioning of n-hexane into the
DOPC bilayer at three temperatures provided the proﬁles of
free energy, enthalpy, entropy, and heat capacity. The
prevalent partitioning into the core was entropy-driven, while
the partitioning into the dense alkyl chain subregion is
dominated by a favorable enthalpy change.997
To study the effects of membrane potential, the standard
setup with one bilayer and two aqueous phases in the unit
cell was replaced by three aqueous phases and two bilayers,
allowing a different salt composition in the central aqueous
phase.998,999
2.1.5.4. Transport of Chemicals. The trans-bilayer trans-
port of chemicals is most frequently characterized experi-
mentally by the permeability coefﬁcients, which are valid
for the steady-state situation in the bilayer. The steady state
can only be achieved if the permeant concentration in the
entry compartment remains constant over the time interval
when permeability is determined. This condition is not
routinely satisﬁed in many experimental permeability mea-
surements and may affect the accuracy of the determined
permeability coefﬁcient values. Under physiological condi-
tions, the need for an invariant entry concentration of the
permeant is satisﬁed by continuous dosing (e.g., intravenous
drug infusions and the exposure of aqueous fauna and ﬂora
to pollutants in large basins with balanced input and output).
However, other transport processes are more completely
characterized by individual transport rate constants as
described in section 2.1.4.6.
Trans-bilayer transport of any permeant is too slow
(section 2.1.4.6) to be simulated completely from the relevant
starting state on one side of the bilayer to a steady state or
equilibrium. Shorter transfers between individual bilayer
regions have a better chance to be sufﬁciently sampled in
simulations. The permeability estimates have been made by
the application of the solubility-diffusion theory, combining
estimates of free energy and diffusion coefﬁcients at given
depths of the bilayer.292,513,1000
The ﬁrst full-atom MD simulations of transport of water292
provided a detailed view of the PC bilayer structure. The
diffusion coefﬁcient proﬁle was obtained by the mean-
squared-displacement method in the headgroup regions, and
by the force correlation method for the molecules conﬁned
at a given depth in the chain subregions. The diffusion was
found almost isotropic except subregion 3, where the
transversal movement was faster. The free-energy proﬁle of
water molecules in the bilayer was calculated directly from
water concentrations in the headgroup subregions 1 and 2,
from the average force acting on conﬁned molecules in
subregion 3, and by the particle insertion method968 in
subregion 4. The diffusion and partitioning data were used
to calculate the permeabilities, which reached their maximum
magnitudes in the center of the bilayer and were minimal in
subregion 3.
Similar studies were performed for oxygen and am-
monia,1001 which are assumed to exhibit the same void-based
transport mechanism as water. The highest permeabilities
were observed in the core subregion 4, and depended greatly
on the polarity of the molecules. Oxygen diffusion was
actually faster in the bilayer than in bulk water. Proton
transport properties were inferred from the formation of
transient water pores1002 and from direct simulations.1003 In
another study of small permeants, diffusion of nitric oxide
was found to be isotropic.1004 The transport of small
molecules was shown to be associated with chain dynamics:
the rate signiﬁcantly decreased for diphytanoylphosphati-
dylcholine, because of a denser packing of branched acyl
chains,892 compared to the straight-chain phospholipids.
The permeability coefﬁcients of eight small organic
compounds (acetamide, non-ionized acetic acid, benzene,
ethane, methanol, methyl acetate, methylamine, and water)
were systematically analyzed using the depth-dependent free
energies of partitioning and diffusion coefﬁcients on the basis
of the solubility-diffusion theory.1005 The approach allows
identiﬁcation of the rate-limiting steps and has a potential
to provide a better correlation with experimental data thanks
to the use of the relevant, depth-speciﬁc partition coefﬁcients
instead of the experimental partition coefﬁcients, which are
based on space-averaged concentrations in the heterogeneous
bilayers. The rate-limiting steps or resistances were identiﬁed
in subregions 1 and 2 for ethane, methylacetate, and benzene;
subregions 3 and 4 for water; and subregion 4 for methanol,
methylamide, non-ionized acetic acid, and acetamide.1005 The
calculated permeability coefﬁcients were about one order of
magnitude larger than the experimental values but the relative
trends were correctly reproduced. Interestingly, the partition
coefﬁcients of the small studied compound series in indi-
vidual bilayer subregions 3 and 4 correlated well with both
hexadecane/water and 1-octanol/water partition coefﬁ-
cients.588 The diffusion coefﬁcients decreased with the
molecular weight and the cross-sectional area of the permeants.
Inclusion of larger drug molecules ( -blockers alprenolol,
atenolol, and pindolol, with the skeleton similar to propra-
nolol: 34 in Table 3 and Chart 2)1006 provided the opportunity
to examine other aspects of the transport process. When
crossing the bilayer, the drug molecules tended to keep their
long axis parallel with the bilayer normal, and deviated from
this orientation only when it was advantageous for the
formation of hydrogen bonds. The polar vectors of permeants
were more ordered than in liquid water. These tendencies
were most pronounced in the dense bilayer subregions 2 and
3. The conformer populations in individual subregions
differed: the molecules were more packed near the interface,
to form hydrogen bonds, and more elongated in the core.
2.2. Vesicle-Mediated Transport
Absorption, distribution, and excretion of some chemicals
can be affected by mechanisms that evolved in specialized
cells for transport of physiological molecules and macro-
molecules, to enable the cells to perform key functions of
living organisms. The transport of chemicals can be mediated
by vesicles pinching off the membranes and delivering the
enclosed cargo into or across the cell, or by membrane
proteins transferring molecules across the membranes (sec-
tion 2.3).
The rates of trans-bilayer transport of chemicals vary in a
broad range (section 2.1.4.6). The mediated mechanisms play
meaningful roles only in the situations when they signiﬁ-
cantly contribute to the actual trans-bilayer transport rates,
regardless of the direction. While the mediated transport can
affect the trans-bilayer transport rates in the specialized cells,
the interactions with the bilayers (section 2.1.4) determine
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absorption and distribution of chemicals are determined by
both passive diffusion and mediated transport, and cannot
be understood without a proper consideration of both
contributions. Currently, we do not know the detailed
transport mechanisms for many chemicals,but this picture
will gradually change, because of intense research in the area
of mediated transport.
Formation of the vesicles can be spontaneous (pinocytosis)
or initialized by the binding of macromolecules or small
molecules to the receptors in cell membranes. Pinocytosis
was ﬁrst studied for amoeba in the 1950s.1007 The concept
of receptor-based endocytosis was elaborated about two
decades later for the intracellular entry of proteins1008 and
low-density lipoproteins.1009,1010 The receptors are encoun-
tered in two distinct domains of cell membranes, for which
the mechanisms and the cargo differ. The receptors for both
small molecules and macromolecules are located in caveolae
and the respective mechanism is termed potocytosis (section
2.2.1).
The exclusively macromolecular receptors that are found
in clathrin-coated pits elicit receptor-mediated endocytosis
(section 2.2.2). Other vesicle-mediated transport mechanisms
are used for secretion of proteins or signaling molecules from
the cells (exocytosis) and will not be described here. This
mechanism can also play a role in drug efﬂux via shedding
of vesicles and leading to multiple drug resistance.1011
Vesiculo-Vacuolar organelles are clusters of vesicles and
vacuoles in endothelial cells of lymphatic vessels and small
veins in normal tissue and tumors, which can interconnect
and create irregular trans-cellular channels.1012 Their openings
at the levels of the cell membrane are either unobstructed or
covered by a glycoprotein diaphragm. The channels can serve
for transport of chemicals and macromolecules.1013
2.2.1. Potocytosis
Caveolae are 50-100 nm wide invaginations of the cell
membrane that are rich in cholesterol, and coated, on the
cytoplasmic side, by caveolins and other proteins.1014 The
most frequently observed invaginations have the ﬂask form,
but tubules and grapelike shapes have also been observed.1015
The ﬂask-shaped invaginations can remain anchored to the
cell membrane or detach and form separate vesicles. The ca-
veolae are ﬂattened by cholesterol depletion, and the
exposure to polyene, cholesterol-binding antibiotics, such as
ﬁlipin and nystatin.
The caveolae are found in many cell types, most frequently
in capillary endothelium, Type I pneumocytes, adipocytes,
as well as in skeletal, cardiac, and smooth muscles.1016,1017
Potocytosis was discovered as a mechanism for pre-
concentration of nutrients and signaling molecules, enabling
their faster carrier-mediated transport.1018,1019 The intracellular
vesicle, which forms upon binding of the ligand to the
receptor, encapsulates the ligand molecules in a higher
concentration than that which is in the cell surroundings.
The vesicle remains attached near the cellular membrane,
and the concentrated molecules are transported into the cell
interior by a carrier-mediated mechanism.
The term potocytosis has been extended to encompass all
types of vesicular transport, which involve caveolae.1020
Chemicals, macromolecules, and viruses may be transported
by one of four possible mechanisms. The original pre-
concentration mechanism, with the carrier-mediated release
of small molecules from the surface-anchored vesicles into
cytoplasm, was observed for folate, retinol, iron, and calcium.
Cholesterol and some proteins are delivered by endocytosis
to the endoplasmic reticulum or other organelles, and the
unloaded vesicles return to the surface. Transcytosis, the
transfer of ligands through the epithelial cell, with relocation
of the caveolae to the opposite surface, was documented for
plasma proteins including albumin and transthyretin. Lastly,
the formation of vesicles functioning as depots for temporary
sequestration, without an immediate intracellular release,
were observed for acetylcholine and several proteins.1020
2.2.2. Receptor-Mediated Endocytosis
Clathrin-coated pits are cell membrane invaginations
containing several receptors. Clathrin is a large coat protein
that associates with the membrane surface. Upon binding of
macromolecular ligands, the invaginations transform into
vesicles, which detach from the cell membrane, with the help
of dynamin and other proteins. Protons are pumped into the
vesicles, causing the ligands to dissociate from the receptors,
and the coat protein to separate from the bilayer. The bilayer
vesicles then associate with endosomes.1015 Endocytosis can
proceed at a signiﬁcant speed; some cultured mammalian
cells can internalize 50% of their surface per hour.1021 The
process is inhibited by ammonium chloride, chlorprom-
azine,1015 and monodansylcadaverine.1022 Endocytosis was
described in detail in the Peyer’s patches in the mucose of
ileum,1022–1028 in renal tubules,1029–1031 and for the cases
involving the receptors for low-density lipoprotein, trans-
ferrin,1032 and scavenger receptors in the blood-brain bar-
rier1033 and liver.1034
2.2.3. Structure-Permeability Considerations
The vesicle-mediated transport has been considered as a
route for targeting of drugs to speciﬁc cells.1034–1041 Chemicals
can participate in the vesicle-mediated transport via direct
binding to the receptors in potocytosis, binding to the
internalized membrane, or piggy-backing on the internalized
macromolecules. These interactions can affect the rate of both
potocytosis and receptor-mediated endocytosis. Currently, no
QSARs are available for the vesicle-mediated transport. It
can be expected that the respective QSARs will be rather
complex. In addition to the direct interactions with the
receptors, the accumulation of chemicals in the internalized
part of the membrane, and the binding of chemicals to the
internalized macromolecules must be included.
2.3. Carrier-Mediated Transport
Some chemicals are transported in specialized tissues via
carrier systems that have evolved for physiological reasons.
The transporters are expressed at the highest levels in
absorptive and excretory tissues such as intestinal epithelia,
renal tubules, and liver;1042 in the blood-tissue barriers in
the brain (also at the surfaces facing cerebrospinal ﬂuid),1043
testis,1044 ovaries,1045 and placenta;1046,1047 as well as in
tumors.1048,1049 In the past decade, hundreds of transporter
proteins have been cloned and characterized,1050 and this
number is expected to grow. The mechanisms of carrier-
mediated transport include (i) facilitated transport along the
concentration gradient; (ii) facilitated inﬂux of cations and
efﬂux of anions due to the inside-negative membrane
potential, which can lead to some pre-concentration; and (iii)
active transport that proceeds against the concentration
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most frequently adenosine triphosphate (ATP) hydrolysis and
the co-transport of Na+,H +, and HCO3
-.1051
Physiological ions, such as Na+,K +,C a 2+, HCO3
-, and
Cl-, are much smaller than the majority of organic molecules.
Consequently, ion channels are not known to be directly
involved in the transport of chemicals, except for their roles
in co-transport. The channels can be blocked by chemicals
and are targeted by several drugs.1052
The transporters are integral membrane proteins that are
difﬁcult to crystallize due to the structural changes, which
can be elicited by the extraction from the natural membrane
environment. Therefore, detailed structural information is
scarcer than for other protein types, despite signiﬁcant
progress made in recent years, especially in elucidation of
the structure of the efﬂux pumps (section 2.3.2.3).
Chemicals utilizing the protein-mediated mechanisms must
resemble the native substrates to the extent that is dependent
on the speciﬁcity of the carrier proteins. Nutrient transporters
seem to have a higher speciﬁcity than other transporter
proteins, which are usually rather promiscuous.
In contrast to facilitated transport,1053–1055 active transport-
ers seem to be strictly unidirectional and mediating either
cellular inﬂux or efﬂux.1051 This feature leads to the typical
polarity of epithelia forming the monolayers of tightly packed
cells separating the bloodstream from non-tissue body
compartments. The apical side of most epithelia, frequently
rich in glycolipids and having villi, is oriented toward the
nontissue compartments, such as the lumen of the gas-
trointestinal tract, air in the lungs, the glomerular ﬁltrate in
the tubule of nephrons, bile in the liver canaliculi, or urine
in the urinary bladder. The basolateral side, facing the
bloodstream, is separated from the apical side by tight
junctions, which prevent both the paracellular transport of
chemicals and the lateral diffusion of transporters.1056 To
ensure a ﬂux through an epithelial layer, the inﬂux and efﬂux
transporters are co-expressed1057 and properly arranged on
the apical and basolateral sides of the cells. Combinations
of active and passive processes (inﬂux and efﬂux, respec-
tively, for some anions;1050 efﬂux and inﬂux, respectively,
for Type II cations,1058 both described in section 2.3.1.2) were
observed in the tubular epithelium of the nephron. In the
intestinal enterocytes, some transporters (GLUT and SGLT;
see section 2.3.1.1) are expressed in both apical and
basolateral cell membranes.
Most transporters are encoded by the solute carrier (SLC)
family genes. The exceptions are the efﬂux pumps that
belong to the ATP-binding cassette (ABC) family. The used
nomenclature is recommended by the Gene Nomenclature
Committee of the Human Genome Organisation.1059 By
convention, the gene symbols are italicized and the respective
protein symbols are not. Human genes and gene products
are shown in upper case, while rodent genes and gene
products are shown in lower case. Additional speciﬁcations
and numbers denoting subfamilies and individual members
complete the characterization of the transporters. All trans-
porter subfamilies include several members. Although the
roles of subfamily members frequently differ, the structural
similarity of transporters within families complicates
structure-activity analyses at the cellular and higher levels.
Several physiological processes are of signiﬁcance in the
context of transport of chemicals: (i) active transport of
nutrients to the bloodstream, with absorption from the
intestine and reabsorption from the tubular ﬁltrate as typical
examples; (ii) active renal and biliary secretion; and (iii)
active transport of nutrients from the blood and the backward
transport of metabolites and signaling molecules through the
barrier tissues in the brain, testis, ovaries, and placenta.
Although the participating transporters are not exclusively
expressed in the aforementioned tissues and perform sig-
niﬁcant roles in other tissues as well, it is convenient to
review the carrier-mediated transport along the themes of
individual physiological processes, because the processes
determine the overall disposition of chemicals in the body.
This approach also leads to an intuitive recognition of the
tissues with prevalent expression of individual transporters.
To maintain the focus on the transport in individual cells,
the inﬂux and efﬂux carriers are covered separately, despite
the fact that there is some overlap between the two groups.
2.3.1. Inﬂux Transporters
Protein carrier systems have evolved in all organisms for
the uptake of sugars,1060–1062 amino acids, dipeptides and
tripeptides,1063,1064 nucleosides,1065 lipids,1062 vitamins,1062,1066
and hormones in higher organisms.1067 This route has been
considered a possible mechanism for the increase in bio-
availability of the drugs bearing, at least in some parts, some
similarity to the nutrient molecules such as antiviral nucleo-
sides1065 and peptidomimetic drugs including  -lactam
antibiotics and inhibitors of angiotensin converting enzyme,
renin, and thrombin.1068
2.3.1.1. Intestinal Absorption. The apical brush-border
membrane of the enterocytes in the small intestine contains
a plethora of carriers for glucose, amino acids, peptides,
nucleosides and other nutrients. Usually, the transporters from
the same families, and, for glucose and amino acids,
sometimes the same transporters, are expressed at both sides
of epithelial cells, supporting enhanced speciﬁcity of nutrient
transport processes.
The carriers for the universal mammalian cell fuel,
D-glucose, belong to the most intensively studied nutrient
transporters. They include1069,1070 facilitative glucose trans-
porters (GLUT) belonging to the SLC2A (facilitated glucose
transporter) family,1059 and concentrative sodium glucose co-
transporters (SGLT) from the SLC5A (sodium/glucose co-
transporter) family.1059 Glucose transport in individual tissues
is regulated, in addition to other factors, by speciﬁc distribu-
tion of transporters. For instance, GLUT1 is found in the
erythrocytes, placenta, brain, kidney, and colon; GLUT2 in
the liver; GLUT3 in the brain; insulin-sensitive GLUT4 in
the adipose tissue and the skeletal and cardiac muscles;
GLUT5 in the small intestine, and others in the kidneys.
Selectivity of the GLUT carriers is high: GLUT1 in
erythrocytes transports D-deoxyglucose and 3-O-methylglu-
cose, but not L-glucose.1071 Insulin elicits recruitment of
intracellular GLUT4 to the cytoplasmic membrane, resulting
in an increase in the D-glucose transport.1072,1073
The results of protein cleavage studies, immunologic
epitope mapping experiments, chemical modiﬁcations, and
glycosylation-scanning and cystein-scanning mutagenesis
allowed for the construction of a working structural model
of GLUTs that is based on 12 transmembrane segments.1061,1074
Similar steps are being made toward the elucidation of the
SGLT structure.1075 These results represent an important
foundation for a rational development of GLUT and SGLT
effectors promoting absorption and inhibiting reabsorption
of glucose, as potential anti-diabetic drugs.1076–1079
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acid transporters.1080 The peptide transporters, the low-afﬁnity
PEPT1 and high-afﬁnity PEPT2 carriers, which are members
of the SLC15A (oligopeptide transporter) family,1059 perform
H+-coupled inﬂux of dipeptides and tripeptides across apical
membranes in the intestine and renal tubules.1081 PEPT1 has
a broader substrate speciﬁcity and was examined as a means
to enhance intestinal absorption of ester prodrugs.1082 The
inﬂux of nucleosides into the enterocytes1080 is facilitated
by equilibrative nucleoside transporters ENT1 and ENT2,
belonging to the SLC29A (nucleoside transporter) family,1059
and by other carriers.1065 Speciﬁc transporters are available
for phosphate, monocarboxylates, fatty acids, bile acids, and
vitamins. Some transporters participating in renal secretion
and reabsorption (OATPs and OCTNs; see the next section)
were also found in the apical membrane of the entero-
cytes.1080
2.3.1.2. Renal Excretion. Renal excretion consists of
glomerular ﬁltration, tubular secretion, and reabsorption,
which proceed in the nephrons of the kidneys. While ﬁltration
and some reabsorption steps are passive processes, transport-
ers are involved in secretion and reabsorption of some
physiologic molecules and chemicals.
Active renal secretion was discovered ∼80 years ago,1083
using an anionic substrate, phenolsulfonphthalein, and proved
for organic cations two decades later.1084 Active secretion
can be extremely fast: p-aminohippuric acid is almost
completely secreted in one pass of the blood through the
kidney.1085 Some of the transporters involved in renal
excretion are also expressed in the intestine, hepatocytes,1086
brain capillaries,1087 and the choroid plexus.1088 The involved
protein carriers include1089 organic anion transporters (OATs)
and organic cation transporters (OCTs and OCTN, where N
stands for novel), all belonging to the SLC22A family,1059
as well as organic anion transporting peptides (OATPs),
which form the SLCO (organic anion transporter) family.1059
The carriers have 12 transmembrane domains, with the N-
and C-terminals located in the cytoplasm.1058,1090,1091 From
the mechanistic viewpoint, they mostly act as exchangers:
OATs exchange organic anions for dicarboxylates,1091 OATPs
exchange organic anions for bicarbonate, glutathione, or
glutathione-S-conjugates,1092 and OCTs and OCTN1 ex-
change organic cations for protons.1093 In contrast, OCTN2
supports Na+ co-transport and electrogenic-facilitated dif-
fusion.1058 The substrates are mostly amphiphilic organic
anions and cations, usually having distinct hydrophobic parts.
Notably, amphiphilic compounds frequently exhibit slow
passive trans-bilayer transport (section 2.1.4.6), so the
transporters signiﬁcantly affect the overall transport rates.
The inﬂux transporters are involved in the ﬁrst step of
active and facilitated tubular secretion, the uptake from the
bloodstream through the basolateral cell membrane into the
renal proximal tubule cells.1094 The systems have evolved
for numerous organic anions and cations as a means to clean
the organisms of endogenous metabolites, toxins, and
hormone and neurotransmitter metabolites, and to maintain
homeostasis.1050 Concentrations of chemicals and their
metabolites are also affected by the secretion process.
Inﬂux of organic anions into the tubular cells proceeds
through a series of three coupled processes. The Na+/K+-
ATPase uses the energy released by the ATP hydrolysis to
support the Na+ efﬂux that drives the R-ketoglutarate (R-
KG) inﬂux via the Li+-blocked Na+-dicarboxylate co-
transporter 3 (NaDC3), member 3 of the SLC13A (sodium-
dependent dicarboxylate transporter) family.1059 Organic
anions are exchanged for R-KG by the probenecid-blocked
dicarboxylate/organic anion exchangers OAT1,1095 OAT3,
and possibly OAT2.1050 Organic cations are classiﬁed as Type
I (smaller, monovalent cations, e.g. tetraethylammonium) and
Type II (bulkier, often polyvalent cations, e.g. daunomycin).
Type I cations enter the tubular cells via facilitated diffusion
mediated by OCT1, OCT2, and OCT3, while Type II cations
probably use passive transport.1058
Many endogenous compounds (e.g., glucose, electrolytes,
and amino acids) and some drugs are subject to active
reabsorption, which occurs predominantly in the proximal
tubule. Glucose transport in the proximal tubules is mediated
by several transporters, e.g., GLUT1 and SGLT2.1078,1094
OATs are involved in reabsorption of anionic substances.1096
Peptides and peptidomimetics are reabsorbed via PEPT1 and
PEPT2 transporters.1097
2.3.1.3. Biliary Excretion. Metabolic and excretion func-
tions of the liver are facilitated by a comparatively dense
network of capillaries, with each capillary serving several
hepatocyte layers (Table 1, section 1.21.2), and by the direct
contact of practically each hepatocyte with a bile canaliculus.
The fenestrated liver capillaries (sinusoids) allow the entry
of plasma proteins with bound ligands into the interstitial
space (the space of Disse), where they can come into a direct
contact with the basolateral membrane of hepatocytes.171
Biliary excretion plays an important physiological role in
the bile formation, by the excretion of synthesized bile salts
from hepatocytes into the bile, and by the concentrative
transport of bile salts from the blood into the bile, contribut-
ing to the bile salts conservation, in a process called
enterohepatic cycling. After synthesis from cholesterol in
hepatocytes, bile salts are excreted into the bile, in which
they enter the digestive tract, and help in emulsiﬁcation of
lipid substances. Bile salts are absorbed in the small intestine,
and retrieved from the bloodstream in hepatocytes. The inﬂux
through the basolateral (sinusoidal) hepatocyte membrane
is mediated by OAT1 and OATPs,1098–1102 which are de-
scribed in section 2.3.1.2. The excretion from hepatocytes
into bile is mediated by speciﬁc biliary transporters and
multidrug resistance related proteins (MRPs), which are
described in section 2.3.2.2.
The bile salt excretion mechanism can be used by some
chemicals to get from the bloodstream into bile and then to
the intestinal content. If the chemicals exhibit slow intestinal
absorption, they will be eliminated in feces. The chemicals
undergoing both intestinal absorption and biliary excretion
can get trapped in enterohepatic cycling.1103
Some data suggest that albumin-bound compounds are
preferentially excreted into bile and metabolized.1100,1104–1106
The mechanism of this interesting phenomenon could include
albumin endocytosis through caveolae (section 2.2.1) or
clathrin-coated regions (section 2.2.2) of the basolateral
membrane of hepatocytes.1107 The signiﬁcance of the en-
docytotic contribution to biliary excretion of chemicals
remains to be assessed.
Biliary excretion is dependent on the structure of chemi-
cals,1108 although no structure-dependent QSAR have been
formulated so far. In a limited series of compounds,
lipophilicity was seen as the rate-determining factor.1109,1110
An atypical convex parabolic dependences of the excretion
rate on lipophilicity were observed for a series of nitroimi-
dazoles.1111
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brain barrier, represented by the brain capillary endothelium
with tight junctions and low endocytotic activity, contains
glucose, amino acid,1112 and nucleoside1033 transporters for
the nutrient uptake. Secretion of organic anions through the
brain capillary endothelial cells and the choroids plexus
epithelial cells is mediated by OAT3 (section 2.3.1.2) at the
brain side, and by the efﬂux via MRP1 (section 2.3.2.3) at
the basolateral membrane.1091
Thanks to therapeutic importance of the blood-brain barrier
permeation, numerous attempts have been made to correlate
structure of chemicals with distribution into the brain. The
models are mostly based on the assumption of passive
diffusion, although the transporters can contribute to per-
meation of some chemicals.1033,1087,1113 In smaller datasets,
lipophilicity,1114,1115 hydrogen-bonding ability,550,1116–1118 po-
larizability, size and shape,1119–1125 cross-sectional area,656,1126
polar surface area,1127–1129 and solvation free energies1130 were
found as the rate- or extent-determining properties. For larger
datasets, numerous topological,1131 electrotopological,1132 and
3-D descriptors based on the VolSurf1133,1134 and GRID1135
approaches were used, and processed by the PLS and
principal component analysis (PCA)1136 techniques. Simple
rules were formulated for the CNS-active compounds: the
number of O and N atoms should be less than ﬁve and
smaller than the logP value.1118
2.3.1.5. QSAR Approaches. In the absence of structural
data on the inﬂux transporters, qualitative pharmacophore
mapping methods1088 and quantitative 3D-QSAR tech-
niques1137 were used to infer the binding site models of
human OATP1B1 and rodent Oatp1a5, respectively. These
approaches provide a spatial arrangement of electrostatic and
steric regions that represent a putative binding site. Assign-
ment of the site model to a speciﬁc state of the protein is
complicated by large-scale protein motions, which are
anticipated for a functioning transporter. Among several
possible interpretations, the simplest one would be that the
protein is in the resting unliganded state, to which the ligands
bind quickly before the molecular machinery is set into
motion.
A descriptor-based QSAR and a pharmacophore model
were derived for human OCT1.1138 The binding to human
dipeptide/tripeptide transporter PEPT1, determined in the
Caco-2 monolayers (section 3.4), was analyzed1139 using the
Volsurf descriptors.655,1140–1142
2.3.2. Efﬂux Transporters
Extrusion of physiologic molecules and chemicals from
cells has mainly been studied for (i) renal and biliary
excretion of physiological molecules, and (ii) cellular efﬂux
of drugs, especially in association with the multidrug
resistance. The two research streams have discovered two
groups of transporters, which are frequently co-expressed
in tissues and have overlapping functions and speciﬁcities,
but differ in structures and mechanisms. The latter attributes
represent the basis for naming the carriers. Some names,
which were initially assigned based on the location and
function (e.g., canalicular multispeciﬁc organic anion trans-
porter, CMOAT), have been changed to reﬂect the structure
and mechanism (CMOAT is now multidrug resistance protein
2sMRP2, which is described in section 2.3.2.3). The
excretion-associated transporters are usually coupled with
compatible inﬂux transporters in the opposite cellular
membrane, while the proteins involved in multidrug resis-
tance may lack this attribute. During intestinal absorption
of nutrients, the efﬂux from enterocytes into the bloodstream
is often performed by the same transporters as the inﬂux
(GLUT, SGLT), reﬂecting the higher speciﬁcity of the
nutrient transporters, compared to other transporters.
2.3.2.1. Tubular Secretion. Excretion of organic ions from
the renal proximal tubule cells into the urine through the
apical membrane proceeds via facilitated diffusion that is
sensitive to membrane potential, and via active exchange
transport.1050,1058 The anion exchange is performed by the
urate transporter (URAT1, SLC22A12),1059 member 12 of the
SLC22A (organic anion/cation transporter) family, OAT4,
and possibly OAT5,1050,1094 as well as by OATP1,1089 and
multidrug resistance associated proteins, such as MRP2,1089,1143
MRP4,1144 and others,1145 which are described in section
2.3.2.3.
Anion transporters with apical location, such as MRP2,
MRP4, PEPT2, OATP1, and some OATs, contain the PDZ
domains, consisting of 70-90 amino acid sequences.1089 The
Type I organic cations (section 2.3.1.2) are excreted into
urine by OCTN1 and OCTN2, while the Type II cations
(section 2.3.1.2) utilize ATP-dependent P-glycoprotein (PGP
or MDR1), which is described in section 2.3.2.3.1058 If the
chemicals, which are actively transported into the tubular
cells, exhibit slow efﬂux, a tubular injury may evolve as a
result of the increase of intracellular concentrations.1094
2.3.2.2. Biliary Excretion. Efﬂux through the apical
(canalicular) membrane of hepatocytes is performed1100–1102
by MRPs, characterized in section 2.3.2.3, which are also
expressed in other organs, and speciﬁc biliary transporters
such as Na+-taurocholate co-transporting polypeptide (NTCP,
SLC10A1),1059 member 1 of the SLC10 (sodium/bile acid
cotransporter) family, and the bile salt export pump (BSEP,
ABCB11),1059 member 11 of the ATP-binding cassette family,
sub-family B MDR/TAP.
2.3.2.3. Efﬂux Pumps. The ATP-binding cassette (ABC)
transporters form a large, ancient family of active transporters
that are widely expressed across species. In bacteria, the ABC
transporters mediate both inward and outward transport, and
they represent up to 4% of all proteins in some proteomes.
Eukaryotes express several dozen ABC transporters each,
all of them acting as efﬂux pumps.1146 They rank among the
most extensively studied transporters, because of their impact
on drug disposition, especially in the connection with the
resistance of bacteria1147,1148 and tumors1149–1154 to drug
treatments. The range of affected compounds is wide and
includes lipids, bile salts, drugs, and toxic and environmental
agents, which are transported against the concentration
gradient across the cell or organelle1155 membranes, using
ATP hydrolysis as the driving force.1044 Human ABC
transporters (49 genes) are divided into seven subfamilies:
ABC1 (subfamily A, 12 members), MDR/TAP (subfamily
B, 11 members), MRP/CFTR (subfamily C, 13 members),
ALD (subfamily D, 4 members), OABP (subfamily E, 1
member), GCN20 (subfamily F, 3 members), and White
(subfamily G, 5 members).1156 Subfamilies B and C seem to
be most relevant for the transport of chemicals.1157 Human
ABC transporters typically consist of 1200-1700 amino
acids. Polypeptides shorter than 800 amino acids, which are
frequently found in subfamilies B and D-G, are mostly half-
transporters, which require dimerization to function. Some
members of subfamily A contain 2100-2600 amino acids,
and the predicted member 13 is even supposed to have more
than 5000 amino acids.1156
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are folded into several trans-membrane domains (TMDs),
each composed of fewer than 10, and most commonly 6
trans-membrane helices. They frequently contain extracellular
N-glycosylation branches that do not seem to be associated
with transport function.1158 The minimal functional unit of
an ABC transporter involved in the efﬂux of chemi-
cals consists of two TMDs and two nucleotide binding
domains (NBDs or ABCs),1159,1160 as illustrated in Figure 9.
The TMDs contain one or more substrate binding sites. The
TMDs exhibit some sequence similarity only if they mediate
transport in the same direction.1161 The NBD sequences are
much more conserved than those of TMDs, because each
contains the conserved Walker A and B motifs, which are
shared by numerous ATP-binding proteins,1162 and an ABC
signature motif (ALSGGQ) that is also called the C motif.
The bound nucleotides (Figure 9) are sandwiched between
the C motif and the Walker A motif from the opposite
NBD.1161,1163,1164 The NBDs act as molecular motors, initiat-
ing conformational changes of TMDs.1160 The same motor
seems to be connected to differing translocation channels.
Therefore, a common mechanism may be shared by the
majority of ABC transporters.1161
Large conformational changes, expected in both the TMDs
and NBDs during the transport process, were conﬁrmed by
diverse conformations that were observed in experimentally
determined structures of transporters. Structural information
for eukaryotic ABC transporters is limited to low-resolution,
electron cryo-microscopy structures of PGP1165–1167 and
MRP1 (see below).1168 For bacterial transporters, structures
of NBDs1169,1170 as well as those of complete transporters
are available. The latter category includes multidrug trans-
porter Sav1866 from Staphylococcus aureus1171,1172 (Protein
Data Bank (PDB)1173 ﬁles 2ONJ, shown in Figure 9, and
2HYD); molybdate/tungstate transporter ModBC-A from
Archaeoglobus fulgidus1174 (2ONK), vitamin B12 permease
BtuCD from Escherichia coli1163 (1L7V), putative metal-
chelate importer HI147Q/71 from Haemophilus inﬂuenzae1175
(2NQ2); multidrug transporter MsbA from E. coli (3B5W),
Vibrio cholerae (3B5X), Salmonella typhimurium (3B5Y,
3B5Z, 3B60), and multidrug transporter EmrE from E.
coli1176 (3B5W, 3B61, 3B62). The MsbA1177–1179 and
EmrE1180,1181 structures were retracted after publication of
the Sav1866 structure1171 and recalculated from original data
to correct the handedness and topology. This structural
insight, as well as the results of the uptake, cross-linking,
labeling, and mutational experiments, and conformational
changes of the NBD domains studied by molecular dynamics
simulations,1182 represent the basis for mechanistic hypoth-
eses. The majority of data in the last four categories are
available for PGP, so most mechanisms are being developed
for this transporter. Various mechanisms for the extrusion
step have been recently proposed.1160,1182,1183 Flipping of the
amphiphilic substrate, i.e., the change of the inward-facing
orientation of the hydrophilic part to the opposite orientation,
is a key step in the extrusion process. A synthesis of
experimental and structural data delineates the following
features of the mechanism, which starts with free PGP in
basal conformation, i.e., with the disengaged NBD domains:
(i) the substrate binds from the inner leaﬂet to a high-afﬁnity
binding site and increases the afﬁnity of the NBDs for ATP;
(ii) binding of ATP brings the NBDs to a closed position
and causes the “power stroke”, which is a movement of the
TMDs leading to the expulsion and ﬂip of the substrate
through the cavity between TMDs to a low-afﬁnity binding
site at the level of the outer leaﬂet; and (iii) ATP hydrolysis
and the release of ADP and phosphate are required to bring
the ABC transporter to the basal state with open NBDs.1159,1184
The most frequently studied efﬂux pump is PGP, also
known as multiple drug resistance protein 1 (MDR1,
ABCB1), which is member 1 of the subfamily B (MDR/TAP)
of ATP-binding cassette family.1059 PGP was discovered as
the cause of the resistance of normal1185 and cancer cells1149–1153
to several cytotoxic agents. The 170-kDa single polypeptide,
consisting of 1280 amino acids, is the most studied ABC
transporter, because of its early discovery and medicinal
importance. The expression in apical membranes of the
intestine,1186–1188 hepatocytes, and renal proximal tubular cells
underlines the actions of PGP in reducing absorption and
enhancing renal and biliary excretion of chemicals. PGP can
also be found in the capillary cells of barrier systems,
especially in the brain, testes, and ovaries,1045 as well as in
a variety of stem cells1189 and tumors. 1149–1153 Its localization
in the cytoplasmic and intracellular membranes leads to the
efﬂux from the cells and changes in the intracellular
distribution of chemicals.1190
The activity of PGP,1191–1193 and probably all transporter
proteins, is heavily dependent on the lipid environment. The
substrate binding sites seem to be in contact with the inner
leaﬂet of the apical cytoplasmic membrane,1194–1196 requiring
special considerations for the description of transport kinet-
ics.1197 The transport kinetics of rhodamine and Hoechst
33342 was explained by a model containing two distinct
binding sites, termed R- and H-sites according to the
increased afﬁnity for the respective substrate.1198 The sites
exhibited positive cooperativity, i.e., binding of one substrate
stimulated the efﬂux of the other substrate, and the efﬂux
was maximal when both sites were modiﬁed. Many but not
all tested substrates could be classiﬁed as either H- or
R-substrates. The H-substrates stimulate the transport of
Figure 9. Structure of the bacterial ABC transporter Sav18661171,1172
(PDB1173 ﬁle 2ONJ) is shown in the ribbon mode (gray). The bound
molecules of the ATP analog adenosine-5′ -( ,γ-imido)triphosphate
are shown in blue.1291 The approximate position of the bilayer is
indicated by horizontal lines.
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the R-substrates exhibit an inverse pattern.1158
In addition to the induction by many chemicals, PGP is
up-regulated in some in vitro models of tissue regeneration,
and in cells treated by growth factors, as recently re-
viewed.1189 The PGP expression prevents apoptosis via a
direct interference with the caspase-dependent pathway.1199,1200
These facts have been put together in a hypothesis stating
that PGP protects the stem cells from apoptosis during natural
stress conditions, aside from the effects of chemicals.1189
Tumors seem to contain a subpopulation of cells with the
stem cell characteristics, which are capable of initiating new
tumor growth.1201 Through PGP induction, some chemo-
therapies could actually enrich the stem cell subpopulation
in tumors and promote their resistance.1189 These facts may
help analyze the failures of clinical trials with the PGP
inhibitors.1202
Extensive photoafﬁnity labeling studies on binding of
different substrates to PGP and single-point mutagenesis
analyses, as recently reviewed,1045 delineate the associations
between structure and function. The PGP ability to bind a
variety of structures was hypothesized to result from the
presence of a large binding site with a set of hydrophobic
and hydrogen-bonding points, which can anchor substrate
molecules in different binding modes.1203
The pregnane X receptor, exhibiting a broad substrate
speciﬁcity, is involved in transcriptional regulation of PGP
and multiple CYPs.1204 A broad substrate speciﬁcity of PGP
overlaps remarkably, although not completely, with that of
CYP3A4 (described in section 2.5.1.1). This fact, along with
the co-localization of the two proteins, indicates the existence
of a concerted defense mechanism against exogeneous
compounds.1157,1205–1207
Multidrug-resistance-related proteins (MRPs), the subfam-
ily C (CFTR/MRP)1059 of the ABC family, have a potential
to confer resistance to chemotherapy. Clinically, this role
has been proven1044 for MRP1 (ABCC11059). MRPs act as
efﬂux pumps for glutathione, glucuronate, and sulfate
conjugates of many drugs and chemicals.1208 The efﬂux
caused by several MRPs was inhibited by plant ﬂa-
vonoids.1209 MRP1 is expressed in all tissues except the liver,
and it is localized at the basolateral pole of the cells. MRP2
is found mainly in the apical membranes in the liver,
intestine, and kidney.1044 MRPs 1-3 contain ∼1530 amino
acids1156 in three TMDs and two NBDs. The N-terminus
protrudes, in contrast to other ABC transporters, outside the
cell, and the C-terminus is located in the cytoplasm.1158,1210
MRPs 4 and 5 are shorter; they contain 1325 and 1437 amino
acids, respectively, which are organized in two TMDs and
two NBDs.1158 For MRP1, the low-resolution structural data
were obtained by electron microscopy of negatively stained
particles and 2D crystals of the protein in a lipid bilayer.1211
The X-ray structure of MRP1 NBD shows a nonproductive
conformation that may be associated with low ATPase
activity.1212
Breast cancer resistance protein (BCRP, ABCG2), member
2 of subfamily G of the ABC family,1059 is a half-transporter
that contains 655 amino acids in only one six-helix TMD,
and one NBD.1044 BCRP needs to dimerize for function.1213
Its substrate spectrum is similar to those of MRPs, but is
more restricted. In addition to the breast tissues, BCRP is
found in the liver, intestine, placenta, and also in stem
cells.1213 Its expression is promoted by hypoxia;1214therefore,
it is found in venous and capillary endothelia, but not in
arteries.1215
2.3.2.4. QSAR Approaches. Medical signiﬁcance and
comparatively early discovery have made PGP a prominent
target of the studies between structure of chemicals and their
efﬂux. The algorithms for prediction of efﬂux transport of
chemicals by PGP and other transporters, and the effects of
chemicals on this process were recently reviewed.1216,1217
Homology between bacterial efﬂux transporters and
PGP1149 was used to obtain structural models of PGP. Kinetic
parameters of the interactions between PGP and 34 drugs
were correlated with the partition coefﬁcients and surface
areas.1218 Structural requirements for binding of chemicals
to PGP, such as amphiphilicity and certain volumes, were
generalized based on a structural comparison of known PGP
substrates.1219 More-detailed information about structural
requirements for binding and, indirectly, the geometry of the
binding site was obtained1220,1221 by classiﬁcation analysis,1222
pharmacophore studies,1203,1223,1224 pseudo-receptor model-
ing,1225 GRIND descriptor studies,1226 and 3D-QSAR
analyses,1227–1232 which were combined with the homology
models, based on the available bacterial ABC transporter
structures.1233,1234 Diverse PGP substrates and modulators
were shown to be predominantly localized at the headgroup/
core interface.1235 In addition to binding afﬁnity, the interface
concentration is an important determinant of the overall efﬂux
rate and must be considered when making quantitative
predictions. In this context, the knowledge of solvation
energies in individual headgroup regions (section 2.1.3.3)
may help in a quantitative understanding of the efﬂux by
PGP and other transporters.
The QSAR studies for MRPs and BCRP were performed
less frequently and generally are less sophisticated than those
for PGP. In many cases, the conclusions are limited to the
importance of individual substructures for efﬂux or its
inhibition in MRP1236–1242 and BCRP.1243 The MRP1 and
MRP2 efﬂux characteristics were correlated with fragment
occurrences1244 and topological indices.1245 A spatial phar-
macophore was generated for MRP11246 and MRP2,1247 and
compared with that for PGP. Ligand-based 3D-QSAR studies
were performed for MRP2.1248
2.4. Binding to Body Constituents
Along with lipids, proteins are the most probable candi-
dates for binding of chemicals, because of their signiﬁcant
physiological concentrations and the ability to participate in
practically all types of intramolecular and intermolecular
interactions. Strong (covalent) and weak (noncovalent)
interactions differ in the magnitude of the liberated interaction
energy (more or less than 40 kJ/mol, respectively), and the
distance between the most closely located atoms of the
molecules of the chemical and the cell constituent (more or
less than 2 Å, respectively).1249 The weak, noncovalent
interactions include hydrogen bonding, electrostatic interac-
tions, dispersion (van der Waals) interaction, and the charge-
transfer interaction. The weak complexes are created quickly
and spontaneously when two molecules come into contact,
while the covalent bond formation requires certain activation
energy to overcome the energy barrier. These facts are
closely related to the kinetics of the processes: while a weak
interaction is completed within milliseconds,1250 formation
of a strong covalent bond often requires minutes, hours, or
days.
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reached, as a rule, within milliseconds, unless covalent bonds
are formed or large protein motions are elicited. Proteins
can be classiﬁed into four types, according to the conse-
quences of the binding event: receptors, metabolizing
enzymes, protein carriers, and the remainder, which are
sometimes called silent receptors. The receptor binding elicits
bioactivity, the binding to enzymes is a prerequisite for
metabolism, and the binding to protein carriers facilitates
some transport steps. In these three structure-speciﬁc events
(see section 1), the binding of chemicals usually exhibits
high afﬁnity, limited capacity, and a tendency toward one
major orientation and conformation (binding mode) of the
bound molecules of chemicals.
The majority of proteins belong to the category of silent
receptors. They frequently contain several binding sites
within each molecule. From the pharmacokinetic viewpoint,
the silent receptors serve as a depot: they bind free molecules
of chemicals, decrease their concentration that is accessible
to other processes, and liberate the bound molecules when
the concentration has dropped. The binding to silent receptors
is typically linked with low afﬁnity, high capacity, and
multiple binding modes.
For the formulation of the QSAR models for large sets of
diverse compounds eliciting the effects at the cell to organism
levels, binding to the most abundant proteins must be
analyzed and correlated with structures. The preponderant
human proteins are albumin in plasma, collagen in interstitial
space, and G-actin in cells. Analyses of a broader set of
proteins would lead to more-precise predictions.
2.4.1. Serum Albumin
Albumin is present in human plasma in concentrations of
∼0.6 mM or 40 g/L.1251 The binding of sulfonamides to
human serum albumin (HSA) and the consequent drug
inactivation were observed in the early 1940s.1252 At the end
of that decade, the ﬁrst comprehensive review on drug
interactions with plasma proteins was published.1253 The
binding to HSA is usually determined after protein separation
by dialysis, ultracentrifugation, or ultraﬁltration.1254 For
compounds absorbing or emitting UV-Vis light, direct
methods avoiding the separation of HSA are available.1255
HSA, immobilized in a way that maintains accessibility of
the binding sites, was used to determine the binding of
chemicals by liquid chromatography,1256–1267 capillary elec-
trophoresis,1268 and surface plasmon resonance analysis.1269
These methods are reproducible and fast, especially the last
technique in combination with microﬂuidics.1270 However,
there is a concern regarding the artifacts, which may originate
from the inability of the immobilized HSA to undergo large-
scale movements, possibly induced in free HSA molecules
by the binding event.1271–1273 While the studies usually
document that the HSA binding afﬁnities for the studied set
are comparable with those determined by other techniques,
the role of large-scale HSA movements may become
important for the next analyzed ligand. The PAMPA setup
(section 2.1.2.2) with HSA present in the acceptor compart-
ment allows the binding afﬁnity determinations at an
intermediate throughput, and without the potential for
aforementioned complications.1274
HSA is composed of three homologous R-helical domains,
differing in structural and functional characteristics. Each
domain contains subdomains A and B, which share common
structural elements. HSA undergoes three pH-dependent
structural transitions: two in the acidic range and one in the
slightly alkaline range.1275 Among the up to 11 binding sites
for fatty acids,1276 there are at least 3 high-afﬁnity sites for
small molecules: the primary hemin site in domain 1,1277 the
primary warfarin site (drug site I) in domain 2A, and the
primary diazepam site (drug site II) in domain 3A.1278
Displacement of ﬂuorescent markers by studied chemicals
can be used to distinguish between associations with some
sites: warfarin and dansyl-sulfonamide mark the 2A site, and
dansyl-sarcosine points to the 3A site.1279
Structural details of the binding sites were clariﬁed after
the 3D structures of albumin1280–1284 and its complexes with
small molecules1276,1285–1290 had become available. One of
the X-ray structures of HSA, with binding cavities and
ligands1287,1290 (structures in Chart 4) bound in sites I and II
visualized using the Sybyl module SiteID,1291 is shown in
Figure 10. Interestingly, the drugs prefer the drug sites I and
II, although each ligand also has at least one secondary site
in other domains.1277 Binding of a fatty acid changes the
polarity and volume of the drug site I.1290 These facts, along
with the pH-dependent transitions, underline the difﬁculty
of the HSA binding predictions under physiologic conditions.
Binding in multiple sites was detected by diffusion NMR
and transferred nuclear Overhauser effect (NOE).1272 The
NOE spectroscopy was combined with conformational
analysis to identify the binding modes of some site I
ligands.1292 Restricted MD simulations were used to analyze
the ionization states, water bridges, and functional roles of
Chart 4. Albumin Ligands with X-Ray Structural Data of
the Complexes (Also See Figure 10)
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metal ions to the N-terminal of HSA was examined by both
classical mechanics and quantum mechanics.1294
The development of prediction approaches to the HSA
binding afﬁnities follows the general trend in the area of
QSAR modeling: qualitative identiﬁcation of binding-
enhancing structural features1295 was developed into the
dependencies, within homologous series, on physicochemical
properties, such as lipophilicity1263,1266,1296,1297 and ioniza-
tion;1254 followed by the fragment-based approaches for
diverse chemicals;1278,1298–1300 and the PLS or neural networks
models with numerous global1263,1301–1303 and 3D varia-
bles.1304,1305 The most advanced step, the estimation of free
energies of binding to HSA based on the atom-level
simulationsusingtheﬂexible3Dstructureofalbumin1276,1280–1290
is yet to appear. A reliable prediction of HSA binding is
important for estimation of the overall fate of chemicals
because, at the high HSA concentration in plasma, even the
modest afﬁnities result in a signiﬁcant decrease of the free
concentrations of chemicals. This task is complicated by two
factors: (i) the low association constants represent a challenge
for the prediction methods; and (ii) the low-afﬁnity binding
to the abundant protein results in an easy replacement of
the bound chemical by another, only slightly better ligand,
with subsequent signiﬁcant effects on the disposition of both
compounds.
2.4.2. Extracellular Matrix
The basement membranes, which are parts of the extra-
cellular matrix (ECM), are formed by Type IV collagen in
association with laminin, entactin, and heparan sulfate
proteoglycans.1306 ECM is the most abundant protein mixture
in the extracellular space. Recently, we described a simple
method for monitoring of the binding of chemicals to
ECM.1307 The simple dependencies of the association con-
stants on lipophilicity hold only for rather small homologous
series.1307 To obtain predictions of ECM binding for large
and diverse series, the 3D-QSAR methods1308 that capture
the averaged shapes and properties of the binding sites have
been applied.1309
2.4.3. Intracellular Proteins
G-actin represents 10%-20% of intracellular protein of
mammalian cells. Analytical techniques to be used for the
determination of the association constants are similar to those
utilized for albumin (section 2.4.1). The G-actin association
constants can be analyzed by receptor-based QSAR methods,
using the available X-ray structure.1310 There seem to be no
QSAR studies available yet for the binding of chemicals to
G-actin.
2.4.4. Binding versus Structure and Properties
The QSAR models for binding to albumin and other
proteins are summarized in the preceding sections. There are
some unique aspects of the QSAR models of nonspeciﬁc
protein binding that deserve attention.
The speciﬁcity of binding to nonreceptor proteins is much
lower than that of the association with the receptors. As a
consequence, multiple binding modes of a compound can
be encountered much more often than in the case of the
receptors. The formulation of QSARs for this situation
requires special treatment, because the observed association
constant is the sum of the association constants for individual
modes. Based on this premise, we have been developing a
ligand-based multimode 3D-QSAR procedure to model
unknown receptor sites for several years.146 The multimode
approach is also useful for the receptors with known
structures, because the standard MD simulations do not
sample the conﬁgurations too different from the starting
situations, and the use of several starting conformation
improves the sampling.1311
Among different weak interactions of ligands in the
binding sites, hydrophobic interactions exhibit the lowest
structural speciﬁcity. The reason is that the substructures
forming hydrophobic interactions, i.e., nonpolar amino acid
residues and alkyl or aromatic ligand parts are quite ﬂexible.
Consequently, within a homologous series, the association
constants K quantifying binding to silent receptors frequently
are dependent on lipophilicity, characterized by the reference
partition coefﬁcient P,1312 as
K)BP
  (4)
Here, B and   are empirical coefﬁcients, which are described
in more detail in eq 43 in section 10.2.2. Equation 4 is also
valid for the reciprocal values of the Michaelis-Menten
constants (eq 45) in some cases.1312 The empirical coefﬁcients
B (for binding) and   are speciﬁc for the chemicals and the
protein. For the binding of various series of chemicals to
the same protein, the Collander exponent   often remains
identical for all series, and the linear coefﬁcient B varies to
reﬂect the involvement of other than hydrophobic interactions
participating in the binding of the parent molecule.1313 It is
not clear if this fact might play a role in the QSAR models
of complex biosystems, where many different proteins
function as silent receptors, and the coefﬁcients B and   in
eq 4 are their averaged values.
Figure 10. The X-ray structure of human serum albumin (HSA)
with ligands bound in the drug sites I (right) and II (left). Structures
of the ligands (tubes shown in colors) are summarized in Chart 4
(number, the Protein Databank (PDB) ﬁle): 3-carboxy-4-methyl-
5-propyl-2-furanopropionic acid, CMPF (46, 2BXA);1290 propofol
(47, 1E7A); halothane (48, 1E7B);1287 diﬂunisal (49, 2BXE);
diazepam (50, 2BXF); ibuprofen (51, 2BXG); indoxyl sulfate (52,
2BXH); azapropazone (53, 2BX8); oxyphenbutazone (54, 2BXB);
phenylbutazone (55, 2BXC); warfarin (56, 2BXD); 3,5-diiodosali-
cylic acid, DIS (57, 2BXL);1290 and 2,3,5-trioiodobenzoic acid, TIB
(58, 1BKE).1285 The PDB1173 ﬁles were superimposed with respect
to C-R carbon atoms. The cyan spheres1290 represent potential
binding cavities identiﬁed using the Sybyl module SiteID.1291 Many
of the cavities serve as binding sites for fatty acids and thyroxine
and as secondary sites for some of the shown drugs. Individual
domains are marked.
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binding to a mixture of proteins can still exhibit speciﬁcity,
as we recently showed for ECM.1309 In such cases, the 3D-
QSAR techniques must be applied, which must be modiﬁed
to describe the averaging process for binding to multiple
proteins. The observed association constant, shown in eq 41
in section 10.2.2, must be described by the expression
containing the elementary association constants in the right-
most term of eq 39. The reason is that the standard 3D-
QSAR equations can only be applied to the elementary
association constants for the binding to one site. The proper
equation for derivation of a conceptual 3D-QSAR study is
obtained from eq 41 by back-substitution from eqs 40 and
39. The resulting 3D-QSAR equation is nonlinear with regard
to the optimized coefﬁcients, and it contains the fractions of
individual binding sites and the fractions of individual
species. While the former fractions are usually unknown and
must be ﬁtted as the optimized coefﬁcients, the latter fractions
may be estimated using the known dissociation constants
and ion-pairing association constants of chemicals in aqueous
media.
Unbound fractions are used in the practical pharmacoki-
netic models for individual drugs to adjust the dosing
regimens. The typical ranges of this parameter are tabulated
for individual drugs in drug monographs. However, the
unbound fraction is not a true drug characteristic, because it
is dependent on the protein concentration. Consequently, a
direct use of this parameter in the QSAR models1304,1314,1315
is not warranted, unless the data are measured under the same
conditions. Rather, the unbound fraction values should be
recalculated to the association constants, which are related
to the free energy of binding.
2.5. Metabolism
Covalent reactions, along with excretion, represent the
route for elimination of chemicals from biosystems. The
reactions are either spontaneous or enzymatically catalyzed.
Metabolism in organisms proceeds predominantly in the
hepatocytes1316 but other cell types also contribute. Metabo-
lism can affect the outcomes of in vitro experiments in
preparations of subcellular organelles and cell suspensions,
as well as in isolated tissues, organs, and organisms.
2.5.1. Enzymatic Reactions
Generally, a distinction is made between two phases of
biotransformation. Phase-I reactions are mostly catalyzed by
cytochromes P450 and include hydrolytic, oxidative, and
reductive processes.1317 The products of the Phase-I reactions
or the unchanged molecules are conjugated with hydrophilic
endogenous molecules (e.g., amino acids, glutathione, glu-
curonide, sulfates) in the Phase-II reactions.
2.5.1.1. Cytochromes P450. The largest fraction of me-
tabolism, up to 90% of the Phase-I metabolism of current
drugs,1318 is performed by cytochromes P450 (CYPs). The
40-50 kD enzymes with a single heme group1319 catalyze
the hydroxylation of numerous substrates, increasing their
aqueous solubility and accelerating renal excretion.1319 Orig-
inally discovered in mammalian liver microsomal prepara-
tions (section 3.1.1)1320 and named after the distinct UV-
Vis absorption band at 450 nm,1321,1322 CYP mono-oxygenases
have subsequently been found in almost all organisms. The
counter-examples are rare and include, e.g., Escherichia coli
and Salmonella typhimurium.1323 In the superfamily of more
than 1000 CYPs, 57 CYPs are expressed in humans.1324
Human CYPs metabolize more than a thousand known
substrates, and ∼15 CYPs are involved in the degradation
of xenobiotics.1323 The CYP isoforms 3A4 and 2D6 are
responsible for the metabolism of 50% and 30%, respec-
tively, of current clinically used drugs.1325 The levels of some
CYPs in humans are highly regulated, whereas others (e.g.,
CYP2D6) exhibit considerable differences,1326 leading to
signiﬁcant individual variation in pharmacokinetics of drugs.
CYP3A4 is upregulated by the nuclear hormone receptor
PXR (pregnane X receptor). Both proteins bind a similar
broad range of lipophilic chemicals1327 and represent the
sensor and executioner of the axis of defense against
xenobiotics.1328 The CYP isoforms 1A1, 1B1, and 1A2 are
regulated by the aryl hydrocarbon receptor.1329,1330 Monitoring
the actual CYP isoform levels in individual patients is one
of the ﬁrst components of modern approaches to personalized
medicine.
In mammals, CYPs are located mainly in the liver;
however, they can also be encountered in the intestine and
tumors. While CYPs of eukaryotes are mainly anchored in
the endoplasmic reticulum, some are also found in mito-
chondrial membranes.1331,1332 All CYPs in the endoplasmic
reticulum receive electrons from a single ﬂavoprotein:
NADPH-P450 reductase. The mitochondrial CYPs use an
electron transport chain with the iron-sulfur protein adreno-
doxin and the ﬂavoprotein adrenodoxin reductase.1323 The
electron transfer proteins bind on the side of the CYP that
is proximal to the heme.1333,1334 Although the structures of
individual components have been determined, only structural
models of the complex are available.1335 CYPs can be
induced by various chemicals and this ability, in limited
series of compounds, increases with lipophilicity.1336 The
studies of CYP interactions with model bilayers355,1337 are
important for understanding the CYP mechanism and the
prediction of CYP metabolism.
Bacterial CYPs are soluble; therefore, they were crystal-
lized and analyzed using XRD much earlier1338–1350 than
rabbit CYP2C5,1333,1333,1351,1352 and human CYP3A41353,1354
(Figure 11) and CYP2C9.1355,1356 The structures show that
CYPs have large, ﬂexible binding sites, which can accom-
modate more than one substrate molecule,1357,1358 and allow
for mutual inﬂuences of chemicals, which can act as
substrates, activators, or inhibitors. The size of the binding
cavity can explain the majority of complicating factors of
CYP-mediated metabolism, which include broad speciﬁcity
of individual subtypes,1359 atypical allosteric kinetics,1360–1362
activation, substrate inhibition,1362 stereoselectivity,1362
regioselectivity,1363–1368 cooperativity,1369,1370 and formation
of multiple metabolites of some chemicals.1369,1371–1373
The active site of CYPs is buried deep in the protein next
to the heme co-factor that plays an important role in
activating the molecular oxygen.1374 In the absence of
substrate, the Fe3+ ion of the heme is hexacoordinated with
four heme-pyrrole nitrogens in a planar arrangement, the
sulfur of a cysteine below the heme, and a water molecule
on the opposite side.1339 When ligated to water, the Fe3+ ion
prefers the hexacoordinated, low-spin state (S ) 1/2), in which
the ﬁve 3d electrons are maximally paired. The spin state
remains low when the inhibitors are bound, forming a
coordination bond with the iron. The substrates interacting
with the binding pocket above the heme and expulsing the
aqua ligand without a substantial interaction with the iron,
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to the high-spin state (S ) 5/2), when the ﬁve 3d electrons
are maximally unpaired.1375 The spin changes are reﬂected
in the UV-Vis spectra and frequently are used for a
convenient measurement of binding afﬁnities of inhibitors
and substrates. The absorbances at 390 and 420 nm have
been linked to the low-spin iron and the high-spin, penta-
coordinated iron, respectively, using a range of quantum-
chemical techniques.1375–1377
The high-spin Fe3+ ion moves out of the heme plane and
becomes more prone to reduction to the Fe2+ i o nb yt h e
electron transfer from NAD(P)H. Dioxygen binds to the Fe2+
ion, where it is stabilized by a network of hydrogen-bonded
water molecules and acidic amino acid residues,1378 and
cleaved, following the second reduction. The resulting iron-
linked O atom is a potent oxidant. The substrate is bound in
the way ensuring proximity of the pertinent substrate atom
to the iron-linked O atom for regioselective and stereose-
lective hydroxylation. The overall stoichiometry of the
hydroxylation reaction includes the chemical, dioxygen, two
protons, and two electrons on the substrate side, and the
hydroxylated metabolite and water on the product side. The
efﬁciency of the process can be diminished by reduction of
the intermediateds to hydrogen peroxide or water. The futile
reactions are facilitated by the presence of water in the active
site. The elementary steps of CYP-catalyzed metabolism have
been studied in great detail,1379 and only the most important
steps have been summarized above.
The CYP active site is often completely isolated from the
medium. The protein must undergo dynamic motions to allow
substrates to enter and products to leave the active site. These
movements are accompanied by complementary water dif-
fusion, for which a water channel was postulated.1340,1380 This
route can also be used by protons.1334 The replacement of
water by a substrate shifts the redox potential toward the
Fe2+ form.1381,1382 Three routes for substrates and products
were identiﬁed, based on Random Expulsion1383 and Steered
MD simulations,1384 and an analysis of the thermal motion
factors in the X-ray structures.1385 The preference for a route
is dependent on properties of the transported chemical and
varies among CYPs.1386 For mammalian CYPs, two routes
were suggested: a one-way route from the bilayer for
membrane-bound substrates, associated with a one-way route
into the aqueous surroundings for the products; and a two-
way route connecting the active site with the aqueous
medium for more water-soluble substrates and products.1387
CYPs are rather ﬂexible, and the X-ray structures with
different geometries of the channels (closed, open just for
water molecules, and open for larger substrates1343) were
observed.1334 Several steps in hydroxylation of camphor by
CYPcam, revealing structures of the intermediates, confor-
mational movements of the amino acid residues, and changes
in the water network, were captured using cryocrystallog-
raphy.1388
Reactive intermediates produced by CYPs may bind to
proteins or react with water and other low-molecular-weight
constituents. The protein adducts have long been implicated
in organ toxicity, especially in the liver.1389–1393 Although
some nontoxic compounds also form protein adducts, the
potential for toxicity leads to a close monitoring of the adduct
formation in the development of bioactive compounds.1394,1395
The approaches include binding of labeled compounds to
microsomal fractions,1394 reaction of chemicals with glu-
tathione that is monitored using a ﬂuorogenic competitor,
and 2D NMR analysis (ALARM NMR) of binding to
isotopically labeled human La antigen, whose two cysteins
can react with chemicals or change the oxidation state in
the presence of chemicals.1396
NMR can potentially play an important role in monitoring
the binding modes of compounds in the active site of CYPs,
thanks to the presence of a natural paramagnetic iron of the
heme. The relaxation induced by unpaired electrons provides
information about the distance to the iron,1397,1398 in addition
to the identiﬁcation of the interacting parts of the molecule.
The proton-iron distances can be used as constraints for
the docking of ligands to CYPs.1399
The importance of CYP metabolism in the development
of bioactive compounds has led to a continuous interest in
prediction of all aspects of CYP interactions with chemi-
cals,1400 including the induction of different CYP isoforms.1401
The induction process in rat hepatocytes was analyzed as a
function of structure of 4-n-alkyl-methylenedioxyben-
zenes.1402
Metabolic rates and their inhibition were often analyzed
as a function of structure or properties of substrates and
inhibitors. In a limited series of substrates and inhibitors,
CYP binding or metabolism were frequently found to
correlate with electronic indices1403 or lipophilicity.1404–1409
The correlations are series-speciﬁc, and different correlations
for the same CYP are not uncommon.1410 Empirical correla-
tions with large numbers of descriptors, processed by soft-
modeling techniques, such as linear regression,1411 neural
networks,1412 PLS regression,1413,1414 and k-nearest-neighbor
variable selection1415 extended the scope to larger sets of
chemicals. Predictions for more-diverse chemicals required
a 3D approach. The long absence of the mammalian CYP
structures resulted in numerous ligand-based 3D-QSAR
models of the CYP binding for both substrates1416–1422 and
inhibitors.1423–1428 The 3D-QSAR models were combined with
comparative structural models, which used bacterial,1425,1429–1432
rabbit,1433–1437 and human1438 CYP structures as templates.
Peculiar properties of the CYP binding sites, including sizes
that often exceed the size of common ligands, conformational
changes, and the possibility of accommodation of two bound
molecules, led to less-predictive docking than for those with
other receptors.1438,1439 The success rates were improved by
re-parameterization of the ligand-iron interactions by knowl-
edge-based potentials, and a new parameterization of lipo-
philicity contributions of the planar heme nitrogens.1440 The
estimation of binding free energies1378,1441 is complicated by
Figure 11. X-ray structure of human CYP3A4, with bound
metyrapone (blue) shown close to the heme (red) and progesterone
(blue) at the top of the protein.1353,1354 The PDB1173 ﬁles 1W0F and
1W0G were superimposed with respect to C-R carbon atoms.1291
The cyan spheres1290 represent the binding cavity identiﬁed using
the Sybyl module SiteID.1291
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problematic exchange of the water molecules displaced by
ligand binding with the medium was emulated by coupling
of MD and Grand Canonical MC simulations.1442 A more
precise description of the CYP metabolism and prediction
of structures and formation rates of individual metabolites
is a formidable task.
Predictions of the sites of metabolism in the structures of
metabolized molecules1443,1444 were performed using quantum-
mechanical (QM) reactivity calculations,1403,1445
QSAR approaches,1446 and pharmacophore-based proce-
dures1420,1430,1431,1433,1447 on substrate molecules, and dock-
ing1439 utilizing the structural information about the binding
site. Practical software applications use either knowledge-
based rules or a simpliﬁed simulation of the interaction
between the pertinent CYP and the metabolized molecule.
The former category includes the commercial expert systems
MetabolExpert,1448 METEOR1449–1452 and META.1453 The
software tool MetaSite1454 is the only representative of the
second category. The binding sites in the homology models
of several CYP isoforms are characterized by the GRID-
based descriptors and the substrate molecules are described
by clustered atom distances.1455 A comparison of the resulting
binding site and substrate ﬁngerprints provides the acces-
sibilities of individual hydrogens in the substrate molecule.
The accessibilities are multiplied by estimated, semi-
quantitative hydrogen abstraction energies to provide a
probability of metabolism for each position.1456
2.5.1.2. Other Enzymes. Phase-II enzymes, hydrolases,
and other metabolizing enzymes were studied less extensively
than CYPs. For a limited series of compounds, the biotrans-
formation rate parameter can be dependent linearly on a
single property, such as the reactivity in the reaction imitating
the pertinent process in the reaction center of the enzyme1457
(section 2.5.2), relevant QM indices,1458–1462 or the partition
coefﬁcient,1463 if the noncovalent binding to the enzyme is
dependent on lipophilicity and all the other parameters are
invariant. For diverse compounds, the ligand-based1464,1465
or receptor-based 3D-QSAR methods1466 were applied. If the
prediction of disposition of diverse chemicals in organisms
is of interest, the in-vitro-measured metabolism parameters
often may be the best choice, considering the complexity of
the QSAR prediction of metabolism. The scale-up procedu-
res1467–1475 can be improved using the SBSP models. Kinetic
issues are addressed in section 10.2.3.
2.5.2. Spontaneous Reactions
This category of elimination processes is comprised of
hydrolysis, as well as the reactions of chemicals with low-
molecular-weight body constituents and macromolecules.
Abundant are the reactions of chemicals with cellular
nucleophiles such as free amino acids, glutathione, and
proteins.1476 Spontaneous reactions do not require a preceding
binding of the chemical to a macromolecule, and they are
comparatively easy to imitate in vitro. The rate constants
measured in the reaction mixtures mimicking biological
conditions belong to the most-precise reactivity parame-
ters.1477,1478 The experimentally determined reaction rate
parameters for a reference reactant (k) can be used to assess
the parameters for other reactants (kx) in similar reactions,
as, e.g., in nucleophilic additions to different acceptors:
kx)Ark
 r (5)
The empirical coefﬁcients Ar and  r are dependent on the
reactants and the reaction conditions. The reference reactants
used include 4-(p-nitrobenzyl)pyridine, thiourea,1479 gly-
cine,1480 cysteine,1481 and thioglycolic acid.1482–1484 Empirical
substituent constants and QM indices related to the electron
density at the reaction centers in intact molecules and
transition intermediates1485–1489 can be used to substitute the
rate parameters of the spontaneous biological reactions.
The reactivity parameters were mainly applied in the
QSAR studies of toxicities or other effects of alkylating
agents. In these studies, the dependence of the effect on
reactivity frequently exhibits an optimum.1457,1490,1491 This
behavior reﬂects the interplay of two phenomena, binding
to the receptors and metabolism, which may both involve
similar chemical reactions behaving according to the non-
linear dependence described in eq 5. While the receptor
binding increases with reactivity, the disposition in the
receptor surroundings is independent of low reactivity and
decreases after reactivity exceeds a certain limit (see eq 13
in section 5.2). The increase in reactivity of chemicals leads
to more-pronounced effects up to the point when high
reactivity causes a fast elimination of the compounds, which
are no longer able to reach the receptors in meaningful
concentrations.
3. Disposition of Chemicals
The disposition of chemicals in biological systems has
been experimentally analyzed at different levels of complex-
ity, starting with membrane vesicles, subcellular organelles,
cells, cell monolayers, biological sheets, up to organs and
organisms. In this section, a brief overview of the most
frequently studied biosystems and used techniques is pro-
vided. The coverage could not keep up with the abundance
of published studies in all mentioned areas, but especially
for the perfused organs (section 3.7) and organisms (section
3.8), and lists only the most important developments. The
relationships between the transport or accumulation and
physicochemical properties are analyzed, where available.
In contrast to section 2, which focused on individual steps,
in complex systems, several interactions between chemicals
and biosystem components participate in the overall outcome.
3.1. Membrane Vesicles
The vesicles form spontaneously under appropriate ex-
perimental conditions from complete membranes in tissue
homogenates and are isolated from other cellular material
by differential centrifugation. Historically, availability of
these systems was associated with the progress in the
biochemical separation techniques: the microsomal fractions
were ﬁrst prepared in the 1940s, while membrane vesicles
appeared in the 1970s.
Some of the membrane proteins in these preparations
function as transporters or metabolizing enzymes, while
others play more-passive roles. Integral and peripheral
membrane proteins diminish the surface area available for
passive transport, causing the process to become slower. The
binding of chemicals to both integral and peripheral mem-
brane proteins leads to a decrease in the free concentration
of chemicals, thus reducing all types of transport.
3.1.1. Endoplasmic Reticulum Vesicles
Microsomal vesicles are derived mainly from endoplasmic
reticulum, but the cell membrane and the membranes from
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present.1492 The majority of these minor microsomal com-
ponents sediments out, along with intact cells, mitochondria,
and nuclei, during centrifugation of a tissue homogenate at
9000g. The resulting supernatant, which is called the S-9
fraction, contains mainly endoplasmic reticulum and soluble
enzymes and is sometimes used for metabolic activation of
chemicals to test biological effects of metabolites.1493,1494
More-intense centrifugation of the supernatant at ∼100 000g
pelletizes the microsomal membranes, which are usually of
a reddish-brown color because of the high content of the
CYP heme.1495 The vesicles were prepared from the
liver,1496–1501 brain,1502,1503 lungs,1504 heart,1505,1506 kidney,1505,1507
intestine,1508,1509 skeletal muscle,1510,1511 placenta,1512 leukemic
cells,1513 and other sources. The vesicular structure of the
microsomes was demonstrated by electron microscopy.1514
The preparations were ﬁrst used to characterize subcellular
location of enzymes,1498 other macromolecules,1515 and
metabolic processes.1503,1504,1512 Microsomes have been mainly
appliedtothestudyofmetabolismofchemicals.1472,1475,1494,1516–1518
Although the microsomal data serve as the input for
prediction of hepatic metabolism,1469,1519,1520 the uptake and
transport studies in the microsomes focused on physiological
molecules,1521–1524 and the data on chemicals are rather scarce.
Because the substrates may access the CYP binding sites
from the membranes,1387 the concentrations of chemicals in
individual bilayer regions (sections 2.1.4.1 and 2.1.3.3) are
important determinants of the overall kinetics.
The assessment of stability of chemicals in microsomes
or S-9 fractions with different levels of expressed CYP
isozymes belongs to the standard components of meta-
bolic1525 and drug-drug interaction1526 tests in preclinical
drug-development process. The data have been processed
by three categories of models: (i) predictions of in vivo
metabolic clearance of individual chemicals,1469,1519,1520 (ii)
QSAR analyses of the rate of metabolism, and (iii) predic-
tions of the site of metabolism. The QSAR models in the
second category usually utilize empirical approaches based
on numerous descriptors, which are calibrated by regression
analyses1411,1527 or by the variable selection based on the
model-free k-nearest-neighbor intrapolation.1415 The predic-
tions of metabolic sites in the third category are listed in
section 2.5.1.1, because they are based on the structure of
pertinent CYPs.
3.1.2. Cell Membrane Vesicles
Different techniques were used to prepare vesicles from
cell membranes of epithelial cells, either from apical, brush
bordermembranesfromtheintestine,1528–1530renaltubules,1531,1532
and placenta,1533–1535 or from renal basolateral mem-
branes.1529,1536,1537 The brush border membrane vesicle form
spontaneously by segmentation of the microvilli in the
preparation process, so the correct polarity of the membrane
is maintained.1538 They were mainly used for the monitoring
of the active transport of physiologic molecules. Studies on
the transport of chemicals are rare.1539
Red blood cells, which represent ∼45% (hematocrit) of
the blood volume, lack a nucleus and organelles. Their
membranes are sometimes isolated and resealed to generate
vesicles for the study of transport and accumulation of
chemicals. Erythrocyte ghosts are prepared by hypotonic1540
or isotonic1541 lysis at 4° C, washing the membranes, and
subsequent resealing at 37° C, whereby lipid asymmetry is
aborted.1542 Membrane proteins of erythrocytes include
several MRP efﬂux pumps (section 2.3.2.3),1543 and the
vesicles were used to measure the outward transport of
amphiphilic molecules.1544 The ease of preparation makes
the vesicles a popular system for the study of asymmetry of
distribution of proteins1545 and lipids,708,714,1546–1548 as well
as for the measurement of the interactions of nonpolar77 and
amphiphilic chemicals82,103,335,441,1549–1553 with membranes.
Accumulation in erythrocyte ghosts was analyzed via the
PCA approach, using Volsurf descriptors.1136
3.2. Subcellular Organelles
The complexity of subcellular organelles is higher than
that of membrane vesicles. Although both are covered by
complete membranes, the organelles contain additional
structures, which may bind the chemicals and complicate
the interpretation of the disposition data.
The most often used subcellular organelle is mitochon-
drion, which became the object of interest for the study of
energy metabolism and the effects of compounds affecting
this process, as well as for the analysis of the mechanism of
apoptosis. Mitochondria are isolated by differential centrifu-
gation from the cell homogenate, which is prepared by
mechanic disruption or nitrogen pulsation,1554 most frequently
from liver,1555–1557 heart,1558 brown adipose tissue,1559 skeletal
muscle,1560 neurons,1554,1561 protozoa,1562 as well as from
yeasts and other sources.1563 The preparations were used to
measure the uptake78,1564 and effects of uncouplers of
oxidative phosphorylation and respiratory inhibitors.78,1564–1576
The uptake into rat liver mitochondria was described by a
conceptual pseudo-equilibrium model (section 7.3.1) and
used to infer membrane concentrations of the uncouplers and
to generate conceptual QSARs for their effects.78,1564
For DNA intercalators, the interactions with isolated nuclei
were studied and compared to the binding of the chemicals
to DNA in intact cells.1577,1578 The results contribute to the
analysis of subcellular distribution of studied chemicals.
3.3. Cells
The accumulation of chemicals in cells has been studied
since the end of the 19th century. The reports amply illustrate
the thinking process, based on sparse and imprecise data. In
the following, the most important milestones are listed in
chronological order, with each paragraph covering about two
decades.
Plant cells and protoplasts, and the eggs of marine
invertebrates were the ﬁrst systems to be studied from the
viewpoint of transport of chemicals, and the permeabilities
were monitored as osmotic volume changes.188,192 The
Overton’s theory on the association between the permeability
and lipophilicity1579 that led to the hypothesis on the lipid
character of the membranes, was developed using the tadpole
irritability data.192 In histology, uneven intracellular distribu-
tion of dyes, which were used to visualize various cell
components for microscopic observation, was considered a
consequence of different solubilities in cellular material (cited
in ref 1580).
The partitioning of acids and bases in surrogate solvent/
water systems exhibited increasing or decreasing sigmoidal
dependences on the pH values of the aqueous phase.1580 With
the objective of monitoring the transport of ionizable
compounds,1581 the pH indicators were introduced into cells
and used to measure the uptake of bases by sea urchin
eggs.1582 To improve survival of the test material, cells
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used.1183,1583–1585 However, these studies did not use single
cells; therefore, they are described in section 3.6. In large
cells of algae (Valonia, Laminara, Chara, Nitella and others),
conductivity was monitored as a measure of the overall ion
movement, and the effects of various chemicals on this
parameter were studied.1586,1587
The size of the algae cells allowed a direct chemical
analysis of the cellular content.1588,1589 A similar analysis of
cellular content was also applied to the protoplasts of oyster
plant (Rhoeo discolor).1590,1591 Micromanipulation of amoeba
cells in the microscope ﬁeld allowed for the analysis of anion
and cation effects, not only by the cell immersion but also
by microinjection.1592,1593 Transport of a series of acids was
tested as hemolytic activity in the author’s own blood,679 and
as the threshold concentrations for the sour taste.1594 The
comparison with physicochemical properties of chemicals
became more quantitative: the oil/water partition coefﬁcients
were used in the former study, and published data on charcoal
adsorption in the second study. The ﬁrst real correlations of
permeabilities with oil/water partition coefﬁcients were
published by Collander521 for the transport of nonelectrolytes
in algae Chara ceratophila and other cells. This work is
remarkable also for other conclusions: the transport process
was described by Fick’s law, and some small molecules
permeated at a faster rate than expected, based on their
partition coefﬁcient. The latter observation formed the basis
of the lipoid-sieVe hypothesis, which assumes the presence
of pores, allowing the passage of smaller molecules. The
nonelectrolyte data in algae Nitella mucronata680 were ﬁtted
by a linear permeability-lipophilicity relationship and later
were shown to adhere better to a parabolic equation.1595
The availability of radiolabeled chemicals opened the door
for autoradiography.1596–1604 For visualization of subcellular
distribution, autoradiographic images were enlarged by light
microscopy.1605,1606 The use of electron microscopy in the
transmission mode1607,1608 or scanning mode1609 increased the
resolution from ∼0.2 µm, which is typical for light micros-
copy, by three orders of magnitude. The technique enabled
important discoveries related to DNA, RNA, and proteins,
but the location of diffusible, noncovalently bound chemicals
could not be analyzed precisely, because of the artifacts
introduced by sample preparation. To monitor the distribution
ofchemicalsanddrugs,theprecisionwasgreatlyimproved1610,1611
by the introduction of precise cryosection1612 of freeze-dried
samples,1613 which avoided ﬁxation and embedding of the
samples.
Other techniques for monitoring membrane accumulation,
including potentiometry, equilibrium dialysis, and 1HN M R
spectrometry, have been recently reviewed.307 Confocal
ﬂuorescence microscopy allows monitoring of the kinetics
of subcellular distribution of ﬂuorescent compounds.1614–1618
The high shutter speeds are of special importance for
capturing the detailed kinetics of the transport process.1619,1620
The rich spatial and temporal data represent an ideal test
bed for the analyses by SBSP models.
Partitioning into erythrocytes and leukocytes was used to
provide a picture about the binding of chemicals in the blood.
Notably, in classical pharmacokinetics the blood corpuscles
represent the components of tissues as opposed to those of
plasma. This anomaly is caused by the deﬁnition of the
distribution volume, which is given as the ratio of the actual
drug amount in the body and the total drug concentration in
plasma. As a consequence, a drug that, after intravascular
administration, does not leave the bloodstream but binds to
erythrocytes or leukocytes will have a distribution volume
that is larger than the plasma volume. Blood corpuscles are
readily available, are easy to purify, have comparatively
simple structures, and their shapes can be comfortably
monitored. Their interactions with chemicals have different
consequences, depending on the used concentrations of
chemicals: simple partitioning,1552,1621–1623 shape changes,1624–1628
aggregation,1629 and even hemolysis.1630,1631 Hemolytic activ-
ity of homologous N-alkylpiperidines and R-monoglycerides
exhibit a bilinear dependence on lipophilicity,8,64,706 indicating
non-equilibrium transport, as decribed in detail in section 5.1.1.
A linear lipophilicity-concentration proﬁle was observed for
the binding to erythrocytes for a series of barbiturates.1314
Understanding the uptake into epithelial cells or entero-
cytes lining the luminal surface of the intestine is important
for orally dosed drugs. Enterocytes are highly polarized and
feature completely different apical and basolateral mem-
branes. Germinal cells in the crypts between the villi differ
from nonproliferative columnar cells that cover the villi,
through which the absorption proceeds. These cell popula-
tions1632 can be separated after the cells are isolated.1633 Upon
isolation, enterocytes will round and depolarize. The cells
respond extensively to environmental factors, are difﬁcult
to maintain in primary cultures, and have a short lifetime.
Therefore, the uptake experiments are mostly performed
using freshly isolated enterocytes.1634 Alternatively, everted
rings of the entire intestine are used to measure the drug
uptake, with the risk that the uptake into the cells other than
enterocytes will affect the results. With proper oxygenation
and nutrition, the rings can be maintained for several hours
before the changes to the mucosa become observable.1635 The
transport through the entire intestine in the form of everted
sacs or sheets is described in section 3.5.2. Continuous
monolayers of human intestinal adenocarcinoma Caco-2
cells, which are more comfortable to maintain and use, found
widespread utility in assessing intestinal absorption in the
drug-development process (section 3.4).1636
The interest in the use of hepatocytes in disposition and
metabolism studies stems from the importance of metabolism
for drug pharmacokinetics. The uptake into hepatocytes1474,1637
was studied frequently, because of its importance for the
prediction of metabolism.1638 The importance of transporters
in hepatocytes, as opposed to microsomes, for the prediction
of transport in humans was emphasized.1639,1640 Human
hepatocytes can be engrafted into immunochemically com-
promised mice, where they repopulate up to 90% of the
liver.1641 The animals can be used as a source of fresh human
hepatocytes or directly for toxicity studies of metabolites.
The uptake of chemicals into various cell types1642 was
measured using the analysis of the medium after the cell
separation by ultracentrifugation, ultraﬁltration, gel ﬁltration,
and dialysis. The disadvantage of the uptake monitoring, the
uncertainty about the localization of the chemical interacting
with the cell either on the cell membrane or inside the cell,
can be alleviated using the SBSP models (see sections 4-7).
This approach was used to estimate the subcellular distribu-
tion and resolve the mechanism of uncoupling of oxidative
phosphorylation for a series of carbonylcyanide phenylhy-
drazones in rat liver mitochondria,78 bacteria Paracoccus
denitriﬁcans, and leukemic P-388 cells.1643 Advanced kinetic
approaches were applied to the modeling of the cellular
uptake data,1644,1645 although accumulation in the bilayers,
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was not included in the analysis.
3.4. Cell Monolayers
Some cell lines form conﬂuent cell monolayers, imitating
biological epithelia, when grown on porous supports. The
monolayer cultures were initially used to study physiological
processes occurring in renal1646,1647 and intestinal1648–1650
epithelia, and later adapted for the analysis of the distribution
of chemicals. Transport across the layer separating two
aqueous compartments is conveniently examined by measur-
ing the compound concentration in the receptor compartment.
Sometimes, accumulation in the cells is also assessed. The
initial use of radiolabeled chemicals was largely replaced
by UV-Vis absorption spectrometry and liquid chromatog-
raphy analyses. The latter technique, especially when coupled
with mass spectrometry, allows the detection of metabolites,
and provides the opportunity to increase the throughput by
simultaneous testing of several chemicals in a mixture.1651
The most frequently used monolayer system is represented
by human colorectal adenocarcinoma cell line Caco-2 that
undergoes epithelial differentiation and forms monolayers1652
of polarized cells1653 on porous supports. The process may
take up to three weeks, and attempts were made to shorten
this period to seven1654 or even fewer days.1655 Initial studies,
focusing on the uptake of physiologic compounds,1656,1657
were soon extended to the transport setup utilizing the porous
supports.1658 The differentiated monolayer imitates intestinal
epithelium and is widely used to assess the oral absorption
potential of chemicals.1659–1671 The unstirred aqueous layers
affect permeation through the Caco-2 monolayer.1672
In several studies, the Caco-2 permeability was shown to
be a predictor of intestinal absorption.1673–1681 An approximate
sigmoidal relationship between intestinal and Caco-2 per-
meabilities was observed for a limited set of compounds.1682,1683
The relevance of the results for the prediction of intestinal
absorption can be improved through the use of media that
imitate the gut content in the apical compartment.1684
The throughput of experiments was increased by
introducing multiwell systems1654 and cassette dosing of
several chemicals.1685 The latter modiﬁcation works well for
passively transported chemicals, but saturable and competi-
tive binding may invalidate the results if any of the protein-
mediated mechanisms (section 2.3) is involved. The Caco-2
monolayer system was used to study the transport of simple
organic molecules (urea and mannitol as the markers of
paracellular transport,1686 creatinine, erythritol, phospho-
nomethanoic acid,1687 amines,1686,1688 amino acids,1689,1690
carboxylates,1686 oxazolidin-2-ones1691), adrenergic receptor
antagonists,1686,1692,1693 -lactams,1694peptides,1664,1691,1695–1699,1699–1702
peptide prodrugs, 1703–1706 and peptidomimetics,1707,1708 as well
as numerous other drugs1683,1709–1714 and drug candi-
dates.1680,1711,1715,1716 The impact on absorption of chemicals
of permeation enhancers,1717–1720 excipients for drug dosage
forms,1710,1721–1724 and polymeric nanoparticles as drug de-
livery vehicles1725 was also analyzed.
Although the Caco-2 cells in monolayer attain several
morphological and functional characteristics of mature en-
terocytes, some differences do exist, primarily because of
the colonic origin of the cell line. Those most important for
the transport studies include very low expression of cyto-
chrome P450,1726 especially that of the 3A4 isoenzyme that
is important in drug metabolism,1651 a lower content of efﬂux
pumps and transporters for active absorption of vitamins,
bile acids, amino acids, nucleosides and peptides,1727 and
tighter cell junctions reminiscent of those in the colon, as
opposed to those in the small intestine.1667,1728
Variability of the Caco-2 monolayers, caused by cellular
factors and culture conditions, complicates the interlaboratory
comparisons. The parental cell line is heterogeneous, and
different subpopulations may become prevalent, depending
on the cultivation conditions.1729 Circumstances such as the
number of passages,1730 the nature of support,1731,1732 and the
presence of nutrients1733 and induction factors1651,1706 affect
the characteristics of the prepared monolayers. Standardiza-
tion of the experimental setup, including the cell source,
cultivation conditions, and the use of media and solvents,
would contribute greatly to the availability of reference-
quality permeability data of chemicals, leading to more-
general models and increased understanding of the structural
dependence of the intestinal transport process.
Depending on the structure of transported chemicals, the
Caco-2 monolayer permeation is affected by any or all of
the following processes: passive transcellular transport,1692,1734
active transport1733,1735 and efﬂux,1697 transport through tight
junctions,1688,1722,1736 endocytosis,1737 transcytosis,1663 and
metabolism.1666,1738 This variety, although providing the
opportunity to study any of the involved mechanisms,
complicates the correlation of the permeability data with
physicochemical properties of transported chemicals. Several
attempts have been made to discern the ﬂuxes through indivi-
dual routes.1686–1688,1692,1728,1739,1740
The polarity of the Caco-2 monolayers provides a simple
means to detect active transport mechanisms, especially the
efﬂux mediated by P-glycoprotein. For this purpose, the
trans-monolayer ﬂuxes in the apical-to-basolateral direction
and backwards are compared. Identity of both ﬂuxes between
two identical aqueous phases indicates passive permeation.
If the backward ﬂux is signiﬁcantly higher, energy-depend-
ent, saturable, and the difference is abolished by a P-
glycoprotein inhibitor such as verapamil, the efﬂux probably
affects the permeation.1700,1741 Mechanistic studies of active
transport are performed preferably in the Caco-2 monolayers,
because isolated intestinal enterocytes are fragile and have
limited viability.1742
Thanks to the importance of oral absorption in the drug
development process, there has been considerable interest
in the elucidation of the relationships between structure or
properties of chemicals and their Caco-2 permeability. The
correlations are obscured by the multitude of processes,
which contribute to the overall outcome of the transport
experiment. Obviously, any mechanistic knowledge is of
great value for the development of reliable descriptions.
Unfortunately, this knowledge was mostly used for explana-
tion of outliers,1691 rather than for a systematic classiﬁcation
of the permeants for the correlations. In addition, the analyses
are complicated by the fact that the determined permeability
coefﬁcient is not a complete characteristics of the transport
process (section 2.1.4.4), and the information about the lag
time1743 and accumulation is not considered.
The simplest models were applied to the data for compounds
permeating without the use of protein carriers (i.e., by passive
transport through enterocytes or through tight junctions). The
former process received more attention because it can be applied
to the majority of tested chemicals. The descriptors used in
mostly linear correlations of permeability were the 1-octanol/
water partition coefﬁcients (P) for neutral molecules, the
distribution coefﬁcient representing the P values for ionized
1834 Chemical Reviews, 2009, Vol. 109, No. 5 Balazmolecules at the pH of experiment,1691,1743,1744 the number
of hydrogen bonds1695 or more quantitative hydrogen-bond
parameters,1745 polar surface area,1746 as calculated from all
low-energy conformations,1747 from 1000 conformations
obtained by an MD simulation,1748 from a single conforma-
tion,1749 or by a fast fragment-based method,1127 molecular
size,1702,1743–1745 charge,1702,1712,1743,1744 and the partition coef-
ﬁcients for IAMs (section 2.1.2.5).536,1702,1707,1711 For several
peptide series, the 1-octanol/water distribution coefﬁcient Pi
was not a good predictor of permeability, especially if the
transport was signiﬁcantly affected by efﬂux.1700 The cor-
relations were mostly linear, with an exception of a sigmoidal
relationship on log Pi, shifted by the contribution of
paracellular transport parametrized by molecular weight.1743,1744
Similar but more-scattered sigmoidal relationships were
observed for the log Pi values measured in the n-hexadecane/
water and PGDP/water systems for 51 diverse drugs.1683
Numerous descriptors (surface-related,1750–1752 hydrogen bond-
ing with log P1128 and charges1679) were simultaneously
correlated as a linear combination using PLS or multiple
linear regression with the permeability of diverse compounds,
demonstrating a large negative impact of hydrogen bonding,
and positive impacts of lipophilicity and sometimes polar-
izability. A linear combination of a hydrogen-bond descrip-
tor, log Pi, molecular weight, and an indicator variable for
charge was used in a permeability-property correlation.1679
Volsurf descriptors were correlated with Caco-2 permeabili-
ties using the PLS655,1140–1142 and PCA1136 methods. The 3D-
QSAR approaches, which are usually suitable for structure-
speciﬁc protein-mediated interactions, were applied to the
passive permeation of 38 inhibitors of rhinovirus replica-
tion.1753 Detailed simulations were performed for passive
uptake and permeation of cells1754 and cell layers,1755
respectively, as affected by physicochemical properties. The
models accommodated the ionization of chemicals and
varying acidities of individual compartments, but they did
not include accumulation of chemicals in the bilayers and
used rather simpliﬁed relationships between the permeability
coefﬁcients and lipophilicities.
The cooperation between P-glycoprotein (section 2.3.2.3)
and CYP3A4 (section 2.5.1.1) at the apical membrane in
creating a defense mechanism to prevent the entry of some
chemicals into the body is an interesting concept that has
important consequences for oral administration of drugs.1756–1758
The idea is supported by similar broad substrate speciﬁcities
of both systems. To improve the suitability of the Caco-2
monolayers for studying this mechanism and intestinal
metabolism in general, the CYP3A4 expression can be
elevated using vitamin D31651,1706 or other inducers. The
metabolizing enzyme levels are generally higher in earlier
passages of the cells in the process of preparing the
monolayers.1730 However, if vitamin D3 is used for CYP3A4
induction, the cultures with higher passage numbers contain
more enzymes.1759 The Caco-2 cells transfected with CYP3A4
represent an alternative option.1760–1762 Other cell lines
forming the polarized monolayer and having a high expres-
sion of both transporters and enzymes can be used to study
their cooperation.1726
Among other than Caco-2 cellular monolayers, the Madin-
Darby canine kidney (MDCK) cell line1763 has been deployed
most frequently. The initial focus on tissue cultures that were
suitable for the monitoring of viral propagation,1764,1765
oncogenesis,1766 and physiological processes1647,1767 was
extended to the monolayers grown on a porous support,
which were used to study the transport of drugs1768,1769 and
ions, imitating tubular reabsorption.1770,1771 The MDCK cells,
transfected with CYP3A4, are available.1762 Transport studies
using MDCK cells have been performed less frequently than
those with Caco-2 monolayers. The QSAR studies of drug1772
and peptide1773,1774 permeation through the MDCK cell
monolayer are of rather preliminary character.
Other studied cellular monolayer systems include intestinal
cell lines HT29-18-C11775 and IEC-18,1776 as well as 2/4/A1
cells with reduced transporter activities1777 for the study of
intestinal absorption, LLC PK1 renal epithelial cells1778 as
an in vitro system for studying tubular reabsorption, brain
microvessel endothelial cells1779,1780 imitating the blood-brain
barrier, and Hep G2 cells1781 for studying aspects of
hepatobiliary clearance. The ability of the human intestinal
goblet cell line HT29-H to produce mucus was deployed to
assess the barrier properties of the mucus.1782 Diffusion of
drugs in the mucus was analyzed and compared to that in
water.1783,1784 Cellular systems imitating skin1785 did not
provide relevant absorption data,1786,1787 but may ﬁnd a more
successful application in reconstructive surgery.1788 The use
of these monolayers was much less frequent than that of
Caco-2 cells and no QSAR studies were performed.
3.5. Biological Sheets
Studies of transport through planar biological systems
consisting of several different cell layers are brieﬂy sum-
marized in this section. The sheets include human, porcine,
rhesus monkey,1789,1790 and mouse skin,1791,1792 dog and cat
pericardia,1793 the walls of the intestine1794 and urinary
bladder,1795 frog skin, goldﬁsh gills,1796 and other planar
objects that are suitable for the study of the transport of
chemicals, because they can be mounted as barriers separat-
ing two media in diffusion chambers of Ussing1797,1798 and
Franz1799,1800 designs. An air-lift system normally is used to
provide a proper gas balance, and stirring is applied to reduce
the diffusion barrier thickness and ensure homogenization
of bulk media. Transport through the skin and the small
intestine, although not fully representative of the real
situation, are by far the most frequently studied processes
in this category. The majority of the experiments with other
sheets was made in the ﬁrst half of the last century, focusing
on general information about biological transport without
placing much emphasis on the practical importance of the
sheets that were used, such as frog skin,1801–1803 toad urinary
bladder,1795 or goldﬁsh gills.1796
In quantitative studies, the transport was characterized by
the permeability coefﬁcients PC. Several relationships for
the dependence of the PC on the structure of transported
chemicals are noted below. They usually make simplifying
assumption about the structure of the studied sheet. The
expression that takes the multilamellar sheet structure into
account is given as eq 51 in section 10.2.7.
3.5.1. Skin
Transdermal absorption can be studied in various skin
preparations, which provide a more realistic picture of events
than the phospholipid systems (section 2.1.2.2); although
some steps are still missing and some may be superﬂuous
(section 3.7). The process was studied in subcutaneous rat
tissue1804 and hairless mouse skin,1791,1792 as well as in human
skin obtained from amputations and cadavers. Macroscopic
dimensions allow mechanical separation of individual skin
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at different depths,1808,1809 and visualization of permeant
positions in the cross sections.1809–1812 The main barrier for
percutaneous absorption of most chemicals is the stratum
corneum1813–1815sthe surface lamina consisting of several
layers of corneocytes, which are embedded in a lipid matrix
represented by multiple bilayers separating the cells.161,1816–1819
The corneocytes are ﬁlled with water and microﬁbrillar
keratin,andtheyaresurroundedbyakeratinizedenvelope,1820,1821
which is covered by a monolayer of covalently bound
lipids1822 that play a role in cell adhesion.1823
Chemicals could permeate the stratum corneum via dif-
fusion through the corneocytes,1824 the voids in continuous
lipid bilayers (as described in section 2.1.4.5), aqueous pores
resulting from either imperfections in lipid bilayers163,397 or
reorganization of the bilayer forming the transitional opening
lined with the headgroups,1825,1826 and shunts represented by
hair follicles and sweat ducts, as well as by lateral diffusion
along the plane of the bilayer.163 Relative contributions of
these parallel mechanisms to transdermal transport of a
speciﬁc chemical are dependent on its physicochemical
properties, although the latter mechanism is considered
dominant for drugs.1820 Impermeable keratinized corneocytes
in the topmost layers of the stratum corneum impede the
transport by creating a tortuous diffusion path for the lipid-
based mechanisms. This fact makes percutaneous absorption
a unique process, with the paracellular mechanism prevailing
for most chemicals. The rate of absorption can be increased
using chemical enhancers1827 or iontophoresis.1828,1829
The importance of the transdermal route of administration
for some drugs1830 led to the development of modeling
approaches for single compounds1805,1831,1832 and QSARs for
sets of chemicals. Simple rules regarding molecular weight,
aqueous solubility, melting point, and the number of
hydrogen-bonding atoms were formulated to classify the
permeants as fast and slow.1833 Additive contributions of
structural fragments to transdermal permeability were de-
termined.1834 For chemicals traversing the skin via the lipid-
based paracellular route, the permeability coefﬁcient was
expressed as the product of the partition coefﬁcient and
diffusion coefﬁcient,1813 as known for the solubility-diffusion
mechanism for transport through a single bilayer (section
2.1.4.4). The simplest property-based QSARs reﬂect this fact
and describe the permeability coefﬁcient as a power function
of the partition coefﬁcient (see the Collander equation 1 in
section 2.1.3.1) in surrogate systems,1835 including the stratum
corneum/water system,1836 for compounds of similar sizes.
For more-diverse compounds, the ﬁts improved via the
addition of molecular weight,1837,1838 molecular volume,1839
hydrogen-bond parameters,1836,1840,1841 and atomic charges,1842
which should characterize the structural dependencies of the
diffusion coefﬁcients. Importance of the difference between
logarithms of 1-octanol/water and alkane/water partition
coefﬁcients, formally equal to the 1-octanol/alkane partition
coefﬁcient and characterizing hydrogen bonding (section
2.1.3.3), was also examined.1843 Acceptable correlations for
heterogeneous chemicals were obtained using Abraham’s
solvatochromic equation.1844–1846 The interesting observation
that asymmetric positions of hydroxyl groups in polyphenols
led to a slower transdermal transport than a symmetric
distribution1847 might be related to the role of amphiphilicity
of the asymmetric molecules in the trans-bilayer transport
(section 2.1.4.6). Complexity of the process was indicated
by the need to break down the sets of compounds to obtain
good linear relationships.1848 Additional equations were
summarized in detailed reviews of simple QSAR approaches
to transdermal permeability.1838,1849
More-detailed models that take into account the structure
of the stratum corneum and tortuosity of the lipid route were
developed,163,1850 describing not only the steady-state trans-
dermal ﬂux but also the lag time. Simpliﬁed two-dimensional
(2D) models164,1851,1852 were extended to more-realistic 3D
representations. The presence of several pathways, each
traversed to the extent given by the properties of chemicals,
was considered.1853–1855
3.5.2. Small Intestine
The second-most frequently studied sheet was the small
intestine, thanks to the importance of intestinal absorption
for chemotherapy. Experiments in this area started at the
beginning of the last century.1856,1857 The intestine was used
in the form of everted sacs1858 or mounted as a barrier
separating two solutions in side-by-side diffusion chamb-
ers.1859–1863 The latter setup utilized either the entire
intestine1864–1866 or mucosal sheets.1867–1873 The viability of
the tissue must be carefully monitored.1874 The in vitro
systems were used to study the absorption of small sets of
chemicals.1687,1868,1875–1877 Other intestine-based test systems
include brush-border vesicles (section 3.1.2), isolated en-
terocytes, and the rings of the entire intestine (section 3.3),
which are used to measure the uptake of chemicals, as
opposed to the transport across the intestine.
Intestinal absorption of a chemical requires that the
molecules cross only a small part of the intestinal structures,
namely, from enterocytes to blood capillaries and lymphatic
capillaries (lacteals) embedded in the villi of the mucosa,
not the entire intestinal wall. Therefore, the relevance, for
intestinal absorption, of the in vitro studies of transport
through the complete intestinal wall is questionable. The use
of mucosal sheets isolated from the small intestine only
reduces the presence of the intestinal structures, which do
not need to be crossed by absorbed molecules, but does not
solve the problem. On the other hand, the intestine-based
systems allow the study of the effects of unstirred layers1878
and intestinal metabolism, as well as a comparison of
absorption in different segments of the intestine.1676
The QSAR studies of intestinal absorption usually utilize
the convenient Caco-2 monolayer permeabilities (section 3.4)
or the more-relevant in situ and in vivo data (section 3.7),
and the data obtained in the in vitro intestinal preparations
are used less often. The permeabilities of a small set of
diverse drugs in rat intestinal sacks were analyzed using the
linear regression analysis and neural networks with the
retention factors on the IAM columns (section 2.1.2.5),
molecular volume, and other physicochemical properties as
the descriptors.1879 Human jejunum permeabilities were
correlated with the polar surface area of a small set of
permeants.1127
3.6. Tissues
In SBSP, tissues are viewed as spatially arranged collec-
tions of similar cells that contain some extracellular ﬂuid.
Historically, the ﬁrst studies were performed with the tissues
containing natural pigments changing colors in response to
the internal pH. Examples include the pieces of mantle edge
of the hermaphroditic nudibranch Chromodoris zebra,1584 and
the testis ﬁlaments of a sea cucumber.1583 The testis and
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regenerate upon the return of the animal to sea water. The
importance of the complete dose-response curve in the tissue
transport studies, as opposed to the measurements at a single
concentration, for the characterization of relative transport
rates of individual acids was noted.1584 Permeabilities of acids
and bases were measured using the ﬂower petals containing
pH-sensitive pigments.1585 With the availability of radiola-
beled chemicals, tracking the distribution at the levels of
tissues, organs, or organisms was made possible by
autoradiography.1596–1604 The ﬁrst attempts at monitoring the
distribution in entire animals were made using natural
isotopes.1880 Further developments of autoradiography at
cellular level are described in section 3.3. Tissues have been
used in two forms: slices for the uptake and metabolism
studies1881,1882 and tissue homogenates for equilibrium binding
studies.1883
The most frequently used tissue slices are the fresh or
vitriﬁed precision-cut slices from the rat liver, which were
used to study metabolism of chemicals.1881,1882 Metabolism
in these systems differs from that in hepatocytes, because
of the diffusion limitations in the former system.1884 This
phenomenon could provide a basis for the analysis of the
distribution process. The data from both slices and hepato-
cytes were used for prediction of in vivo metabolic clear-
ance.1519 Brain slices were used to analyze metabolism1885
and the mechanisms of learning and addiction.1886–1889
Tissue homogenates were ﬁrst used by anesthesiologists
who wanted to understand the partitioning of anesthetic gases
between blood and tissues, especially the brain.1883 The
technique was also used in occupational toxicology to assess
the exposure risks of industrial chemicals1890 and in envi-
ronmental toxicology to understand disposition of chemicals
in ﬁsh.1891
Depending on the structures and properties of chemicals,
the transport rates into tissues vary over a broad range. For
quickly transported chemicals, the distribution is character-
ized by the tissue/plasma or tissue/blood partition coefﬁcients,
which are measured using tissue and blood samples. For
slower transport, which is observed most frequently in
perfused organs, more-sophisticated, nonequilibrium descrip-
tions are required. In the following, we will focus on
equilibrium binding to tissue constituents.
For compounds quickly transported through membranes,
tissue/plasma partition coefﬁcients (PTP) are important
characteristics, which are deﬁned as the ratio of the average
concentration of a chemical in the respective tissue and the
concentration in plasma. The PTP values represent pseudo-
equilibrium inputs in physiologically-based pharmacokinetics
(PBPK) models of quickly transported chemicals. The
relation between PTP and elementary processes is given by
eq 57 or eq 58 in section 10.3.2. A sum of the PTP values
for all tissues in the body, each weighted by the tissue
volume, is equal to the volume of distribution.1892 Therefore,
the product of the PTP value and the volume of the tissue
can be viewed as the distribution volume of the tissue.
Historically, the PTP values were ﬁrst measured1883 and
utilized in QSAR studies for simple chemicals such as rare
and other gases (H2,N 2, CO, CO2, NO),1893 gaseous narcotics,
alkanes,1894 and alcohols. These data correlated well with
properties of the chemicals,1895–1897 especially using a model-
based nonlinear function of lipophilicity expressed as a
surrogate partition coefﬁcient (section 2.1.3).1898 Several
approaches were developed for modeling the data for more-
diverse compounds.
The solvatochromic equation, which describes solvation-
related phenomena as a linear combination of solute excess
molar refractivity, dipolarity/polarizability, hydrogen-bond
donor and acceptor abilities, and McGowan characteristic
volume, was frequently applied to PTP or similar para-
meters.1119,1121,1124,1125,1846,1899–1904 Generally, the correlations
were worse than those for one-phase1905 or two-phase
systems,1906,1907 for which the solvatochromic equation was
originally devised. In addition to more-pronounced data
variability in biological samples, there are two other potential
sources of error. First, protein binding for diverse sets cannot
be described as a structure-nonspeciﬁc process, using the
same approach as for solvation and partitioning. Second, the
equation that is used applies to one- or two- phase systems
and cannot be used for tissues that contain multiple phases.
The correlation equation should contain similar terms as eq
57 or eq 58 in section 10.3.2, and the solvatochromic
equation should be applied to each phase separately. These
changes would make the correlation equation more complex
and nonlinear in optimized coefﬁcients, but the number of
independent variables would not increase. The situation is
even more complicated for the tissue/blood partition coef-
ﬁcients, which were also frequently modeled using the
solvatochromic equation.1901,1902 As compared with plasma,
the blood contains additional phases in the corpuscles.
A series of publications advocated the use of the vegetable
oil/water partition coefﬁcients in modeling the tissue
distribution.665,1908,1909 Vegetable oil, although composed
mainly of triglycerides, contains other lipid species, varying
by the source and preparation conditions, which may
signiﬁcantly affect the partitioning process. A better-deﬁned
triglyceride phase, such as triolein192,562,563 or trioctanoylg-
lycerol (see section 2.1.4.2) would help standardize the results
and provide a good surrogate for adipose tissue. The
partitioning to phospholipids was treated as if they were
composed of 30% vegetable oil (triglycerides) and 70%
water. This combination does not seem to create a good
surrogate system, because the fatty acid chains differ in
structure from triglycerides and water is not a good surrogate
for the headgroup region, despite its high water content (see
section 2.1.3.3). The estimates of the accumulation in neutral
phospholipids, assuming the 30:70 lipid/water composition,
were also used in otherwise-sound models for tissue parti-
tioning of basic drugs.1910 Later, in a study of the volume of
distribution,559 vegetable oil was replaced by 1-octanol for
nonadipose tissues. Interactions with proteins were treated
by using the measured fraction unbound in plasma,1911 and
assuming that a similar protein binding is taking place in
tissues. Albumin, although present in tissues, does not
represent their major component (sections 2.4.2 and 2.4.3).
Consequently, this assumption could affect the descriptive
and predictive abilities of the models. The used equations
are mostly conceptual and similar in form to eqs 57 and 58.
A major drawback is the use of the implausible assumption
regarding the proportionality or even equal magnitudes of
the partition coefﬁcients in surrogate solvents and biological
systems. An application of the Collander equation to relate
the partitioning in surrogate and biological phases via
adjustable coefﬁcients usually provides better results.
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also used for the correlation of the tissue/blood partition
coefﬁcients of both neutral1912 and ionizable compounds.1913–1915
While the tissues were decomposed into lipids, proteins, and
water, the blood was considered as a homogeneous phase,
thus neglecting the partitioning into the membranes of blood
corpuscles and lipoproteins, as well as plasma protein
binding. This omission could affect the results, especially
for compounds with higher afﬁnities to blood components.
Extrathermodynamic relationships were used to describe the
partition coefﬁcients and proteins association constants. In
the latter case, this description could be problematic for more-
diverse compounds.
The approach was further reﬁned by inclusion of neutral
lipids, as well as neutral and acidic phospholipids, and was
applied to tissue/plasma partition coefﬁcients.543 The experi-
mental values of fraction unbound in plasma were used to
describe protein binding in plasma and also in interstitial
ﬂuid, which has a similar protein composition. The binding
to intracellular proteins was correlated with experimental
partition coefﬁcients for phospholipids,1916 which limits the
application to the studied chemicals.
All published approaches to the correlation of tissue
partitioning of chemicals with their structures and properties
treat the interactions with proteins as structure-nonspeciﬁc
processes, which are related to the properties of entire
molecules. This assumption limits the applicability of the
techniques to sets of homologues. For larger and more-
diverse sets of chemicals, protein binding must be treated
as a structure-speciﬁc process, using 3D-QSAR techniques,
as we recently demonstrated for the binding to the proteins
of extracellular matrix (section 2.4.2).1307,1309
3.7. Organs
When transport rates are comparable with those of
metabolism or excretion, the distribution models become
more complex and require kinetic data for characterization.
These experiments are usually performed in perfused organs,
because they have longer lifetimes than isolated tissues.
Perfused organs such as frog legs;1917 frog, cat, and dog
hearts;1918–1921 dog livers,1922–1927 and rabbit and pig ears,1928,1929
have been used to study the effects of physiological
molecules since the beginning of the last century. Currently,
the organ preparations are used in situations when simpler
models provide a very limited picture of the disposition
events. Typical examples are the skin and intestine, which
can be mounted as sheet barriers in the diffusion chambers
(sections 3.5.1 and 3.5.2), but the results are not completely
representative of the situation in vivo. In both cases, more
rigorous results are obtained with perfused preparations,
which better imitate the actual transport routes. On the other
hand, the cost and labor of these preparations limits the
number of available data.
Organ preparations can be used in either ex vivo or in
situ conditions, the difference being the disconnection from
the natural bloodstream of the test animal in the former case.
The ex vivo setup allows a better control of the vascular
perfusion but often results in a shorter lifetime of the
preparation. The in situ preparation preserves a natural
environment of the studied organ and maintains many in vivo
features, while providing controlled inputs and outputs, which
allow application of precise analytical techniques and the
use of the mass balance in the description.
Intestinal absorption rate is one of the key parameters of
orally dosed drugs. The absorption route from the intestinal
content through the epithelial cells and connective tissue into
the capillaries inside the villi cannot be precisely duplicated
in in vitro intestine-based systems, such as the brush-border
membrane vesicles (part 3.1.2), isolated enterocytes, everted
rings of the entire intestine (section 3.3), and the entire
intestinal wall or mucosal sheets (section 3.5.2). Instead, it
requires the use of comparatively complex ex vivo and in
situ preparations, or in vivo conditions. The ex vivo, isolated
intestine with adjacent vasculature, perfused both luminally
and vascularly though the superior mesenteric artery and the
portal vein, provides a better control of the experimental
conditions, although the viability is shorter.1930–1934 A prepa-
ration of the ex vivo perfused rat intestine and liver was
described.1935 Different models were developed and evaluated
for the description of absorption from the perfused intes-
tine.1936 A structure-permeability relationship was described
for steroid absorption in perfused rabbit ileum.1937
A similar controversy between simple in vitro systems and
reality applies to transdermal absorption, because the bilayer
stacks of skin phospholipids (section 2.1.2.2), cell monolayers
(section 3.4), and sheet-like skin preparations (section 3.5.1)
do not capture all details of the in vivo situation. To
reproduce the absorption route from the surface of stratum
corneum into the capillaries, several perfused skin prepara-
tions were described,1938–1942 of which the perfused skin ﬂap
technique for pigs,1943–1946 weaning pigs,1947 or horses1948
received the most attention. Small regions of skin, sometimes
with tumors,1947 which are primarily perfused by a single
superﬁcial artery, are incised and formed into a tubelike shape
around the artery. Later, the artery is cannulated, the ﬂap is
removed from the body and placed into a tissue chamber,
where the venous perfusate is collected and analyzed.
Specialized models for the description of the recorded data
have been developed for single chemicals1949 and mix-
tures.1950
In situ preparations, where the artiﬁcially perfused organ
remains attached to the systemic circulation, include the rat
intestine,1864,1951–1959 kidney,1960 and liver.1961–1969 The small
intestine can be perfused in situ in humans, using stoppers
to deﬁne a perfused segment.1970 The externalized rat kidney
was used for a direct monitoring of renal clearance of
ﬂuorescent compounds.1971 The methods utilizing perfused
organs have been used extensively in the drug-development
process.1636,1972–1977
Intestinal permeability in rats was studied using in situ
techniques for small sets of compounds,1978 and a sigmoidal
relationship on lipophilicity, containing a molecular weight
term, was formulated.1979
Quantitative studies of distribution in terms of structure
and properties of compounds are limited to small sets of
homologous chemicals,1967,1980–1986 because of the cost and
labor associated with the use of perfusion techniques.
Because of the importance of the process in the metabolism
of chemicals, distribution in the liver has been modeled using
advanced techniques, which take into account spatial dif-
ferences of the compound’s and enzymes’ concentrations in
individual organ parts.1638,1961,1962,1964,1987–1996 Interestingly, the
heterogeneity at the cellular level, which is caused by
different accumulation in the membranes and aqueous phases,
was not considered, although the importance of the binding
to endoplasmic reticulum for the overall metabolism rate has
been recognized.1472
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Historically, the ﬁrst technique that allowed the distribution
of chemicals at the level of organisms to be tracked was
autoradiography,1596–1604 which was initially performed using
natural isotopes.1880 In addition to autoradiography,1603,1997–1999
the distribution of chemicals in entire organisms can be
directly and noninvasively monitored by magnetic resonance
imaging based on 7Li,2000 13C,2001 19F,2002 and proton
nuclei,2003–2006 positron emission tomography,2007 and speciﬁc
imaging techniques for ﬂuorescent compounds in nude
mice.2008–2012
Indirect techniques, based on the extraction of chemicals
from the body ﬂuid and tissue samples, have been used much
more extensively, especially in the areas of drug development
and environmental toxicology. The resulting data have been
processed by pharmacokinetic modeling methods. A brief
overview of the development of these approaches2013 is
provided below.
Pseudo-equilibrium accumulation of a chemical in an
aquatic organism2014,2015 is usually characterized by the
bioconcentration factor (BCF),2016 given as the ratio of the
chemical concentrations in an organism and the surrounding
aqueous phase. BCFs were frequently and successfully
correlated with the reference partition coefﬁcients,1891,2017–2027
aqueous solubilities,2017,2021,2023 and acidities.2028 For very
lipophilic compounds, nonlinearities were observed in the
relationships with lipophilicities2029–2033 and reactivities.2034
Nonlinear dependences on the reference partition coefﬁcients
were also observed for the uptake and release rate cons-
tants.60,2035,2036 Clearances were inversely related to the
reference partition coefﬁcients.2024,2035 For reactive chemicals,
the toxicities were conceptually correlated with the reference
partition coefﬁcients and reactivies.1478 Because the chemicals
studied in environmental toxicology usually have much
simpler structures than drugs, research in this area contributed
several interesting ideas to SBSP.
The disposition of chemicals in animals and humans has
been studied mainly in relation to chemotherapy. The history
of classical pharmacokinetics is summarized in Figure 12,
and more details are given in the following text. The notion
of a relationship between an anesthetic effect and the
concentration of ether in the brain dates back to the middle
of the 19th century.2037 The kinetics of disposition of
chemicals has been studied quantitatively in animals and
humans and documented since the second decade of the 20th
century.2038–2048 During the same time period, the Michaelis-
Menten description of saturable kinetics2049 and the one-
compartment model2050 were developed. The 1930s brought
the two-compartment models2051 and the key concepts of the
mean residence time,2052 clearance,2053,2054 and the volume
of distribution.2055 The one-compartment model and two-
compartment models were later applied to the disposition
kinetics of drugs2056–2058 and radioactive substances2059–2064
in the organisms. Since the 1950s, kinetic models of multiple
dosage regimens2056,2065–2068 have had a broad impact on how
therapeutic interventions are performed. The research area
was called pharmacokinetics2058 and developed2013 into a key
pharmacy discipline75 that is taught in all pharmacy programs
around the world. More-detailed descriptions of the fates of
chemicals in the body, the PBPK models, were spearheaded
by physiologists, who routinely monitored the blood ﬂows
and the concentrations of oxygen, carbon dioxide, and
anesthetic gases in individual organs.2069 The compartments
in PBPK models are individual organs or their speciﬁed sets,
in contrast to the models of classical pharmacokinetics, which
utilize loosely deﬁned compartments, the number and func-
tion of which is dictated by the ﬁt of the model to the data.
Principles of PBPK modeling were formulated in the
1960s.2070–2073
The pseudo-equilibrium models of SBSP in section 7
provide useful descriptions for clearance, the elimination rate,
and the volume of distribution. The QSAR models for
individual pharmacokinetic parameters are summarized and
compared with the pseudo-equilibrium models in sections
8.2.1-8.2.3.
4. Disposition Function in QSAR
The fates and effects of chemicals in biosystems are
governed by a myriad of interactions. As outlined in section
1.1, some interactions can be described using global,
conformation-averaged properties of the molecules, and the
descriptions of other interactions require the knowledge of
precise conformations. SBSP attempts to sort the interactions,
lump together kinetically similar processes, identify the rate-
and extent-determining steps, and systematically formulate
model-based QSARs and their time-dependent forms
(QSTARs, where T represents time), which we call the SBSP
models. The SBSP models serve two main purposes:
prediction of distribution and/or bioactivity of untested
chemicals in biosystems, and elucidation of the mechanism
of action. In the drug development process, the predictions
are used in lead ﬁnding and mainly in the optimization of
lead structures by derivatization.
Regardless of the size and complexity of the biosystem,
formulation of a model-based QSTAR for an effect of
chemicals requires appropriate descriptions for three steps
of action of a chemical as shown in Figure 13: (i) disposition
in the receptor surroundings, (ii) the interaction with receptor,
and (iii) transformation of the receptor modiﬁcation into
biological response. In most cases, the loss of the chemical
caused by its interaction with the receptors is negligibly
small. Consequently, step (i) can be described separately.
Linearity of the processes is an important concept that greatly
simpliﬁes the description of the fates of chemicals in
biosystems. Linear (or, in other words, ﬁrst-order) processes
have the rate and/or extent proportional to the concentration
of the chemical (denoted as [C]). Linearity is a plausible
approximation, because the concentrations of chemicals in
living biosystems are generally low. If the processes that
Figure 12. Milestones in the history of classical pharmacokinetics.
More details and references are given in the text.
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cumulation, binding to body constituents, and elimination)
are linear, the time course of [C] in the receptor surroundings
can be expressed symbolically as
[C])A(pp,t)c0 (6)
where c0 is the initial concentration, proportional to the dose,
of the chemical in the entry compartment, and A(pp,t)i st h e
disposition function, with the time of exposure (t) and
physicochemical properties (pp) of both the chemicals and
the biosystem as variables.143 The term “disposition function”
has been used in classical pharmacokinetics,2074 in a sense
similar to that illustrated by eq 6, but without the property
variables. The actual form of the disposition function is
dependent on the complexity of the studied biosystem and
on the properties of analyzed chemicals.
Using eq 6, the kinetics of the interaction between the
receptor and a chemical can be described for various
mechanisms of this step.54,143,2075 For the simplest mechanism
of the chemical-receptor interaction that (i) consists of a
fast and reversible 1:1 interaction, (ii) is characterized by
the association constant K, and (iii) leads to a primary effect
that (iv) is an immediate consequence of the receptor
modiﬁcation and (v) is proportional to the fraction of the
occupied receptors,143 the effects are related to K and the
disposition function as follows:
1
cX
)KA(ppi,t)(
1-X
X ) (7)
The predeﬁned relative intensity of the chemical’s effect
(X) is a number between 0 and 1 (frequently, X ) 0.5). The
experimentally determined isoeffective concentration cX,
eliciting the fraction X of the maximum effect, serves as a
measure of the potency of individual chemicals. Equation 7
can be easily converted to a model-based QSTAR equation,
if the chemical-receptor association constant and the
disposition function are expressed via the structures and
physicochemical properties of the chemicals. The bioactivity
directly mirrors the disposition of a set of chemicals in the
receptor surroundings, if K in eq 7 is invariant for all studied
chemicals. In the rest of this communication, when compar-
ing the derived form of the disposition function with
biological effect data, as opposed to the disposition data, we
will assume that these conditions are met, and that bioactivity
and disposition are proportional at each moment. The
relationships correlating potency with the chemical-receptor
association constant K and the disposition function A(ppi,t)
for more-complicated mechanisms of the chemical-receptor
interaction can be found elsewhere.54,143,2075
The form of the disposition function is heavily affected
by the size and complexity of the biosystem, as well as by
the kinetics and types of the interactions of chemicals with
the components of the biosystem. The construction of the
disposition functions for various scenarios is described in
the following parts, starting with simple cases, and gradually
progressing to more-complex situations.
5. Numerical Simulations for Multi-Bilayer
Systems
Some of the simplest model systems that imitate small
biosystems are represented by a series of the alternating
aqueous phases and the bilayer cores, in which the chemicals,
which do not interact with the headgroups, are transported
passively. Movement of molecules in a multimembrane
system can be envisaged as a series of partitioning steps
through alternating aqueous and lipid compartments,2076 as
shown in Figure 14. Protein binding and elimination that
inﬂuence the disposition of chemicals are also depicted. The
majority of experimental systems used for the monitoring
of the interactions with chemicals are actually multimem-
brane systems: some subcellular organelles; suspensions of
cells from organisms and some microorganisms, such as
gram-negative bacteria, yeasts, and fungi (section 3.3); cell
monolayers (section 3.4); and various physiological sheets
Figure 13. Phases of drug action. Under certain conditions (details
in the text), the phases can be described by separate models, with
little feedback from the subsequent process, as indicated by the
dotted backward-facing arrows. Structure-based subcellular phar-
macokinetics explicitly addresses disposition; however, the results
are used to formulate the descriptions for the other two phases.
Figure 14. Schematic outline of the distribution of the chemicals, which do not interact with the headgroups, in a morphologically
compartmentalized system consisting of alternating aqueous phases and membranes (represented by the cores). The chemicals can be present
as free non-ionized molecules (Ci), free molecules ionized to the jth degree (Cij), or ion pairs with the kth counterion (CZijk); each species
can be bound to proteins (P) or enzymes (E), and eliminated by spontaneous and/or enzymatic reactions. The subscripts i, j, and k are
typically used throughout the paper, in the meanings that are shown here. Two-sided arrows represent fast processes, whereas one-sided
arrows represent time-dependent processes.
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gallbladder, stomach, and the intestine (section 3.5).
The approaches to the description of the disposition of
chemicals via the disposition function, deﬁned by eq 6, can
be classiﬁed as numerical simulations and explicit descrip-
tions, and are summarized in sections 5 and 6, respectively.
Note that all the results presented below are valid for
chemical disposition following a single dose, except those
in section 6.3, which is devoted to continuous dosing. The
situations after repeated doses would be completely different
and could be described by applying the principle of
superposition, using the results for the single dose, as known
in classical pharmacokinetics.2056,2065–2068
To understand the contributions of the individual processes
to chemical disposition quantitatively, it is advantageous to
examine them separately.
5.1. Pure Transport
From the viewpoint of chemical distribution, biosystems
are generally open, because of irreversible elimination
processes. Under certain conditions, however, the concept
of a closed biosystem is useful. Providing that the reversible
processes (transport and protein binding) are much faster than
irreversible elimination, a closed model properly represents
the in vivo situation for the time interval until elimination
becomes observable. Among the processes summarized in
Figure 14, transport has long been studied intensively as the
primary cause of nonlinearities in the concentration-
lipophilicity proﬁles of chemicals.2077
Hansch and Fujita56 assumed, with remarkable intuition,
that the probability of the occurrence of molecules inside a
biosystem after a predetermined time interval could follow
a Gaussian distribution, with respect to lipophilicity, ex-
pressed as the logarithm of the 1-octanol/water partition
coefﬁcient, P. The resulting parabolic dependence of the
intracellular concentration or bioactivity on lipophilicity,
log c or log(
1
cX))A(log P)
2+B log P+C (8)
proved to be rather robust and usable. Here, c is the actual
concentration in an intracellular compartment, cX is the
isoeffective concentration that characterizes the bioactivity,
and A, B, and C are adjustable coefﬁcients that are optimized
by linear regression analysis. Coefﬁcient A is usually
negative, so the function has a concave shape, with the
maximum marking the optimum lipophilicity. Hansch and
Clayton6 compiled almost 200 parabolic dependencies of
bioactivity on lipophilicity. A searchable QSAR database that
includes 553 concave dependencies is available.1
The ﬁrst mathematical treatment of the distribution versus
properties problem was performed by Penniston et al.58
Because the experimentally veriﬁed dependencies of the
transfer rate parameters li and lo (Figure 7 in section 2.1.4.6)
on the partition coefﬁcient (eqs 3 in section 2.1.3.4) were
not available at that time, the authors used the assumption
lilo ) 1. Their system consisted of the aqueous and lipid
compartments with identical volumes and interfacial areas.
The intuitively assumed fast equilibration of chemicals in
the compartment volumes proved to be one of the most
important simplifying steps in the SBSP modeling. This
assumption is justiﬁed by the small distances (x), which the
molecules of chemicals cross in the subcellular compart-
ments. The typical distance, considering the average cell size,
is smaller than δ ) 10-5 m and reaches the nanometer
dimensions in the bilayer headgroup and core regions (see
section 2.1.1). The diffusion coefﬁcients of the low-molec-
ular-weight compounds are of the order of 10-9 m2/s in most
liquids.2078 Fluorescence recovery after photobleaching and
other experiments showed that small molecules and macro-
molecules up to 100 kDa exhibited diffusion coefﬁcients in
the cytoplasm that are only 4-5 times smaller than those in
saline.2079 The time t that the molecules require to cross the
small subcellular aqueous compartments then can be esti-
mated2080 as t ) δ2/(2D), i.e., t ) 0.2 s, under these
conditions. The equilibration times inside the bilayer regions
are shorter by several orders of magnitude. The equilibration
process in the miniature compartments is practically instan-
taneous on the timescale of most experiments. This fact
warrants the representation of a biosystem by a set of
alternating aqueous phases and membranes, with the mol-
ecules of chemicals diffusing quickly in bulk water and in
the bilayer headgroup and core regions. The three phases
have much lower density than subregions 2 and 3 in the
bilayers (section 2.1.1, Figure 3). The stochastic kinetic
effects of the crowded environment2081 seem to be far more
important for larger macromolecules than for chemicals. The
differential equations for the fast intracompartmental equili-
bration, similar to eqs 35 in section 10.2.1, were integrated
numerically.58 The concave concentration-lipophilicity de-
pendencies, consisting of two linear parts connected by a
curve, observed after a constant distribution period, were
interpreted as a support for the already known parabola.56
McFarland59 used a probabilistic approach to describe the
movement of chemicals in the Penniston model.58 For
constant transport periods, symmetrical concave concentra-
tion-lipophilicity relationships with linear ascending and
descending parts were obtained. The relationships were not
suitable for ﬁtting to real data, because the maximum
concentration was always attained by the chemical with equal
afﬁnities for both core and aqueous phases, i.e., having the
core/water partition coefﬁcient P ) 1.
Kubinyi64 re-examined the McFarland’s approach and
considered the substantial differences in the volumes of
aqueous and lipid phases in biosystems. The resulting
concave concentration-lipophilicity proﬁles for aqueous
phases were also symmetrical, but they were not restricted
in the peak position.59 Assuming that the receptor binding
is also lipophilicity-dependent and making all the coefﬁcients
A, B, C, and D freely adjustable, Kubinyi obtained the
asymmetrical bilinear equation:
log c or log(
1
cX))A log P-B log(CP+1)+D
(9)
Equation 9 has been shown to ﬁt the concentration-
lipophilicity proﬁles generated by numerical simulations of
chemical transport with the experimentally measured de-
pendencies of the transfer rate parameters li and lo on
lipophilicity, as described by eqs 3 in section 2.1.3.4. If a
reference partition coefﬁcient is used instead of the model
partition coefﬁcient, the Collander exponent   must be used
with each P term in eq 9, according to eq 1 in section 2.1.3.1.
The magnitude of   determines the sharpness of the curved
stretch that joins the two linear parts in the concentration-
lipophilicity plots8 described by eq 9. The ability to describe
the simulation results gives eq 9 the stature of a model-based
description of the transport, although its original derivation
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in sections 5.1.2 and 7.1.1, eq 9 also describes the equilibrium
distribution. This versatility makes the bilinear equation a
valuable tool for describing the relationships between bio-
activity and lipophilicity, which was used by many research-
ers.30 A linearized biexponential expression that also de-
scribes the bilinear dependencies was recently introduced.2082
Dearden65 further developed the Penniston model58 and
drew attention to the importance of the exposure time in the
transport simulations and, generally, QSAR. The most-
signiﬁcant results include the behavior of the optimum
lipophilicity (log P of the compound with the maximum
concentration in the concentration-lipophilicity proﬁles) in
dependence on the exposure time and on the number of the
partitioning steps, as well as the dependence of the time to
maximal response on lipophilicity.28,46
Van de Waterbeemd2083 described the transport in a three-
compartment model with equal compartment volumes ana-
lytically. He extended the results for the initial distribution
period to multiple bilayer systems and showed that the
concentrations are proportional to the product of the transfer
rate parameters of involved steps.2084,2085
Some attempts67,2086 at description of the concentration-
lipophilicity proﬁles were based on the use of a reduced time
τ (where τ ) lot, with lo being the transfer rate parameter
for the membrane-water direction and t being time; see
Figure 7 in section 2.1.4.6). The reduced time τ is propor-
tional to the real time t only when lo is a constant, which
holds for P , 1/Bt, as follows from eqs 3 in section 2.1.3.4.
Thus, the presented results are valid just for hydrophilic
compounds.
We examined the complete time course of the chemical
transport in closed systems with identical lipid phases.2087–2089
For this purpose, the set of linear differential equations
corresponding to the reduced equations described by eqs 47
(section 10.2.4) was integrated numerically. The transfer rate
parameters used are dependent on the partition coefﬁcient
as given by eqs 3 with the experimentally determined
values631 of the coefﬁcients At and Bt. The results are
illustrated in Figure 15, using the kinetics of the passive
chemical transport in a 10-compartment system, composed
of ﬁve aqueous phases, interspersed with ﬁve bilayer cores.
Before the start of the simulation, the compounds are present
only in the ﬁrst aqueous compartment. The concentrations
are plotted as a function of the reference partition coefﬁcient
(P) and the exposure time (t). The kinetics of distribution is
dependent on the position and nature of the sampling
compartment. In the third compartment, representing the
aqueous phase immediately following the ﬁrst bilayer core,
the concentrations of the chemicals initially increase and later
decrease to their equilibrium magnitudes, resulting, for a
certain time period, in a remarkable accumulation of the
chemicals above their equilibrium levels. This phenomenon
was observed in the ﬁrst half of the compartments (i.e., in
compartments 2-5 in this case), regardless of their aqueous
or lipid nature. The decline of the concentration caused by
pure transport, taking the molecules to deeper compartments
(no elimination was considered in this case), can be important
in biosystems that contain many compartments, such as
tissues, organs, and organisms (sections 3.6-3.8, respec-
tively). The situation in the second half of the compartments,
which are more distant from the site of administration, is
completely different, as illustrated by the transport kinetics
in the sixth compartment, which is shown in Figure 16. The
concentrations asymptotically approach the equilibrium
magnitudes, and no accumulation above the equilibrium
levels is observed.
The concentration-lipophilicity-time proﬁles, similar to
those shown in Figures 15 and 16, can be described by
semiempirical equations. We call these equations semiem-
pirical, because they currently do not have an obvious
mechanistic underpinning. In contrast to empirical equations,
Figure 15. Transport kinetics in the third, aqueous compartment
of a 10-compartment system (c is the concentration, the subscript
“eq” denotes equilibrium, t is time), relative to lipophilicity.2089 For
compartment numbering, see Figure 14. The chemicals accumulate
above the equilibrium level (c/ceq ) 1) for a signiﬁcant fraction of
the distribution period. The data were obtained by numerical
simulation of the pure transport of the compounds, which do not
interact with the headgroups, in a system of alternating aqueous
phases (5) and bilayers (5), with the transfer rate parameters li and
lo related to the partition coefﬁcient P according to eqs 3.2089 The
surface corresponds to eq 10 with the values of the coefﬁcients
speciﬁed in Table 5.
Figure 16. Transport kinetics in the sixth, core compartment of a
10-compartment system, relative to lipophilicty.2089 The system
consists of alternating aqueous (5) and core (5) phases. The
concentrations of chemicals do not exceed the equilibrium con-
centrations at any moment. The surface corresponds to eq 10 with
the values of the coefﬁcients speciﬁed in Table 5. Other details are
as given in Figure 15.
Table 5. Optimized Values of Adjustable Coefﬁcients in eq 10
Describing the Transport Kinetics in Compartments 3 and 6, as
shown in Figures 15 and 16, Respectively
Compartment 3 Compartment 6
parameter value
standard
error t-value value
standard
error t-value
A1 18.05 0.52 34.86
A2 0.05701 0.00186 30.64
A3 0.07373 0.00428 17.21 0.002719 0.000171 15.87
A4 0.002358 0.000131 17.97 0.02691 0.00171 15.72
B1 0.05003 0.00241 20.76
B2 0.1407 0.0102 13.84 0.2955 0.0097 30.35
 2 1.565 0.0148 105.7 1.571 0.019 83.54
 3 see text 1.694 0.019 87.05
1842 Chemical Reviews, 2009, Vol. 109, No. 5 Balazour equations are nonlinear in optimized coefﬁcients and
provide an almost-perfect ﬁt to simulated data. Polynomials,
which are typically used in empirical equations, do not
perform well in SBSP models, because they are not able to
properly ﬁt planar areas in the surface plots as seen in Figures
15 and 16, and linear stretches in two-dimensional plots (see
Figures 17-25, shown in this section through section 6.2.2).
The semiempirical equations represent an important step
enabling a straightforward use of the simulations in quantita-
tive characterization of biological data. The excellent ﬁts to
simulation data help select a proper form of the empirical
equation for ﬁtting the experimental data.
The simulated data subsets with constant P values in
Figures 15 and 16 were ﬁrst ﬁtted by eq 11 (see below),
and the optimized coefﬁcients A, B, C, and D were
subsequently ﬁtted as a function of P and the exposure time
t. This approach resulted in the following empirical equation:
c
ceq
)log[
(A1t
 1+B1)P
 2+1
(A2t
 1+B1)P
 2+1]
-
log[
(A3t
 3+B2P
 2)P
 2+1
(A4t
 3+B2P
 2)P
 2+1]
(10)
The overall ﬁt to the data simulated for the third compart-
ment of a 10-compartment system, shown in Figure 15, was
characterized by the following coefﬁcients. The exponents
 1 and  3 were linearly dependent on log P, with slopes of
(5.604 ( 4.3101) × 10-2 and (8.607 ( 2.982) × 10-2,
respectively, and the same intercept (1.681 ( 0.0129). The
values of the other adjustable coefﬁcients, as optimized by
nonlinear regression analysis,443 are summarized in Table 5.
All coefﬁcients are statistically signiﬁcant. The overall ﬁt is
very satisfactory, as shown in Figure 15 and by the values
of statistical indices: number of experimental points, n )
1212; the squared correlation coefﬁcient (equal to the
percentage of explained variance), r2 ) 0.992; the standard
error of the ﬁt, s ) 0.063; and the Fisher test value, F )
18 210. These statistical indices will be used throughout the
paper, to characterize the quality of a ﬁt. For comparison,
the best typical empirical equation (a polynomial with cross
terms) with the same number of optimized coefﬁcients as
eq 10, achieved values of r2 ) 0.743, s ) 0.375, and F )
389.2.
In the sixth compartment, no accumulation above the
equilibrium concentrations was observed, as seen in Figure
16. The data were ﬁtted with the second term in eq 10 (see
Table 5). The ﬁt was also very satisfactory, as illustrated by
Figure 16 and the values of the statistical indices (n ) 780,
r2 ) 0.996, s ) 0.029, and F ) 49 147). The best polynomial
with the same number of optimized coefﬁcients achieved
values of r2 ) 0.815, s ) 0.196, and F ) 1731.
The compounds with different lipophilicities reach the
equilibrium at different times. Figures 15 and 16 show that
the total period of distribution can be subdivided into three
parts: the nonequilibrium period (log t < 2.5 in this case;
no compounds have reached the equilibrium), the mixed
period (2.5 < log t < 5), and the equilibrium period (log t
> 5; all compounds have attained equilibrium).
The dependencies of the concentrations or effects on
lipophilicity proﬁles are most frequently measured after a
constant exposure time for all chemicals. The proﬁles are
different for individual distribution periods and will be
described in detail below. To facilitate the discussion, an
empirical equation describing all simulated proﬁles2087 is
introduced at this point:
log c or log(
1
cX))A log P
 +∑
i)1
3
Bi log(CiP
 +1)+D
(11)
Equation 11 describes the multilinear dependencies with up
to four linear parts and can be considered an extended form
of the bilinear equation described by eq 9. The model
partition coefﬁcient was substituted by a reference partition
coefﬁcient using the Collander equation 1 in section 2.1.3.1.
The ﬁrst term on the right side is written in a way that
emphasizes the substitution of the partition coefﬁcients. The
connection between the adjustable coefﬁcients A, B, and C
and the shape of the corresponding curves is outlined in
Figure 17. The coefﬁcients A and Bi determine the slopes of
linear parts, as shown in the upper panel of Figure 17. The
coefﬁcients Ci are associated with the position of the
curvatures. The Collander exponent   modulates the sharp-
ness of the curvatures. The upper curve, which is charac-
teristic for the mixed period of distribution, is described using
the integer values of the coefﬁcients A and Bi, which are
selected from available combinations, summarized in Table
6. The lower curve is typical for open systems. The leftmost
and rightmost linear parts still maintain the integer values
that are speciﬁed in Table 6. However, the slopes of two
linear parts that characterize the convex dip are no longer
conﬁned to the integer values and, consequently, the coef-
ﬁcients B1 and B2 are freely adjustable. The adjustable
coefﬁcients of eq 11, for the dependencies shown in Figure
17 and other cases discussed in sections 5-7, were ﬁtted to
the experimental data using nonlinear regression analysis,
deploying the Fletcher and Powell algorithm.2090
5.1.1. Nonequilibrium Period
The majority of previously published studies by other
authors on the description of movement of chemicals through
a series of alternating aqueous phases and membranes focus
exclusively on the nonequilibrium period of transport when
none of the studied chemicals have achieved the partitioning
equilibrium. We also simulated this period and compared
the results with those obtained in the most advanced studies
by Kubinyi.8,64 The results of the simulations for the
nonequilibrium period were practically identical, despite
Figure 17. Meanings of the adjustable coefﬁcients in eq 11 that
describes the relationship between the subcellular concentrations c
and lipophilicity expressed as the partition coefﬁcients P. The slopes
of the linear parts, relative to the coefﬁcients A and Bi, are given
in the upper part (all expressions are to be multiplied by the
coefﬁcient  ). The positions of the curvatures are determined by
the values of the coefﬁcients Ci.2089
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of the results and their application to experimental data were
somewhat different. Kubinyi made all the coefﬁcients in eq
9 freely adjustable, whereas, in our approach, a tighter
adherence to the simulation results had been chosen. The
resulting concentration-lipophilicity proﬁles for individual
compartments are given in Figure 18. For the ﬁrst two
compartments, the curves exhibit the zero slope values in
some linear parts. Other curves consist of linear ascending
and descending parts, connected with a rounded apical part.
The curves are symmetrical for the aqueous phases (odd
compartment numbers) and asymmetrical for the membranes
(even compartment numbers). The slopes of the linear parts
(Figures 18-20 and 22A) are integers, which are charac-
teristic of the corresponding compartments (Table 6).8,2083,2087
This fact signiﬁcantly promotes elucidation of the action
mechanisms of bioactive chemicals, as the shape of the
relationship between bioactivity and lipophilicity under the
nonequilibrium conditions could indicate the sequential
number and the nature of the compartment, where the
receptors for the studied bioactivity are localized.
This phenomenon2091 is illustrated in Figure 19, showing
the dependence of mutagenic activity of N-substituted alkyl
amides of 3-(5-nitro-2-furyl)-acrylic acid (59 in Chart 5) after
1-h incubation with two strains of Salmonella typhimurium
TA100 (rfa+ and rfa-) on lipophilicity. The strains differ in
regard to the structure of the cell walls. In contrast to the
rfa- strain, which has an exposed cell membrane, the cells
of the rfa+ strain are covered by a lipopolysaccharidic
complex that contains the second lipid bilayer, in addition
to the cell membrane. The mutagenic effects of nitrofurans
are likely caused by unstable metabolites formed in the
course of enzymatic reduction of the nitro group.2092 Because
the compounds are n-alkyl derivatives, it is plausible that
they do not differ in regard to the electronic properties of
the nitro group and, consequently, in the rate of reduction.
The data were ﬁtted by eq 11 with i ) 1; the optimized
coefﬁcient values are given in the ﬁrst two rows of Table 7
and the corresponding lines are shown in Figure 19. The
integer values of coefﬁcients A and B1 in eq 11 indicate (cf.
Table 6, nonequilibrium period) that the receptors are located
in the fourth compartment of the rfa- strain and in the sixth
compartment of the rfa+ strain (cf. Figure 19). The receptor
compartment would correspond to the lipophilic DNA-core
in both cases, because the cells of the rfa+ strain are covered
by two membranes, and the rfa- strain only has the cell
membrane.
Table 7 also contains some other examples of eq 11 with
i ) 1 and the integer values of the coefﬁcients A and B1
ﬁtted to experimental dependencies of bioactivity2093,2094 on
lipophilicity. The concave dependencies were also ﬁtted quite
well by the parabolic equation 8 and the bilinear equation 9
with freely adjustable coefﬁcients A and B (the results not
shown). Nevertheless, the adherence of our approach to the
results of model simulations brings an additional advantage,
especially in the possibility to locate the compartment, where
the interactions of the chemicals with the receptor occur.
Table 6. Integer Slopes of Linear Parts of the Concentration-Lipophilicity Proﬁles (Figures 18-20) and the Values of the Coefﬁcients
A, B1, B2, and B3 in eq 11 for the ith Compartment during Individual Distribution Periods
Coefﬁcients
phase Slopes
(left to right) AB 1 B2 B3
Nonequilibrium Period
aqueous (i - 1)/2 (1 - i)/2 (i - 1)/2 1 - i
lipid i/2 1 - i/2 i/2 1 - i
Mixed Period
aqueous (i - 1)/2 0 -1( 1 - i)/2 (i - 1)/2 (1 - i)/2 -13 - i/2
lipid i/2 1 0 1 - i/2 i/2 1 - i/2 -12 - i/2
Equilibrium Period
aqueous 0 -10 -1
lipid 1 0 1 -1
Figure 18. Nonequilibrium concentration-lipophilicity proﬁles for
individual phases of a 10-compartment system of alternating
aqueous and core phases at a constant time of distribution.2089 Other
details as in Figure 15. The compartment numbers are shown near
the respective curves. The aqueous phases are denoted by the odd
numbers and the bilayers are marked by even numbers, as in Figure
14 in section 5.
Figure 19. Mutagenicity of alkyl amides of 3-(5-nitro-2-furyl)-
acrylic acid (59 in Chart 5) against Salmonella typhimurium TA100
rfa+ (full points) and rfa- (open points), as dependent on the
1-octanol/water partition coefﬁcient P. The concentration cX (mol/
l) elicits, under given conditions, 600 revertants per plate. The
curves correspond to eq 11 with i ) 1 and the optimized values of
the coefﬁcients given in the ﬁrst two lines of Table 7.2091
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In the closed system without elimination (as illustrated in
Figure 14, if all elimination processes are omitted), the
transport of chemicals will continue up to the achievement
of the partitioning equilibrium (e.g., for log t > 5 in Figures
15 and 16).
The bilayer cores of individual membranes may have
different solvation properties, and the differences are assumed
to be minimal, as discussed in section 2.1.4.1. Nevertheless,
this factor may lead to the multiple partition coefﬁcients Pi
(up to a total number M). For ionizable chemicals, differing
compositions of the aqueous phases also generate multiple
apparent partition coefﬁcients, and this situation will be
treated in section 7.1.1. The corresponding expressions for
the concentration-lipophilicity proﬁles can be derived easily
from the deﬁnition of the partition coefﬁcient (Pi ) cMi/cW):
cW) n
Pi∑
i)1
M
VMi+VW
(12)
where n is the total amount, VM the total volume of the
bilayers, and VW the total volume of water. The correspond-
ing expression for the concentrations in the ith membrane is
obtained as shown in eq 12, multiplied by Pi. Equation 12
truly describes the partitioning equilibrium and can be used
to assess the accuracy of the integration method used for
numerical simulations. The concentration-lipophilicity pro-
ﬁles resulting from eq 12 were approximated by the concave,
bilinear curves, with the slopes of the linear parts having
non-integer values.8 If all bilayer cores have identical
solvation properties (M ) 1), eq 12 corresponds to a special
form of the bilinear equation 9 and the multilinear equation
describedbyeq11.Theequilibriumconcentration-lipophilicity
dependencies are bilinear on the bilogarithmic scale. The
slopes in the linear parts are equal to 1 and 0 (left to right -
hydrophilic compounds to lipophilic compounds) for the
membranes, and 0 and -1 for the aqueous phases. The de-
pendence for the membranes has a similar shape as the red
curve in Figure 20A. This curve, ﬂipped horizontally, deﬁnes
the shape of the dependence for the aqueous phases.
5.1.3. Mixed Period
In this period, the fastest chemicals with the optimum
partition coefﬁcients have already reached the equilibrium,
while other chemicals, which are either more lipophilic or
more hydrophilic, are still diffusing. The concentration-
lipophilicity proﬁle in this case is a combination of the
equilibrium and nonequilibrium proﬁles. As can be seen in
Figure 20B, the mixed proﬁles consist of four linear parts,
connected by the curved portions. The characteristic integer
slopes of the linear parts are summarized in Table 6. The
joining portions are mostly U-shaped. The S-shaped and
Chart 5. Compounds Used in the Distribution or Bioactivity Studies
Table 7. Optimized Values of the Adjustable Coefﬁcients in eq 11 with i ) 1 Describing the Dependencies between Bioactivity and
Lipophilicity during the Nonequilibrium Period of Distribution
Coefﬁcients
biosystem process compounda AB 1   C1 Dn r 2 s F ref
S. typhimurium rfa+ mutagenicity 5-NFA R-amides, 59 3 -5 0.638 ( 0.073 (4.390 ( 1.027) × 10-1 6.027 ( 0.421 7 0.976 0.120 20.5 Balaz et al.2091
S. typhimurium rfa- mutagenicity 5-NFA R-amides, 59 2 -3 0.650 ( 0.082 (4.270 ( 1.135) × 10-1 5.221 ( 0.543 6 0.949 0.084 4.62 Balaz et al.2091
C. Vulgaris growth 4-R-semicarbazides, 60 1 -2 0.983 ( 0.097 12.60 ( 2.345 6.265 ( 0.567 14 0.951 0.098 43.3 Kramer et al.2094
S. aureus growth BzN+(R)(CH3)2, 61 2 -3 0.604 ( 0.052 (1.370 ( 0.221) × 10-1 4.395 ( 0.324 12 0.980 0.134 86.2 Hansch and Clayton6
C. albicans growth BzN+(R)(CH3)2, 61 1 -2 1.041 ( 0.874 (4.396 ( 0.712) × 10-2 3.178 ( 0.146 11 0.962 0.219 38.3 Hansch and Clayton6
S. typhosa growth BzN+(R)(CH3)2, 61 2 -3 0.405 ( 0.097 (2.371 ( 0.286) × 10-1 4.328 ( 0.259 10 0.910 0.232 12.7 Hansch and Clayton6
M. tuberculosis growth 2-OR-3-NH2-Py, 62 2 -3 1.165 ( 0.186 (1.043 ( 0.102) × 10-1 2.385 ( 0.128 7 0.958 0.549 11.5 Hansch and Clayton6
C. diphtheriae growth R-NH2 (C5H11-C18H37)1 -2 0.915 ( 0.013 (6.747 ( 1.112) × 10-7 -0.225 ( 0.051 15 0.998 0.073 1250 Ko ¨lzer and Bu ¨chi2093
B. subtilis growth R-NH2 (C5H11-C18H37)1 -2 0.813 ( 0.007 (2.338 ( 0.210) × 10-6 0.071 ( 0.028 15 1.000 0.041 3123 Ko ¨lzer and Bu ¨chi2093
S. faecalis growth R-NH2 (C5H11-C18H37)1 -2 0.773 ( 0.009 (5.209 ( 0.586) × 10-6 0.385 ( 0.035 15 0.996 0.051 1250 Ko ¨lzer and Bu ¨chi2093
erythrocytes hemolysis R-monoglycerides, 63 1 -2 0.864 ( 0.067 (2.768 ( 0.201) × 10-4 1.457 ( 0.083 8 0.996 0.056 187 Kubinyi706
erythrocytes hemolysisb R-monoglycerides, 63 1 -2 1.054 ( 0.075 (3.689 ( 0.231) × 10-4 1.079 ( 0.073 7 0.994 0.096 83.0 Kubinyi706
mice neurotoxicity R-OH (CH3-C10H21)1 -2 0.904 ( 0.075 (1.759 ( 0.154) × 10-2 1.606 ( 0.095 10 0.996 0.109 311 Kubinyi706
a Some structures are shown in Chart 5. 5-NFA ) 3-(5-nitro-2-furyl)-acrylic acid, Bz ) benzyl, and Py ) pyridine. b With 2% ethanol.
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compartments, where the chemicals temporarily accumulate
in the concentrations exceeding their equilibrium values, as
seen in Figure 15. Equation 11 with i e 3 is suitable only
for the description of the curves that contain the U-shaped
connecting parts. A description of the curves with the
S-shaped and Z-shaped parts would require the addition of
more nonlinear terms to eq 11.
The experimental examples of the complete concentration-
lipophilicity proﬁles typical for the mixed period of distribu-
tion are rather rare, because they are only observed if the
tested chemicals cover a broad range of the lipophilicity
scale. Nevertheless, the fragments consisting of more than
two linear parts connected by curved portions were discern-
ible in some published concave proﬁles. The data usually
did not cover the sufﬁcient range of lipophilicity, and only
three linear parts were seen. Such proﬁles were observed
among those for the growth inhibition of 17 fungal strains
and 14 bacterial strains by n-alkylamines with 4-18 car-
bons.2093 The resulting descriptions by the bilinear equation
described by eq 9 and the trilinear equation described by eq
11 with i ) 2 are summarized in Tables 8 and 9, respectively.
The statistical indices in Table 8 deviate slightly from the
published values,27 because of the more-precise log P
values544 used in the present study. The differences in
statistical indices between eqs 9 and 11 enable an assessment
of the degree of trilinearity present in the experimental data.
Both equations provide almost perfect ﬁts. The data exhibit
small but systematic deviations from the bilinear equation
described by eq 9, as illustrated in Figure 21 for the growth
inhibition of Ctenomyces mentagrophytes.2093 The fact that
this behavior occurred in 12 of the 17 fungal strains, as
compared to only 1 of the 14 bacterial strains, speaks in favor
of the hypothesis about the mixed period of distribution. In
contrast to bacteria, fungi contain intracellular membranes,
in addition to the cell membrane. Therefore, to achieve the
partitioning equilibrium, the chemicals need more time in
fungi than in bacteria. The mixed period of distribution has
been observed in other experimental datasets.2087,2088
For the analyzed data of a homologous series of chemicals,
the differences between bilinear and trilinear ﬁts are small
and play a minor role in the quality of the ﬁt. They are more
important from the mechanistic viewpoint, because they
conﬁrm the existence of the mixed period of distribution.
As illustrated in the next part, dramatic changes have been
observed in the simulated concentration-lipophilicity proﬁles
during the mixed distribution period, if elimination has a
role.
5.2. Transport with Elimination
In principle, biosystems must be treated as open systems,
because of irreversible elimination. In multicellular organ-
isms, elimination of chemicals includes metabolism and
excretion, via specialized organs, into urine, sweat, expired
air, or bile and feces. In the cell suspensions and tissues,
elimination is represented by catalyzed or spontaneous
metabolic reactions. Efﬂux, which could be viewed as a cell-
level excretion process, is treated in SBSP as a part of carrier-
mediated transport. Consequently, in this section, which
involves cellular systems, elimination is synonymous with
metabolism.
Elimination is one of the key processes in the disposition
of chemicals, and it has a pronounced effect on the
concentration-lipophilicity proﬁles. The phenomenon was
ﬁrst described by Dearden and Townend,65 who studied the
Penniston transport model58 after prolonged periods of
distribution. For a constant exposure time, they observed a
distortion of the initially concave concentration-lipophilicity
proﬁles in the region of optimum lipophilicity. The maximum
of the initially bilinear curve decreased at longer times,
forming a double-peaked dependence, as shown in the blue
curve in Figure 22C. Similar dependencies were also
observed in other simulations.706 The minimum between the
two maxima arises from the following situation. The
compounds with optimum lipophilicity are transported at
the highest rates and are present in the highest concentrations
in the internal compartments where elimination occurs.
Because the rate of elimination is proportional to the
concentration, these chemicals are eliminated most rapidly,
and their concentrations decrease faster than those of slowly
transported compounds.
To compare behaviors of the open and corresponding
closed models,2089 the concentration-lipophilicity proﬁles are
shown for a four-compartment closed system (see Figure
22A), as well as for the situations when the system is made
open via the introduction of hydrolysis proceeding in both
extracellular and intracellular aqueous phases (see Figure
22B) and metabolism, which is conﬁned to the intracellular
space (see Figure 22C). The dependencies in the closed and
open systems have similar shapes in the initial period of
distribution, corresponding to the nonequilibrium period in
the closed system. The curves are bilinear with the integer
values of the slopes, which are equal to those given in Table
6 for the nonequilibrium period. The inﬂuence of elimination
becomes noticeable at the time when the mixed period of
distribution starts in the corresponding closed system (the
blue curve in Figure 22A). The lipophilicity of the most
rapidly eliminated chemicals, determining the position of the
deformation in the concentration-lipophilicity proﬁle, is
dependent on the compartment where elimination occurs.
Elimination proceeding in both aqueous compartments, e.g.,
hydrolysis, affects preferentially hydrophilic compounds, and
the concentration-lipophilicity proﬁles drop in the region
Figure 20. Concentration-lipophilicity proﬁles in the membranes
of a 10-compartment system of alternating water and bilayer phases
in the (A) nonequilibrium (10 time units) and (B) mixed (1000
time units) periods of distribution.2089 Curves for compartments 2
(the ﬁrst bilayer, red lines), 6 (the third bilayer, blue lines), and 10
(the ﬁfth bilayer, green lines) are shown, along with the equilibrium
curve (black lines). In compartment 2, chemicals accumulate above
the equilibrium concentration in both nonequilibrium and mixed
periods. The numbering is as given in Figure 14 in section 5,
whereas other details are as shown in Figure 15 in section 5.1.
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remain more or less bilinear, with the slopes in the distorted
part having non-integer values, which are much higher than
the original integer values of the nonequilibrium proﬁles
(Table 6). Equation 9, with the optimized coefﬁcient A and
the coefﬁcient B, which is dependent on A to maintain the
integer slope of the rightmost part of the proﬁle (cf. Figure
17), describes each with sufﬁcient precision. The situation
is completely different when only intracellular elimination
is considered. The maxima of the curves are distorted,
because the chemicals with the optimum lipophilicity are
eliminated at the fastest pace. The concentration-lipophilicity
proﬁles have two maxima separated by a minimum (Figure
22C) and can be described by eq 11 with i ) 3. Coefﬁcients
B1 and B2 are optimized, and coefﬁcient B3 is dependent on
B1 and B2 to maintain the integer slope value of the rightmost
linear part (the association between the slope values and the
magnitudes of coefﬁcients A and B is depicted in Figure 17).
During the initial period of distribution, the overall shapes
of the curves are similar, regardless of elimination. However,
the curves are shifted along the log c-axis, depending on
the rate and location of the elimination process. The
Table 8. Optimized Values of the Adjustable Coefﬁcients in eq 9 Describing the Relationships between Antimicrobial Activity2093 and
Lipophilicity of n-Alkyl Amines (C4H9NH2-C18H37NH2) for the Nonequilibrium Period of Distribution16a
microorganism A -BC × 107 -Dn b r2 sF
Candida albicans 0.975 ( 0.014 2.942 ( 0.262 2.534 ( 0.548 0.816 ( 0.051 12 0.998 0.051 1331
Candida tropicalis 0.957 ( 0.026 2.195 ( 0.086 7.414 ( 1.613 0.265 ( 0.086 15 0.996 0.103 913.9
Cryptococcus neoformans 0.892 ( 0.026 2.372 ( 0.185 1.651 ( 0.512 0.027 ( 0.097 15 0.994 0.127 608.4
Ctenomyces mentagrophytes 0.927 ( 0.053 2.038 ( 0.102 18.14 ( 6.191 0.529 ( 0.175 14 0.984 0.155 205.8
Fusarium moronei 1.016 ( 0.041 2.749 ( 0.271 32.85 ( 11.65 0.652 ( 0.120 12 0.992 0.128 164.7
Geotrichum candidum 0.965 ( 0.022 2.401 ( 0.074 5.244 ( 0.869 0.605 ( 0.081 14 0.996 0.080 830.8
Microsporum gypseum 0.910 ( 0.039 2.131 ( 0.087 12.36 ( 3.221 0.434 ( 0.132 14 0.990 0.121 330.8
Penicillium citrinum 0.989 ( 0.040 2.084 ( 0.113 16.93 ( 5.072 0.885 ( 0.134 13 0.992 0.118 372.7
Rhinocladium schenckii 0.910 ( 0.029 2.274 ( 0.088 6.101 ( 1.304 0.378 ( 0.102 14 0.994 0.099 553.1
Saccharomyces cereVisiae 0.907 ( 0.012 2.350 ( 0.111 1.009 ( 0.168 0.181 ( 0.045 15 0.998 0.060 1830
Saccharomyces fragilis 0.813 ( 0.031 2.104 ( 0.177 2.351 ( 0.856 0.406 ( 0.110 15 0.990 0.141 363.9
Staphylococcus aureus hosp 0.846 ( 0.027 1.575 ( 0.180 1.818 ( 0.839 -0.043 ( 0.098 15 0.994 0.127 608.4
Trichophyton tonsurans 0.911 ( 0.032 1.930 ( 0.089 7.798 ( 2.097 0.296 ( 0.114 14 0.994 0.108 553.1
a The minimum inhibitory concentrations were recalculated to molar basis. The partition coefﬁcients were found in the ClogP database for the
ﬁrst four congeners and calculated using the ClogP method544 for the other compounds. b All compounds with determined minimum inhibitory
concentrations are included.
Table 9. Optimized Values of the Adjustable Coefﬁcients in eq 11 with i ) 2, A ) 2, B1)- 1, B2)- 3, Describing the Dependencies of
Antimicrobial Activity of n-Alkyl Amines (C4H9NH2-C18H37NH2) on Lipophilicity during Mixed Period of Distribution16a
microorganism   C1 × 102 C2 × 106 -Dn r 2 sF
Candida albicans 0.963 ( 0.012 12.95 ( 7.834 0.440 ( 0.073 1.637 ( 0.226 12 1.000 0.041 3331
Candida tropicalis 0.818 ( 0.022 4.785 ( 1.660 4.119 ( 1.381 1.008 ( 0.095 15 0.996 0.091 913.9
Cryptococcus neoformans 0.831 ( 0.011 6.965 ( 1.396 1.618 ( 0.269 0.812 ( 0.057 15 1.000 0.047 4580
Ctenomyces mentagrophytes 0.700 ( 0.018 1.223 ( 0.272 45.06 ( 13.50 1.381 ( 0.064 14 0.998 0.060 1664
Fusarium moronei 0.935 ( 0.034 8.821 ( 4.978 5.592 ( 2.366 1.397 ( 0.166 12 0.996 0.102 664.7
Geotrichum candidum 0.857 ( 0.015 2.564 ( 0.648 2.332 ( 0.532 1.712 ( 0.077 14 0.998 0.059 1664
Microsporum gypseum 0.765 ( 0.016 2.308 ( 1.070 14.69 ( 3.328 1.388 ( 0.085 14 0.998 0.064 1664
Penicillium citrinum 0.771 ( 0.030 1.314 ( 0.419 13.33 ( 6.071 1.821 ( 0.098 13 0.996 0.084 747.7
Rhinocladium schenckii 0.809 ( 0.117 2.879 ( 0.568 5.468 ( 0.995 1.446 ( 0.058 14 0.998 0.046 1664
Saccharomyces cereVisiae 0.877 ( 0.007 19.75 ( 4.643 0.477 ( 0.049 0.739 ( 0.082 15 1.000 0.032 4580
Saccharomyces fragilis 0.754 ( 0.014 7.671 ( 1.961 6.679 ( 1.490 0.376 ( 0.069 15 0.998 0.059 1830
Staphylococcus aureus hosp 0.732 ( 0.010 4.826 ( 0.688 3.278 ( 0.507 0.727 ( 0.034 15 1.000 0.036 4580
Trichophyton tonsurans 0.724 ( 0.021 1.609 ( 0.398 14.53 ( 4.852 1.218 ( 0.072 14 0.998 0.067 1664
a Other details are given in Table 8.
Figure 21. Growth inhibition of Ctenomyces mentagrophytes by
alkyl amines (cX is the minimum inhibitory concentration),2093
relative to the lipophilicity, expressed as the partition coefﬁcient
P. The dotted curve corresponds to the bilinear equation 9, and the
full curve represents eq 11 for the mixed period of distribution (i
) 2). The optimized coefﬁcient values are given in Tables 8 and
9, respectively.
Figure 22. Concentration-lipophilicity proﬁles of chemicals in
the last compartment of the water-bilayer-water-bilayer system
(A) without elimination, (B) with elimination from either both
aqueous phases, or (C) with elimination from the intracellular
aqueous phase after the following distribution periods (in time
units): 0.1 (green), 1 (blue), 100 (red), and ∞ (black).2089 The
elimination rate constants are identical for all compounds and set
to zero, except k1 ) k3 ) 1/(time unit) in panel B and k3 ) 1/(time
unit) in panel C. Other details are as given in Figure 15 in section
5.1.
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modiﬁcation of eq 11:
log c or log(
1
cX))A log P
 -B1 log(C1P
 +1)-
log(Dk+1)+E (13)
where k is the elimination rate parameter. The results for
the fourth compartment of a four-compartment system are
presented in Figure 23. Evidently, elimination becomes
important when the value of the rate parameter k exceeds a
certain limit that decreases with prolongation of the time of
distribution. The dependence of the intracellular concentra-
tion on the elimination rate parameter k is bilinear, with
slopes of 0 and -1. For a real situation, the rate parameter
k can be substituted by the reactivity of the chemical in a
reference reaction mimicking the metabolic elimination
process, or by other experimental or computational reactivity
parameters, according to eq 5 in section 2.5.2.
6. Explicit Descriptions for Multi-Bilayer Systems
Some biologically relevant systems are sufﬁciently simple
to be described by explicit solutions to the set of differential
equations 47 (section 10.2.4), which characterize the disposi-
tion of chemicals in multimembrane systems. Complexity
can be reduced by considering a few compartments or by
neglecting the reverse transport processes, if applicable. Both
simpliﬁcations result in several useful descriptions. The
advantage of the explicit descriptions is that the transfer rate
parameters l do not need to be strictly limited to the passive
diffusion and can be replaced by characteristics of active
transport mechanisms in a linear regime. The explicit
descriptions represent realistic yet comparatively simple
SBSP models.
6.1. Transport through a Single Bilayer
A description of transport through the single membrane
is relevant for simple systems such as gram-positive bacteria
and unilamellar vesicles, as well as for various absorption
simulators, if the studied sheet only consists of one lipophilic
phase in a transport simulator2095 or a single phospholipid
bilayer, such as BLM (section 2.1.2.2), if the chemicals do
not signiﬁcantly interact with the headgroups. The frequently
published applications of single-membrane-based mathemati-
cal treatments to the description of transport through various
physiological sheets of multimembrane nature (e.g., the
intestine or skin; see section 3.5) will hardly promote our
understanding of the processes.
The rate of transport through a single membrane is usually
characterized by the permeability coefﬁcient PC (Figure 7,
row 1, section 2.1.4.6), relating the trans-membrane ﬂux of
the chemical to the surface area and the difference in the
concentrations in the donor and acceptor aqueous phases.
The magnitude of PC is equal to the reciprocal value of the
total resistance, which can be calculated in a laminary system
as the sum of the reciprocal values of the diffusional
resistancesinindividuallaminae.Theclassicalsolubility-diffusion
model (section 2.1.4.6) uses just a single lamina. The partial
resistance in the ith lamina can be written as1000,2096 Ri )
hi/(DiPi), where h is the effective thickness of the lamina, D
the diffusion coefﬁcient, and P the partition coefﬁcient for
the ith lamina, with respect to the external phase (if both
phases are identical, P ) 1). This generalization has been
frequently used for the construction of membrane transport
modelsdifferinginthenumberandqualityofthelaminae,2097–2103
as well as for the calculation of the permeability coefﬁcients
from the MD simulation data.292,588,1005 The membrane
transport models mostly result in the dependence of the
permeability coefﬁcient on the partition coefﬁcient, which
initially linearly increases and later becomes stable, such as,
e.g., the black curve in Figure 22. Some reports document
the effect of the solute size on permeability.2104,2105 A
comprehensive treatment showed that the solubility-diffusion
mechanism (section 2.1.4.6) overpredicts the permeabilities
through the liquid-ordered bilayers, and the correction factors
were proportional to the surface density of phosholipids506
and to the minimal cross-sectional area of the seven studied
permeants.73 It can be shown that, for the transport of non-
amphiphilic chemicals through a symmetrical bilayer (Figure
7, rows 2 and 3), PC ) li/2, where li is the water-to-bilayer
transfer rate parameter.2106
The permeability coefﬁcient PC (Figure 7, row 1) char-
acterizes the steady-state rate of passage through the
membrane. For most chemicals, the direct use of PC to
calculate the time course of the concentration in the acceptor
aqueous phase leads to substantial errors. The reason is that
the concept resulting in the deﬁnition of the permeability
coefﬁcient considers the membrane an inert diaphragm. As
illustrated in Figure 7, this assumption is not plausible for
the majority of chemicals, which accumulate to some level
in the membranes. The membranes represent a small volume
fraction of the biosystem. Nevertheless, even considering the
volume of the surrounding aqueous phases being a thousand
times larger than that of the membranes, a chemical with
the value of the membrane/water partition coefﬁcient of
∼1000 will partition in equal amounts in the aqueous phases
and in the membranes. The equilibrium concentrations
calculated without the consideration of membrane accumula-
tion would be ∼2 times higher than the experimentally
observed quantities.
Membrane accumulation can be taken into account via the
use of at least two transfer rate parameters: one for the
transfer of the chemical into the membrane and one for its
exit (li and lo, respectively). The transfer rate parameters are
characterized in section 2.1.3.4; their most important at-
tributes are the dependencies on the partition coefﬁcients,
as described by eqs 3. The representation of the membrane
by a single hydrocarbon core is a valid approximation for
the chemicals, which do not interact with the headgroups.
Figure 23. Reactivity dependence of the concentrations in
compartment 4 of a four-compartment, water-bilayer-water-bilayer
model that were corrected for the contribution of lipophilicity to
show only the reactivity portion of this form of the disposition
function (eq 13). The exposure time is increasing from top to
bottom. Other details are as given in Figure 22.
1848 Chemical Reviews, 2009, Vol. 109, No. 5 BalazThe explicit solutions to differential equations 47 were
published for the simple water-core-water system (section
10.2.5),2095 and for the system containing an additional
lipophilic phase.2107 The concentration-lipophilicity proﬁles
for individual distribution periods t, as generated by the
explicit solutions, are similar to those given in Figure 20.
6.2. Unidirectional Transport
The disposition of chemicals involving only unidirectional
transport often represents real situations, at least for a certain
time period.2108 Transport in any multimembrane system
proceeds initially in one direction, away from the site of
administration. The duration of the period of unidirectionality
is primarily dependent on the length of the sequence of
compartments, as well as on the rates and equilibria of the
processes, which reduce the free concentrations in individual
compartments either reversibly (noncovalent binding to
macromolecules, section 2.4) or irreversibly (metabolism and
excretion, section 2.5). The approximation may occasionally
be sufﬁciently precise even for the complete period of
distribution, especially in two borderline cases: (i) for large
systems, where the total number of compartments approaches
several hundred, as described in section 1.2 for the muscles,
connective tissues, and fat; and (ii) for rapidly biotransformed
chemicals, even in the biosystems with a few bilayers, as in
the cell suspensions.
6.2.1. Model Description
The model system depicted in Figure 14 in section 5, if
the transport is considered unidirectional, is described by the
set of linear differential equations 47 (section 10.2.4) with a
bi-diagonal matrix B. The elements above the diagonal
represent the backward process and vanish for the unidirec-
tional transport. If all compartments of the model are different
(also known as the normal case), the free concentration in
the mth compartment can be expressed2064,2109 as a multi-
exponential function of the exposure time t:
cm)
n∏
i)1
m-1
Fi,i+1
∏
i)1
m
Vi∑
j)0
S
∑
k)0
Z
dijpijk(1+bijk)
∑
j)1
m
e
-λjt
∏
k)1
m
(λk-λj)
(14)
Here, n is the dose. The eigenvalue λi (eq 49, section 10.2.6)
comprises the traits of the ith compartment: the volume Vi,
the interfacial area Si connecting it to the (i + 1)th
compartment (in the ﬂux terms Fi,i+1, c.f., eq 46), the pH
value of the phase (in the dissociation terms dij, c.f., eqs 36
and 46), and the concentration of protein binding sites sij (in
the binding terms bijk, c.f., eq 38), as well as the properties
of the tested chemicals, such as the rate parameters for the
transfer from water to the core and backwards (li and lo,
respectively, in the terms Fi,i+1, c.f., eqs 35 and 46), the
ionization constant to the jth degree (in dij), ion pairing with
the kth counterion (in the pairing term pijk, c.f., eqs 36 and
46), the elimination rate parameters kijk (in Ei, deﬁned in eq
46), and afﬁnities for proteins Kij, (in bijk, c.f., eq 38).
The descriptions equivalent to eq 14 were published for
simpler scenarios when protein binding or elimination was
not signiﬁcant.2110–2112 Equation 14 supports the previously
published conclusion about the proportionality between the
concentration at a given time and the product of the rate
parameters of involved transport processes.2083
The cellular structure of tissues leads to the situation in
which all membranes and all aqueous phases have the same
characteristics (also known as the degenerate case). This
phenomenon may also be observed in isolated mammalian
cells and eukaryotic microbial cells, because they are
subdivided into the sets of similarly sized compartments by
endoplasmic reticulum and other intracellular membranes.
The time courses of the drug concentrations in all compart-
ments, preceding the cellular structure with repeated pairs
of identical compartments, are described by eq 14. Inside
the cellular structure, recurrent formulae should be applied,
as has been shown for a reduced scenario.2112
Equation 14 and the recurrent formulae can be used in
two ways: (i) for a direct construction of the SBSP models
in smaller systems, such as suspensions of bacteria or
mammalian cells, which comprise a few compartments; and
(ii) as a basis for a derivation of more-manageable limit
expressions, when the compartment number is large.
6.2.2. Concentration-Lipophilicity Proﬁles
Equation 14, with the transfer rate parameters expressed
by eqs 3, which is valid for chemicals that are not
accumulating in the headgroups and at the interface, describes
transport2113 as being combined with elimination2111 and
protein binding.2112 For pure transport and transport with
elimination, the generated concentration-lipophilicity pro-
ﬁles have been shown to be identical to those obtained by
numerical simulations. The inﬂuence of protein binding on
disposition of chemicals has only been investigated in SBSP
models using the explicit relationship described by eq 14.2110
As the ﬁrst approximation, protein binding was assumed to
be dependent on lipophilicity, according to eq 4 in section
2.4.4. More-precise models will require replacement of the
association constants Kij, which are contained in the terms
bijk in eq 14, by the 3D-QSAR models for protein binding,
as reviewed in sections 2.4.1-2.4.4. All adjustable coef-
ﬁcients, such as those in eq 14, as well as those in the 3D-
QSAR model, may need to be optimized simultaneously.
The corresponding concentration-lipophilicity proﬁles for
shorter periods, corresponding to the nonequilibrium distri-
bution period in closed systems, are depicted in Figure 24.
The bilinear proﬁles without the inﬂuence of protein binding
have characteristic integer slopes (see Table 6 in section
5.1.1). Lipophilicity-dependent protein binding changes the
slope of the decreasing linear part, as can be seen in Figure
24. This fact could explain why the experimentally observed
smooth concentration-lipophilicity proﬁles cannot always
be described using eq 11 with the integer values of the
adjustable coefﬁcients, as given in Table 6. The dependencies
for a plummeting right-hand part, which are similar to those
in Figure 24, are accurately described using a simple
empirical relation:2114
log c)A log P-BP+C (15)
Here, A, B, and C are optimized coefﬁcients. Equation 15
provided excellent ﬁts to several published datasets.2114
The results for the longer distribution periods are plotted
in Figure 25. Analogous curves for pure transport (Figure
25A) have been described in sections 5.1.1 and 5.2. The
initially bilinear concentration-lipophilicity proﬁles are
distorted after longer distribution periods in the region of
optimum lipophilicity and form the double-peaked curves.
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creases the actual drug concentrations at shorter times.
For the longer distribution periods, the depot function of
proteins for chemicals with log P > 0 starts to play a role.
The slowdown of the transport of the molecules with the
optimum lipophilicities is the reason why the minima in
Figure 25B become shallower than those without the protein
inﬂuence (Figure 25A). The depot effect is more pronounced
in the presence of elimination (Figure 25C). While hydro-
philic compounds have been eliminated at longer times and
the left-hand peaks have completely disappeared, lipophilic
compounds are still present in the system, because of the
depot function of protein binding.
6.3. Steady-State Distribution
Continuous dosing at a steady rate is frequently used for
therapeutic purposes, in the form of intravenous infusions
for critical drugs or via the steady-release dosage forms,
producing long-lasting effects. Environmental scenarios with
practically invariant pollution levels also provide a steady
input. If the continuous input of chemicals is maintained at
the same rate for a sufﬁciently long period, the system will
ultimately attain the steady state, manifested by the time-
invariant concentrations in all compartments, which are
depicted in Figure 14 in section 5. Consequently, all the left-
hand-side derivatives in SBSP models, which are represented
by eqs 46 in section 10.2.4, vanish. To describe the situation,
eqs 47 are not needed in this case, because the factors that
are used to convert eqs 46 to eqs 47 would cancel each other
in the solutions of the algebraic equations resulting from eqs
46 for the steady-state conditions. Because of a sustained
concentration pressure from the site of dosing, reverse
transport is negligible, and the back-ﬂux terms Fi,i-1 and Fi+1,i
in eqs 46 can be omitted. This simpliﬁcation affords a
compact solution for the steady-state concentration of the
free non-ionized molecules in the ith compartment (see the
numbering in Figure 14 in section 5), obtained by back-
substitution:2115
ci(ss))
c1∏
j)2
i
Fj-1,j
∏
j)2
i
(Fj,j+1+Ej)
(for i)2, 3, ..., N)
(16)
Here, c1 is the invariant concentration of the free non-
ionized chemical in entry (aqueous) compartment 1, and
the ﬂux and elimination terms F and E are deﬁned in eqs
46. The last compartment is usually an aqueous phase, so
the sequence number of this compartment (N in eq 16) is
an odd number, according to the numbering scheme in
Figure 14 (section 5).
If the studied biosystem, such as a tissue, consists of the
cells of the same type with similar intracellular compart-
ments, the ﬂux terms F are practically identical for the
transport from all aqueous phases (FA, odd initial subscript
i) and from all bilayers (FM, even initial subscript i). For
this common situation, eq 16 can be simpliﬁed to eq 17 for
the aqueous phases and eq 18 for the bilayers,2115 with the
compartment numbering given in Figure 14 in section 5:
ciA(ss))c1[
FAFM
(FA+EA)(FM+EM)]
(i-1)⁄2
(for i)3, 5, 7,...,N) (17)
ciM(ss))c1(
FA
FM+EM)
i⁄2(
FM
FA+EA)
(i-2)⁄2
(for i)2, 4, 6,...,(N-1)) (18)
The dependencies on the lipophilicity of the free, non-ionized
steady-state concentrations, which were attained during
continuous dosing, are illustrated in Figures 26 and 27. The
transfer rate parameters li and lo contained in the ﬂux terms
were expressed using eqs 3 in section 2.1.3.4, so the results
are valid for the chemicals, which do not accumulate in
the headgroups and at the interfaces. Interestingly, no peaks
are apparent in the bilogarithmic dependencies; rather, the
concentrations of chemicals are, after an initial linear increase
for hydrophilic chemicals, independent of lipophilicity for
aqueous phases, and rise at a lower rate for membranes. The
slopes of the leftmost linear parts are dependent on the
compartment number (see Figure 26). The break-point log
P value is affected less by the compartment number (see
Figure 26) than by the magnitude of the elimination rate
(Figure 27).
Apparently, the peaks in the concentration-lipophilicity
proﬁles after single doses (e.g., Figures 17-24) are caused
by a slow transport of lipophilic compounds. As can be seen
Figure24. Inﬂuenceofproteinbindingontheconcentration-lipophilicity
proﬁles of nonionizable chemicals in the nonequilibrium period in
the ﬁfth aqueous compartment of a system of alternating aqueous
phases and bilayers, as calculated using eq 14. Protein binding is
lipophilicity-dependent, according to eq 4 with bi00 ) BiP , Bi )
B1 ) B3 ) B5, and B2 ) B4 ) 0 (see eqs 38 and 43). The transfer
rate parameters li and lo are dependent on the partition coefﬁcient
P, according to eq 3. Panel A illustrates the effect of the increasing
protein concentration:   ) 1 and Bi ) 0 (black), 0.01 (red), 1 (blue),
and 100 (green). Panel B illustrates the effect of the increase in
the sensitivity of binding to lipophilicity: Bi ) 0 (black); and Bi )
1 and   ) 0.75 (red), 1.00 (blue), and 1.25 (green).2110
Figure 25. Dependencies2112 of the concentration c in the ﬁfth
compartment of the system of alternating aqueous and bilayer
phases on the partition coefﬁcient P for (A) pure unidirectional
transport, (B) transport combined with protein binding, and (C)
transport inﬂuenced by protein binding and metabolism, after the
following times of distribution (in time units): 3.2 (green), 10 (blue),
32 (red), and 100 (black). Calculated using eq 14, with the
parameters as in Figure 24A (Bi ) 1) and ki ) 1/(time unit).
1850 Chemical Reviews, 2009, Vol. 109, No. 5 Balazin Figures 26 and 27, this phenomenon does not exist under
the continuous dosing regimens, after the distribution reaches
the steady state. However, there is a string attached to the
last phrase. The duration of the transient period, before the
steady state is established, varies with lipophilicity, and can
be very long for extremely hydrophilic and extremely
lipophilic compounds. Achievement of the steady state for
chemicals with a broad range of lipophilicities requires long
exposure periods, which are typical for environmental
scenarios but may be much longer than the common infusion
periods of drugs. Consequently, in real situations, a type of
concave concentration-lipophilicity proﬁle can also be
expected for the continuous dosing of drugs, if the lipophi-
licity range is sufﬁciently broad. The concentrations of very
hydrophilic and very lipophilic drugs would be lower than
expected on the basis of the steady-state proﬁles, which are
shown in Figures 26 and 27.
The concentrations in individual phases, as expressed by
eqs 17 and 18, are of interest, when the studied chemicals
act by a speciﬁc mechanism on well-deﬁned receptors, which
are localized in spatially limited compartments. However,
environmental pollutants frequently elicit their effects in all
phases by mechanisms, which cannot be tracked back to the
modiﬁcation of a single receptor, such as polar and nonpolar
narcosis, and alkylation of body constituents.1487,2116,2117 These
effects are caused by interactions proceeding in all aqueous
phases or in all membranes; consequently, the average
concentrations in all aqueous phases and all membranes are
important for their descriptions. If individual steady-state
concentrations in membranes are enumerated according to
eq 18 and used to calculate the average concentrations, the
result contains a practically inﬁnite (N may reach several
hundred; see section 1.2) geometric sequence with the
argument x ) FAFM/(FA + EA)(FM + EM) < 1 and the
powers 0, 1,..., (N - 3)/2. The sum of such a sequence is
equal to 1/(1 - x) and can be used to calculate the average
concentrations for all (N - 1)/2 membranes (eq 20).2115 For
the aqueous phases, the ﬁrst term with the power of 0 (i.e.,
term ) 1) is missing and the sum is then [1/(1 - x)] - 1.
The average concentration for all (N - 1)/2 aqueous phases,
except the ﬁrst phase, which maintains the constant concen-
tration c1, is given by eq 19:2115
cA(ss, av))
2c1FAFM
N-1
[(FA+EA)(FM+EM)-FAFM]
(19)
cM(ss, av))
2c1FA(FA+EA)
N-1
[(FA+EA)(FM+EM)-
FAFM] (20)
Here, N is the number of compartments. The dependencies
of the average concentrations in the aqueous phases and
membranes on lipophilicity are shown in Figure 28. In
aqueous phases, saturation-type curves are observed, whereas
biphasic increasing dependencies result for the membranes.
The elimination rate affects the average aqueous concen-
trations much more signiﬁcantly than the average membrane
concentrations. This fact is consistent with experimental
observations regarding pollutants acting by narcosis, which
is presumably elicited by a membrane perturbation. The
toxicity of these chemicals is linearly dependent on lipophi-
licity, with a slope that approaches unity. The dependencies
are perfectly linear for persistent pollutants, and reactive
chemicals exhibit only modest deviations from the line.2118–2121
Figure 26. Steady-state concentrations versus lipophilicity in (A)
individual aqueous phases and (B) individual bilayers for the
invariant elimination rate constants. The aqueous phases are
represented by compartments 3-23 and membranes are represented
by compartments 2-22, both with step 4 (curves 1-6, respectively;
compartment numbering is as shown in Figure 14 in section 5).
The curves correspond to eqs 17 and 18 with c1 ) 1 unit and EM
) 1 (time unit)-1. The ﬂux terms in eqs 17 and 18 are deﬁned in
eqs 46 and only contain the surface areas and the transfer rate
parameters. The transfer rate parameters are expressed by eqs 3.2115
The dotted line indicates c1 in A and c1P in B.
Figure 27. Steady-state concentration-lipophilicity proﬁles for
(A) aqueous compartment 7 and (B) bilayer 8 of a catenary system
of alternating aqueous and bilayer phases, relative to the elimination
rate constant k.2115 The elimination terms only contain k, in (time
unit)-1:1 0 -4 (curve 1), 10-2 (curve 2), 1 (curve 3), 10 (curve 4),
102 (curve 5), and 103 (curve 6). Other details are as shown in
Figure 26.
Figure 28. Average steady-state concentration-lipophilicity pro-
ﬁles in (A) all aqueous phases and (B) all bilayers of a system of
alternating aqueous and bilayer phases, as a function of the
elimination rate constant. Curves correspond to eqs 19 and 20, with
other details as given in Figure 26. The elimination rates constants
k, in (time unit)-1, are 10-4 (curve 1 in both parts), 10-2 (curve 2),
1 (curve 3), 102 (curves 4 and 3 in parts A and B, respectively),
104 (curves 5 and 3 in parts A and B, respectively), and 106 (curves
6 and 3 in parts A and B, respectively).2115
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The SBSP models, utilizing the pseudo-equilibrium ap-
proximation to describe the disposition, include all processes,
which chemicals undergo in biosystems, besides absorption.
Absorption is usually much faster than elimination and is
considered a fast process under the pseudo-equilibrium
approximation. The models capture essential features of the
disposition process, including a substantial portion of its
kinetics, exhibit a low complexity of the description, and
allow for incorporation of external 3D-QSARs for protein
binding and metabolism where necessary. From this view-
point, the pseudo-equilibrium models belong to the most
advanced tools of SBSP. The pseudo-equilibrium models
evolved from equilibrium models, which represent the ﬁrst
non-empirical models of SBSP.
The equilibrium approach is applicable to the distribution
of the chemicals, with the transport being much faster than
elimination. The equilibrium models describe the disposition
accurately in the time interval after the transport has been
ﬁnished and before elimination is measurable. The ﬁrst
equilibrium model was formulated by Higuchi and Davis.2122
Their expressions, after a later conversion to QSAR
equations,706,2123 were equivalent to the bilinear equation 9
in section 5.1.1, under some circumstances. The addition of
ionization by Martin34,35,63 to the equilibrium models repre-
sents an important advance because many chemicals and
most drugs ionize under physiologic conditions.
The extension from the equilibrium to pseudo-equilibrium
approach was accomplished by a conceptual inclusion of
elimination.2124 As a result, the elimination period, represent-
ing usually the major portion of the residence time of
chemicals in the biosystems after a single dose, has become
a part of the time interval covered by the model. In contrast
to the selection of special model structures and reduced
scenarios, as used in sections 6.1-6.3, here, the time
hierarchy of the distribution processes was deployed to
reduce mathematical complexity. The number of the time-
dependent variables decreased dramatically, because of the
approximate representation of the fast processes as instan-
taneous events. The objective was to introduce a new type
of the disposition function, which would be sufﬁciently
robust (i.e., describing the main features yet simple) for a
direct application in the formulation of model-based QSTARs
(where T represents time), and advance SBSP modeling.
7.1. Model Construction
Interactions with bilayer regions determine the trans-
bilayer transport rates of chemicals, as summarized in
sections 2.1.4.6 and 10.1.2. For a single bilayer under
physiological conditions and dimensions, the rates vary from
milliseconds for chemicals with intermediate strength of
interactions with bilayer regions, to minutes or hours for
substances with extreme lipophilicities, to days for some
amphiphilic compounds. The overall distribution rates are
dependent on the complexity of biosystems, in addition to
the properties of the chemicals. If only transport is consid-
ered, the complexity of a biosystem can be characterized by
the number of membranes. The time a chemical requires to
achieve the lipo-hydrophilic equilibrium increases with the
number of the membranes it must cross.
The real rate of transport, encompassing both the absorp-
tion and distribution phases, is dependent on the interplay
of all these factors. For non-amphiphilic chemicals with
optimal lipophilicity, the process is completed within an
interval ranging from milliseconds to minutes in simple
biosystems such as liposomes,82,704,2125 subcellular organelles,
and cells.78,2126–2128 For amphiphilic permeants,710,711,2129 very
hydrophilic or lipophilic permeants2130 in simple biosystems,
or non-amphiphilic and optimally lipophilic chemicals in
large biosystems such as organs or organisms,2131 the period
needed to achieve the lipo-hydrophilic equilibrium may be
as long as several minutes,2132,2133 hours,709 or even days710–712
after the administration. Ionization of a chemical, which
makes it more amphiphilic, also signiﬁcantly slows its trans-
bilayer transport.711,2132
The transport of chemicals is usually faster than elimina-
tion. Provided that the rates of the two processes differ
sufﬁciently, transport can maintain the actual concentrations
in individual cellular phases permanently near the lipo-
hydrophilic equilibrium. This is the premise of the pseudo-
equilibrium disposition model. A corresponding morpho-
logically compartmentalized biosystem was shown in Figure
14 in section 5. The only modiﬁcation that must be made in
Figure 14 is to depict the transport as an instantaneous
process. In the aqueous phases, both ionized and non-ionized
molecules are present, but only the latter are assumed to
readily cross the hydrocarbon core of the bilayers readily,
according to the pH-partition hypothesis.2134 Provided that
it is much faster than elimination, the transport can be
considered instantaneous and reversible, as are the intrac-
ompartmental processes, which include ionization and non-
covalent binding to enzymes and proteins. Irreversible
elimination then represents the only time-dependent step.
Under such conditions, all the phases of the biosystem
become kinetically undistinguishable. From the viewpoint
of the chemicals’ disposition, it means that the originally
N-compartment system loses its structure and collapses to a
one-compartment open system. The free non-ionized species
move quickly in such a system; therefore, their concentrations
are identical at each moment in all aqueous phases and in
all membranes. The aqueous and membrane concentrations
are time-dependent, and are, at any moment, related by the
partition coefﬁcient, according to the Nernst distribution law.
A similar time hierarchy has been used in the development
of the model-based equilibrium dependencies of bioactivity
on lipophilicity and acidity.34,35
The decisive criterion for applicability of the pseudo-
equilibrium approach is the ratio between the rates of
transport and elimination. If this ratio is higher than 5-10,
the transport is able to maintain the actual concentrations of
chemicals in individual cellular phases permanently near the
lipo-hydrophilic equilibrium. Then transport joins ionization,
ion pairing, and protein binding in the category of fast,
reversible processes, and elimination remains the only time-
dependent step.
The pseudo-equilibrium disposition is characterized in a
standard way using the Law of Mass Action. The concentra-
tions of individual species in the multiple, rapid equilibria
are mutually inter-related at each moment; therefore, any of
them can serve as a reference variable for the expression of
all of the other concentrations, as documented in section
10.1.4. The free non-ionized concentration cA was selected
as the reference concentration, because it has the same
magnitude in all aqueous compartments under the conditions
of the adopted time hierarchy. The concentrations of the free
1852 Chemical Reviews, 2009, Vol. 109, No. 5 Balaznon-ionized molecules in all membranes are also equal and
related to cA via the membrane/water partition coefﬁcient
PM.
The molecules are present in each aqueous phase in nine
different states: free and bound to proteins and enzymes, all
three states comprising non-ionized molecules, ionized
molecules, and ion pairs (see Figure 14 in section 5 and
consider only monovalent acids or bases and one type of
counterions). The scenario is characterized by 13 equations
(6 deﬁnitions of the association constants for the binding of
the non-ionized, ionized, and ion-paired molecules to proteins
and enzymes, plus 6 deﬁnitions of the ionization constants
and ion-pair formation constants for the free, protein-bound,
and enzyme-bound molecules, plus the mass balance equa-
tion). Four equations are redundant. The deﬁnitions of the
ionization constants for the complexes of the chemical C
with proteins (CPij) and enzymes (CEij), and the deﬁnitions
of the ion-pairing association constants for CZPijk and CZEijk
for the counterion Z were set aside and not used (the
processes are not indicated by the double-head arrows in
Figure 14 in section 5), because they do not comprise the
reference concentration of free non-ionized chemicals, cA.
7.1.1. Accumulation in Membranes
As the ﬁrst approximation, the hydrocarbon cores of the
bilayers are considered as having practically identical sol-
vation properties in all membranes. For the chemicals, which
do not interact with the headgroups and only accumulate in
the core of the bilayer, as shown in rows 2 and 3 of Figure
7 in section 2.1.4.6, the partition equilibrium is described
by the apparent partition coefﬁcient Pi that can be expressed
as
Pi)aiPC (21)
Here, PC is the core/water partition coefﬁcient and the
proportionality constant ai is deﬁned by eq 56 in section
10.3.1. The aqueous phase that is more distant from the site
of entry of chemicals was chosen for the deﬁnition of Pi by
eq 21. The composition of this phase (pH, the concentrations
of the counterions) determines, along with other factors (see
section 10.3.1), the magnitude of the accumulation factor
ai. The partition coefﬁcient PC is an additive-constitutive
property that can be expressed as the product of the
hypothetical partition coefﬁcients (fragment contributions)
of substructures, and the factors correcting for the interactions
among the substructures.649,2135 This principle enables a fast
prediction of the PC values for new structures.
Partitioning of amphiphilic and cephalophilic chemicals
is more complicated, and its quantitative description requires
the use of the headgroups/water partition coefﬁcients.
However, these chemicals are transported slowly20 (see
section 2.1.4.6), and their behavior may not conform to the
assumptions of the pseudo-equilibrium model.
7.1.2. Ionization in Aqueous Phases
Extracellular and intracellular aqueous phases of biosys-
tems differ in composition, including the proton concentra-
tions, as illustrated by the following examples. The stomach
content has different acidities in fasted and fed states. A pH
gradient exists along the intestine. The acidity of the urine
is dependent on physiological factors. Among the intracel-
lular compartments, lysozomes and mitochondria exhibit
more-acidic aqueous milieu than other organelles. The
differences in the pH values of individual aqueous phases
affect both the rate and the extent of transport processes,
especially for ionizable chemicals.
The pH-partition hypothesis states the non-ionized
species of a ionizable molecule are transported at a faster
rate than their ionized counterparts.2134 This well-known
concept was developed for intestinal absorption, although
the inﬂuences of the pH value of the medium on intracellular
uptake and biological effects were studied earlier, ﬁrst
qualitatively1580–1582,2136–2144 and later quantitatively.2145–2147
In 1942, a comparatively smooth dependence of the bacte-
riostatic activity of sulfanilamides against Escherichia coli
on the pKa values, exhibiting a maximum at pKa ≈ 6.5, was
observed and explained by a conceptual quantitative
model.2148 The peak in bioactivity results from an interplay
between the ionization equilibrium affecting the uptake and
the intrinsic activity,2149 which exhibit opposite tendencies
with regard to the pKa values. The effects of substituents on
the acidity of organic acids2150,2151 and other reactions2152 led
to the formulation of the Hammett equation, which greatly
contributed to the QSAR development.
The pH-related variability in the accumulation of ionizable
chemicals is one of the factors that affects pseudo-equilibrium
distribution. A typical example are cationic drugs, for which
ion-trapping in lysozomes and mitochondria,1754 along with
other interactions, leads to the increase in distribution
volumes.2153,2154 The accumulation is pronounced in lyso-
zome-rich organs, including lungs, kidneys, and the liver.2155
Ionization has long been recognized as an important factor
that affects the disposition of chemicals. The experimental
determination2156,2157 and prediction of the dissociation
constants2158–2171 belong to standard procedures in preclinical
drug development. The presence of several ionizable groups
with the pKa values closer than 2-3 units requires a special
attention in both experimental2172–2176 and computational2177,2178
approaches. Four programs for estimating the pKa valuess
PALLAS/pKalc,2179 MARVIN,2180 ACD/pKa DB,2180,2181 and
SPARC2182 swere compared, using three datasets.2183
In the context of pseudo-equilibrium distribution, the
ionization equilibria in the aqueous phases are described
using the factors dij, given by eq 36 in section 10.2.2. The
concentration of the jth ionized species is obtained as
the product of the factor dij and the free concentration of the
neutral species. The formation of the ion pairs is character-
ized by the factor pijk, which is deﬁned in eq 37.
7.1.3. Elimination
The loss of chemicals via elimination is the summation
of excretion, reactions with low-molecular-weight body
constituents, and enzymatic biotransformation of all low-
molecular-weight species (neutral molecules, ions, ion pairs)
in all compartments. The ﬁrst-order elimination rate constant
k includes the contributions from all the ﬁrst-order processes,
i.e., excretion and spontaneous and enzymatic reactions,
affecting each low-molecular-weight drug species in the ith
compartment, as deﬁned in eq 45 in section 10.2.3. The
overall elimination rate constant can be partitioned into its
components: spontaneous reactions r, enzymatic reactions e
(the subscript “P” indicates lipophilicity-dependent reactions),
and excretion processes x, as shown in eq 45.
There is usually no need to differentiate between enzy-
matically catalyzed biotransformation to inactive metabolites
(eijk) and covalent binding to proteins (typical, e.g., for
alkylating agents), if the latter proceeds in a small, nontoxic
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tion, the same role: they cause the irreversible loss of the
molecules of chemicals, which are originally noncovalently
bound to them. The covalent protein binding must be taken
into account only if it is signiﬁcant and leads to toxicity.
7.2. Model Description
The amount (n) of a chemical is, at any moment,
proportional to its free non-ionized concentration in water
(cA). The proportionality factor is the unbound non-ionized
volume of distribution, Vdf (eq 60 in section 10.3.3), that
accounts for accumulation in membranes and aqueous phases,
and protein binding of all species of the chemical. The total
rate of loss of the chemical from the biosystem is the
summation of the elimination processes proceeding in all N
subcellular compartments with the ﬁrst-order and zero-order
kinetics (the respective clearances Cl are speciﬁed in eqs 62
and 63 in section 10.3.4). The eliminated amount per time
unit is converted to the free concentration, cA, using Vdf:
-
dcA
dt
)(
Cl
Vdf)cA+ Cl
0
Vdf
)kecA+ke
0 (22)
The elimination rate constants are equal to the clearances
divided by Vdf. Integration of eq 22 gives
cA)(
n0
Vdf
+
ke
0
ke)e
-ket-
ke
0
ke
(23)
The ﬁrst term in eq 23 represents the initial concentration
of the free non-ionized compound in the aqueous phases as
given by eq 60, with the dose n0, instead of the actual amount
n. In eq 23, the resulting concentration (cA) would become
negative for the inﬁnitely long exposure time t. This anomaly
is explained by the fact that eq 23 is not valid for the
complete duration of the residence of chemicals in the
biosystem. During elimination, when the concentration drops
below a certain limit, the zero-order character of the process
will change to the ﬁrst order.
Equation 23 is suitable not only for the cases with
combined zero- and ﬁrst-order elimination, but also for the
ﬁrst-order elimination alone (simply ke
0 ) 0). For the opposite
case, when only the zero-order elimination is encountered
in a limited time interval (i.e., ke ) 0), eq 23 results in an
undeﬁned expression. The corresponding description (eq 24)
can be derived either de novo or from the limit of eq 23 for
ke approaching zero using the L’Hospital rule:
cA)
n0
Vdf
-ke
0t (24)
At any moment, the free non-ionized concentrations (cA)
are identical in all aqueous phases. However, the total
concentrations in individual phases differ, because of ioniza-
tion, ion pairing, and protein binding. The actual concentra-
tion of any molecular species in the given compartment can
be easily calculated as the product of cA and the respective
proportionality factor as shown in eqs 36-38 in section
10.2.2. The concentrations of metabolites and excreted
molecules can be described using the integral of the time
dependence of the corresponding precursor concentration,
multiplied by the respective rate parameter.
Note that the global elimination rate parameters ke and ke
0
in eqs 23 and 24, as speciﬁed in eqs 62 and 63 (section
10.3.4), are not plain summations: the rate parameters in
individual compartments are weighted by the respective
volumes, Vi, to scale the contributions to the total elimination
according to the size of the compartments. The unbound non-
ionized volume of distribution, Vdf, accounts for the effect
of protein binding and membrane accumulation of chemicals
on the available concentrations (eqs 23 and 24), and on the
decrease in the elimination rates (eqs 62 and 63). An
illustration of the latter phenomenon is given later in Figure
29 in section 7.3.1.
Equations 22-24, with further speciﬁcations given in eqs
60-63 in sections 10.3.3 and 10.3.4, can be used to derive
model-based expressions relating pharmacokinetic parameters
or bioactivities to the structure of chemicals, for interspecies
scaling, and for population pharmacokinetics. The application
in the QSAR ﬁeld is illustrated in the next section. The
biosystem parameters (membrane volumes, protein concen-
trations, the pH values of the aqueous phases) must be
speciﬁed for interspecies scaling and expressed as a function
of conveniently measurable characteristics of individuals for
population pharmacokinetics.
7.3. Use in QSAR
In the following, we will only address the ﬁrst-order
elimination (eq 23 with ke
0 ) 0), which is more typical for
low concentrations of chemicals, such as those used in drug
therapy and environmental toxicology. To convert eq 23 to
a QSTAR expression, the model parameters should be
substituted by the structural and physicochemical properties
of the chemicals. The association constants for the structure-
dependent processes (binding to prevalent proteins, transport-
ers, enzymes) in ke ) Cl/Vdf and Vdf (eqs 62 and 60) must
be replaced by the appropriate 3D-QSAR relations where
necessary. The parameters for property-related processes in
ke and Vdf (partitioning, ionization, reactivity) are replaced
by physicochemical properties using plausible extrathermo-
dynamic assumptions, as introduced by the pioneers of the
QSAR ﬁeld.56 The core/water partition coefﬁcient, PC,i s
related to the reference partition coefﬁcient, P, according to
the Collander equation (eq 1) in section 2.1.3.1. The
reactivity to body constituents can be related to the reference
reactivity using eq 5 in section 2.5.2. Ionization is usually
characterized by the pKa values for diluted aqueous solutions.
The quantities for individual chemicals can be dispropor-
tionately affected by the ionic strength of the cell environ-
ment, but this effect is usually deemed insigniﬁcant. We will
analyze, in detail, the situation when the observed disposition
or bioactivity, and, consequently, all participating processes,
are smooth functions of physicochemical properties of the
chemicals. In such cases, elimination proceeds via property-
related processes, and the nonspeciﬁc noncovalent binding
of homologous series of chemicals to proteins is structure-
independent and obeys eq 4 in section 2.4.4.
A combination of eq 1 in section 2.1.3.1 and eq 4 in
section 2.4.4 with eq 23 results in the disposition function
(eq 6 in section 4), with lipophilicity, acidity, ion pairing,
and elimination rate parameters as variables, and a large
number of adjustable coefﬁcients. To adapt the expression
to a real situation, many simpliﬁcations are available, based
either on information about the used biosystem and chemi-
cals, or on a hypothesis to be tested. The possibilities are
numerous and the procedure is comparatively straightfor-
ward. Therefore, an exhaustive overview of all equations is
not given; rather, the concept is illustrated by the application
to some simple cases.
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siﬁcation of the fate-determining processes into two groups:
lipophilicity-dependent processes (membrane accumulation,
protein binding, binding to some metabolizing enzymes, as
described by eqs 45 and 4 in sections 10.2.3 and 2.4.4,
respectively), and lipophilicity-independent processes (ion-
ization, ion pairing, spontaneous reactions, some enzymatic
reactions, and excretion). We will further assume that all
lipophilicity-dependent processes have practically identical
magnitudes of the Collander exponent   in eqs 1 and 4, when
correlated with the 1-octanol/water partition coefﬁcient P.
Equation 23, with ke
0 ) 0, then can be rewritten for the
distribution or for the effects that are proportional to receptor
modiﬁcation (see eq 7 in section 4 for the explanation of
symbols):
c
c0
or 1
cX[
X
K(1-X)]) 1
AP
 +B
exp(-CP
 +D
AP
 +B
t)
(25)
The complete expressions for terms A, B, C, and D are
listed in section 10.3.5. The terms describe the individual
processes that affect the chemicals’ disposition: A describes
membrane accumulation and protein binding, B describes
distribution in the aqueous phases, C describes lipophilicity-
dependent elimination processes (based on eqs 45 and 4),
and D describes other ﬁrst-order elimination processes. The
terms A, B, C, and D can be either constant within the series
tested or dependent on global physicochemical properties of
the chemicals (e.g., the pKa values, which are contained in
the parameters dij, which are deﬁned in eq 36), and of the
biosystem (e.g., the pH values of aqueous compartments,
which also appear in the parameters dij). Moreover, the terms
C and D may also be dependent on the exact 3-D geometry
of individual molecules, as well as on the spatial distribution
of their properties. Similar complex dependencies are to be
expected for the chemical-receptor association constant K
in eq 25. In all three cases, the terms can be substituted by
3D-QSAR expressions, if necessary. In a restricted series of
homologous compounds, K, C, and D may be dependent on
the global properties of tested chemicals.
Equation 25 can be used to construct a model-based
QSTAR expression or an SBSP model for various scenarios
differing in diversity of studied compounds and biosystems.
In the following sections, the application of eq 25 will be
illustrated for some simple situations.
7.3.1. Lipophilicity-Bioactivity Proﬁles
Membrane accumulation and protein binding of chemicals
can affect the elimination rates and lead to the frequently
observed concave bioactivity-lipophilicity proﬁles, in ad-
dition to transport56,58,59,64,65,2087–2089 and equilibrium distri-
bution,34,35,63,706,2122,2123 which have been considered as the
causes of this behavior previously. This phenomenon will
be illustrated in more detail with the following simple yet
realistic example for a set of compounds with invariant
acidity, lipophilicity-dependent binding to membranes, inert
proteins, and metabolizing enzymes according to eq 25 with
the Collander exponent   ) 1, and metabolized solely by
lipophilicity-dependent enzymatic reactions (i.e., D ) 0i n
eq 25).2124 We are interested in the concentrations of the
chemicals bound to proteins (which may well represent the
receptors); therefore, eq 25 must be multiplied by the term
BP , as expressed in eq 4 in section 2.4.4.
The concentration-lipophilicity proﬁles at a constant
exposure time, which are commonly measured for the QSAR
studies, can be seen in Figure 29A. For short times (log t <
-1.5), there is no signiﬁcant difference between the initial
and actual concentrations. The relationships have the bilinear
form that is characteristic of the lipo-hydrophilic equilibrium
(curves 1-3). Later (log t >- 1), the equilibrium depend-
encies become distorted in the region of high lipophilicity
and adopt trilinear shapes (curves 5-10).
The time courses of the concentrations of the chemical-pro-
tein complexes for varying lipophilicities of chemicals are
presented in Figure 29B. They have comparatively simpler
shapes. The concentrations (c) are initially independent of
the exposure time (t) and suddenly decrease after t reaches
a certain value. The limiting value of log t is constant for
lipophilic compounds (log P > 1, curves 1-4) and is
inversely proportional to lipophilicity for other compounds
(curves 6-10).
Figure 29C depicts the combined inﬂuence of both the
exposure time and lipophilicity on distribution. The low
apparent concentrations of the complexes of hydrophilic
compounds (logP < 0) bound to the proteins remain
practically intact, even after comparatively long incubation
periods: the lower the logP values, the longer the stability
period. The comparatively slow elimination of hydrophilic
solutes is caused by the low afﬁnity for the biotransformation
enzymes. Moreover, the aqueous compartment, containing
a prevailing part of the hydrophilic molecules, might serve
as a depot that supplies the molecules for the binding
processes, after the concentrations of bound chemicals
decrease. This compensation mechanism works until the
eliminated amount is no longer negligible in comparison with
the total amount. In contrast, the concentrations of lipophilic
solutes signiﬁcantly decrease when the exposure is longer
than log t > 0, because of the stronger binding to metaboliz-
ing enzymes, resulting in higher elimination rate constants.
Figure 29. Relationship2124 between the concentration c of the
protein-bound chemical, the partition coefﬁcient P, and the exposure
time of distribution t for a pseudo-equilibrium situation: (A)
projection into the plane c-P, (B) projection into the plane c-t,
and (C) overall view. The values were calculated using eq 25
multiplied by P, with c0 ) 1 unit,   ) A ) 1, B ) 0.1, C ) 0.01,
and D ) 0. Individual curves in projection A are valid for log t )
-4 (curve 1), -3 (curve 2), -1.75 (curve 3), -0.5 (curve 4), 0.75
(curve 5), 1.25 (curve 6), 1.75 (curve 7), 2.75 (curve 8), 3.75 (curve
9), and 4.75 (curve 10). Individual curves in projection B are valid
for log P )- 4 (curve 10), -3 (curve 9), -2 (curve 8), -1 (curve
7), 0 (curve 6), 1.25 (curve 5), 2.5 (curve 4), 3.75 (curve 3), 5
(curve 2), and 6 (curve 1).2124
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any particular example with speciﬁc assumptions about the
terms A, B, C, and D in eq 25. Their main features can be
described semiquantitatively as follows. The concentration-
lipophilicity proﬁles initially have the equilibrium shapes
similar to curves 1-3 in Figure 29A. At longer times after
the administration, the concentrations of the chemicals start
to decrease, but the decrease is not equal for all compounds.
Preferably lipophilic compounds are eliminated, if lipophi-
licity is a prerequisite for the binding to metabolizing
enzymes (curves 5-10, Figure 29A) and mainly hydrophilic
solutes disappear during elimination of the free molecules
(e.g., as in excretion or spontaneous hydrolysis). The locale
of the elimination process is reﬂected in the nonlinear shape
of the relationships between the concentrations and time
(Figure 29B), which can be characterized by the moment
when the concentrations start to decrease. The break-point
values are dependent on increasing lipophilicity in two
different ways. If hydrophilic chemicals are preferably
eliminated, the break-point value of log t is initially constant
and then increases; for elimination that affects predominantly
hydrophobic chemicals, the break-point ﬁrst declines and then
levels off (see Figure 29B).
The dependencies in Figure 29 were calculated using eq
25. The coefﬁcient C, characterizing lipophilicity-dependent
elimination, appears only once in eq 25, as the product with
the exposure time t. Therefore, the aforementioned qualitative
conclusions made for t also apply for the elimination rate
constants ke or its product with the exposure time. For this
reason, the exposure time t was plotted on the logarithmic
scale in Figure 29.
For homologous series of non-ionizable chemicals or
ionizable chemicals with approximately identical pKa values,
bioactivity at a predetermined exposure time is frequently a
smooth, nonlinear function of lipophilicity.6,2184 In such cases,
distribution must be property-related and is probably de-
pendent on lipophilicity. Equation 25 indicates that smooth
relations can be obtained only if all the terms A, B, C, and
D are either zero or constant. The terms dij and pijk (see eqs
36 and 38 in section 10.2.2), accounting for ionization and
ion pairing in eq 25, then can be expected to have either
zero or constant values.
For a restricted series of homologous chemicals, the
chemical-receptor association constant K in eq 25 sometimes
is dependent on the reference partition coefﬁcient P, and can
be substituted by eq 4 (section 2.4.4) with the exponent. The
lipophilicity-activity proﬁles at a given exposure time then
can be described by the following modiﬁcation of eq 25,
where all terms were divided by B:
log(
1
cX))  log P-log(AP
 +1)- CP
 +D
AP
 +1
+E
(26)
The coefﬁcients C and D contain the ﬁxed exposure time t.
They both describe elimination: C characterizes the lipophi-
licity-dependent process and D characterizes the lipophilicity-
independent process. Usually, one of the processes domi-
nates, and eq 26 can be simpliﬁed by presetting the
coefﬁcient characterizing the minor process to zero. Selection
of the term to neglect can be made by a visual comparison
of the experimental lipophilicity-activity proﬁles with the
model curves. A pragmatic rule of thumb can be formulated
as follows: if the left-hand portion of the experimental
lipophilicity-bioactivity proﬁle has the strictly equilibrium
shape (as curves 5-10 in Figure 29A), then D ) 0; if this
comparison holds for the right-hand side, then C ) 0.
Equation 26 generates the lipophilicity-bioactivity proﬁles
with a maximum, if both the receptor binding and elimination
are either lipophilicity-dependent (D ) 0) or invariant for
the tested compounds (the ﬁrst term   log P is omitted and
C)0).Otherwise,eq26generatesthelipophilicity-bioactivity
proﬁles with plateaus.
With regard to the limited number of compounds in the
series exhibiting lipophilicity-dependent distribution and
bioactivity, eq 26, with its ﬁve adjustable coefﬁcients at a
maximum, seems to be a reasonable compromise between
the exactness of the description and accessible experimental
information. Equation 26 with D ) 0 was used to ﬁt the
published data,2124,2185 and the results are summarized in
Table 10. Satisfactory ﬁts were obtained in all analyzed cases.
Within the framework of the proposed model, this fact
indicates that the binding to the receptors and to biotrans-
formation enzymes are both lipophilicity-dependent processes
in each case. Inspection of the statistical indices, which were
summarized for the pseudo-equilibrium, parabolic, and
bilinear models in Table 10, shows that the ﬁrst model
provides the best ﬁt to the analyzed data, not only with regard
to the correlation coefﬁcients, but also in terms of the
standard deviations. Some systematic deviations for the
parabolic and bilinear models can be seen in the smooth
lipophilicity-bioactivity proﬁle presented in Figure 30.
The concave lipophilicity-bioactivity proﬁles were most
frequently explained by the equilibrium accumulation and
Table 10. Fits of eq 26 with D ) 0 to Published Lipophilicity-Bioactivity Proﬁles and a Comparison with the Parabolic and Bilinear
Models
model
pseudo-equilibrium parabolic bilinear
compounda bioactivityb A × 103   C × 103 En F r2 sr 2 sr 2 s ref
C6H5CH2N+R(CH3)2, 61c Candida albicans, MKC 0.719 ( 0.381 1.056 ( 0.040 2.014 ( 0.381 3.144 ( 0.049 11 146 0.990 0.095 0.923 0.243 0.968 0.170 d
C6H5CH2N+R(CH3)2, 61 Pseudomonas aeruginosa, MKC 2.831 ( 0.473 0.929 ( 0.035 7.534 ( 1.078 2.614 ( 0.039 12 155 0.988 0.090 0.925 0.219 0.980 0.122 d
C6H5CH2N+R(CH3)2, 61 Pseudomonas aeruginosa, MIC 21.34 ( 7.384 0.821 ( 0.108 35.75 ( 9.846 2.867 ( 0.081 9 11 0.920 0.136 0.774 0.208 0.878 0.168 d
C6H5CH2N+R(CH3)2, 61 Clostridium welchii, MKC 2.813 ( 0.734 0.999 ( 0.048 4.393 ( 0.805 3.690 ( 0.046 12 152 0.990 0.107 0.960 0.190 0.984 0.125 d
C6H5CH2N+R(CH3)2, 61 Clostridium welchii, MIC 3.456 ( 1.299 0.922 ( 0.068 5.441 ( 1.416 3.758 ( 0.066 12 64 0.974 0.154 0.933 0.230 0.966 0.172 d
C6H5CH2N+R(CH3)2, 61 Proteus Vulgaris, MKC 5.958 ( 1.730 0.697 ( 0.067 17.13 ( 4.619 2.896 ( 0.076 10 27 0.956 0.138 0.922 0.172 0.947 0.153 d
chlorinated phenyl
methacrylates, 64
Hansenula anomala 2.335 ( 1.647 0.650 ( 0.123 2.267 ( 1.655 1.656 ( 0.309 10 11 0.895 0.078 0.795 0.101 0.884 0.082 e
n-alkanes, C5H12-C17H36 mice, LD100 0.482 ( 0.214 0.639 ( 0.043 1.042 ( 0.447 0.217 ( 0.016 13 94 0.980 0.065 0.748 0.217 0.947 0.104 f
a Some structures are given in Chart 5. b MKC, minimum killing concentration; MIC, minimum inhibitory concentration, LD100, dose that is
lethal in 100% of cases. c Chlorides. d The data and the parabolic equation are taken from ref 6; the bilinear equation is taken from ref 64. e The data
are taken from ref 2353, the parabolic and bilinear equations are taken from ref 2124. f The data are taken from ref 64, the parabolic and bilinear
equations are taken from ref 2124.
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another alternative: the inﬂuence of a lipophilicity-governed
accumulation of chemicals in the membranes and lipophilic
binding sites of proteins on the actual rate of elimination
(Figure 29A). For simple biosystems such as cellular
suspensions, the pseudo-equilibrium model, assuming a fast
attainment of the lipo-hydrophilic equilibrium, is more
realistic than the transport-based models. The concave
lipophilicity-activity proﬁles are frequently observed several
hours after drug administration, but the results of uptake
experiments indicate that the transport and distribution are
ﬁnished within a few seconds or minutes.2126–2128
The description of experimental data by concave lipophili-
city-activity proﬁles serves mainly as an elementary valida-
tion of the pseudo-equilibrium model. In the case of one
independent variable, the model helps in the interpretation
of the results, and in the prediction of the behavior for longer
exposure times. The real value of the pseudo-equilibrium
model becomes apparent in more-complex situations with
the interplay of several properties, where ﬁnding the optimum
magnitudes of properties is much more difﬁcult.
7.3.2. Inﬂuence of Ionization
The majority of drugs and many other chemicals ionize
under physiological conditions. This process signiﬁcantly
affects their disposition in biosystems. Ionization is charac-
terized by the dissociation factors dij in the terms A, B, C,
and D in eq 25 (details are given in section 10.3.5).
According to eq 36 in section 10.2.2, each factor dij is the
product of two terms: one contains only the pKa values, and
the other term contains only the pH values of the subcellular
compartments. The order of summations in section 10.3.5
can be changed so that the jth summation with the terms dij
becomes the leftmost summation. Each term A, B, C, and D
(collectively represented as Y) can be deconvoluted into the
sum of terms that are associated with each ionization degree:
Y)Y0+∑
j)1
S-1
Yj10
sgn∑
k)1
j
pKak (27)
The terms Y can be treated as adjustable coefﬁcients, if the
terms they contain do not vary for the tested series. As in
eq 33 (section 7.3.3), the sign function (sgn) has the value
of the ion charge: sgn )- 1 for anions and sgn )+ 1 for
cations. The subscripts 0 and j indicate the coefﬁcients, which
are valid for the non-ionized compounds and for the jth
ionization species (total number S-1), respectively.
Equation 27 can be used for a series of compounds that
have the same ionizable groups, with the pKa values separated
by 2-3 units. More-similar macroscopic pKa values are no
longer equal to the microscopic pKa values, and the popula-
tion of the molecular species becomes more complex.
Different species may have the same charge (e.g., neutral
molecules and zwitterions), and their prevalence cannot be
calculated using the macroscopic pKa values. Under such
conditions, the ionization fractions Rij of individual species
must be calculated before the optimization of the coefﬁcients
in the QSAR equations. The microconstants and the ioniza-
tion fractions can be calculated for the given pH value, e.g.,
by the SPARC (SPARC Performs Automated Reasoning in
Chemistry) approach,2159,2160,2177,2186,2187 which performs well
for druglike compounds2168 and is also available as a web-
based service.2188 The approach utilizes the linear free-energy
relationships51 for prediction of thermodynamic effects and
perturbation molecular orbital theory2189 to describe delo-
calization and polarizability. For compounds with close pKa
values, the deconvolution of individual terms A, B, C, and
D in eq 25 or eq 26 is preferably made as
Y)∑
j)0
S
RijYj (28)
The ionization fractions Rij are related to the quantities dij
(deﬁned by eq 36 in section 10.2.2) as dij )R ij/Ri0, where
Ri0 is the fraction of the neutral species. Note that the terms
Y have different meanings in eqs 27 and 28.
Equation 25 with the coefﬁcients A, B, C, and D decon-
voluted according to eq 27, was applied to the inhibition of
Sarcina lutea by 32 lincomycin analogs2190 (65 in Chart 5),
with the inhibitory concentrations cX expressed as the ratios
to the lincomycin activity. The following form, with the
indicator variable Itrans used for the trans-derivatives, gener-
ated the best ﬁt:
log(
1
cX))-log(A0P+B0+B110
pKa)-
D0+D110
pKa
A0P+B0+B110
pKa +EItrans (29)
The nonlinear regression analysis provided the following
optimized values of adjustable coefﬁcients: A0 ) (1.183 (
0.017) × 10-2, B0 ) (1.123 ( 0.011) × 10-2, B1 ) (2.077
( 0.016) × 10-10, D0 ) (5.145 ( 0.049) × 10-2, D1 )
(5.504 ( 0.032) × 10-10, and E ) 0.283 ( 0.056. The
satisfactory quality of the ﬁt can be seen in Figure 31, and
it is also indicated by the low values of the standard errors
of coefﬁcients and the following statistical indices: n ) 31,
r2 ) 0.968, s ) 0.125, F ) 103.2.
In the context of the pseudo-equilibrium model, the results,
including the optimal form of eq 29 and the optimized values
of the adjustable coefﬁcients, can be interpreted as follows.
The values of the lincomycin-receptor association constants
K (eq 25) are identical for all cis derivatives and all trans
derivatives, the latter set showing a higher afﬁnity, as
indicated by the optimized value of coefﬁcient E.I ft h e
cis-trans isomerism would affect processes other than
Figure 30. Inhibitory activity of n-alkanes in mice (LD100 in mol/
kg)64 versus lipophilicity, expressed as the 1-octanol/water partition
coefﬁcient P. Data were ﬁtted with eq 26 (D ) 0, the values of
other adjustable coefﬁcients are given in the bottom line in Table
10) (solid line),2124 the bilinear equation described by eq 9 (dashed
line), and the parabolic equation described by eq 8 (dotted line).2124
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EItrans would be combined with the term A in the case of
binding to inert proteins, or the term D in the case of binding
to metabolizing enzymes. The remaining variation in the
antimicrobial potency of lincomycins seems to be explained
by their distribution in the microbial suspension. Non-ionized
and ionized molecules are eliminated at two different rates,
which are contained in the coefﬁcients D0 and D1, respec-
tively. Neither elimination rate is dependent on lipophilicity,
indicating that the responsible processes are either spontane-
ous reactions or lipophilicity-independent enzymatic reac-
tions. Protein binding is exclusively lipophilicity-related, and
the ionized and non-ionized molecules do not differ in this
aspect, as indicated by the absence of the coefﬁcient A1 from
eq 27 in eq 29. The distribution of lincomycins in the aqueous
phases is inﬂuenced by ionization, because eq 29 contains
both B0 and B1 terms from eq 27.
Equation 25 was used to correlate, with lipophilicity and
acidity, the published toxicities against Tetrahymena pyri-
formis of 129 monoprotic phenols2191 and 7 phenols contain-
ing two or three ionizable groups.2192 The Tetrahymena
toxicities were frequently analyzed by other approaches.2193–2222
For the monoprotic phenols, the following modiﬁcation of
eq 25, with the values of the coefﬁcients A, B, C, and D
deconvoluted according to eq 27 and the entire expression
divided by B0, provided the best ﬁt:
log 1
cX
)-log(A0P
 +B1Ka+1)-
D0+D1Ka
A0P
 +B1Ka+1
-
EpKa+F (30)
The toxicity cX is expressed as the concentration (mmol/
L) of the tested phenolic compounds causing 50% reduction
in the growth of the protozoa after the 96-h exposure. The
ﬁrst two terms in eq 30 come from the disposition function,
as given by eqs 25 and 27, and the third term represents
nonspeciﬁc binding to the receptors (K in eq 7 in section 4
or in eq 25). The values of individual adjustable coefﬁcients
were optimized as follows: A0 ) 0.1830 ( 0.1033,   )
0.2665 ( 0.0631, B1 ) 6407 ( 3805, D0 ) 5.471 ( 0.929,
D1 ) 16020 ( 8630, E ) 0.1758 ( 0.0143, and F ) 5.393
( 0.330. Some coefﬁcients were preset (B0 ) 1 and A1 )
C0 ) C1 ) 0), because their optimization did not improve
the ﬁt. Statistical indices of the ﬁt for n ) 122 experimental
points were r2 ) 0.908, s ) 0.257, and F ) 191.0. One
compound was omitted due to an additional mechanism of
action, and six compounds were inactive. All inactive
compounds were predicted to have lower activities than the
highest tested concentrations. The agreement between the
experimental and calculated toxicities is satisfactory, as
shown in Figure 32A.
The model described by eq 30 can be interpreted as
follows. The differences in toxicity are essentially ascribable
to distribution, although a small effect of the receptor binding
is apparent. Signiﬁcantly lower toxicities are observed for
compounds with (i) pKa > 6 and log P < 4, and (ii) pKa <
2, as seen in Figure 32A. The low toxicities are caused by
metabolism that occurs in aqueous phases of the cells and
proceeds with approximately equal rate (micro)parameters
for all non-ionized and all ionized molecules, as expressed
by the coefﬁcients D0 and D1 in eq 30, respectively. The
faster metabolism of the ionized species (D1 . D0) causes
a rapid decrease in the toxicity of very acidic derivatives
(pKa < 2), regardless of their lipophilicity (Figure 32A). The
hydrophilic compounds are metabolized faster because they
are present in the aqueous phases in higher concentrations
than lipophilic derivatives, which are preserved from being
metabolized by accumulation in the membranes, and by
nonspeciﬁc binding to proteins. Membrane accumulation and
protein binding of ionized species do not contribute signiﬁ-
cantly to the total distribution of the compounds in the
protozoan suspension, as indicated by A1 ) 0 in eq 30. The
term EpKa reﬂects the association of phenol molecules with
the receptors. The sign of the optimized value of the
coefﬁcient E is negative, i.e., the strength of the association
rises with the increase in the electron withdrawal from the
phenol group. According to the model, the receptors seem
to be localized in the aqueous phases. Phenols probably bind
in one ionization state, because a multispecies binding would
require a more-complex expression. The data do not provide
enough information to identify the binding species. Other
plots in Figure 32 will be analyzed in section 8.1, which
compares the performance of the pseudo-equilibrium ap-
proach with that of empirical models.
For all phenolic compounds, including those capable of
multiple ionizations, the best results were obtained using the
following equation:
log (
1
cX))-log(A0P
 +1)-
D0+D1Ka1+D3Ka1Ka2Ka3
A0P
 +1
-E1pKa1-E2pKa2+F
(31)
Individual adjustable coefﬁcients were optimized as follows:
A0 ) (9.269 ( 3.838)×10-3,   ) 0.6106 ( 0.0422, D0 )
3.582 ( 0.118, D1 ) 3.860 ( 1.171, D3 ) (1.250 ( 0.286)
× 10-25, E1 ) 0.1248 ( 0.0158, E2 ) (4.789 ( 1.246) ×
10-2 and F ) 4.437 ( 0.173. Statistical indices of the ﬁt
were r2 ) 0.870, s ) 0.277, and F ) 121.9. To the best of
our knowledge, eq 31 is the ﬁrst QSAR correlation that
conceptually includes multiple ionizations.
7.3.3. Inﬂuence of pH of the Medium
In the case of ionizable compounds, the in vitro bioactivity
determination can be done under conditions of varying
acidity of the external medium. A study of the pH depen-
Figure 31. Growth-inhibiting activity of lincomycin derivatives2190
against Sarcina lutea in the agar diffusion test, as a function of
acidity, given as the negative logarithm of the dissociation constant
Ka, and lipophilicity, parametrized by the 1-octanol/water partition
coefﬁcient P.34 The surface corresponds20 to eq 29. The ﬁtted
activities of the trans derivatives (not shown) form a similar surface,
raised by 0.283 logarithmic units. The outlier did not conform to
the smooth surface. More details are given in the text.
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into the role of ionizable groups in distribution and receptor
binding. The buffering capacity of the intracellular compart-
ments in biosystems is heavily dependent on the presence
of inhibitors, as well as on the metabolic and physiologic
state of the cells.2223 As the ﬁrst approximation, the intra-
cellular pHi changes under the inﬂuence of external pHe can
be expressed, assuming identical sensitivity (ϑ)i na l l
compartments, as
pHi)ϑpHe+ηi (32)
Despite its simplicity, eq 32 could describe the situation with
sufﬁcient precision, because the variation in pHe in the
experiment usually cannot be greater than ∼3 units, to
preserve the proper function of the cells. The robust eq 32
allows for some ﬂexibility: it allows pHi to respond
proportionally to the change in pHe, as well as keeping pHi
independent of pHe,i fϑ ) 0.
The extracellular and intracellular aqueous compartments
differ in the pH values. Therefore, it is useful to distinguish
them also in the expressions for the coefﬁcients A, B, C,
and D in eqs 25 and 27. Equation 27 then can be extended
by deconvoluting each term Yj for ionizable compounds into
two termssYje for the external aqueous phase and Yji for the
intracellular aqueous phasessas
Y)Y0+∑
j)1
S-1
(Yje10
-sgn pHe+Yji10
-sgn ϑpHe)10
sgn∑
k)1
j
pKak
(33)
The model was applied to the data on antimicrobial effects
and lipophilicity of the homologous series of R-bromoal-
kanoic acids,6 which were measured in media with pH values
6.0, 6.5, 7.5, and 8.5. The compounds have approximately
identical dissociation constants and belong to the group of
alkylating agents, which are readily eliminated, even in vitro,
by reactions with the nucleophilic groups of the cell
components. Satisfactory ﬁts were obtained with the fol-
lowing modiﬁcation2224 of eq 25, with all terms divided by
B0:
log (
1
cX))  log P-log(AP
 +1)-BpH- CP
 
AP
 +1
+
D (34)
Here, cX is the minimal killing concentration. The ﬁrst term
reﬂects the dependence of the acid-receptor association
constants K (eqs 7 and 25) on the P values. The linear pH
term originated from a graphical analysis2224 of the behavior
of eq 33. The application of the concept of varying pH in
the intracellular compartments was an important step in the
model development, which allowed for a successful ﬁt to
the data. Otherwise, if the internal pH would be considered
invariant, the magnitude of the slope B in the pH term could
only be 1 or 0, while the ﬁtted values varied in the range of
0.3-0.4.
The optimized values of the adjustable coefﬁcients are
given in Table 11. As follows from the values of the standard
deviations of the coefﬁcients and those of statistical indices
in Table 11, as well as from Figure 33, the ﬁt is satisfactory.
All coefﬁcients are statistically signiﬁcant, despite the fact
that the ratio between the value and the standard deviation
of the coefﬁcient C is somewhat larger than are those of the
other linear coefﬁcients B and D. This fact is due to the small
number of lipophilic compounds (log P > 3) in the dataset.
The ﬁt of eq 34 to the experimental data highlights several
characteristics of the process.2224 The pH dependencies of
Figure 32. Acidity-lipophilicity-toxicity proﬁles for phenols against Tetrahymena pyriformis55 generated by the model-based eq 30
(panels A and C) and the best empirical model (panels B and D) for the complete set of compounds (panels A and B) and for the reduced
set of compounds (panels C and D) as used in leave-extremes-out cross validation. The omitted points in the reduced set are indicated by
empty circles.55 The model-based equations are able to predict beyond the used parameter space, whereas the empirical models fail in this
aspect. Toxicity (T) values are the inverse values of the isoeffective concentrations (in mmol/L) causing 50% growth inhibition after 96 h
of exposure. More details are given in the text.
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accumulation of chemicals in the membranes and protein
binding, the pure distribution in aqueous phases, and
enzymatic biotransformation, respectively, are parallel. The
dependence on lipophilicity of the chemical-receptor as-
sociation constant, the membrane/water partition coefﬁcient,
and the chemical-protein association constant can be
described by the Collander equation (eq 1 in section 2.1.3.1),
with the averaged value of the exponent given in Table 11.
Unfortunately, the linearity of the pH term in eq 34 precludes
the identiﬁcation of the species (ionized or non-ionized
molecules), which participate in the receptor binding.
The potential number of adjustable coefﬁcients is rather
high in eq 25, which must be combined with eq 27 in the
case of chemicals with differing pKa values, or with eq 33
if media with varying pH values were used. Therefore, each
QSAR application of these equations should carefully
examine, which of the adjustable coefﬁcients A, B, C, and
D really must be deconvoluted, according to eqs 27 or 33.
Initial estimates can be based on a graphical examination of
the model behavior for a realistic range of coefﬁcient
values,2224 as well as on the comparison of the plotted
experimental data with the model plots. The guesses must
be conﬁrmed by coefﬁcient optimization. A more rigorous
approach is to automatically examine all possible combina-
tions of the adjustable coefﬁcients in the ﬁts.
8. Comparison with Other Approaches
SBSP involves the interactions of chemicals with organ-
isms at all complexity levels. These interactions are also a
subject of other techniques, methods, and approaches. The
following two sections compare SBSP with two widely used
approaches: empirical QSAR analysis and classical pharma-
cokinetics.
8.1. SBSP versus Empirical QSAR Approaches
Model-free ﬁtting methods have always been popular,
because of their ease of use. In drug design, neural networks,
as well as empirical models consisting of polynomials with
or without cross terms, with the coefﬁcients optimized by
linear regression analysis, PLS, and genetic algorithms, have
been used routinely. If a simple linear combination of
lipophilicity and acidity does not provide a good ﬁt, some
modelers resort to a search for new descriptors, instead of
looking for the true causes of the nonlinearity or the scatter.
As a result, hundreds of descriptors have been suggested,
without showing that they are related to the kinetics or
thermodynamics of any of the processes, which chemicals
undergo in biosystems. Instead of the quest for conceptual
models, construction of a QSAR model has been reduced to
the deployment of hundreds of descriptors, the number of
which frequently widely exceeds the number of tested
chemicals. The aforementioned methods always ﬁnd many
of the numerous solutions in these underdetermined systems.
The best solutions are then picked based on a cross
validation. In contrast to conceptual SBSP models, there is
no mechanistic information utilized or tested by the empirical
approaches. Conclusions based on the presence or absence
of certain descriptors in the ﬁnal selection of descriptors are
of limited value, because of the incorrect, oversimpliﬁed form
of the ﬁtting equations. The main outcome of the model-
free techniques is the prediction of disposition or effects of
untested chemicals.
How do the prediction abilities of conceptual SBSP models
and empirical models compare? Let us illustrate this issue
by ﬁtting the phenol toxicities against Tetrahymena pyrifor-
mis (section 7.3.2). Polynomials with cross terms have been
shown to perform equally well or better than several neural
network architectures with a higher number of adjustable
weights.2225 The polynomials with cross terms of log P and
pKa, containing up to 10 optimized coefﬁcients, were chosen
as representative empirical models and were ﬁtted to the
data.55 The ﬁt of the best polynomial model was satisfactory,
as seen in Figure 32B. The statistical indices were slightly
better than those for the model-based equation described in
eq 30. A similar trend was also observed for the standard
cross-validation approaches using either the omission of one
compound or a random omission of several compounds (see
rows 1-3 in Table 12). By all common criteria, the empirical
model was carefully cross-validated and would be recom-
mended as a reliable prediction tool by any QSAR practitioner.
Table 11. Fits of eq 34 to the Data on Inhibitory Potency and Lipophilicity of r-Bromo-Alkanoic acids6 (RCHBrCOOH, where R )
C4H9-C20H41 with even numbers of carbons) in Media with pH ) 6.0, 6.5, 7.5, or 8.5
microorganism   ABCD n r 2 s F
V. cholerae 0.692 ( 0.050 (5.214 ( 1.362) × 10-3 0.389 ( 0.045 (1.612 ( 0.365) × 10-2 5.356 ( 0.335 19 0.951 0.195 51
D. pneumoniae 0.849 ( 0.053 (1.117 ( 0.495) × 10-4 0.339 ( 0.079 (4.733 ( 2.008) × 10-4 5.364 ( 0.601 24 0.933 0.315 50
S. haemolyticus 0.847 ( 0.046 (8.445 ( 3.457) × 10-5 0.357 ( 0.075 (4.029 ( 1.595) × 10-4 5.083 ( 0.569 24 0.947 0.299 63
Figure 33. Dependence of the inhibitory activity of R-bromoal-
kanoic acids against V. cholerae on the 1-octanol/water partition
coefﬁcient P and the pH values of the medium. Toxicities (T) are
given as the inverse values of the minimum killing concentrations.
The surface corresponds to eq 34, with the optimized values of
adjustable coefﬁcients given in Table 11.2224
Table 12. Cross Validation of the QSAR Models for Toxicity of
Phenolic Compounds against Tetrahymena pyriformis2191,2192
PRESSa
method number of groups eq 30 empirical model
leave-one-out 122 9.577 7.981
leave-several-out 20 9.458 7.486
leave-several-out 7 9.821 7.242
leave-extremes-out 1 6.055 30.40
a PRESS is the predictive sum of squares of deviations between the
calculated and experimental values of the omitted points. The optimized
coefﬁcients of the SBSP-based equation 30 are given in the text, and
the corresponding surfaces are shown in Figures 32A and 32C. The
best empirical model is described in the text, and the corresponding
surfaces are shown in Figures 32B and 32D.
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parameter space. The reason is that predictions for new
compounds, which have the parameter values in the ranges
deﬁned by the parameter values of tested compounds, can
essentially be done using various model-free intrapola-
tions.1415,2226,2227 Cross validation based on a random omission
of data points does not rigorously address predictions outside
the tested parameter space. To address this issue, a cross-
validation technique that we call leave-extremes-out (LEO
cross validation) was devised.55 As the name indicates, the
data points with high and low values of both independent
variables were omitted. For the phenol toxicities, the dataset
then included 97 compounds with logP values of 1.0-5.3,
and pKa values in the range of 5.0-11.0. These limits were
chosen arbitrarily to leave out at least four compounds
beyond each side of the log P-pKa property rectangle. The
calculated predictive sum of squares of deviations (PRESS)
values (see Table 12, last row) for 25 omitted compounds
show that the LEO cross validation provides signiﬁcant
discrimination between the SBSP and empirical models. The
model-based eq 30 predicts outside the parameter space much
better than the best empirical model. As seen in Figure 32D,
the omission of compounds with extreme log P and pKa
values causes the empirical equations to dramatically change
the surface shape in the region of omission. The ﬂexible
polynomials are not able to approximate the ﬂat surfaces,
which are typical for the SBSP models. In contrast, the
model-based eq 30 maintains the shape of the associated
surface, even if optimized for the reduced parameter ranges,
as shown in Figure 32C.
The authors working with empirical approaches frequently
state that the models cannot be used for predictions outside
the tested parameter space. The results of the LEO cross
validation show that they are correct, as long as they talk
about empirical models.
8.2. SBSP and Classical Pharmacokinetics
Among the attempts to describe the relationship between
chemical structure and the kinetics of disposition, two main
directions can be distinguished, based on either classical or
subcellular pharmacokinetics. Although having similar objec-
tives, both approaches have developed separately, and the
mutual connections are rather loose. This situation is partially
related to different purposes, for which the resulting expres-
sions are used. Classical pharmacokinetics focuses on a
description of the time course of a single drug in the body.
The primary objective of SBSP is describing the differences
in the kinetics of disposition of sets of chemicals in
subcellular compartments.
Classical pharmacokinetics involves a phenomenological
description of the time course of the drug concentration in
tissues, organs, and organisms. The biosystem is represented
by a variably structured set of kinetically distinct macroscopic
compartments, which may correspond to the blood plasma
and organs; however, more often, they have very loosely
deﬁned morphological basis. Drug disposition is expressed
in terms of the space-averaged drug concentrations in the
nonhomogeneous macroscopic compartments. Although these
concentrations are of great value for therapeutic purposes,
the analysis of the drug effects at the molecular level requires
the use of the actual drug concentrations in the immediate
surroundings of the receptors. The phenomenological coef-
ﬁcients in the models of classical pharmacokinetics are not
inherently related to drug structure. The relations are sought
additionally from partial models for individual pharmaco-
kinetic parameters,45,68,1313,2228–2232 such as the absorption rate
constants (section 8.2.1),34,35,57,69,1747,1979,2097,2099,2100,2102,2233–2250
volumes of distribution (section 8.2.2),665,1965,2251 and elimina-
tion rate constants (section 8.2.3).1404,1980,1981,1984,2252–2254
The objective of SBSP is to describe the time course of
the chemicals’ concentrations in individual physically distinct
subcellular compartments such as the extracellular and
intracellular aqueous phases and membranes. This fact allows
for broadening the scope to the fates of chemicals in
microorganisms, suspensions of cells, or subcellular or-
ganelles. Numerical simulations of the fates of chemicals in
biosystems provide insight into distribution-based QSARs
(section 5). Complexity of the mathematical description in
the explicit SBSP models has been reduced in the solution
of the pertinent differential equations using simpliﬁed
scenarios (section 6) or the experimentally veriﬁed time
hierarchy of the processes that determine the disposition of
chemicals (section 7).
The form of expressions describing the time courses of
drug distribution has been repeatedly proven by the com-
partmental models of classical pharmacokinetics. Therefore,
a proper application of the SBSP concepts to the chemical
disposition in organisms should result in expressions that
provide similar time dependencies as the compartmental
equations of classical pharmacokinetics, the difference being
that the global model parameters of classical pharmacoki-
netics are now given in terms of structure of both the
biosystem and drugs. Equation 25, which is equivalent to
the one-compartment open model of classical pharmacoki-
netics, is a good example of this premise.
The most advanced models of classical pharmacokinetics
are the entire-body physiological models, which provide a
more-detailed picture of the concentrations of chemicals in
individual organs and different parts of the bloodstream.2255
The use of physiological models, currently hampered by the
need for more-detailed experimental data,2256 is expected to
expand. The SBSP principles can be applied to physiologic
models to the same extent as the compartmental models.
There is an overlap between individual approaches to the
modeling of the interactions of chemicals with biosystems.
For instance, the terms A, B, C, and D of eq 25 can help
correlate pharmacokinetic parameters with the properties of
drugs (quantitative structure-pharmacokinetics relationships)
and biosystems (interspecies scaling, population pharmaco-
kinetics). A comparison of individual features of distribution-
based QSAR (section 5), classical pharmacokinetics, and
SBSP (sections 6 and 7) is given in Table 13.
8.2.1. Absorption
Absorption denotes the transport of chemicals from the
site of their ﬁrst contact with a multicellular organism into
the bloodstream. The main routes in humans are represented
by intestinal, transdermal, and pulmonary absorption. For
drug administration, the buccal, ocular, rectal, and vaginal
routes are used when appropriate.
Transdermal absorption can be conveniently studied using
various skin preparations, and is described for the systems
of increasing complexity, including the available QSAR
models, in sections 2.1.2.2, 3.5.1, and 3.7. SBSP can
contribute to the improvement of these models by taking into
account the cellular nature of the subdermal tissue and
capillary walls.
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intestine, is more difﬁcult to study than transdermal absorp-
tion, because of the roles of carrier-mediated transport
(section 2.3.1.1), vesicle-mediated transport (section 2.2.2),
differences in physiology of individual intestinal segments,
and the transit of the changing intestinal content through the
intestine. The systems for studying some aspects of intestinal
absorption range in complexity from brush border membrane
vesicles (section 3.1.2), isolated enterocytes (section 3.3),
everted intestinal rings (section 3.3), Caco-2 cell monolayers
(section 3.4), the entire intestine used as everted sacs or a
barrier in diffusion chambers (section 3.5.2), to the ex vivo
orinsituperfusedintestine(section3.7).Thestructure-transport
relationships are covered in the respective parts.
Here, we will only review the approaches that utilize the human
or animal data and attempt to predict the fraction absorbed as a
function of properties of chemicals. The organism-level data capture
all details of the intestinal absorption process, but they are also
affected by possible interactions of chemicals with other body
components. Consequently, the data have signiﬁcant potential for
errors if treated as purely absorption data. The fraction absorbed
adopts a limited range of values; therefore, it should not be used
as a dependent variable in linear models, because they cannot be
properly calibrated in this situation.2257 A transformation of the
fraction absorbed values to the ﬁrst-order absorption rate
constants69,2249,2258–2260 is a better approach, which, however,
may not always lead to a proper representation of the
absorption process. Numerous reviews,25,46,2231,2257,2261–2279 as
well as some book chapters1313,2228,2280-2283 and books,2284
examine the relationship between oral bioavailability and the
structures and properties of chemicals. Intestinal absorption
of drugs is affected by many factors, such as dosage forms,
physiological and psychological status, food, physical activ-
ity, and differs even if a person is lying on the left side or
right side. The data for the model calibration must be
standardized or, otherwise, only fuzzy and approximate
models can be generated.
We will ﬁrst focus on the models for water-soluble
compounds. Early models of intestinal absorption were often
plagued by the use of oversimpliﬁed biosystem representa-
tions, based on a hydrophobic slab, which is a single bilayer
or membrane, whereas the data used for the model calibration
weremeasuredinanorganism.Asanexample,linear1937,2233,2285
and parabolic2286 dependences of the absorption rate constants
of several chemicals in rabbits and rats on lipophilicity can
be mentioned.
Conceptual nonlinear expressions on lipophilicity were
formulated for the equilibrium extraction as the rate-limiting
process of absorption2235 and for the effect of diffusion in the
unstirred layers on the overall process.57,560,2099,2101,2287,2288 A
series of models with lipophilicity and dissociation constants
as variables was created69 based on the pH-partition hypoth-
esis.2134 The models explained the experimentally observed
pH shift, as the consequence of the diffusion in unstirred
layers. A size exclusion limit of 250 Da was suggested for
intestinal absorption by the paracellular route, giving rise to
further nonlinearities in the rate-lipophilicity depende-
nce.2238,2289–2291 Similar considerations led to the formulation
of the permeability model consisting of a molecular-weight-
dependent set of sigmoids on lipophilicity.2292,2293
Sigmoidal dependences were found for the measures of
hydrogen-bonding ability of molecules, the sum of the
hydrogen-bond donor and acceptor fragment values,2294 the
sum of the molecular hydrogen-bonding potentials,2295 and
the sum of hydrogen-bond donors and acceptors.2296 The
predictions were improved if the chemicals were classiﬁed
according to similarity and the sigmoidal dependence was
applied to the subsets.2297
Similar sigmoidal dependences of the fraction absorbed
were found for the polar surface area (PSA).2245 Although
the initially used PSA was obtained as a Boltzmann-weighted
average of all low-energy conformations, a much simpler
approach based on a single low-energy conformation,1749
even using a fast fragment-based approach,1127 provided
similar results for the studied datasets. For more-diverse
datasets, the sigmoidal dependence still held but contained
much more scatter.1749,2269,2272 Limiting both PSA and mo-
lecular ﬂexibility was claimed to improve absorption of
chemicals in rats,2298 but this conclusion could not be
generalized.2299 The PSA combined with lipophilicity were
able to distinguish, to some extent, between compounds with
poor and good human intestinal absorption.2300
In a more-complex quantitative model of fraction absorbed,
PSA was augmented by the partition coefﬁcient at pH 6.5,
the square of the hydrogen-bond count, and the number of
Rule of Five2301–2303 (see below) violations.2304 A PLS model
of human oral bioavailability, combined with Caco-2 perme-
ability, was derived using easy-to-calculate parameters.2305
A classiﬁcation scheme for four categories of human oral
bioavailability identiﬁed the 1-octanol/water partition coef-
ﬁcient at pH 6.5 and its difference with that at pH 7.4 as
important parameters, capturing the overall trend of increas-
ing bioavailability: bases < neutral compounds < acids.2248
Neural network models with numerous descriptors were used
to predict oral bioavailability.2306–2308 The solvatochromic
approach, valid for solvation of molecules in one or two
phases, was applied to human absorption data,2249,2258–2260
subject to limitations described in section 3.6. Fragment-
based approaches, which work well for the prediction of
individual partition coefﬁcients, were applied to more-
complex human permeability data, with limited success.2309–2311
Molecular interaction ﬁelds as used in the 3D-QSAR
techniques were generated for the inertial ﬁeld superposition
of chemicals and related to human absorption by the principal
component analysis (PCA).2312 The PLS regression on a set
of lipophilic and electronic descriptors was used to models
human absorption.1315 Topological descriptors, with loosely
deﬁned relations to the processes, which the chemicals
Table 13. Some Differences between Distribution-Based QSAR, Subcellular Pharmacokinetics, and Classical Pharmacokinetics
pharmacokinetics
aspect distribution-based QSAR subcellular classical
compartment nature microscopic, homogeneous microscopic, homogeneous macroscopic, nonhomogeneous
model simpliﬁcation ﬁxed time time-hierarchy-based phenomenological
concentrations actual actual space-averaged
relation “parameters vs. properties” of
chemicals LFER-based LFER-based loose
biosystem loose deﬁned loose
kinetics included no yes yes
1862 Chemical Reviews, 2009, Vol. 109, No. 5 Balazundergo during absorption, were used for a correlation with
human absorption data via fuzzy adaptive regression,2313
neural networks,2314,2315 and linear discriminant analysis,2316
and for the classiﬁcation-based descriptor selection.2317
Semiquantitative ranges of properties that are typical for
drugs entering Phase II clinical trials, presumably having a
good absorption, were summarized as the Rule of Five:2301–2303
molecular weight < 500 Da, the estimated 1-octanol/water
partition coefﬁcient < 105, number of hydrogen-bond donors/
acceptors (sum of OH and NH) < 5, number of hydrogen-
bond acceptors (sum of O and N) < 10. A compound
violating any two rules has an increased probability of
absorption problems. The ranges were reduced and sum-
marized as the Rule of Three for fragments, which serve as
the building blocks of drug candidates and have the structures
furtherdevelopedandoptimized.2318Theoriginalauthors2301–2303
observed that the Rule of Five does not hold for actively
transported chemicals. Other exception for families of drugs
acting against speciﬁc receptors was highlighted.2319 A
comparison of the Rule of Five properties between orally
and intravenously administered drugs indicated signiﬁcant
differences.2320 A more-detailed scheme, titled “A Bioavail-
ability Score” (ABS), used the ranges of different properties
for different overall charges of the permeants.2321
Intestinal absorption of sparingly soluble drugs and
chemicals is further complicated by the availability of free
molecules for the transport process.2322 The effect of solubil-
ity was ﬁrst addressed by the use of the Absorption Potential,
which was deﬁned as the product of the 1-octanol/water
partition coefﬁcient, the fraction non-ionized at pH 6.5,
aqueous solubility, the intestinal lumen volume, and the
inverse value of the dose. For seven diverse drugs, a
sigmoidal dependence of the fraction absorbed on this
descriptor was observed.2322 The Absorption Potential was
later modiﬁed by the introduction of the liposome distribution
coefﬁcients342 and simpliﬁed by the use of intrinsic aqueous
solubilities.2323 The veracity of the experimental solubilities
for intestinal absorption in humans is increased by the use
of media imitating the relevant physiological media.2324
A semiquantitative estimate of oral bioavailability can be
made using the Biopharmaceutics Classiﬁcation System,
which divides drugs and drug products into four categories,
using low and high magnitudes of permeability and solubil-
ity.72 The classiﬁcation is used to determine the type and
extent of the tests, which are required for legal approval of
drugs. Extensions of the system to include elimination criteria
were proposed.74,180,2325
Physiology-based models have the best chance to
capture all relevant factors affecting oral bioavailability:
geometry of the intestine, intestinal transit times, dissolu-
tion and permeation of the given dose of a chemical from
the intestinal content exhibiting a pH gradient, metabolism,
and excretion.2326 The small intestine is represented by a
tube ∼280 cm long, which is subdivided into the duodenum,
jejunum, and ileum, representing ∼5%, ∼50%, and ∼45%,
respectively, of the overall length. The tube has the gradually
decreasing radius, from 1.75 cm at the pyloric sphincter to
1 cm at the ileocecal sphincter. The surface area in contact
with the lumen is increased by folds, villi, and microvilli,
which are less abundant toward the ileocecal sphincter,
resulting in the gradual decrease of the effective transfer area.
Absorption of chemicals in physiological systems was
simulated using compartment models,2327–2332 a heterogeneous
tube model,2333 a segmented-ﬂow model,2334 and an intestinal
transit function.2335 In addition to the modeling framework,
individual models differ in the quality of the approximations,
which are used to replace the model parameters, which would
be too tedious to measure for each chemical. For instance,
intestinal permeability can be replaced by in vitro rabbit or
monkey data (section 3.5.2)2247,2336 or by predictions from
QSAR models.
8.2.2. Elimination and Clearance
Elimination represents the summation of all processes
contributing to the irreversible removal of chemicals from
the biosystem. In the context of the pseudo-equilibrium
model, the global ﬁrst-order elimination rate parameter is
deﬁned by eq 23 in section 7.2 as ke ) Cl/Vdf, where Cl is
given by eq 62 and Vdf by eq 60 (in sections 10.3.4 and
10.3.3, respectively). The elimination rate constant is the sum
of the apparent rate parameters of all eliminating processes,
each weighted by the volume of the phase where the process
is encountered and divided by the unbound non-ionized
distribution volume (Vdf). Equations 23 and 24, if processed
as described in section 7.3.2, deﬁne the relations between
the elimination rate constant and properties of chemicals and
biosystems. The approach was used to correlate microbial
degradation rates of simple chemicals with lipophilicity.2337
More-precise estimates for a broader series of compounds
would require the use of the 3D-QSARs for structure-speciﬁc
process such as metabolism and active secretion, replacing
the rate parameters e and x in eq 62 in section 10.3.4.
The QSAR models for overall elimination and clearance
can be considered to be in an early stage of development.
The dependence of the dose-dependent elimination in rabbits
on lipophilicity was studied for a small set of barbiturates.1981
The clearance of barbituric acids in rats exhibited a nonlinear
dependence on lipophilicity.1314 The clearance of 14  -adr-
energic antagonists was deconvoluted into the renal and
nonrenal contributions, both depending in a parabolic way
on lipophilicity.1296 A classiﬁcation scheme for high and low
urinary excretion of drugs was created using numerous
descriptors processed by linear discriminant analysis and
recursive partitioning.2338 The kth-nearest neighbor technique
was used to predict clearance of 44 antibiotics.2339 Renal
clearance was correlated with 3D descriptors,1304 with
electronic and lipophilicity descriptors1315 and with Volsurf
descriptors,2340 using either multivariate or PLS regression,
and with topological descriptors using neural networks.1303
8.2.3. Volume of Distribution
In classical pharmacokinetics, the volume of distribution
Vd relates the administered dose of a drug or the actual drug
amount at a given moment, to the total plasma drug
concentration ciT, which can be easily measured. The pseudo-
equilibrium model uses the unbound non-ionized distribution
volume Vdf (eq 60 in section 10.3.3) that is equal to the ratio
of the dose to the free non-ionized drug concentration cA.
The conversion of Vdf to Vd is described by eq 61 in section
10.3.3. The resulting equations are in accordance with the
expression for the volume of distribution being equal to the
plasma volume and the summation of products of the tissue/
plasma partition coefﬁcients and the tissue volumes.2341 A
combination of eqs 60 and 61 provides a recipe for the
correlation of the distribution volume with the properties of
chemicals and biosystems. For nonionizable compounds or
congeneric acids, the fragments of the dependencies on
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served.68,1296,1314,2230,2251,2342–2344 For ionizable drugs, the ﬁrst
estimates have been made without ﬁtting, using the 1-octanol/
water and olive oil/water partition coefﬁcients,559 the distri-
bution coefﬁcients and fractions ionized at pH 7.4,2345 and
the experimentally determined fraction unbound in plasma
as the input parameters. Numerous descriptors were utilized
in the stepwise regression analysis,2346,2347 the fuzzy adaptive
regression analysis,2348 the variable selection by the genetic
algorithms,2349thePLSregression,1304,1315andneuralnetworks1303,2350
to create the empirical models of the volume of distribution.
The IAM partitioning and albumin binding data were used
for the same purpose.2351 The kth-nearest neighbor technique
in the space of numerous topological and physicochemical
descriptors was used to predict the distribution volumes of
44 antibiotics.2339 Lipophilicity, ionization, molecular weights,
and various drug fragments served as the variables in a
discriminant analysis and the Random Forest model for the
human distribution volume of 384 drugs.2352
For more-precise correlations, eqs 60 and 61 must be
processed analogously as was done for the derivation of
model-based QS(T)ARs in section 7.3.2. Further increase
in the quality of description can be expected with the use of
more appropriate surrogate phases for phospholipids and
triglycerides, and the replacement of the parameters for
protein binding, which are contained in the parameter bijk
(eqs 60 and 61), by the 3D-QSARs for binding to preponder-
ant proteins, as described in section 2.4.
9. Conclusions and Outlook
SBSP models the behavior and, in some cases, the effects
of chemicals in biosystems, as determined by the physico-
chemical properties and structures of both chemicals and
biosystems. Absorption, distribution, metabolism, excretion,
and toxicity (ADMET) are, in practice, often predicted using
empirical modeling with molecular descriptors selected from
large pools using exclusively statistical criteria, without
paying much attention to the mechanisms of involved steps.
These approaches try to capture the complexity of the
ADMET processes via the unjustiﬁed use of a plethora of
descriptors, rather than by focusing on the relevant chemico-
biological interactions and building mechanistic models,
which are often nonlinear in optimized coefﬁcients. SBSP,
in contrast, relies on the model-based descriptions of the
underlying processes, including their kinetics. The conceptual
SBSP models include transport and accumulation in a series
of membranes, ionization, protein binding, hydrolysis, and
other interactions with body constituents. The resulting
differential equations are solved either numerically or
explicitly, after appropriate simpliﬁcations. Individual rate
and equilibrium parameters are related either to the properties
of the chemicals, using extra-thermodynamic LFERs, or to
the structures of the chemicals, using 3D-QSARs. The
kinetics of disposition is described as a nonlinear disposition
function of the lipophilicity, acidity, reactivity, and 3D
structure of chemicals. Once calibrated for a given biosystem,
the SBSP models provide a signiﬁcantly more accurate
prediction of ADMET than empirical models, especially
outside the tested parameter space. The calibrated SBSP
models are excellent tools for tailoring the properties of drug
candidates to ensure optimum pharmacokinetics, understand-
ing bioaccumulation of chemical pollutants, and advancing
physiologic pharmacokinetic models, population pharmaco-
kinetics, allometric scaling, and other disciplines studying
chemico-biological interactions.
SBSP is in early stages of the development. The pseudo-
equilibrium SBSP models treat absorption as a fast process.
A more-detailed treatment is required for the chemicals,
which exhibit slower transport rates. Current SBSP models
predominantly involve the compounds that do not signiﬁ-
cantly interact with the headgroup regions of phospholipid
bilayers. The future development of SBSP must focus more
on cephalophilic and amphiphilic chemicals, which may
exhibit lower transport rates than other compounds. To enable
a rigorous treatment of these chemicals, a reliable system is
required for the prediction of the solvation energies of
chemicals in individual bilayer regions.
Current SBSP applications correlate the behavior or effects
of chemicals mainly with their global properties such as
lipophilicity, acidity, and reactivity. The use of structural
features of chemicals in the SBSP models is conceptually
feasible. The inclusion of 3D-QSARs for structure-speciﬁc
processes is necessary to broaden the application domain of
the SBSP models to more-diverse chemicals and biological
systems. This step is paramount for the development of SBSP
toward the ultimate goal: an integrated description of human
pharmacokinetics and toxicokinetics dependent on structures
and properties of chemicals.
10. Modeling Details
To facilitate the reading, the details of the model construc-
tion, including the used approximations and their justiﬁca-
tions, and the equations used for the description of the SBSP
models were concentrated in this section.
10.1. Model Construction Principles
In most cases, chemicals cross biological membranes by
consecutive passive diffusion steps through different regions
of the bilayer (section 2.1). The properties of the bilayer,
composed of physically distinct regions (sections 2.1.1 and
10.1.2), change discontinuously in space. Therefore, the
concentration gradients are discontinuous at the interfaces.
The exact description of the chemical diffusion in the
nonhomogeneous space would require the use of the Fick’s
Second Law for each phase separately, because of the
different solvation energies of chemicals in individual phases.
Moreover, the diffusion coefﬁcients in individual phases
should be space-dependent, because of the inhomogeneity
of the phases, caused by structured layers at both sides of
the interfaces, represented by subregions 2 and 3 (see section
2.1.1). Such a description would probably be too tedious for
any practical use; therefore, the application of some simpli-
fying assumptions seems unavoidable.
10.1.1. Diffusion inside Compartments
The intracompartmental diffusion of chemicals is so fast
that it can be treated as instantaneous in the SBSP models.
Although, in classical pharmacokinetics that involves mac-
roscopic compartments, this concept represents a crude
approximation, in SBSP, it belongs to plausible assumptions,
because of small distances that the molecules of chemicals
must cross in the subcellular compartments (more details are
given in section 5.1). This fact warrants the representation
of a biosystem by a set of alternating aqueous phases and
membranes, with the molecules of chemicals diffusing
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The approximation of the fast diffusion inside the miniature
intracellular compartments greatly simpliﬁes the descripion
of the transport of chemicals. The second-order partial
differential equations based on the Fick’s Second Law can
be replaced by a set of ﬁrst-order linear differential equations.
Consequently, the exact intracellular localization of mol-
ecules, in terms of coordinates, is substituted by a coarse
mesh of compartments. The real shape of biological com-
partments is losing its signiﬁcance in the approximation, as
the geometry of the system is fully speciﬁed by the volumes
and interfacial areas of individual compartments.
The actual number of compartments and their assignment
to the individual parts of the biosystem is crucial for
preserving physical soundness of the model. Each part of
the biosystem, where the chemical is at least temporarily
accumulated during disposition in the amount contributing
signiﬁcantly to the mass balance, represents a compartment.
Aqueous phases containing proteins and other macromol-
ecules, which can bind chemicals, qualify as compartments
in practically all situations. Individual bilayer regions may
or may not represent individual compartments, depending
on the properties of distributed chemicals. As a result, SBSP
depicts a biosystem as a set of homogeneous, morphologi-
cally based compartments, representing the bilayer regions,
and extracellular and intracellular aqueous compartments.
10.1.2. Bilayer Representation
Based on the solvation properties, three main layers can
be distinguished in the phospholipid bilayer: two headgroup
regions and the hydrocarbon core. The bilayers can be further
divided into subregions that are characterized by (i) low
headgroup density, (ii) high headgroup density, (iii) high tail
density, and (iv) low tail density292,699,912 (see Figure 3 in
section 2.1.1.5). Subregions 2 and 3 represent structured
laminae at both sides of the headgroups/core interface,698
which are also known as the polar and nonpolar diffusion
layers. A more-detailed classiﬁcation of bilayer subregions
was used to analyze the distribution of intermolecular
voids.814
The actual number of compartments representing the
bilayer in a phenomenological description of interactions with
chemicals is dependent on the accumulation of chemicals in
individualregions.Theuseofsevencompartmentssrepresented
by the outer headgroup/water interface, the outer headgroup
region, the outer core/headgroup interface, the hydrocarbon
core, the inner core/headgroup interface, the inner headgroup
region, and the inner headgroup/water interfacesseems
appropriate, given the current knowledge about interactions
of chemicals with the bilayers (section 2.1.4.1). Because the
accumulation is dependent on the properties of chemicals,
this is the maximum setup that can be reduced for speciﬁc
chemicals. For compounds with low lipophilicity, which do
not accumulate in the core, the core is not considered a
compartment. If the studied compounds exhibit low ceph-
alophilicity, they do not bind in the headgroup regions, and
the headgroup regions can be omitted in the model. For
nonamphiphilic compounds, the interfaces do not represent
compartments. For compounds that do not interact with
phospholipids, the bilayer is treated as an inert barrier and
does not need to be represented in the compartment model.
The situation is depicted in Figure 7 in section 2.1.4.6.
10.1.3. Strong and Weak Interactions
In individual compartments, the chemicals undergo nu-
merous strong (covalent) and weak (noncovalent) interactions
with the low-molecular-weight molecules and macromolecu-
lar components of the cell (more details are given in section
2.4). For SBSP, the most important difference between weak
and strong interactions lies in the kinetics of the complex
formation. While the weak interactions are completed within
milliseconds, the formation of strong covalent bonds often
proceeds with half-times on the order of minutes or hours.1249
Because the shortest biological tests usually last at least a
minute, weak interactions can obviously be treated as
practically instantaneous. This approach greatly simpliﬁes
the mathematical description of the fates of chemicals in
biosystems.
10.1.4. Lumping
The number of variables in a realistic model is, strictly
speaking, identical to the number of different states of the
molecules of chemicals (e.g., dissolved in the extracellular
and intracellular aqueous phases, accumulated in different
membrane regions, covalently or noncovalently bound to
various proteins in individual compartments, etc.). All
processes in the same compartment that proceed on similar
time scales, and are dependent on the same physicochemical
properties, can be lumped together and described by one
variable. This procedure is well known in the theory of
dynamic modeling.53 The reduction in the number of
variables can be applied to ionization, ion pairing, and
nonspeciﬁc binding of chemicals to various proteins (section
2.4), and the ﬁrst-order elimination processes (section 10.2.3).
10.2. Model Description
Using the aforementioned approximations, the distribution
of a chemical in a biosystem can be described by the scheme
given in Figure 14 in section 5. The scheme is valid for the
chemicals, which do not interact with the headgroups (see
Figure 7, rows 2 and 3, in section 2.1.4.6), because most
SBSP results were obtained for this class of compounds. This
simpliﬁed scenario illustrates all aspects of the model
description. The scheme can be easily modiﬁed for other
classes of compounds (Figure 7, rows 1 and 4-6), via the
replacement of the core compartment by a proper combina-
tion of the intrabilayer compartments.
Absorption and distribution are represented as diffusion
in a catenary chain of alternating aqueous phases and
membranes, with rapid equilibration within the bulks of the
compartments. In the membranes, only the cores are included,
because the model is only valid for the compounds, which
do not interact with the headgroups. The sizes of interfacial
areas connecting individual compartments may differ sig-
niﬁcantly, unless they represent two sides of the same
membrane. The extracellular aqueous phase represents the
incubation medium for the biosystem consisting of a suspen-
sion of subcellular organelles, cells, tissues, or organs. For
organisms, the assignment of individual compartments to
their physiological counterparts is dependent on the route
of administration. If a chemical is taken orally, the ﬁrst
aqueous compartment corresponds to the part of the gas-
trointestinal tract from which the absorption proceeds, i.e.,
to the content of the small intestine in most cases. The
molecules must cross several membranes to get into the
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aqueous compartments. For intravenous administration, the
blood represents the ﬁrst aqueous compartment. The effect
of the blood ﬂow on the rate of diffusion through the ﬁrst
capillary membrane can be taken into account via the
dependence of the transfer rate parameters (section 2.1.3.4)
on the ﬂow rate. In organs with porous capillary walls, such
as the liver or spleen, most chemicals use the paracellular
route to pass easily into the interstitial ﬂuid, which can be
therefore considered a part of the same aqueous compartment
as the blood. The cells of capillary walls in other organs
and the cells in tissues must be decomposed into individual
bilayer regions and aqueous phases in the model, as shown
in Figure 14 in section 5.
Chemicals may exist in each compartment in several states,
comprising the low-molecular-weight species, such as the
free non-ionized and ionized molecules, and the ion pairs
with low-molecular-weight counterions, which can be non-
covalently or covalently bound to macromolecules or elimi-
nated. The last category includes the molecules undergoing
the zero-order or ﬁrst-order elimination, via metabolism
(biotransformation) and excretion. For the mathematical
description of the system, linear differential equations of the
ﬁrst order are suitable. Because the applied doses of speciﬁc
drugs and contamination levels of environmental pollutants
are generally low, it can be assumed that chemical activities
are equal to the concentrations.
10.2.1. Transport in Multimembrane Systems
The ﬁrst model of subcellular distribution of chemicals58
described the pure transport of free molecules. Variations
in the volumes of the compartments and in the interfacial
areas between them were not considered. To take the
geometry of the system into account, the mass balance for
the ith compartment can be written as
-
dni
dt
)-Si-1lyci-1+(Si-1+Si)lxci-Silyci+1
(i)1,2, ...,N) (35)
where n is the amount and c are the concentrations of the
chemical in the compartment speciﬁed by the subscript, Si
is the interfacial area between the ith and (i + 1)th
compartment (S0 ) SN ) 0), l are the transfer rate parameters,
and t is time. For l, the subscripts are x ) i and y ) o for
the odd compartment numbers, and x ) o and y ) i for the
even compartment numbers. Here, the subscript i indicates
the water-to-membrane direction (only when associated with
l, otherwise the subscript i indicates the compartment
number), and the subscript o denotes the backward process
(section 2.1.3.4). The total number of compartments is N.
To place eq 35 on the concentration basis, it needs to be
divided by the volume of the ith compartment (Vi).
The majority of models used are based on the assumption
that diffusion inside all subcellular compartments is practi-
cally instantaneous, because of the small dimensions of the
compartments (more details are given in sections 5.1 and
10.1.1).
10.2.2. Fast Intracompartmental Processes
Now let us consider the processes in which the molecules
of chemicals participate in each of the compartments.
Noncovalent protein binding, ionization, and ion pairing are
much faster than transport and spontaneous or enzymatically
catalyzed chemical reactions1250 and are treated as instanta-
neous. This fact allows for simpliﬁcation of the model by
lumping together the concentrations of all molecular species
that are present inside an aqueous compartment. From the
viewpoint of the pH-partition hypothesis2134 stating that non-
ionized molecules diffuse passively through the hydrocarbon
core of membranes much faster than ionized molecules, it
is advantageous to choose the concentration of free non-
ionized molecules in the ith compartment (ci)a st h e
representative variable. The concentrations of other species
can be calculated from ci by multiplication with a proper
factor resulting from the deﬁnition of the respective equi-
librium constants. This generalization is based on the
assumption that the concentrations of the interaction partners
of chemicals (protons, counterions, and protein binding sites)
are not signiﬁcantly affected by the interactions and practi-
cally do not change upon binding of chemicals. This
assumption is plausible because, in most cases, the com-
pounds are present in living biosystems in comparatively low
concentrations. Moreover, homeostasis and the buffering
capacity of intracellular aqueous compartments contribute
to the stability of proton and counterion concentrations.2344
For an ionizable chemical encompassing S species, one
of them being neutral and (S - 1) species being ionized, the
indices j are assigned in the following way: the most
protonated species has j ) 1, and the least protonated species
has j ) S. The position of the neutral species in this sequence
is marked as n (1 < n < S), although, formally, in the
equations, we will use the subscript j ) 0 for the neutral
species. For this special notation, the sum or product of j
running from 0 to S has S members, because the term with
j ) n is omitted. The concentration of the molecules ionized
to the jth degree in the ith compartment, [C]ij, is equal to
the free non-ionized concentration ci multiplied by the factor
dij (where d represents dissociation). The factor dij is
calculated in different ways for the positively charged species
with j < n and for negatively charged species with j > n,
respectively:
dij)
[C]ij
ci
)
∏
k)j
n-1
Kaik
[H
+]
n-j (for j)1, 2, ...,(n-1))
dij) [H
+]
(j-n)
∏
k)1
j-n
Kai(k+n-1)
(for j)(n+1),(n+2),...,S)
(36)
Equations 36 are derived from the deﬁnition of the ionization
constant Kaik ) [Ci(k+1)]/[Cik][H+], characterizing the equi-
librium between species k and k + 1, and using the proton
concentration in the ith compartment. This treatment is
applicable only if the pKak values are at least 3-4 units apart
and, consequently, the Kak values are equal to the micro-
constants. Otherwise, the number of species is higher than
the number of pKak values plus one, because of the presence
of two or more species with the same charge (e.g., neutral
molecules and zwitterions for the overall zero charge). In
this case, the factors dij must be calculated using the
microconstants2177 (more details are given in sections 7.1.2
and 7.3.2).
The formation of ion pairs with low-molecular-weight
counterions leads to charge neutralization of the ionized
species and is important mainly for membrane accumulation.
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the counterions Z (total number of Z) and the association
constant Kijk. The proportionality factor pijk ) Kijk[Z]ijk (p as
in pairing) relates the concentration of the kth ion pair, [CZ]ijk,
to the concentration [C]ij of chemicals ionized to the jth
degree in the ith compartment. The ion-pair concentration
is proportional to the free non-ionized concentration ci:
[CZ]ijk)[C]ijpijk)cidijpijk (37)
with dij being deﬁned by eqs 36.
The proportionality factor between the protein-bound
concentration and the concentration of the respective low-
molecular-weight species is derived in a similar way, using
the association constant Kijkl for the binding to the lth binding
site, and assuming linear binding (i.e., a negligible loss of
the binding site concentration on binding). The concentration
of the compound ionized to the jth degree, paired with the
kth counterion, and bound to the lth binding site on proteins
in the ith compartment can be calculated as the product of
the corresponding ion-pair concentration, Kijkl and the
concentration of the binding sites sil of the lth type, as follows
from the deﬁnition of Kijkl,i fsil is practically unaffected by
the binding and can be considered constant. The total bound
concentration of the species in the ith compartment is then
the sum over all T types of binding sites in the ith
compartment:
[CZP]ijk)[CZ]ijk∑
l)1
T
Kijklsil)cidijpijkbijk (38)
The ion-pair concentration [CZ]ijk is expressed as the
product of the free non-ionized concentration ci and the
proportionality factors dij and pijk, as deﬁned in eqs 36 and
37. The proportionality factor bijk (b for binding) is equal to
the l-summation in the middle term of eq 38 and relates the
free and protein-bound concentrations of the chemical in the
jth ionization degree and kth ion pair, which are present in
the ith compartment. The proportionality factor bijk can be
used to calculate the protein-bound concentration of any
species in the ith compartment, as the product of bijk and the
free concentration of the species.
The observed association constant for the protein binding
of the kth ion pair of the jth species in the ith compartment
can be written for linear binding as
Kijk)
[CZP]ijk
[CZ]ijk∑
l)1
T
sil
)
∑
l)1
T
[CZP]ijkl
[CZ]ijksi
)
∑
l)1
T
Kijklsil
si
(39)
The concentration of the protein-bound ion pair in the third
term of eq 39 was replaced using the second term in eq 38.
The l-summation over all types of binding sites in the second
term was, in the subsequent terms, written as the overall
concentration of the binding sites in the ith compartment, si.
The association constant for an ion pair is a weighted average
of the association constants for individual binding sites,
where the weights are the fractions of individual types of
binding sites. The comparison of eqs 38 and 39 shows that
the proportionality factor bijk can be viewed as the product
of the association constant Kijk and the overall concentration
of the binding sites, si. Equation 39 also applies to the protein
binding of neutral and ionized species.
The association constant for the protein binding of the jth
species in the ith compartment is
Kij)
[CP]ij
[C]ijsi
)
∑
k)0
Z
[CZP]ijk
∑
k)0
Z
[CZ]ijksi
)
∑
k)0
Z
Kijk[CZ]ijk
∑
k)0
Z
[CZ]ijk
(40)
The concentration of the bound ion pairs in the third term
of eq 40 was replaced using an expression resulting from
the ﬁrst three terms in eq 39. Obviously, Kij is the weighted
average of the association constants for individual ion pairs
and the free species (subscript k ) 0), with the weight equal
to the fractions of ion pairs and the free species.
The protein binding of a chemical in the ith compartment
is characterized by the association constant that can be written
as
Ki)
[CP]i
[C]isi
)
∑
j)0
S
[CP]ij
∑
j)0
S
[C]ijsi
)
∑
j)0
S
Kij[C]ij
∑
j)0
S
[C]ij
(41)
Here, Ki is the weighted average of the association constants
of individual species, with the weights given as the fractions
of individual species. In the third term, the protein-bound
concentration of the jth species was expressed using the ﬁrst
two terms of eq 40.
For the pseudo-equilibrium distribution (section 7), protein
binding in the biosystem comprising N compartments is of
interest, because it appears in term A of eq 25 in section
7.3. The process is characterized by the overall association
constant, K:
K) [CP]
[C]s
)
∑
i)1
N
[CP]iVi
s∑
i)1
N
[C]iVi
)∑
i)1
N
Ki
si
s
[C]iVi
∑
i)1
N
[C]iVi
)∑
i)1
N
Ki
si
s
Vi∑
j)0
S
∑
k)0
Z
dijpijk
∑
i)1
N
Vi∑
j)0
S
∑
k)0
Z
dijpijk
(42)
In the third term, the free and bound concentrations of the
chemical from the second term were expressed as the
weighted averages of the respective concentrations in
individual compartments, with the weights given by the
volume fraction Vi/V of the compartment, whereby the V
terms mutually cancel in the numerator and the denominator.
In the fourth term, the protein-bound concentration in the
ith compartment, [CP]i, was expressed from the ﬁrst two
terms of eq 41. The pool of free species includes the non-
ionized species, ionized species, and ion pairs, with the
concentrations expressed as cA, cAdij, and cAdijpijk, as shown
in eqs 36 and 37. The appropriate summations, discussed in
more detail in eq 44 with bijk ) 0 below, replace the overall
concentration of free species [C]i in the fourth term of eq
42. Under the pseudo-equilibrium conditions, the free non-
ionized concentration cA is the same in all compartments
and mutually cancels in the numerator and denominator of
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weighted average of the association constants Ki in individual
compartments, with the weights given by the product of two
fractions in individual compartments: the concentration of
the binding sites, si/s, and the factor accounting for ionization
and ion pairing of the chemical, multiplied by the volume.
Application of a 3D-QSAR technique for the binding of
a diverse set of chemicals to silent receptors in the biosystems
consisting of several compartments, such as mitochondria,
eukaryotic cells, tissues, organs, and organisms, requires that
the overall association constant given by eq 42 be expressed
in terms of the elementary association constant Kijkl from eq
39, using the back-substitution based on eqs 40 and 41. The
reason is that the 3D-QSAR equations can only be applied
to Kijkl and not to the composite association constants Kijk,
Kij, Ki,o rK.
Within a homologous series, the association constant Kijkl
that characterizes the binding of a chemical to the lth silent
receptor, is frequently dependent on lipophilicity, expressed
by the reference partition coefﬁcient P, as given by eq 4 in
section 2.4.4:
Kijkl)BijklP
 ijkl or bijk)∑
l)1
T
BijklsijklP
 ijkl)BijkP
 ijk
(43)
The second equality is valid for the binding of one molecular
species to T protein sites in the ith compartment (see eq 38
for symbol deﬁnitions), if the Collander exponents   do not
signiﬁcantly differ for the proteins in the ith compartment.
For generality, we assume that all ion pairs can bind to
proteins. Obviously, the unpaired molecules (k ) 0) with
charge j may have high association constants Kij0l. Their
binding factor will be denoted bij0. The neutral molecules (j
) 0) do not form ion pairs (k ) 0). They bind to protein
sites with the association constants Ki00l and their binding
factor is bi00 ) [CP]i0/ci.
The overall concentration of the chemical in the ith
compartment can be expressed using eqs 36-38 as the sum
of concentrations of (i) free non-ionized molecules; (ii)
molecules that are ionized to various degrees (j), encompass-
ing (S - 1) species, (iii) ion pairs with up to Z counterions,
each denoted by the subscript k, which can originate from
each ionized molecule, giving rise to (S - 1) × Z species;
and (iv) molecules bound to the proteins, which can originate
from each species, i.e., S + (S - 1) × Z species, if binding
of each species in the given compartment is characterized
by one averaged binding parameter bijk:
ciT)ci∑
j)0
S
∑
k)0
Z
dijpijk(1+bijk) (44)
To keep eq 44 compact: (i) the j-summation runs from zero
to include the non-ionized molecules (with the subscript j
) 0), but the term with j ) n is omitted, so that the overall
number of the terms is S; (ii) the k-summation runs from
zero to include the nonpaired ionized molecules (with k )
0); and (iii) the following deﬁnitions, which do not directly
follow from eqs 36-38, are introduced. For neutral mol-
ecules, di0 ) 1, pi00 ) 1, pi0k ) bi0k ) 0( k ) 1, 2,..., Z). For
ionized molecules, which are not paired with a counterion,
pij0 ) 1( j ) 1, 2,..., S, for j * n).
In any subcellular compartment, the k- and l-summations
for the ion pairs in eq 44 and for the chemical-protein
complexes in eq 38 formally go up to the overall maximum
number of counterions (Z) and protein binding sites (T),
respectively. If a particular counterion or binding site is not
present in a particular compartment, the corresponding factors
p or b are set to zero. In this way, the use of subscripts to
the numbers Z and T is avoided, although both quantities
are compartment-speciﬁc.
10.2.3. Elimination
Chemicals can be eliminated in each compartment via
spontaneous and enzymatically catalyzed reactions and, from
some compartments, by excretion. In the ith compartment,
spontaneous reactions of a chemical in the jth ionization
degree and kth ion pair are characterized by the products of
the actual rate constants Fijk and the concentrations of the
reaction partners [R]i, which do not substantially change on
the reactions with chemicals, because of low concentrations
of the chemicals and homeostasis.
The kinetics of a saturable metabolic process of the same
species in the ith compartment can be conveniently described
by the Michaelis-Menten equation:2049
Vijk)
miVmijk[C]ijk
Kmijk+ [C]ijk
Here, m is the enzyme concentration, V is the reaction rate,
and the subscript “m” refers to its maximum saturated value.
The Michaelis-Menten constant Km can represent, under
certainassumptions,thereciprocalvalueofthechemical-enzyme
association constant. To avoid nonlinearity, two borderline
cases are usually considered: for [C]ijk,Kmijk, the enzymatic
reaction is a ﬁrst-order process,
Vijk)
miVmijk[Cijk]
Kmijk
and for [C]ijk.Kmijk, the reaction is of the zero order,
Vijk)miVmijk
All the ﬁrst-order elimination processes (i.e., spontaneous
reactions, enzymatic reactions, and excretion that affect a
molecular species in one compartment) are characterized by
the overall ﬁrst-order rate parameter, kijk:
kijk)∑
l)1
R
Fijkl[R]il+
∑
l)1
E
milVmijkl
Kmijkl
+∑
l)1
X
xijkl)
rijk+ePijk+eijk+xijk (45)
Here, R, E, and X are the total numbers of spontaneous
reactions, enzymatic reactions, and excretion processes (with
the individual rate constants xijkl), respectively. The subscripts
refer to the ith compartment, the jth ionization degree, the
kth ion pair, and the lth process. The second equality in eq
45 will be used in a pseudo-equilibrium description of
disposition (see sections 7.1.3 and 10.3.4). The term e for
the enzymatic reactions has been split in two parts: lipophi-
licity-dependent reactions have been singled out and marked
with the subscript P (indicating the relation to the reference
partition coefﬁcient P).
10.2.4. Differential Equations
Disposition of the chemicals, which do not interact with
the headgroups, includes bidirectional transport of free
1868 Chemical Reviews, 2009, Vol. 109, No. 5 Balazmolecules (both non-ionized and ionized) and ion pairs,
ionization, binding to proteins and enzymes, and the unidi-
rectional, ﬁrst-order elimination of all low-molecular-weight
species, as illustrated in Figure 14 in section 5. The mass
balance for the ith compartment can be written using the
ﬂux terms F (the ﬁrst subscript indicates the originating
compartment, and the second subscript represents the receiv-
ing compartment) and the elimination term E (the subscript
indicates the compartment where elimination occurs):
-
dni
dt
)-Fi-1,ici-1+(Fi,i-1+Fi,i+1+Ei)ci-
Fi+1,ici+1 (for i)1,2, ...,N) (46)
where
F0,1)F1,0)FN,N+1)FN+1,N)0
Ei)Vi∑
j)0
S
∑
k)0
Z
dijpijkkijk
Fi-1,i)Si-1∑
j)0
S
∑
k)0
Z
di-1,j pi-1,jklyjk
Fi,i+1)Si∑
j)0
S
∑
k)0
Z
dijpijklxjk
Fi,i-1)Si-1∑
j)0
S
∑
k)0
Z
dijpijklxjk
Fi+1,i)Si∑
j)0
S
∑
k)0
Z
di+1,j pi+1, jklyjk
Equations 46 are extensions of eqs 35 and describe the
distribution scheme given in Figure 14 in section 5. All the
ﬂux parameters F must be deﬁned simultaneously for the
given compartment number i, because the number will
determine the values of the subscripts x and y, as introduced
in eqs 35. Other symbols are deﬁned in eqs 36-45.
In eqs 46, n is the total amount and c are the free non-
ionized concentrations of the chemical. To obtain the
concentration c on the left side, eqs 46 must be divided by
Vi∑ j)0
S ∑ k)0
Z dijpijk(1 + bijk) as follows from eq 44. The ﬁnal
set of linear differential equations can then be written in
matrix notation as
-dc
dt
)B·c (47)
where c is the column vector of the chemical concentrations
in individual compartments (their total number is N), and B
is the tridiagonal matrix with dimensions N × N with the
elements:
Bi,i)
Fi,i-1+Fi,i+1+Ei
Vi∑
j)0
S
∑
k)0
Z
dijpijk(1+bijk)
(for i)1,2, ...,N)
Bi,i+1)-
Fi+1,i
Vi∑
j)0
S
∑
k)0
Z
dijpijk(1+bijk)
(for i)1,2, ...,N-1)
Bi-1,i)-
Fi-1,i
Vi∑
j)0
S
∑
k)0
Z
dijpijk(1+bijk)
(for i)2,3, ...,N)
Generally, the differential equations described by eq 47 do
not have explicit solutions and must be solved numerically
(see section 5). Explicit solutions can only be found for
special, reduced scenarios (see section 6).
10.2.5. Explicit Solutions for Single Bilayer
The differential equations described by eq 47 can be solved
explicitly for the transport through one bilayer, providing
the chemicals bind neither to the interfaces nor to proteins
(bijk ) 0) and do not ionize (dij ) pijk ) 0). The transport is
then described by two rate parameters, li and lo (Figure 7,
rows 2 and 3, in section 2.1.4.6). If the chemicals are initially
present in the ﬁrst (donor) aqueous compartment in the
concentration c0, the time course of the drug concentration
in the ith phase of the water-core-water system (i ) 1-3,
respectively) can be described by the solution to the set of
three differential equations (eq 47 with N ) 3) corresponding
to the scheme given in Figure 14 in section 5:
ci
c0
)a1i exp[-S(y+z)t]+a2i exp[-S(y-z)t]+a3i
(48)
where
y)
li
V1
+
2lo
V2
+
li
V3
z) 
li
2(V1-V3)
2
V1
2V3
2 +
4lo
2
V2
2
a11)
(li
2⁄V1
2)-[li
2⁄(V1V3)]+(li y⁄V1)
z(y+z)
a21)
[2li
2⁄(V2V3)]-[li(x+y)⁄V2]
z(y+z)
a31)a33)
loV1
lo(V1+V3)+liV2
a12)
[li
2⁄(V1V3)]-(li
2⁄V1
2)+(liz⁄V1)
z(y+z)
a22)
[li(y-z)⁄V2]-[2li
2⁄(V2V3)]
z(y-z)
a32)
liV1
lo(V1+V3)+liV2
a13)
2lilo
V2V3y(y+z)
a23)
2lilo
V2V3z(y-z)
Equations 48 can be simpliﬁed for some real-life situations.
For dilute suspensions of gram-positive bacteria or liposomes
V1 . V2 ≈ V3 and then y = 2(lo/V2) + (li/V3) and z = [(li
2/
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2) + 4(lo
2/V2
2)]1/2. In an absorption simulator, V1 ) V3 and,
consequently, y ) 2[(li/V1) + (lo/V2)] and z ) 2lo/V2.
The rate parameters li and lo are dependent on the
membrane/water partition coefﬁcient P ) li/lo, according to
eqs 3 in section 2.1.3.4. For the constant exposure time t,
lipophilicity is the only property of the chemicals governing
their membrane transport under the given conditions. The
concentration-lipophilicity proﬁles for individual distribution
periods t as generated by eq 48 are equivalent to those
generated by numerical simulations (curves 1-3 in Figure
18 in section 5.1.1). Obviously, the simple three-compartment
model provides the concave dependences of biological
activity or concentration on lipophilicity, which are so often
encountered in the QSAR practice (section 1). This is in
contrast with the statement that the three-compartment system
(Figure 14 with N ) 3) with elimination from the ﬁrst
compartment is the simplest system, which is able to generate
the concave concentration-lipophilicity proﬁles.2086 These
proﬁles result also from closed three-compartment system,
with reversible transport as shown in eq 48 with i ) 3, and
even with unidirectional transport (not shown).
10.2.6. Equations for Unidirectional Transport
For unidirectional transport, the set of differential equations
47 has the bidiagonal coefﬁcient matrix B with Bi,i+1 ) 0
and Fi,i-1 ) 0i nBi,i. The eigenvalues λi of the coefﬁcient
matrix B are simply the diagonal elements:
λi)Bi,i)
(Fi,i+1+Ei)
Vi∑
j)0
S
∑
k)0
Z
dijpijk(1+bijk)
(49)
The ﬂux terms Fi,i+1 and the elimination terms Ei are deﬁned
in eq 46.
The differential equations 47 with the bidiagonal matrix
B can be solved easily by standard methods.2108,2109 The
solutions2110–2112 differ according to whether all the eigen-
values λi deﬁned by eq 49 are different (the normal case) or
at least two eigenvalues have identical values (the degenerate
case). The solution for the normal case is represented by eq
14 in section 6.2.1. Some solutions for the degenerate case
have been published.2112
10.2.7. Steady-State Solutions
If the concentration in the entry compartment is maintained
at a constant level, the system will attain the steady state,
when the concentrations in individual compartments do not
change. The corresponding differential equations 46 or 47
will become algebraic equations, by nullifying the left-hand
time derivatives. The steady-state concentrations can be
found by solving the algebraic equations using standard
determinant-based techniques. An especially compact solu-
tion exists for the system without elimination, when all Ei
) 0 in eqs 46 or 47. This situation is relevant for the
description of the permeability coefﬁcients in terms of
individual steps. Under the steady-state conditions, the net
ﬂuxes through each interface are equal to the overall ﬂux  :
φ)Fi,i+1ci-Fi+1,ici+1 (for i)1,2, ...,N-1)
(50)
The overall ﬂux can be expressed as a function of individual
steps, the constant concentration c1 in the entry (donor)
compartment, and the concentration cN in the last (acceptor)
compartment. Back-substitution can be conveniently used,
as demonstrated in the classical work on the rate theory:2096
φ)
F12c1-F21cN∏
2
N-1
(Fi+1,i⁄Fi,i+1)
1+∑
i)2
N-1
∏
j)2
i
(Fj,j-1⁄Fj,j+1)
(51)
For the steady-state assumption to hold, the concentrations
c1 and cN must be time-independent. For the application of
eq 51 to a permeation through a biological sheet (section
3.5), the only choice is to set c1 = c1(0), and cN f 0, causing
the second term in the numerator to vanish. The overall ﬂux
then is the product of the permeability coefﬁcient PC and
the constant concentration c1. PC is equal to the ﬂux from
the donor compartment, divided by the term containing a
summation of products of ratios of the forward and backward
ﬂuxes from individual compartment. If the two interfaces
surrounding the compartment are identical to the point of
having the same transfer rate parameters l (eq 46), the
respective ﬂux ratio is reduced to a constant number given
as the ratio of the surface areas S.
10.3. Pseudo-Equilibrium Disposition
This type of disposition originates if absorption is either
fast or absent, distribution is fast, and elimination is the only
time-dependent process. The scenario works best for chemi-
cals that exhibit fast trans-bilayer transport. As the overall
amount of the chemical decreases in time because of
elimination, the fast transport is able to maintain, at any given
moment, approximately the same free concentrations of the
chemical in all aqueous phases (cA) and in all membranes
(cM), and these two concentrations are related by the apparent
partition coefﬁcient (see below). The resulting description
does not include absorption, which is present if the chemical
is not dosed directly into the bloodstream. The overall time
course of the chemical’s concentration consists of the
absorption and elimination phases, which are characterized
by the increase and decrease in the concentration, respec-
tively. The duration of the absorption phase is dependent on
the size of the biosystem, in addition to the transport rates
of chemicals. In the pseudo-equilibrium models, absorption
is considered instantaneous.
10.3.1. Apparent Partition Coefﬁcient
The apparent core/water partition coefﬁcient Pi accounts
for partitioning of non-ionized molecules, ionized mol-
ecules (subscript j indicates the jth ionization degree), and
ion pairs (subscript k indicates the kth counterion). Two
aqueous phases contacting the membrane may have a
different composition, so the phase that is more distant
from the site of entry of chemicals was chosen for the
deﬁnition of Pi. For the chemicals, which do not interact
with the headgroups, Pi is deﬁned as the ratio of the total
concentration of the chemical in the membrane core and
in the aqueous phase:
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cM+∑
j)1
S
([C]Mij+∑
k)1
Z
[CZ]Mijk)
cA+∑
j)1
S
([C]Aij+∑
k)1
Z
[CZ]Aijk)
(52)
Subscripts indicate the places where the concentrations are
measured: M and A refer to the membrane core and the
aqueous phase, respectively.
Using eq 44 with ci ) cA or cM, cM ) PCcA, and bijk ) 0
(no protein binding), eq 52 can be rearranged as
Pi)PC
∑
j)0
S
∑
k)0
Z
dMijkpMijk
∑
j)0
S
∑
k)0
Z
dAijkpAijk
)PC ai (53)
The proportionality factors relating the free non-ionized
concentrations cA and cM to the concentrations of ionized
species (dij) and ion pairs (pijk) in the membrane and the
aqueous phase (subscripts M and A were added to distinguish
the phases) were deﬁned in eqs 36-44. The accumulation
factor ai is dependent on the properties of both the tissue
and the chemical.
The factor ai can also be looked at in a different way.
Each of the present molecular species has its own partition
coefﬁcient that is given as the ratio of the species’ concentra-
tions in the core and in the aqueous phase. The membrane
concentration of each species can be expressed as the product
of the respective partition coefﬁcient and the aqueous
concentration of the species:
Pi)
PCcA+∑
j)1
S
(Pij[C]Aij+∑
k)1
Z
Pijk[CZ]Aijk)
cA+∑
j)1
S
([C]Aij+∑
k)1
Z
[CZ]Aijk)
(54)
The use of proportionality factors for ionized species (dAij)
and ion pairs (pAijk) in the aqueous phase, as deﬁned in eqs
36-44, leads to
Pi)
PCcA+∑
j)1
S
(PijcAdAij+∑
k)1
Z
PijkcAdAijpAijk)
cA+∑
j)1
S
(cAdAij+∑
k)1
Z
cAdAijpAijk)
)
∑
j)0
S
∑
k)0
Z
PijkdAijkpAijk
∑
j)0
S
∑
k)0
Z
dAijkpAijk
(55)
Equation 55 was made compact by the extensions of the
j- and k-summations to the index zero, to include non-ionized
molecules (j ) 0) and free (non-paired) ionized molecules
(k ) 0), in a similar way as in eq 44. For neutral molecules,
dAi0 ) 1, pAi00 ) 1, pAi0k ) PAi0k ) 0 for k ) 1, 2,..., Z (this
notation is valid solely in section 10). For ionized molecules,
which are not paired with a counterion, pAij0 ) 1( j ) 1,
2,..., S; j * n). The core/water partition coefﬁcients of non-
ionized molecules (PC ) Pi00), molecules ionized to the jth
degree (Pij0), and ion pairs with the kth counterion (Pijk) have
the same magnitudes for all membranes. Equation 55 can
frequently be simpliﬁed using the following comparisons:
(i) the partition coefﬁcients of the ionized species Pij will
be much lower than the partition coefﬁcients of the ion pairs
(Pijk) and occasionally can be neglected; and (ii) ion pairing
in water can be neglected, i.e., in the denominator, all pAijk
) 0, except pAij0 ) 1( j ) 0, 1,..., S; j * n).
The partition coefﬁcient is an additive-constitutive
property that can be expressed as the product of the
fragment contributions of properly deﬁned substructures649
and the factors correcting for the interactions among the
substructures,501,2135 jointly denoted as f (this deﬁnition of f
slightly differs from that in original literature, to keep the
expressions compact). Applying this principle, the partition
coefﬁcients of each ionized species or ion pair can be
expressed as the product of the partition coefﬁcient of non-
ionized molecules (PC) and the ratio π of the factors f for
the ionized substructure and the respective counterion on one
side, and the non-ionized substructure on the other. The
apparent partition coefﬁcient Pi is proportional to the core/
water partition coefﬁcient for non-ionized molecules PC as2344
Pi)PC
∑
j)0
S
∑
k)0
Z
dAijpAijkπijk
∑
j)0
S
∑
k)0
Z
dAijpAijk
)PCai (56)
The magnitude of the apparent partition coefﬁcient Pi is
dependent on the composition (pH, concentration of coun-
terions) of the ith aqueous phase that is more distant from
the site of entry of chemicals, the nature of the ionizable
substructures, and the concentration of counterions. This
dependence is described by the accumulation factor ai that
can be larger or smaller than unity. The terms dijk and pijk
were deﬁned in eqs 36-44; the subscripts for the factors f
for free non-ionized and ionized molecules are deﬁned
analogously, with fi00 ) 1.
10.3.2. Tissue/Plasma Partition Coefﬁcient
The tissue/plasma partition coefﬁcient PTP is deﬁned as
the ratio of the total concentrations of a chemical in tissue
and in plasma under equilibrium conditions. For these
conditions, the tissue is represented by a set of M membranes
and A aqueous phases, which are organized in pairs
represented by a membrane and the aqueous phase that is
more distant from the site of application. This arrangement
is necessary to account for a different composition of
individual phases. The chemical can be present in any or all
of these phases as neutral, ion-paired, or ionized molecules.
The total concentrations of chemicals in each membrane and
each aqueous phases were given in eq 44 in section 10.2.2
(ci ) cM and cA, cM ) PCcA). Multiplication by the volumes
of membranes and aqueous phases (VMi and VAi, respectively)
gives the respective amounts, which can be used to deﬁne
PTP as1898
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cT
cP
)
PC∑
i)1
M
∑
j)0
S
∑
k)0
Z
VMidMijkpMijk(1+bMijk)
VT∑
j)0
S
∑
k)0
Z
dPjkpPjk(1+bPjk)
+
∑
i)1
A
∑
j)0
S
∑
k)0
Z
VAidAijkpAijk(1+bAijk)
VT∑
j)0
S
∑
k)0
Z
dPjkpPjk(1+bPjk)
(57)
The free non-ionized concentration cA appeared in each term
and was cancelled. The concentrations of all low-molecular-
weight species in each membrane/water pair can be assumed
to be given by the respective partition coefﬁcient. Following
the approach given in eqs 54-56 for the apparent partition
coefﬁcient, we get
PTP)
∑
i)1
A
∑
j)0
S
∑
k)0
Z
[PCVMidAijkpAijkπijk(1+bMijk)+
VAidAijkpAijk(1+bAijk)]
VT∑
j)0
S
∑
k)0
Z
dPjkpPjk(1+bPjk)
(58)
All membrane-related terms except the protein-binding term
(bMijk) were converted to the terms for the aqueous phase.
The i-summation runs through all membrane/water pairs.
10.3.3. Distribution Volume
For the pseudo-equilibrium conditions, the distribution
volume relates the dose to the initial plasma concentration
or the actual drug amount in the body to actual plasma
concentration. For fast distribution, the concentration of free
non-ionized molecules is equal to cA in all aqueous compart-
ments, and equal to cM in all membranes. The deﬁnition of
the core/water partition coefﬁcient PC for the non-ionized
molecules was used to ﬁnd the relation between the total
amount n and cA:
PC)
cM
cA
)
n-[∑
i)1
M
∑
j)0
S
∑
k)0
Z
PCcAVMidAij×
pAijkπijk(1+bMijk)-∑
i)1
M
cAVMiPC]
cA∑
i)1
M
VMi
-
∑
i)1
A
∑
j)0
S
∑
k)0
Z
cAVAidAijpAijk(1+bAijk)
cA∑
i)1
M
VMi
(59)
In the numerator, the non-ionized amount in the membranes
was expressed as the difference between the actual amount
n, the amount in membranes (total number M) in the form
of all species except free non-ionized molecules (the term
in the square brackets), and the amount of all species in
aqueous phases (total number A). The volumes V of the
aqueous phases and the membranes are indicated by the
subscripts A and M, respectively. The amounts are expressed
in a similar way as in eq 58 for the tissue/plasma partition
coefﬁcient. Separating cA ) n/Vdf, we get an expression for
the free non-ionized volume of distribution, Vdf:2344
Vdf)PC∑
i)1
M
∑
j)0
S
∑
k)0
Z
VMidAijpAijkπijk(1+bMijk)+
∑
i)1
A
∑
j)0
S
∑
k)0
Z
VAidAijpAijk(1+bAijk) (60)
The two summations could have been combined into one
summation going through all membrane/water pairs, as used
in eq 58. The separate summations allow for the following
interpretation of Vdf. The second term represents the volume
of the aqueous phases corrected for ionization, ion pairing,
and protein binding. The ﬁrst term represents the volume of
membranes corrected for the same processes, and membrane
accumulation.
In classical pharmacokinetics, the volume of distribution
Vd relates the dose of a drug administered to the total drug
concentration ciT in plasma. Vdf in eq 60 is based on the free
non-ionized concentration cA instead of ciT. Using eq 44,
which relates ciT and cA (identical to ci) in plasma, the
expression for the distribution volume is
Vd)
Vdf
∑
j)0
S
∑
k)0
Z
dPjpPjk(1+bPjk)
(61)
The summations in eq 61 run through all species of the given
chemical and all counterions, which are available in plasma
(denoted by the subscript “P”). The term bPjk describes protein
binding of the jth species and the kth ion pair in plasma.
A comparison of eqs 60 and 61 with eq 58 shows that
they have similar forms, and there are only two differences:
(i) the summations are through different sets of membranes
and aqueous phases corresponding to the entire organism
and a tissue, respectively; and (ii) eq 58 contains the tissue
volume VT in the denominator. This similarity means that
the volume of distribution can be viewed as a weighted
summation of the tissue/plasma partition coefﬁcients, where
the weights are the volumes of individual tissues.2341
10.3.4. Clearance
The total loss of the chemical from the biosystem is the
summation of the ﬁrst-order elimination processes encoun-
tered in all N macroscopic, extracellular, and subcellular
compartments with the volumes Vi. The rate of each process
is given as the product of the rate parameter kijk deﬁned in
eq 45 in section 10.2.3, and the respective concentration of
the chemical as given by eqs 36 and 37 in section 10.2.2:
-dn
dt
)cA∑
i)1
N
∑
j)0
S
∑
k)0
Z
Vidijpijkkijk)
cA∑
i)1
N
∑
j)0
S
∑
k)0
Z
Vidijpijk(rijk+ePijk+eijk+xijk))cACl (62)
The term that is multiplied by cA in all equalities is the
1872 Chemical Reviews, 2009, Vol. 109, No. 5 Balazclearance (Cl) of the ﬁrst-order processes. The summations
run through N compartments; (S - 1) ionized species of the
chemical, plus one uncharged species; and Z counterions (the
parameters for k ) 0 have preset values to keep eq 62
compact).
The zero-order elimination processes in the ith compart-
ment will be lumped together, and characterized by the zero-
order rate parameter kijk
0 for the species ionized to the jth
degree (j ) 0 for non-ionized molecules) and bound to the
kth counterion (k ) 0 for the free ionized molecules).
Because the zero-order processes will only be included in
the pseudo-equilibrium model (see section 7), which assumes
a parallel elimination of chemicals from all phases, the
overall zero-order clearance for the entire biosystem is of
interest:
Cl
0)∑
i)1
N
∑
j)0
S
∑
k)0
Z
Vikijk
0 )∑
i)1
N
∑
j)0
S
∑
k)0
Z
Vi∑
l)1
E
milVmijkl
(63)
The symbols are explained in eq 45. The volumes of
individual phases V are used to convert the concentration-
based rate constants kijk
0 to amount-based quantities, which
constitute clearance.
10.3.5. Pseudo-Equilibrium QSAR Model
As speciﬁed in section 7.3, the combination of eqs 1, 4,
and 43 with eq 23 provides the pseudo-equilibrium QSAR
model that is described by eq 25. The terms A, B, C, and D
in eq 25 are deﬁned as
A)∑
i)1
M
∑
j)0
S
∑
k)0
Z
VMidAijpAijkπijkAijk+
∑
i)1
M
∑
j)0
S
∑
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i)1
A
∑
j)0
S
∑
k)0
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VAidAijpAijkBAijk
B)∑
i)1
A
∑
j)0
S
∑
k)0
Z
VAidAijpAijk
C)∑
i)1
N
∑
j)0
S
∑
k)0
Z
VidijpijkmijkVmijkBijk
D)∑
i)1
N
∑
j)0
S
∑
k)1
Z
Vidijpijk(rijk+eijk+xijk)
The summations run through all membranes (the total
number M), all aqueous phases (A), all compartments (N),
all ionization species (S), and all ion-pair species (Z; the
parameters for k ) 0 have preset values to keep the terms
A, B, C, and D compact). Other parameters are deﬁned in
eqs 36-45, 55, and 56. The subscripts A and M were added,
where it was necessary to distinguish the dissociation terms
d or the ion-pairing terms p for aqueous phases and
membranes, respectively.
11. Abbreviations and Symbols
Abbreviations
R-KG R-ketoglutarate
ABC ATP-binding cassette (family)
ABS a bioavailability score
ADME(T) absorption, distribution, metabolism, excretion
(toxicity)
ADP/ATP adenosine diphosphate/adenosine triphosphate
ALARM La assay to detect reactive metabolites (by NMR)
ATR attenuated total reﬂection
BCF bioconcentration factor
BCRP breast cancer resistance protein
BD Brownian dynamics (simulations)
BSEP bile salt export pump
Bz benzyl
C chemical
C16 n-hexadecane
CD circular dichroism
Cl clearance
CMOAT canalicular multispeciﬁc organic anion transporter
CMPF 3-carboxy-4-methyl-5-propyl-2-furanopropionic acid
CP/CE complex of a chemical with a protein/enzyme
CYP cytochrome P450
CZP/CZE complex of CP/CE with a counterion Z
DAcPC diacetylphosphatidylcholine
DIS 3,5-diiodosalicylic acid
DMPC dimyristoylphosphatidylcholine
DOPC dioleoylphosphatidylcholine
DPD Dissipative Particle Dynamics (simulations)
DPH 1,6-diphenyl-1,3,5-hexatriene
DPPC dipalmitoylphosphatidylcholine
ECM extracellular matrix
ENT equilibrative nucleoside transporter
EPR electron paramagnetic resonance
FT-IR Fourier-transform infrared (spectroscopy)
GLUT glucose transporter (facilitative)
HSA human serum albumin
IAMs immobilized artiﬁcial membranes
LEO leave-extremes-out (cross-validation)
LFER linear free-energy relationship
MAS magic-angle spinning
MC Monte Carlo (simulations)
MD molecular dynamics (simulations)
MDR multiple drug resistance protein
MIC minimum inhibitory concentration
MKC minimum killing concentration
MRP multidrug resistance related protein
MSAB 4-(methylsulfonylamid)-butyl
NAD(P)H nicotinamide adenine dinucleotide (phosphate) -
reduced
NBD nucleotide binding domain
5-NFA 3-(5-nitro-2-furyl)-acrylic acid
NMR nuclear magnetic resonance
NOE nuclear Overhauser effect
NOESY nuclear Overhauser enhancement spectroscopy
NTCP Na+-taurocholate cotransporting polypeptide
OAT organic anion transporter
OATP organic anion transporting peptide
OCT/OCTN organic cation transporter (N stands for novel)
ODS octadecylated silica
PAMPA Parallel Artiﬁcial Membrane Permeation Assay
PBPK physiology-based pharmacokinetic (models)
PC phosphatidylcholine
PCA principal component analysis
PDB Protein Data Bank
PE phosphatidylethanolamine
PEPT peptide transporter
PFG pulsed ﬁeld gradient
PGDP propyleneglycol dipelargonate
PGP P-glycoprotein
PLS partial least squares projection to latent structures
POPC 1-palmitoyl-2-oleoylphosphatidylcholine
POPE 1-palmitoyl-2-oleoylphosphatidylethanolamine
PRESS predictive sum of squares of deviations
PSA polar surface area
PXR pregnane X receptor
Py pyridine
QSAR quantitative structure-activity relationship
Modeling of Subcellular Disposition of Chemicals Chemical Reviews, 2009, Vol. 109, No. 5 1873QSTAR quantitative structure-time-activity relationship
R reactant; substituent
ss solid-state (NMR)
SBSP structure-based subcellular pharmacokinetics
SCMFT Self-Consistent Mean-Field Theory
SGLT sodium glucose co-transporter
SLC solute carrier (family)
SLCO organic anion transporter (family)
TAG triacylglycerol
TIB 2,3,5-triiodobenzoic acid
TMD trans-membrane domain
URAT urate transporter
UV-Vis ultraviolet and visible (light)
XRD X-ray diffraction substituent
Parameters
a accumulation factor
A total number of aqueous phases
Ax membrane accumulation coefﬁcient
At interface transfer coefﬁcient
Ar reactivity coefﬁcient
A, B, C, D, E,
F
adjustable coefﬁcients optimized by regression
analysis
A(pp,t) disposition function with t and pp as variables
b binding factor
B aqueous distribution coefﬁcient in pseudo-equi-
librium models
B coefﬁcient relating protein binding to lipophilic-
ity
Bt coefﬁcient relating interfacial transfer to lipophi-
licity
c concentration
cX isoeffective concentration, eliciting the fraction
X of the maximum effect
C lipophilicity-dependent elimination coefﬁcient in
pseudo-equilibrium models
d dissociation factor
D lipophilicity-independent elimination coefﬁcient
in pseudo-equilibrium models
D diffusion coefﬁcient
e rate parameter of enzymatic reactions
E elimination term
E total number of enzymatic reactions in a compart-
ment
f hypothetical log P value of a substructure or a
correction factor
F ﬂux term
F Fisher test value
g standard gravity
h effective thickness
k rate parameter of metabolism or elimination
K association constant for binding to proteins or
receptors
Km Michaelis constant of an enzymatic reaction
l rate parameter for transport between bilayer
regions and water
m enzyme concentration
M total number of membranes (in eq 12, with
different solvation properties of the cores)
n amount
n position of neutral species in the sequence of
species ordered by protonation level
N number of subcellular compartments
p ion-pairing factor
P reference partition coefﬁcient
Pi apparent partition (distribution) coefﬁcient for
the given pH value of the aqueous phase,
which may be indicated in the subscript
PB/W bilayer/water partition coefﬁcient
PC16/W hexadecane/water partition coefﬁcient
PO/W 1-octanol/water partition coefﬁcient (sometimes
referred to as P)
PTP tissue/plasma partition coefﬁcient
PC permeability coefﬁcient
pp physicochemical properties
r rate parameter of spontaneous reactions in a
compartment
r2 squared correlation coefﬁcient
R resistance of a stratum to transport
R total number of spontaneous reactions in a com-
partment
s concentration of protein binding sites in a biosys-
tem
si concentration of protein binding sites in a com-
partment
sl concentration of protein binding sites represent-
ing a speciﬁc type
s standard error of the ﬁt
S interfacial area; number of species of a chemical
τ reduced time
t exposure time
T number of types of protein binding sites in a
compartment
V rate of an enzymatic reaction
Vm maximum rate of an enzymatic reaction
V volume
Vd distribution volume
Vdf distribution volume of free non-ionized molecules
Zdf the total number of countions in a compartment
x rate parameter of excretion
X relative intensity of the chemical’s effect
X total number of excretion processes in a compart-
ment
y,z terms in the description of the transport through
a single bilayer
Y one of the terms A, B, C, D describing pseudo-
equilibrium distribution
Z the total number of counterions in a compart-
ment
Z counterion
Greek Symbols
R ionized fraction
  Collander equation exponent
δ diffusion distance
λ eigenvalue
ϑ sensitivity of a compartment to a change in
external pH value
π ratio of factors f for ionized and non-ionized
substructures
F rate parameter of a spontaneous reaction
Subscripts
A subscript referring to the aqueous phase
B subscript referring to the bilayer
m subscript denoting the maximum rate or the
Michaelis constant
O subscript referring to 1-octanol
P subscript referring the plasma
T subscript referring to tissues
W subscript denoting the aqueous phase
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